<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Efficacy and safety of COVID‐19 vaccines - Graña, C - 2022 | Cochrane Library</title> <meta content="Efficacy and safety of COVID‐19 vaccines - Graña, C - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015477/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Efficacy and safety of COVID‐19 vaccines - Graña, C - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015477/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD015477" name="dc.identifier" scheme="DOI"/> <meta content="Efficacy and safety of COVID‐19 vaccines" name="citation_title"/> <meta content="Carolina Graña" name="citation_author"/> <meta content="Lina Ghosn" name="citation_author"/> <meta content="Theodoros Evrenoglou" name="citation_author"/> <meta content="Université de Paris" name="citation_author_institution"/> <meta content="Alexander Jarde" name="citation_author"/> <meta content="Silvia Minozzi" name="citation_author"/> <meta content="Cochrane Review Group on Drugs and Alcohol" name="citation_author_institution"/> <meta content="Hanna Bergman" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Brian S Buckley" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Katrin Probyn" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Gemma Villanueva" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Nicholas Henschke" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Hillary Bonnet" name="citation_author"/> <meta content="Rouba Assi" name="citation_author"/> <meta content="Sonia Menon" name="citation_author"/> <meta content="Cochrane France" name="citation_author_institution"/> <meta content="Melanie Marti" name="citation_author"/> <meta content="World Health Organization" name="citation_author_institution"/> <meta content="Declan Devane" name="citation_author"/> <meta content="National University of Ireland" name="citation_author_institution"/> <meta content="Patrick Mallon" name="citation_author"/> <meta content="University College Dublin" name="citation_author_institution"/> <meta content="Jean-Daniel Lelievre" name="citation_author"/> <meta content="Vaccine Research Institute, Université Paris Est Créteil" name="citation_author_institution"/> <meta content="Lisa M Askie" name="citation_author"/> <meta content="World Health Organization" name="citation_author_institution"/> <meta content="Tamara Kredo" name="citation_author"/> <meta content="South African Medical Research Council" name="citation_author_institution"/> <meta content="Gabriel Ferrand" name="citation_author"/> <meta content="Cochrane France" name="citation_author_institution"/> <meta content="Mauricia Davidson" name="citation_author"/> <meta content="Carolina Riveros" name="citation_author"/> <meta content="David Tovey" name="citation_author"/> <meta content="Cochrane France" name="citation_author_institution"/> <meta content="Joerg J Meerpohl" name="citation_author"/> <meta content="Giacomo Grasselli" name="citation_author"/> <meta content="University of Milan" name="citation_author_institution"/> <meta content="Gabriel Rada" name="citation_author"/> <meta content="Asbjørn Hróbjartsson" name="citation_author"/> <meta content="Philippe Ravaud" name="citation_author"/> <meta content="Anna Chaimani" name="citation_author"/> <meta content="Isabelle Boutron" name="citation_author"/> <meta content="isabelle.boutron@aphp.fr" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD015477" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/12/07" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015477/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015477/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015477/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*2019-nCoV Vaccine mRNA-1273; *COVID-19 [prevention &amp; control]; SARS-CoV-2" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015477&amp;doi=10.1002/14651858.CD015477&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="STpJR8yz";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD015477\x26doi\x3d10\x2e1002\x2f14651858\x2eCD015477\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015477\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015477\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ms","hr","fr","hu","zh_HANS","zh_HANT","th","ja","fa","pl"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD015477",title:"Efficacy and safety of COVID\\u201019 vaccines",firstPublishedDate:"Dec 7, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Emergency and Critical Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=STpJR8yz&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015477&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015477';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD015477/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD015477/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015477%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD015477/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015477/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD015477/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015477/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD015477" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD015477/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD015477" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD015477/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD015477/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>70021 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD015477" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015477/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015477/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-sec-0296"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-sec-0019"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-sec-0020"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-sec-0047"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-sec-0285"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD015477/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015477/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015477/appendices#CD015477-sec-0300"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015477/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015477/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015477/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015477/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015477/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015477/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD015477/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD015477/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Efficacy and safety of COVID‐19 vaccines</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0004">Carolina Graña</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0005">Lina Ghosn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0006">Theodoros Evrenoglou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0007">Alexander Jarde</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0008">Silvia Minozzi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0009">Hanna Bergman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0010">Brian S Buckley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0011">Katrin Probyn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0012">Gemma Villanueva</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0013">Nicholas Henschke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0014">Hillary Bonnet</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0015">Rouba Assi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0016">Sonia Menon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0017">Melanie Marti</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0018">Declan Devane</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0019">Patrick Mallon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0020">Jean-Daniel Lelievre</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0021">Lisa M Askie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0022">Tamara Kredo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0023">Gabriel Ferrand</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0024">Mauricia Davidson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0025">Carolina Riveros</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0026">David Tovey</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0027">Joerg J Meerpohl</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0028">Giacomo Grasselli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0029">Gabriel Rada</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0030">Asbjørn Hróbjartsson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0031">Philippe Ravaud</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0032">Anna Chaimani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015477/information#CD015477-cr-0033"><i class="icon corresponding-author fa fa-envelope"></i>Isabelle Boutron</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD015477/information/en#CD015477-sec-0484">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 07 December 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD015477/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD015477">https://doi.org/10.1002/14651858.CD015477</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD015477-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015477-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015477-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015477-abs-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015477-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD015477-abs-0015">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015477-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD015477-abs-0001" lang="en"> <section id="CD015477-sec-0001"> <h3 class="title" id="CD015477-sec-0001">Background</h3> <p>Different forms of vaccines have been developed to prevent the SARS‐CoV‐2 virus and subsequent COVID‐19 disease. Several are in widespread use globally.  </p> </section> <section id="CD015477-sec-0002"> <h3 class="title" id="CD015477-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of COVID‐19 vaccines (as a full primary vaccination series or a booster dose) against SARS‐CoV‐2. </p> </section> <section id="CD015477-sec-0003"> <h3 class="title" id="CD015477-sec-0003">Search methods</h3> <p>We searched the Cochrane COVID‐19 Study Register and the COVID‐19 L·OVE platform (last search date 5 November 2021). We also searched the WHO International Clinical Trials Registry Platform, regulatory agency websites, and Retraction Watch. </p> </section> <section id="CD015477-sec-0004"> <h3 class="title" id="CD015477-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) comparing COVID‐19 vaccines to placebo, no vaccine, other active vaccines, or other vaccine schedules. </p> </section> <section id="CD015477-sec-0005"> <h3 class="title" id="CD015477-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. We used GRADE to assess the certainty of evidence for all except immunogenicity outcomes.  </p> <p>We synthesized data for each vaccine separately and presented summary effect estimates with 95% confidence intervals (CIs).  </p> </section> <section id="CD015477-sec-0006"> <h3 class="title" id="CD015477-sec-0006">Main results</h3> <p>We included and analyzed 41 RCTs assessing 12 different vaccines, including homologous and heterologous vaccine schedules and the effect of booster doses. Thirty‐two RCTs were multicentre and five were multinational. The sample sizes of RCTs were 60 to 44,325 participants. Participants were aged: 18 years or older in 36 RCTs; 12 years or older in one RCT; 12 to 17 years in two RCTs; and three to 17 years in two RCTs. Twenty‐nine RCTs provided results for individuals aged over 60 years, and three RCTs included immunocompromized patients. No trials included pregnant women. Sixteen RCTs had two‐month follow‐up or less, 20 RCTs had two to six months, and five RCTs had greater than six to 12 months or less. Eighteen reports were based on preplanned interim analyses. </p> <p>Overall risk of bias was low for all outcomes in eight RCTs, while 33 had concerns for at least one outcome. </p> <p>We identified 343 registered RCTs with results not yet available. </p> <p>This abstract reports results for the <i>critical outcomes</i> of confirmed symptomatic COVID‐19, severe and critical COVID‐19, and serious adverse events only for the 10 WHO‐approved vaccines. For remaining outcomes and vaccines, see main text. The evidence for mortality was generally sparse and of low or very low certainty for all WHO‐approved vaccines, except AD26.COV2.S (Janssen), which probably reduces the risk of all‐cause mortality (risk ratio (RR) 0.25, 95% CI 0.09 to 0.67; 1 RCT, 43,783 participants; high‐certainty evidence). </p> <p><b>Confirmed symptomatic COVID‐19</b> </p> <p>High‐certainty evidence found that BNT162b2 (BioNtech/Fosun Pharma/Pfizer), mRNA‐1273 (ModernaTx), ChAdOx1 (Oxford/AstraZeneca), Ad26.COV2.S, BBIBP‐CorV (Sinopharm‐Beijing), and BBV152 (Bharat Biotect) reduce the incidence of symptomatic COVID‐19 compared to placebo (vaccine efficacy (VE): BNT162b2: 97.84%, 95% CI 44.25% to 99.92%; 2 RCTs, 44,077 participants; mRNA‐1273: 93.20%, 95% CI 91.06% to 94.83%; 2 RCTs, 31,632 participants; ChAdOx1: 70.23%, 95% CI 62.10% to 76.62%; 2 RCTs, 43,390 participants; Ad26.COV2.S: 66.90%, 95% CI 59.10% to 73.40%; 1 RCT, 39,058 participants; BBIBP‐CorV: 78.10%, 95% CI 64.80% to 86.30%; 1 RCT, 25,463 participants; BBV152: 77.80%, 95% CI 65.20% to 86.40%; 1 RCT, 16,973 participants). </p> <p>Moderate‐certainty evidence found that NVX‐CoV2373 (Novavax) probably reduces the incidence of symptomatic COVID‐19 compared to placebo (VE 82.91%, 95% CI 50.49% to 94.10%; 3 RCTs, 42,175 participants). </p> <p>There is low‐certainty evidence for CoronaVac (Sinovac) for this outcome (VE 69.81%, 95% CI 12.27% to 89.61%; 2 RCTs, 19,852 participants). </p> <p><b>Severe or critical COVID‐19</b> </p> <p>High‐certainty evidence found that BNT162b2, mRNA‐1273, Ad26.COV2.S, and BBV152 result in a large reduction in incidence of severe or critical disease due to COVID‐19 compared to placebo (VE: BNT162b2: 95.70%, 95% CI 73.90% to 99.90%; 1 RCT, 46,077 participants; mRNA‐1273: 98.20%, 95% CI 92.80% to 99.60%; 1 RCT, 28,451 participants; AD26.COV2.S: 76.30%, 95% CI 57.90% to 87.50%; 1 RCT, 39,058 participants; BBV152: 93.40%, 95% CI 57.10% to 99.80%; 1 RCT, 16,976 participants). </p> <p>Moderate‐certainty evidence found that NVX‐CoV2373 probably reduces the incidence of severe or critical COVID‐19 (VE 100.00%, 95% CI 86.99% to 100.00%; 1 RCT, 25,452 participants). </p> <p>Two trials reported high efficacy of CoronaVac for severe or critical disease with wide CIs, but these results could not be pooled. </p> <p><b>Serious adverse events (SAEs)</b> </p> <p>mRNA‐1273, ChAdOx1 (Oxford‐AstraZeneca)/SII‐ChAdOx1 (Serum Institute of India), Ad26.COV2.S, and BBV152 probably result in little or no difference in SAEs compared to placebo (RR: mRNA‐1273: 0.92, 95% CI 0.78 to 1.08; 2 RCTs, 34,072 participants; ChAdOx1/SII‐ChAdOx1: 0.88, 95% CI 0.72 to 1.07; 7 RCTs, 58,182 participants; Ad26.COV2.S: 0.92, 95% CI 0.69 to 1.22; 1 RCT, 43,783 participants); BBV152: 0.65, 95% CI 0.43 to 0.97; 1 RCT, 25,928 participants). In each of these, the likely absolute difference in effects was fewer than 5/1000 participants. </p> <p>Evidence for SAEs is uncertain for BNT162b2, CoronaVac, BBIBP‐CorV, and NVX‐CoV2373 compared to placebo (RR: BNT162b2: 1.30, 95% CI 0.55 to 3.07; 2 RCTs, 46,107 participants; CoronaVac: 0.97, 95% CI 0.62 to 1.51; 4 RCTs, 23,139 participants; BBIBP‐CorV: 0.76, 95% CI 0.54 to 1.06; 1 RCT, 26,924 participants; NVX‐CoV2373: 0.92, 95% CI 0.74 to 1.14; 4 RCTs, 38,802 participants). </p> <p>For the evaluation of heterologous schedules, booster doses, and efficacy against variants of concern, see main text of review. </p> </section> <section id="CD015477-sec-0007"> <h3 class="title" id="CD015477-sec-0007">Authors' conclusions</h3> <p>Compared to placebo, most vaccines reduce, or likely reduce, the proportion of participants with confirmed symptomatic COVID‐19, and for some, there is high‐certainty evidence that they reduce severe or critical disease. There is probably little or no difference between most vaccines and placebo for serious adverse events. Over 300 registered RCTs are evaluating the efficacy of COVID‐19 vaccines, and this review is updated regularly on the COVID‐NMA platform (<a href="https://covid-nma.com/" target="_blank">covid-nma.com</a>). </p> <p><b>Implications for practice</b> </p> <p>Due to the trial exclusions, these results cannot be generalized to pregnant women, individuals with a history of SARS‐CoV‐2 infection, or immunocompromized people. Most trials had a short follow‐up and were conducted before the emergence of variants of concern. </p> <p><b>Implications for research</b> </p> <p>Future research should evaluate the long‐term effect of vaccines, compare different vaccines and vaccine schedules, assess vaccine efficacy and safety in specific populations, and include outcomes such as preventing long COVID‐19. Ongoing evaluation of vaccine efficacy and effectiveness against emerging variants of concern is also vital.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD015477-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015477-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD015477-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD015477-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015477-abs-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015477-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD015477-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/hu#CD015477-abs-0009">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ja#CD015477-abs-0017">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD015477-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD015477-abs-0020">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD015477-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD015477-abs-0016">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015477-abs-0013">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD015477-abs-0014">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD015477-abs-0002" lang="en"> <h3>What are the benefits and risks of vaccines for preventing COVID‐19?</h3> <p><b>Key messages</b> </p> <p>– Most vaccines reduce, or probably reduce, the number of people who get COVID‐19 disease and severe COVID‐19 disease. </p> <p>– Many vaccines likely increase number of people experiencing events such as fever or headache compared to placebo (sham vaccine that contains no medicine but looks identical to the vaccine being tested). This is expected because these events are mainly due to the body's response to the vaccine; they are usually mild and short‐term. </p> <p>– Many vaccines have little or no difference in the incidence of serious adverse events compared to placebo.  </p> <p>– There is insufficient evidence to determine whether there was a difference between the vaccine and placebo in terms of death because the numbers of deaths were low in the trials. </p> <p>– Most trials assessed vaccine efficacy over a short time, and did not evaluate efficacy to the COVID variants of concern.  </p> <p><b>What is SARS‐CoV‐2 and COVID‐19?</b> </p> <p>SARS‐CoV‐2 (severe acute respiratory syndrome coronavirus 2) is the virus that causes COVID‐19 disease. Not everyone infected with SARS‐CoV‐2 will develop symptoms of COVID‐19. Symptoms can be mild (e.g. fever and headaches) to life‐threatening (e.g. difficulty breathing), or death. </p> <p><b>How do vaccines prevent COVID‐19?</b> </p> <p>While vaccines work slightly differently, they all prepare the body's immune system to prevent people from getting infected with SARS‐CoV‐2 or, if they do get infected, to prevent severe disease. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out how well each vaccine works in reducing SARS‐CoV‐2 infection, COVID‐19 disease with symptoms, severe COVID‐19 disease, and total number of deaths (including any death, not only those related to COVID‐19). </p> <p>We wanted to find out about serious adverse events that might require hospitalization, be life‐threatening, or both; systemic reactogenicity events (immediate short‐term reactions to vaccines mainly due to immunological responses; e.g. fever, headache, body aches, fatigue); and any adverse events (which include non‐serious adverse events). </p> <p><b>What did we do? </b> </p> <p>We searched for studies that examined any COVID‐19 vaccine compared to placebo, no vaccine, or another COVID‐19 vaccine. </p> <p>We selected only randomized trials (a study design that provides the most robust evidence because they evaluate interventions under ideal conditions among participants assigned by chance to one of two or more groups). We compared and summarized the results of the studies, and rated our confidence in the evidence based on factors such as how the study was conducted. </p> <p><b>What did we find? </b> </p> <p>We found 41 worldwide studies involving 433,838 people assessing 12 different vaccines. Thirty‐five studies included only healthy people who had never had COVID‐19. Thirty‐six studies included only adults, two only adolescents, two children and adolescents, and one included adolescents and adults. Three studied people with weakened immune systems, and none studied pregnant women. </p> <p>Most cases assessed results less than six months after the primary vaccination. Most received co‐funding from academic institutions and pharmaceutical companies. Most studies compared a COVID‐19 vaccine with placebo. Five evaluated the addition of a 'mix and match' booster dose. </p> <p><b>Main results </b> </p> <p>We report below results for three main outcomes and for 10 World Health Organization (WHO)‐approved vaccines (for the remaining outcomes and vaccines, see main text). There is insufficient evidence regarding deaths between vaccines and placebo (mainly because the number of deaths was low), except for the Janssen vaccine, which probably reduces the risk of all‐cause deaths.  </p> <p><i>People with symptoms</i> </p> <p>The Pfizer, Moderna, AstraZeneca, Sinopharm‐Beijing, and Bharat vaccines produce a large reduction in the number of people with symptomatic COVID‐19. </p> <p>The Janssen vaccine reduces the number of people with symptomatic COVID‐19.</p> <p>The Novavax vaccine probably has a large reduction in the number of people with symptomatic COVID‐19. </p> <p>There is insufficient evidence to determine whether CoronaVac vaccine affects the number of people with symptomatic COVID‐19 because results differed between the two studies (one involved only healthcare workers with a higher risk of exposure). </p> <p><i>Severe disease</i> </p> <p>The Pfizer, Moderna, Janssen, and Bharat vaccines produce a large reduction in the number of people with severe disease. </p> <p>There is insufficient evidence about CoronaVac vaccine on severe disease because results differed between the two studies (one involved only healthcare workers with a higher risk of exposure). </p> <p><i>Serious adverse events</i> </p> <p>For the Pfizer, CoronaVac, Sinopharm‐Beijing, and Novavax vaccines, there is insufficient evidence to determine whether there was a difference between the vaccine and placebo mainly because the number of serious adverse events was low. </p> <p>Moderna, AstraZeneca, Janssen, and Bharat vaccines probably result in no or little difference in the number of serious adverse events.  </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Most studies assessed the vaccine for a short time after injection, and it is unclear if and how vaccine protection wanes over time. Due to the exclusion criteria of COVID‐19 vaccine trials, results cannot be generalized to pregnant women, people with a history of SARS‐CoV‐2 infection, or people with weakened immune systems. More research is needed comparing vaccines and vaccine schedules, and effectiveness and safety in specific populations and outcomes (e.g. preventing long COVID‐19). Further, most studies were conducted before the emergence of variants of concerns. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is up to date to November 2021. This is a living systematic review. Our results are available and updated bi‐weekly on the COVID‐NMA platform at covid‐nma.com. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD015477-sec-0296" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD015477-sec-0296"></div> <h3 class="title" id="CD015477-sec-0297">Implications for practice</h3> <section id="CD015477-sec-0297"> <p>Several COVID‐19 vaccines are highly effective or probably highly effective in preventing SARS‐CoV‐2 infection, symptomatic COVID‐19 and severe or critical COVID‐19.  </p> <p>There is moderate‐ to high‐certainty evidence that most vaccine candidates increased the risk of systemic reactogenicity events (e.g. fever). Evidence related to any adverse event was mainly uncertain. </p> <p>There is moderate‐ to high‐certainty evidence that there is probably no difference between mRNA‐1273, CVnCoV, ChAdOx1, Ad26.COV2.S, Gam‐COVID‐Vac, WIBP‐CorV and BBIBP‐CorV and placebo in terms of serious adverse events. Evidence was uncertain and very uncertain for serious adverse events for other vaccines and for all‐cause mortality for most vaccines, mainly because of the low number of events. </p> <p>In addition, as most RCTs only followed up participants for 2 months after full vaccination, all reports are related to short‐term impacts of the vaccine.  </p> <p>Results cannot easily be generalized to pregnant women and immunocompromized individuals; more evidence is needed to elucidate the degree of additional protection conferred by COVID‐19 vaccines in these populations. </p> <p>Finally, the advent of variants of concern has highlighted the need for further research on each of the vaccine’s capacity to limit infection, disease, and death in regard to specific variants of concern.  </p> </section> <h3 class="title" id="CD015477-sec-0298">Implications for research</h3> <section id="CD015477-sec-0298"> <p> <ul id="CD015477-list-0020"> <li> <p>Three hundred and forty‐four RCTs are currently registered, of which 10 are completed. The findings from these trials will contribute to the body of evidence on efficacy and safety outcomes. The findings of this review will be updated as soon as new data are available on the COVID‐NMA platform. </p> </li> <li> <p>Since the efficacy of vaccines is well established at this point, the ethics of RCT designs using a placebo as the comparison group should be questioned, and active comparators should be considered. </p> </li> <li> <p>With the notable impact of variants of concern on vaccine efficacy, it is crucial that variant type is assessed in clinical trials and reported for future meta‐analyses to assess vaccine efficacy on considerably different variants. </p> </li> <li> <p>As a non‐negligible global population has been infected by SARS‐CoV‐2, robust evidence‐based vaccination schemes are also required. </p> </li> <li> <p>Finally, considering the rapidly changing situation (in terms of variants, policies, etc.) and the increasing and important heterogeneity in the population in terms of combinations of vaccines received, history of SARS‐CoV‐2 infection (and by which variant), type of booster vaccine received, and predominant variants at the time of data collection, RCTs might become increasingly difficult to conduct in such a rapidly‐changing context and large population‐based observational studies could provide relevant information. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD015477-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD015477-sec-0008"></div> <div class="table" id="CD015477-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">BNT162b2 – Pfizer/BioNTech + Fosun Pharma compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with BNT162b2 </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3923 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>85 per 100,000</b><br/>(3 to 2187) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 97.84</b> </p> <p>(44.25 to 99.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44,077<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b><sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>100 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>4 per 100,000</b><br/>(0 to 26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 95.70</b><br/>(73.90 to 99.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46,077<br/>(1 RCT)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b><sup>g</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>64 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>68 per 100,000</b><br/>(33 to 142) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.07</b><br/>(0.52 to 2.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43,847<br/>(1 RCT)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 additional studies (<a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a> (adolescents aged 12–15 years); <a href="./references#CD015477-bbs2-0038" title="WalshEE , FrenckR , FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.08.17.20176651]WalshEE , Frenck RW Jr, FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine2020;383(25):2439-50. ">Walsh 2020</a> (adults aged 18–85 years)) reported this outcome in 2302 participants (1131 versus 1129 participants and 24 versus 18 participants in the BNT162b2 versus placebo groups, respectively). There were no events in either group and the trials did not contribute to the effect estimate.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Outcome not pooled due to considerable heterogeneity (I² = 90%) between included studies: <a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a> (≥ 16 years): RR 2.17, 95% CI 2.09 to 2.26; n = 43,847; <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a> (12–15 years): RR 1.01, 95% CI 0.73 to 1.41; n = 2260; <a href="./references#CD015477-bbs2-0038" title="WalshEE , FrenckR , FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.08.17.20176651]WalshEE , Frenck RW Jr, FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine2020;383(25):2439-50. ">Walsh 2020</a> (≥ 18 years): RR 1.50, 95% CI 0.53 to 4.21; n = 42 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46,149<br/>(3 RCTs)<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>508 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>660 per 100,000</b><br/>(279 to 1558) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.30</b><br/>(0.55 to 3.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46,107<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>l,m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 additional trial (<a href="./references#CD015477-bbs2-0038" title="WalshEE , FrenckR , FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.08.17.20176651]WalshEE , Frenck RW Jr, FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine2020;383(25):2439-50. ">Walsh 2020</a> (adults aged 18–85 years)) reported this outcome in 42 participants (24 BNT162b2 versus 18 placebo). There were no events in either group and the trial did not contribute to the effect estimate.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019; <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 3 May 2022<br/><sup>b</sup>Follow‐up: from 7 days following the second dose to 1.81 months and six months.<br/><sup>c</sup>BioNTech/Fosun Pharma/Pfizer: <a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a> (adolescents and adults aged from 16 years); <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a> (adolescents aged 12–15 years)<br/><sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.<br/><sup>e</sup>Follow‐up: from seven days following the second dose to six months.<br/><sup>f</sup>BioNTech/Fosun Pharma/Pfizer: <a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a> (adolescents and adults aged from 16 years)<br/><sup>g</sup>Follow‐up: six months<br/><sup>h</sup>Imprecision: downgraded two levels due to small number of events observed and a wide CIs that encompasses a potential benefit and a potential harm with the intervention.<br/><sup>i</sup>Follow‐up: 1.7 months<br/><sup>j</sup>BioNTech/Fosun Pharma/Pfizer: <a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a> (adolescents and adults aged from 16 years); <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a> (adolescents aged 12–15 years); <a href="./references#CD015477-bbs2-0038" title="WalshEE , FrenckR , FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.08.17.20176651]WalshEE , Frenck RW Jr, FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine2020;383(25):2439-50. ">Walsh 2020</a> (adults aged 18–85 years)<br/><sup>k</sup>Inconsistency: downgraded two levels (I² = 90%)<br/><sup>l</sup>Inconsistency: downgraded one level (I² = 76%)<br/><sup>m</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of benefit and the possibility of harm. This outcome was not downgraded an additional level for imprecision because it was downgraded one level for inconsistency, which is related to and would have contributed to the severity of the imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015477-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">mRNA‐1273 – ModernaTX compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with mRNA‐1273 </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confirmed SARS‐CoV‐2 infection<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>8957 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>2394 per 100,000</b><br/>(997 to 5749) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 73.27</b><br/>(35.82 to 88.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31,632<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁◯<br/>Moderate<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Substantial heterogeneity (I² = 66%) between included studies: <a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> (adolescents aged 12–17 years, median 2.3 months' follow‐up): VE 55.7% (95% CI 16.8 to 76.4), n = 3181; <a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a> (adults aged 18–95 years, 5.3 months' follow‐up): VE 82% (95% CI 79.5 to 84.2), n = 28,451 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confirmed symptomatic COVID‐19 <sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4939 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>336 per 100,000</b><br/>(255 to 442) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 93.20</b> </p> <p>(91.06 to 94.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31,632<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁⨁<br/>High<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe or critical COVID‐19<sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>748 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>13 per 100,000</b><br/>(3 to 54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 98.20</b> </p> <p>(92.80 to 99.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28,451<br/>(1 RCT)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁⨁<br/>High<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality<sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>106 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> </p> <p><b>112 per 100,000</b><br/>(57 to 222) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.06</b><br/>(0.54 to 2.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30,346<br/>(1 RCT)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁◯◯<br/>Low<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 additional trial: (<a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> (adolescents aged 12–17 years)) reported on this outcome in 3726 participants (2486 mRNA‐1273 and 1240 placebo). There were no events in either group and the trial did not contribute to the pooled effect estimate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systemic reactogenicity events<sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>432 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>553 per 1000</b><br/>(527 to 579) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.28</b><br/>(1.22 to 1.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34,037<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁⨁<br/>High<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any adverse event<sup>k</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not pooled due to considerable heterogeneity (I² = 100%) between included studies: <a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> (all solicited adverse events, adolescents aged 12–17 years, median 2.8 months' follow‐up): RR 1.47 (95% CI 1.41 to 1.54), n = 3726; <a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a> (all solicited adverse events, adults aged 18–95 years, 5.3 months' follow‐up): RR 2.15 (95% CI 2.11 to 2.19), n = 29,269 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32,995<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁◯◯<br/>Low<sup>l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events<sup>l</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1792 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1649 per 100,000</b><br/>(1398 to 1936) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.92</b><br/>(0.78 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34,072<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁◯<br/>Moderate<sup>m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Local reactogenicity events<sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>211 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>697 per 1000</b><br/>(427 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.30</b><br/>(2.02 to 5.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34,037<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁⨁<br/>High<sup>n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>COVID‐19:</b> coronavirus disease 2019; <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Last updated: 01 March 2023</p> <p>b. Follow‐up: from 14 days after dose 2 to 2.3 months (median) and 5.3 months </p> <p>c. Moderna TX: <a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> (adolescents aged 12–17 years); <a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a> (adults aged 18–95 years) </p> <p>d. Despite some concerns with deviations from intervention, not downgraded for risk of bias </p> <p>e. Inconsistency: downgraded one level: I² = 66.37% </p> <p>f. Follow‐up: 5.3 months</p> <p>g. Moderna TX: <a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a> (adults aged 18–95 years) </p> <p>h. Imprecision downgraded two levels due to small number of events observed and wide CIs that encompass a potential benefit and a potential harm with the intervention </p> <p>i. Follow‐up: seven days</p> <p>j. Despite inconsistency (I² = 61%) not downgraded for inconsistency, as the same direction of effect in both effect estimates  </p> <p>k. Follow‐up: 2.8 months (median) and 5.3 months</p> <p>l. Inconsistency: downgraded two levels (I² = 100%) </p> <p>m. Imprecision: downgraded one level due to wide CIs that encompass a potential benefit and a potential harm with the intervention. </p> <p>n. Despite inconsistency (I² = 99%), not downgraded for inconsistency, as the same direction of effect in both effect estimates  </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015477-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">CVnCoV – CureVac AG compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with CVnCOV</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1187 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>615 per 100,000</b><br/>(464 to 811) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 48.20</b> </p> <p>(31.70 to 60.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,062<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b><sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>82 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>30 per 100,000</b><br/>(7 to 82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 63.80</b> </p> <p>(0.00 to 91.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,062<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊖⊖⊖<br/><b>Very low</b><sup>d,e,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b><sup>h</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>30 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>40 per 100,000</b><br/>(14 to 116) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.33</b><br/>(0.46 to 3.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39,529<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊖⊖⊖<br/><b>Very low</b><sup>e,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>635 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>940 per 1000</b><br/>(908 to 971) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.48</b><br/>(1.43 to 1.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3982<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>j</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>679 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>965 per 1000</b><br/>(937 to 999) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.42</b><br/>(1.38 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3982<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>k</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>334 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>414 per 100,000</b><br/>(301 to 572) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.24</b><br/>(0.90 to 1.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39,529<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>e,l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b><sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>241 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>847 per 1000</b><br/>(782 to 920) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.51</b><br/>(3.24 to 3.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3982<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 10 May 2022<br/><sup>b</sup>Follow‐up: from 14 days following the second dose to 6.23 months<br/><sup>c</sup>CureVac AG: <a href="./references#CD015477-bbs2-0021" title="KremsnerPG , Ahuad GuerreroRA , Arana-ArriE , Aroca MartinezGJ , BontenM , ChandlerR , et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3, randomized, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3911826]">Kremsner 2021</a> (adults aged 18–98 years)<br/><sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.<br/><sup>e</sup>Indirectness: downgraded one level as data are from interim analyses of the trial and from the available information it is unclear whether these were preplanned.<br/><sup>f</sup>Follow‐up: from seven days following the second dose to six months<br/><sup>g</sup>Imprecision: downgraded two levels due to small number of events observed and wide CIs that encompass a potential benefit and a potential harm with the intervention.<br/><sup>h</sup>Follow‐up: 6.23 months<br/><sup>i</sup>Follow‐up: seven days<br/><sup>j</sup>Follow‐up: one month<br/><sup>k</sup>Follow‐up: 1.7 months<br/><sup>l</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of benefit and the possibility of harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015477-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">ChAdOx1 – AstraZeneca + University of Oxford  compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with ChAdOx1</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3199 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1300 per 100,000</b><br/>(1017 to 1663) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 59.35</b> </p> <p>(48.00 to 68.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43,390<br/>(5 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Substantial heterogeneity (I² = 68%) between included studies: <a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a> (VE 64.35%, 95% CI 56.10% to 71.00%; n = 26,212); <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> (VE 54.10%, 95% CI 44.70% to 61.90%; n = 17,178) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2207 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>657 per 100,000</b><br/>(516 to 836) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 70.23</b> </p> <p>(62.10 to 76.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43,390<br/>(5 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b><sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>52 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>25 per 100,000</b><br/>(10 to 59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.48</b><br/>(0.20 to 1.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56,727<br/>(5 RCTs)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 additional trials (<a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a>; <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>) reported this outcome in 1392 participants (192 ChAdOx1 versus 64 placebo and 900 SII‐ChAdOx1 versus 300 placebo, respectively). There were no events in either group in either trial and they did not contribute to the pooled effect estimate.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>141 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>553 per 1000</b><br/>(297 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.93</b><br/>(2.11 to 7.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>256<br/>(1 RCT)<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>l</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Outcome not pooled due to considerable heterogeneity (I² = 90%) between included studies: <a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a> (RR 2.54, 95% CI 1.73 to 3.74; n = 256); <a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a> (RR 1.37, 95% CI 1.33 to 1.42; n = 32,379); <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a> (RR 1.39, 95% CI 1.12 to 1.74; n = 1200); <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> (RR 0.74, 95% CI 0.56 to 0.96; n = 23,745) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57,580<br/>(7 RCTs)<sup>m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>o</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>794 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>699 per 100,000</b><br/>(572 to 850) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.88</b><br/>(0.72 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58,182<br/>(7 RCTs)<sup>p</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>q</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b><sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>94 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>604 per 1000</b><br/>(279 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 6.44</b><br/>(2.98 to 13.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>256<br/>(1 RCT)<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>k,r</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 4 May 2022<br/><sup>b</sup>Follow‐up: from 14 days after second dose up to 1.34 months (median) and 2 months (median)<br/><sup>c</sup><a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a>; <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> (data from four pooled RCTs)<br/><sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.<br/><sup>e</sup>Inconsistency: downgraded one level (I² = 68%).<br/><sup>f</sup>Follow‐up: 2 months, 4.2 months and 2 months (median)<br/><sup>g</sup><a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a>; <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> (data from four pooled RCTs); <a href="./references#CD015477-bbs2-0026" title="MadhiSA , KoenAL , IzuA , FairlieL , CutlandCL , BaillieV , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomized, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV2021;8(9):e568-80. ">Madhi 2021a</a> (participants with HIV, trial already counted in <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>)<br/><sup>h</sup>Imprecision: downgraded two levels due to small number of events observed and wide CIs that encompass a potential benefit and a potential harm with the intervention.<br/><sup>i</sup>Follow‐up: seven days<br/><sup>j</sup><a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a><br/><sup>k</sup>Imprecision: downgraded one level due to low number of participants/few events observed.<br/><sup>l</sup>Follow‐up: 1 month, 1.16 months, 1.9 months, and 3.4 months<br/><sup>m</sup><a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a>; <a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a>; <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>; <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> (data from four pooled RCTs)<br/><sup>n</sup>Inconsistency: downgraded two levels (I² = 90%).<br/><sup>o</sup>Follow‐up: 1 month, 1.9 months, 6 months, and 3.64 months (median)<br/><sup>p</sup><a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a>; <a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a>; <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>; <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> (data from four pooled RCTs). <a href="./references#CD015477-bbs2-0026" title="MadhiSA , KoenAL , IzuA , FairlieL , CutlandCL , BaillieV , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomized, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV2021;8(9):e568-80. ">Madhi 2021a</a> (participants with HIV, trial already counted in <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>)<br/><sup>q</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of benefit and the possibility of no effect.<br/><sup>r</sup>Despite some concerns with selection of reported results, not downgraded for risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015477-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of Oxford compared to ChAdOx1 – University of Oxford for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with ChAdOx1</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with SII‐ChAdOx1</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 study reported this outcome in 400 participants (<a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>). There were no events in either group and no effect estimate could be calculated.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>390 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>285 per 1000</b><br/>(211 to 382) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.73</b><br/>(0.54 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>200 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>166 per 1000</b><br/>(104 to 266) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.83</b><br/>(0.52 to 1.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>g</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2000 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1000 per 100,000</b><br/>(160 to 5900) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.50</b><br/>(0.08 to 2.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>360 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>274 per 1000</b><br/>(198 to 378) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.76</b><br/>(0.55 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 10 May 2022<br/><sup>b</sup>Follow‐up: seven days<br/><sup>c</sup><a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a><br/><sup>d</sup>Imprecision: downgraded one level due to low number of events/participants.<br/><sup>e</sup>Follow‐up: 1.9 months<br/><sup>f</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit and the possibility of harm and low number of events/participants.<br/><sup>g</sup>Follow‐up: six months<br/><sup>h</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of no effect and the possibility of benefit and low number of events/participants. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015477-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">AD26.COV2.S – Janssen Pharmaceutical Companies compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with AD26.COV2.S</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1796 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>594 per 100,000</b><br/>(478 to 735) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 66.90</b> </p> <p>(59.10 to 73.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39,058<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>409 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>97 per 100,000</b><br/>(51 to 172) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 76.30</b> </p> <p>(57.90 to 87.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39,058<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>91 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>23 per 100,000</b><br/>(8 to 61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.25</b><br/>(0.09 to 0.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43,783<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>448 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 100,000</b><br/>(309 to 546) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.92</b><br/>(0.69 to 1.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43,783<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>34,575 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>63,273 per 100,000</b><br/>(44,602 to 89,896) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.83</b><br/>(1.29 to 2.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7222<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>h</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Outcome not pooled due to considerable heterogeneity (I² = 96%) between included studies: <a href="./references#CD015477-bbs2-0031" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; February 26, 2021; FDA briefing document: Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. www.fda.gov/media/146217/download (accessed prior to 1 November 2022). SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Interim results of a Phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. New England Journal of Medicine2021;384(19):1824-35. SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.09.23.20199604]">Sadoff 2021a</a> (RR 1.09, 95% CI 0.96 to 1.24; n = 6736); <a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a> (RR 2.31, 95% CI 1.80 to 2.97; n = 486) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7222<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>d,i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE</b>: vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 4 May 2022<br/><sup>b</sup>Follow‐up: 1.9 months (median)<br/><sup>c</sup><a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a><br/><sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.<br/><sup>e</sup>Follow‐up: seven days and 14 days<br/><sup>f</sup><a href="./references#CD015477-bbs2-0031" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; February 26, 2021; FDA briefing document: Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. www.fda.gov/media/146217/download (accessed prior to 1 November 2022). SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Interim results of a Phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. New England Journal of Medicine2021;384(19):1824-35. SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.09.23.20199604]">Sadoff 2021a</a>; <a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a><br/><sup>g</sup>Despite I² = 83%, not downgraded for inconsistency, as the same direction of effect in both effect estimates.<br/><sup>h</sup>Follow‐up: 0.23 months and 0.92 months<br/><sup>i</sup>Inconsistency: downgraded two levels (I² = 96%).<br/><sup>j</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of no effect and the possibility of benefit.<br/><sup>k</sup>Follow‐up: seven days<br/><sup>l</sup>Despite I² = 84%, not downgraded for inconsistency, as the same direction of effect in both effect estimates. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015477-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Gam‐COVID‐VAC – Sputnik V compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with Gam‐COVID‐VAC</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1022 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>92 per 100,000</b><br/>(51 to 167) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 91.10</b> </p> <p>(83.80 to 95.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18,695<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>408 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 100,000</b><br/>(0 to 23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 100.00</b> </p> <p>(94.40 to 100.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,866<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b><sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>18 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>18 per 100,000</b><br/>(2 to 176) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.99</b><br/>(0.10 to 9.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21,862<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊖⊖⊖<br/><b>Very low</b><sup>d,e,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>423 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>275 per 100,000</b><br/>(165 to 453) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65</b><br/>(0.39 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21,862<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>d,e,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019; <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 27 May 2022<br/><sup>b</sup>Follow‐up: from seven days after second dose<br/><sup>c</sup><a href="./references#CD015477-bbs2-0025" title="LogunovDY , DolzhikovaIV , ShcheblyakovDV , TukhvatulinAI , ZubkovaOV , DzharullaevaAS , et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia. Lancet2021;397(10275):671-81. ">Logunov 2021</a><br/><sup>d</sup>Indirectness: downgraded one level as data are from interim analyses of the trial and from the available information it is unclear whether these were preplanned.<br/><sup>e</sup>Concern regarding the internal validity of the trial.<br/><sup>f</sup>Follow‐up: 1.6 months (median)<br/><sup>g</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit and the possibility of harm and few events.<br/><sup>h</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of no effect and the possibility of benefit. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015477-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">CoronaVac – Sinovac compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with CoronaVac</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2398 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>724 per 100,000</b><br/>(249 to 2104) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 69.81</b> </p> <p>(12.27 to 89.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,852<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>d,e,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Considerable heterogeneity (I² = 92%) between included studies: <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a> (VE 83.50%, 95% CI 65.40% to 92.10%; n = 10,029); <a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a> (VE 50.70%, 95% CI 35.90 to 62.00%; n = 9823) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>2 studies report on severe or critical disease due to COVID‐19: <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>, with 0/6559 events in the CoronaVac group versus 1/3470 events in the placebo group and a VE of 100%, 95% CI (20.40% to 100.00%); and <a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>, with 0/4953 events in the CoronaVac group and 6/4870 events in the placebo group and a VE of 100%, 95% CI (16.90% to 100.00%). (Note: estimates could not be pooled due to asymmetry in the CIs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,852<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>d,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b><sup>h</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>20 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>10 per 100,000</b><br/>(1 to 113) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.50</b><br/>(0.05 to 5.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22,610<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>j</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>409 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>487 per 1000</b><br/>(409 to 581) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.19</b><br/>(1.00 to 1.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23,966<br/>(6 RCTs)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>l,m,n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>o</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>531 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>579 per 1000</b><br/>(568 to 590) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.09</b><br/>(1.07 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23,367<br/>(6 RCTs)<sup>p</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>q</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>r</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>372 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>361 per 100,000</b><br/>(231 to 562) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.97</b><br/>(0.62 to 1.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23,139<br/>(4 RCTs)<sup>s</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>i,q</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 additional trials (<a href="./references#CD015477-bbs2-0005" title="BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.03.31.21254494]BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile. Clinical Infectious Diseases 2021 Sep 19 [Epub ahead of print]. [DOI: 10.1093/cid/ciab823]">Bueno 2021</a>; <a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a>) reported this outcome in 482 participants (270 versus 164 and 24 versus 24 respectively, receiving CoronaVac versus placebo). There were no events in either group and the trials did not contribute to the pooled effect estimate.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b><sup>j</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>227 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>400 per 1000</b><br/>(384 to 414) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.76</b><br/>(1.69 to 1.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23,962<br/>(6 RCTs)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 4 May 2022<br/><sup>b</sup>Follow‐up: from 14 days after the second dose up to two months (median)<br/><sup>c</sup><a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>; <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a><br/><sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.<br/><sup>e</sup>Inconsistency: downgraded one level (I² = 92%).<br/><sup>f</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of benefit and the possibility of harm.<br/><sup>g</sup>Imprecision: downgraded two levels due to low number of events and wide CIs.<br/><sup>h</sup>Follow‐up: 1.4 and 2 months (median)<br/><sup>i</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit and the possibility of harm and few events.<br/><sup>j</sup>Follow‐up: 7–28 days<br/><sup>k</sup><a href="./references#CD015477-bbs2-0005" title="BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.03.31.21254494]BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile. Clinical Infectious Diseases 2021 Sep 19 [Epub ahead of print]. [DOI: 10.1093/cid/ciab823]">Bueno 2021</a>; <a href="./references#CD015477-bbs2-0012" title="FadlyanaE , RusmilK , TariganR , RahmadiAR , ProdjosoewojoS , SofiatinY , et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: an interim analysis in Indonesia. Vaccine2021;39(44):6520-8. ">Fadlyana 2021</a>; <a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>; <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>; <a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>; <a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a><br/><sup>l</sup>Despite some concerns with adequate randomisation, deviation from intended intervention, missing data, and selection of reported results not downgraded for risk of bias.<br/><sup>m</sup>Inconsistency: downgraded one level (I² = 55%).<br/><sup>n</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of no effect and the possibility of harm.<br/><sup>o</sup>Follow‐up: one to three months (median)<br/><sup>p</sup><a href="./references#CD015477-bbs2-0005" title="BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.03.31.21254494]BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile. Clinical Infectious Diseases 2021 Sep 19 [Epub ahead of print]. [DOI: 10.1093/cid/ciab823]">Bueno 2021</a>; <a href="./references#CD015477-bbs2-0018" title="HanB , SongY , LiC , YangW , MaQ , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(12):1645-53. ">Han 2021</a>; <a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>; <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>; <a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>; <a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a><br/><sup>q</sup>Despite some concerns with adequate randomisation, not downgraded for risk of bias.<br/><sup>r</sup>Follow‐up: 4.1 months, 2 months (median), 3 months (median)<br/><sup>s</sup><a href="./references#CD015477-bbs2-0018" title="HanB , SongY , LiC , YangW , MaQ , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(12):1645-53. ">Han 2021</a>; <a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>; <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>; <a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a> </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015477-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">WIBP‐CorV – Sinopharm‐Wuhan compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with WIBP‐CorV</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>912 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>328 per 100,000</b><br/>(231 to 467) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 64.00</b> </p> <p>(48.80 to 74.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,449<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>746 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>203 per 100,000</b><br/>(131 to 313) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 72.80</b> </p> <p>(58.10 to 82.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,480<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 trial reported on this outcome in 26,917 participants (13,464 WIBP‐CorV versus 13,453 placebo) (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). There were no events in either group and no effect estimate could be calculated for this outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>278 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>275 per 1000</b><br/>(264 to 286) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.99</b><br/>(0.95 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27,029<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>h</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>504 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>484 per 1000</b><br/>(469 to 494) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.96</b><br/>(0.93 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27,029<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>579 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>480 per 100,000</b><br/>(347 to 665) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.83</b><br/>(0.60 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27,029<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>g,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b><sup>k</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>290 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>255 per 1000</b><br/>(247 to 267) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.88</b><br/>(0.85 to 0.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27,029<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 4 May 2022<br/><sup>b</sup>Follow‐up: from 2 weeks after the second dose up to 2.6 months (median)<br/><sup>c</sup><a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a><br/><sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.<br/><sup>e</sup>Follow‐up: seven days and 28 days<br/><sup>f</sup><a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>; <a href="./references#CD015477-bbs2-0016" title="GuoW , DuanK , ZhangY , YuanZ , ZhangYB , WangZ , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 1/2 trial. eClinicalMedicine2021;38:101010. ">Guo 2021</a><br/><sup>g</sup>Despite some concerns with adequate randomisation, not downgraded for risk of bias.<br/><sup>h</sup>Follow‐up: one month<br/><sup>i</sup>Follow‐up: 1.6 and 2.6 months (median)<br/><sup>j</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of no effect and the possibility of benefit and few events.<br/><sup>k</sup>Follow‐up: seven days </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015477-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">BBIBP‐CorV – Sinopharm‐Beijing  compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with BBIBP‐CorV</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>912 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>242 per 100,000</b><br/>(162 to 359) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 73.50</b> </p> <p>(60.60 to 82.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,435<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>746 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>163 per 100,000</b><br/>(102 to 263) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 78.10</b> </p> <p>(64.80 to 86.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,463<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 study reported this outcome in 26,924 participants (13,471 BBIBP‐CorV versus 13,453 placebo) (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). There were no events in either group and no effect estimate could be calculated for this outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>274 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>288 per 1000</b><br/>(236 to 351) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.05</b><br/>(0.86 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27,540<br/>(3 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>h</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>3 studies (n = 27,540) reported any adverse event with 1 month or 2.9 months' follow‐up. 2 of the studies reported an effect estimate in favour of BBIBP‐CorV: 1 with RR 0.91, 95% CI 0.89 to 0.94; n = 26,924; and 1 with CIs crossing the line of no effect (RR 0.83, 95% CI 0.36 to 1.95; n = 112). 1 study reported an effect estimate in favour of placebo with CIs not crossing the line of null effect (RR 2.05, 95% CI 1.47 to 2.87; n = 504)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26,924<br/>(3 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>i,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>k</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>580 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>441 per 100,000</b><br/>(313 to 615) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.76</b><br/>(0.54 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26,924<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 additional study reported this outcome in 112 participants (84 BBIBP‐CorV versus 28 placebo) (<a href="./references#CD015477-bbs2-0040" title="XiaS , DuanK , ZhangY , ZhaoD , ZhangH , XieZ , et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA2020;324(10):951-60. XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infectious Diseases2020;21(1):39-51. ">Xia 2020</a>). There were no events in either group and the trial did not contribute to the effect estimate.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b><sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>3 studies (n = 27,540) reported local adverse events with 7 days' follow‐up. 1 study reported an effect estimate in favour of BBIBP‐CorV: RR 0.71, 95% CI 0.68 to 0.74; n = 26,924. 2 studies reported an effect estimate in favour of placebo with CIs not crossing the line of null effect (RR 10.00, 95% CI 2.36 to 42.34; n = 504 and RR 3.33, 95% CI 0.45 to 24.89; n = 112). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26,924<br/>(3 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>i,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 4 May 2022<br/><sup>b</sup>Follow‐up: from 2 weeks after second dose up to 2.6 months (median)<br/><sup>c</sup><a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a><br/><sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.<br/><sup>e</sup>Follow‐up: seven days<br/><sup>f</sup><a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>; <a href="./references#CD015477-bbs2-0041" title="XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1/2 trial. Lancet Infectious Diseases2021;22(2):196-208. ">Xia 2021</a> (children); <a href="./references#CD015477-bbs2-0040" title="XiaS , DuanK , ZhangY , ZhaoD , ZhangH , XieZ , et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA2020;324(10):951-60. XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infectious Diseases2020;21(1):39-51. ">Xia 2020</a><br/><sup>g</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of no effect and the possibility of harm.<br/><sup>h</sup>Follow‐up: one month and 2.9 months<br/><sup>i</sup>Inconsistency: downgraded one level as studies are not pooled, effect estimates and direction of effect inconsistent between included studies.<br/><sup>j</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of benefit and the possibility of harm.<br/><sup>k</sup>Follow‐up: 2.6 months (median)<br/><sup>l</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of no effect and the possibility of benefit and few events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015477-tbl-0011"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">BBV152 – Bharat Biotech compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with BBV152 </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1841 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>575 per 100,000</b><br/>(322 to 982) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 68.80</b> </p> <p>(46.70 to 82.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6289<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1247 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>277 per 100,000</b><br/>(170 to 434) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 77.80</b> </p> <p>(65.20 to 86.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16,973<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>176 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>12 per 100,000</b><br/>(0 to 76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 93.40</b> </p> <p>(57.10 to 99.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16,976<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b><sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>78 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>39 per 100,000</b><br/>(13 to 113) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.50</b><br/>(0.17 to 1.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,753<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>g</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>26 per 1000</b><br/>(23 to 31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.34</b><br/>(1.15 to 1.58) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,925<br/>(2 RCTs)<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>124 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>124 per 1000</b><br/>(117 to 133) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.00</b><br/>(0.94 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,753<br/>(1 RCT)<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>463 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>301 per 100,000</b><br/>(199 to 449) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.65</b><br/>(0.43 to 0.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,928<br/>(1 RCT)<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 additional trial reported this outcome in 175 participants (100 BBV152 versus 75 placebo) (<a href="./references#CD015477-bbs2-0008" title="EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. A Phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.12.11.20210419]EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomized, phase 1 trial. Lancet Infectious Diseases2021;21(5):637-46. ">Ella 2021a</a>). There were no events in either group and the trial did not contribute to the pooled effect estimate.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b><sup>g</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>31 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>34 per 1000</b><br/>(30 to 39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.08</b><br/>(0.95 to 1.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,750<br/>(2 RCTs)<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 4 May 2022<br/><sup>b</sup>Follow‐up: from two weeks after second dose to 3.3 months (median)<br/><sup>c</sup><a href="./references#CD015477-bbs2-0008" title="EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. A Phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.12.11.20210419]EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomized, phase 1 trial. Lancet Infectious Diseases2021;21(5):637-46. ">Ella 2021a</a><br/><sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.<br/><sup>e</sup>Follow‐up: 3.3 months (median)<br/><sup>f</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit and the possibility of harm and low number of events.<br/><sup>g</sup>Follow‐up: seven days<br/><sup>h</sup><a href="./references#CD015477-bbs2-0008" title="EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. A Phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.12.11.20210419]EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomized, phase 1 trial. Lancet Infectious Diseases2021;21(5):637-46. ">Ella 2021a</a>; <a href="./references#CD015477-bbs2-0009" title="EllaR , ReddyS , BlackwelderW , PotdarV , YadavP , SarangiV , et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.06.30.21259439]">Ella 2021b</a><br/><sup>i</sup>Follow‐up: 4.9 months (median)<br/><sup>j</sup><a href="./references#CD015477-bbs2-0009" title="EllaR , ReddyS , BlackwelderW , PotdarV , YadavP , SarangiV , et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.06.30.21259439]">Ella 2021b</a> </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015477-tbl-0012"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">NVX‐CoV2373 – Novavax compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with NVX‐CoV2373</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1140 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>195 per 100,000</b><br/>(67 to 564) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 82.91</b> </p> <p>(50.49 to 94.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42,175<br/>(3 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Substantial heterogeneity (I² = 65%) between included studies: <a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a> (VE 90.40%, 95% CI 82.88 to 94.62%; n = 25,452); <a href="./references#CD015477-bbs2-0019" title="HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine2021;385(13):1172-83. HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant. medRxiv 2021 [Preprint]. ">Heath 2021</a> (VE 89.70%, 95% CI 80.20% to 94.60%; n = 14,039); <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a> (VE 49.40%, 95% CI 6.10% to 72.80%; n = 2684) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>172 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 100,000</b><br/>(0 to 22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 100.00</b><br/>(86.99 to 100.00) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,452<br/>(1 RCT)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>d,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b><sup>h</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>51 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>46 per 100,000</b><br/>(15 to 136) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.90</b> (0.30 to 2.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29,582<br/>(1 RCT)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>d,i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 additional study reported on this outcome in 14,039 participants (7020 NVX‐CoV2373 versus 7019 placebo) (<a href="./references#CD015477-bbs2-0019" title="HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine2021;385(13):1172-83. HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant. medRxiv 2021 [Preprint]. ">Heath 2021</a>). There were no events in either group and the trial did not contribute to the pooled effect estimate.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>j</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>363 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>439 per 1000</b><br/>(425 to 454) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.21</b><br/>(1.17 to 1.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31,063<br/>(3 RCTs)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>m</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>173 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>199 per 1000</b><br/>(182 to 218) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.15</b><br/>(1.05 to 1.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46,231<br/>(5 RCTs)<sup>n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>l,o</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Substantial heterogeneity (I² = 57%) between the 5 included studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>m</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>777 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>715 per 100,000</b><br/>(575 to 886) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.92</b><br/>(0.74 to 1.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38,802<br/>(4 RCTs)<sup>p</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>i,q</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 additional trial reported on this outcome in 52 participants (29 NVX‐CoV2373 versus 23 placebo)  (<a href="./references#CD015477-bbs2-0020" title="KeechC , AlbertG , ChoI , RobertsonA , ReedP , NealS , et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. New England Journal of Medicine 2020;383:2320-32. ">Keech 2020</a>). There were no events in either group and the trial did not contribute to the pooled effect estimate.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b><sup>j</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>191 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>532 per 1000</b><br/>(381 to 742) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.78</b><br/>(1.99 to 3.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31,063<br/>(3 RCTs)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>l,r</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 2 June 2022<br/><sup>b</sup>Follow‐up: from seven days after second dose up to three months (median)<br/><sup>c</sup><a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>; <a href="./references#CD015477-bbs2-0019" title="HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine2021;385(13):1172-83. HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant. medRxiv 2021 [Preprint]. ">Heath 2021</a>; <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a><br/><sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.<br/><sup>e</sup>Inconsistency: downgraded one level (I² = 65%).<br/><sup>f</sup><a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a><br/><sup>g</sup>Indirectness: downgraded one level as outcome in this trial included participants with moderate severity.<br/><sup>h</sup>Follow‐up: two months (median)<br/><sup>i</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit and the possibility of harm and few events.<br/><sup>j</sup>Follow‐up: seven days<br/><sup>k</sup><a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>; <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a>; <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a><br/><sup>l</sup>Despite some concerns with adequate randomisation and missing data, not downgraded for risk of bias.<br/><sup>m</sup>Unsolicited adverse events, follow‐up to three months (median)<br/><sup>n</sup><a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>; <a href="./references#CD015477-bbs2-0014" title="FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. PLOS Medicine2021;18(10):e1003769. FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.26.21252482]">Formica 2021</a>; <a href="./references#CD015477-bbs2-0019" title="HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine2021;385(13):1172-83. HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant. medRxiv 2021 [Preprint]. ">Heath 2021</a>; <a href="./references#CD015477-bbs2-0020" title="KeechC , AlbertG , ChoI , RobertsonA , ReedP , NealS , et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. New England Journal of Medicine 2020;383:2320-32. ">Keech 2020</a>; <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a><br/><sup>o</sup>Inconsistency: downgraded one level (I² = 57%).<br/><sup>p</sup><a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>; <a href="./references#CD015477-bbs2-0014" title="FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. PLOS Medicine2021;18(10):e1003769. FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.26.21252482]">Formica 2021</a>; <a href="./references#CD015477-bbs2-0019" title="HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine2021;385(13):1172-83. HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant. medRxiv 2021 [Preprint]. ">Heath 2021</a>; <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a><br/><sup>q</sup>Despite some concerns with adequate randomisation, deviation from intended intervention and missing data, not downgraded for risk of bias.<br/><sup>r</sup>Despite I² = 86%, not downgraded for inconsistency, as the same direction of effect in both effect estimates. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015477-tbl-0013"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">FINLAY‐FR‐2 – Instituto Finlay de Vacunas compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with FINLAY‐FR‐2</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1084 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>314 per 100,000</b><br/>(226 to 445) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 71.00</b> </p> <p>(58.90 to 79.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28,674<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b><sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>168 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>62 per 100,000</b><br/>(29 to 134) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.37</b><br/>(0.17 to 0.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28,674<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 6 May 2022<br/><sup>b</sup>Follow‐up: from seven days after second dose up to three months (median)<br/><sup>c</sup><a href="./references#CD015477-bbs2-0036" title="Toledo-RomaniME , Garcia-CarmenateM , Silva-ValenzuelaC , Baldoquin-RodriguezW , Martínez-PérezM , Rodríguez-GonzálezM , et al. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomized, placebo-controlled phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.31.21265703]">Toledo‐Romani 2021</a><br/><sup>d</sup>Risk of bias downgraded one level: some concerns regarding adequate randomisation and deviation from intended intervention.<br/><sup>e</sup>Follow‐up: 1.7 months (median) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015477-tbl-0014"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 14.</span> <span class="table-title">Heterologous vaccination scheme compared to homologous vaccination scheme for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with homologous vaccination scheme</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with heterologous vaccination scheme</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>60 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>118 per 1000</b><br/>(31 to 445) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.96</b><br/>(0.52 to 7.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>3 studies (n = 564) that compared heterologous versus homologous vaccination schemes reported any adverse event with 1 or 2 months' follow‐up. 2 of the studies reported an effect estimate in favour of homologous scheme but with CIs crossing the line of no effect (RR 1.21, 95% CI 0.87 to 1.68; n = 234; and RR 1.03, 95% CI 0.75 to 1.43; n = 229). 1 study reported an effect estimate in favour of homologous scheme with CIs not crossing the line of null effect (RR 3.19, 95% CI 1.11 to 9.11; n = 101) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(3 RCTs)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊖⊖⊖<br/><b>Very low</b><sup>h,i,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>k</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>1 study (<a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>: ChAdOx1/BNT162b2 versus ChAdOx1/ChAdOx1) that compared heterologous versus homologous vaccination schemes reported no serious adverse events in the heterologous scheme (0/114) versus 1 serious adverse event (1/115) in the homologous scheme (RR 0.34, 95% CI 0.01 to 8.17). 2 more studies reported the outcome, with 0 events in both groups: <a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>: CoronaVac/Ad5 versus CoronaVac/CoronaVac in n = 51 versus n = 50 and <a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>: BNT162b2/ChAdOx1 versus BNT162b2/BNT162b2 in n = 115 versus n = 119 respectively, in heterologous versus homologous scheme </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>229<br/>(1 RCT)<sup>l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊖⊖⊖<br/><b>Very low</b><sup>h,m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>235 per 1000</b><br/>(32 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 11.76</b><br/>(1.59 to 87.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>d,n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 4 May 2022<br/><sup>b</sup>Follow‐up: 28 days<br/><sup>c</sup><a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>: CoronaVac/Ad5 versus CoronaVac/CoronaVac<br/><sup>d</sup>Despite some concerns with deviation from intended intervention, not downgraded for risk of bias.<br/><sup>e</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit for heterologous and benefit for homologous vaccination scheme and the low number of events/participants.<br/><sup>f</sup>Follow‐up: one and two months<br/><sup>g</sup><a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>: CoronaVac/Ad5 versus CoronaVac/CoronaVac; <a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>: BNT162b2/ChAdOx1 versus BNT162b2/BNT162b2; <a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>: ChAdOx1/BNT162b2 versus ChAdOx1/ChAdOx1<br/><sup>h</sup>Risk of bias downgraded one level: some concerns regarding outcome measurement.<br/><sup>i</sup>Inconsistency: downgraded one level as studies are not pooled, effect estimates and direction of effect inconsistent between included studies.<br/><sup>j</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of no effect and benefit for homologous vaccination scheme and the low number of events/participants.<br/><sup>k</sup>Follow‐up: one month<br/><sup>l</sup><a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>: ChAdOx1/BNT162b2 versus ChAdOx1/ChAdOx1<br/><sup>m</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit for the heterologous and benefit for homologous vaccination scheme and the low number of events/participants.<br/><sup>n</sup>Imprecision: downgraded two levels due to very few events or participants (or both). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015477-tbl-0015"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 15.</span> <span class="table-title">Booster compared to placebo/no booster for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo/no booster</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with booster</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>63 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>80 per 100,000</b><br/>(33 to 191) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.27</b><br/>(0.52 to 3.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28,254<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊖⊖⊖<br/><b>Very low</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>102 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>183 per 1000</b><br/>(72 to 464) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.80</b><br/>(0.71 to 4.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119<br/>(1 RCT)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b><sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>119 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>766 per 1000</b><br/>(377 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 6.46</b><br/>(3.18 to 13.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119<br/>(1 RCT)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 4 May 2022<br/><sup>b</sup>Follow‐up: 1.7 months (median)<br/><sup>c</sup><a href="./references#CD015477-bbs2-0036" title="Toledo-RomaniME , Garcia-CarmenateM , Silva-ValenzuelaC , Baldoquin-RodriguezW , Martínez-PérezM , Rodríguez-GonzálezM , et al. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomized, placebo-controlled phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.31.21265703]">Toledo‐Romani 2021</a>: FINLAY‐FR‐2/booster FR‐1 versus FINLAY‐FR‐2<br/><sup>d</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit and the possibility of harm and few events.<br/><sup>e</sup>Risk of bias downgraded one level: some concerns regarding adequate randomization and deviation from intended intervention.<br/><sup>f</sup>Follow‐up: seven days<br/><sup>g</sup><a href="./references#CD015477-bbs2-0017" title="HallVG , FerreiraVH , KuT , IerulloM , Majchrzak-KitaB , ChaparroC , et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. New England Journal of Medicine2021;385(13):1244-6. ">Hall 2021</a>: mRNA‐1273 booster versus placebo (solid organ transplant recipients).<br/><sup>h</sup>Imprecision: downgraded one level due to low number of participants. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD015477-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD015477-sec-0009"></div> <section id="CD015477-sec-0010"> <h3 class="title" id="CD015477-sec-0010">Description of the condition</h3> <p>In December 2019, a novel coronavirus, severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) outbreak began in Wuhan, Hubei Province, China. SARS‐CoV‐2 began to spread worldwide, and on 11 March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID‐19) a pandemic (<a href="./references#CD015477-bbs2-0164" title="World Health Organization. Coronavirus disease 2019 (COVID-19). Situation report – 51. apps.who.int/iris/handle/10665/331475 (accessed prior to 1 November 2022).">WHO 2020a</a>). </p> <p>In many countries, the number of cases increased exponentially during the first and subsequent waves (<a href="./references#CD015477-bbs2-0170" title="Worldometer. COVID-19 coronavirus pandemic. www.worldometers.info/coronavirus/#countries (accessed prior to 1 November 2022).">Worldometer 2022</a>). The clinical spectrum of COVID‐19 ranges from mild to critical, and approximately 15% to 30% of patients infected with the wild‐type variant of SARS‐CoV‐2 experienced acute respiratory distress syndrome (<a href="./references#CD015477-bbs2-0056" title="AttawayAH , ScheragaRG , BhimrajA , BiehlM , HatipoğluU . Severe Covid-19 pneumonia: pathogenesis and clinical management. BMJ2021;372:n436.">Attaway 2021</a>). Persons with underlying conditions and weakened immune systems were at higher risk of becoming severely sick (<a href="./references#CD015477-bbs2-0014" title="FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. PLOS Medicine2021;18(10):e1003769. FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.26.21252482]">Formica 2021</a>).  </p> <p>Further, genetic variants of SARS‐CoV‐2 have been emerging and circulating at a global level: B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta) variants, and more recently B.1.1.529 (Omicron) (<a href="./references#CD015477-bbs2-0167" title="World Health Organization. Tracking SARS-CoV-2 variants. www.who.int/activities/tracking-SARS-CoV-2-variants (accessed prior to 1 November 2022).">WHO 2022a</a>). Consequently, the WHO has developed a definition of variants of concern for molecular surveillance (<a href="./references#CD015477-bbs2-0167" title="World Health Organization. Tracking SARS-CoV-2 variants. www.who.int/activities/tracking-SARS-CoV-2-variants (accessed prior to 1 November 2022).">WHO 2022a</a>). </p> <p>Intensive research and development of vaccines is currently underway to curtail the pandemic and prevent disease outbreaks that could overwhelm health systems worldwide (<a href="./references#CD015477-bbs2-0158" title="vanRielD , deWitE . Next-generation vaccine platforms for COVID-19. Nature Materials2020;19(8):810-2.">van Riel 2020</a>; <a href="./references#CD015477-bbs2-0168" title="World Health Organization. COVID-19 vaccine tracker and landscape. www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (accessed prior to 1 November 2022).">WHO 2022b</a>). </p> </section> <section id="CD015477-sec-0011"> <h3 class="title" id="CD015477-sec-0011">Description of the intervention</h3> <p>Vaccines exploit the ability of the immune system to respond to and remember encounters with pathogenic antigens. COVID‐19 vaccine development, aimed at conferring protection against infection, or symptomatic disease, or both, has been accelerated due to priority funding over other diseases. </p> <p>Different vaccine platform technologies (i.e. technologies that have in common the use of a ‘backbone’ carrier or vector) are being, and have been tested: live attenuated virus vaccines or inactivated virus vaccines (either inactivated whole or altered pathogens); protein‐based vaccines (protein subunits or virus‐like particles); viral vector vaccines (non‐replicating viral vector, replicating viral vector); and nucleic acid‐based vaccines (DNA‐ and RNA‐based vaccines)(<a href="./references#CD015477-bbs2-0054" title="AbbasiJ . COVID-19 and mRNA vaccines – first large test for a new approach. JAMA2020;324(12):1125-7.">Abbasi 2020</a>).  </p> <p>Vaccines may be categorized as either live or non‐live (<a href="./references#CD015477-bbs2-0066" title="Centers for Disease Control and Prevention. Understanding mRNA COVID-19 vaccines. www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html (accessed prior to 1 November 2022).">CDC 2021</a>), distinguishing those vaccines that contain an attenuated (live) form of the pathogen from those that harbour the killed (inactivated, non‐live) version of the pathogen. Non‐live vaccines predominantly induce humoral immunity, whereas live vaccines create a robust cellular and humoral response. The present review includes 12 vaccines within four different non‐live vaccine platform technologies. </p> <p> <ul id="CD015477-list-0001"> <li> <p>Inactivated virus vaccines</p> <ul id="CD015477-list-0002"> <li> <p>CoronaVac</p> </li> <li> <p>WIBP‐CorV</p> </li> <li> <p>BBIBP‐CorV</p> </li> <li> <p>BBV152</p> </li> </ul> </li> <li> <p>Protein subunit vaccines</p> <ul id="CD015477-list-0003"> <li> <p>NVX‐CoV2373</p> </li> <li> <p>FINLAY‐FR‐2</p> </li> </ul> </li> <li> <p>Viral vector (non‐replicating) vaccines</p> <ul id="CD015477-list-0004"> <li> <p>ChAdOx1</p> </li> <li> <p>Ad26.COV2.S</p> </li> <li> <p>Gam‐COVID‐Vac</p> </li> </ul> </li> <li> <p>Nucleic acid‐based (RNA) vaccines</p> <ul id="CD015477-list-0005"> <li> <p>BNT162b2</p> </li> <li> <p>mRNA‐1273</p> </li> <li> <p>CVnCoV</p> </li> </ul> </li> </ul> </p> </section> <section id="CD015477-sec-0012"> <h3 class="title" id="CD015477-sec-0012">How the intervention might work</h3> <p>Vaccines aim to generate an immune response that prevents SARS‐CoV‐2 infection or reduces the risk of severe disease or death. </p> <section id="CD015477-sec-0013"> <h4 class="title">Live attenuated virus vaccines</h4> <p>Live attenuated virus vaccines use a weakened form of the virus and are developed so that in an immunocompetent host, they replicate sufficiently to generate a robust immune response (<a href="./references#CD015477-bbs2-0134" title="PollardAJ , BijkerEM . A guide to vaccinology: from basic principles to new developments. Nature Reviews Immunology2021;21(2):83-100.">Pollard 2021</a>). Live attenuated vaccines may potentially replicate in an uncontrolled manner in immunosuppressed individuals, thus rendering them less suitable for use within this population (<a href="./references#CD015477-bbs2-0144" title="RubinLG , LevinMJ , LjungmanP , DaviesEG , AveryR , TomblynM , et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromized host. Clinical Infectious Diseases2013;58(3):e44-e100.">Rubin 2013</a>). </p> </section> <section id="CD015477-sec-0014"> <h4 class="title">Inactivated virus vaccines</h4> <p>In contrast, inactivated vaccines contain either inactivated whole or altered pathogens, thus precluding their replication; however, inactivated vaccines do not always induce as strong or long‐lasting an immune response as live attenuated vaccines. </p> <p>Inactivated virus technologies present multiple viral proteins for immune recognition. They have a stable expression of conformation‐dependent antigenic epitopes (<a href="./references#CD015477-bbs2-0142" title="RoperRL , RehmKE . SARS vaccines: where are we?Expert Review of Vaccines2009;8(7):887-98.">Roper 2009</a>). Pitfalls include their potential to alter viral epitopes, which may adversely affect immunogenicity if the native structure of the viral antigen is not maintained (<a href="./references#CD015477-bbs2-0075" title="DeZureAD , BerkowitzNM , GrahamBS , LedgerwoodJE . Whole-inactivated and virus-like particle vaccine strategies for chikungunya virus. Journal of Infectious Diseases2016;214(Suppl 5):S497-9.">DeZure 2016</a>). As a result, the administration of multiple doses, booster injections, or adjuvant addition is often needed to elicit protective humoral immune responses(<a href="./references#CD015477-bbs2-0134" title="PollardAJ , BijkerEM . A guide to vaccinology: from basic principles to new developments. Nature Reviews Immunology2021;21(2):83-100.">Pollard 2021</a>). </p> <p><i>Protein subunit vaccines</i> are composed of fragments of the virus. Akin to inactivated whole‐cell vaccines, protein subunit vaccines do not harbour live components of the pathogen. They are distinguished from inactivated whole‐cell vaccines by containing only the necessary antigenic parts of the pathogen for mounting a protective immune response. As the subunit vaccine only relies on the antigen of interest made using recombinant technology, it is considered a more reliable and safer technique than inactivated vaccines(<a href="./references#CD015477-bbs2-0077" title="DongY , DaiT , WeiY , ZhangL , ZhengM , ZhouF . A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy2020;5(1):237.">Dong 2020</a>). Nevertheless, this advantage may be offset by its inability to display the virus's full antigenic complexity. This may cause an unbalanced immune response and lower its protective effect (<a href="./references#CD015477-bbs2-0081" title="EnjuanesL , ZuñigaS , Castaño-RodriguezC , Gutierrez-AlvarezJ , CantonJ , SolaI . Molecular basis of coronavirus virulence and vaccine development. Advances in Virus Research2016;96:245-86.">Enjuanes 2016</a>). Consequently, adjuvants may be required to boost immune responses and increase immunogenicity.  </p> <p>Several other platforms have developed over the past few decades. These include virus‐like particles, viral vectors, nucleic acid‐based RNA and DNA vaccines (<a href="./references#CD015477-bbs2-0134" title="PollardAJ , BijkerEM . A guide to vaccinology: from basic principles to new developments. Nature Reviews Immunology2021;21(2):83-100.">Pollard 2021</a>), all of which have been employed in COVID‐19 vaccine development.  </p> <p><i>Virus‐like particle (VLP) vaccines</i> contain virus‐like particles which closely resemble viruses, but are non‐infectious as they contain no viral genetic material (<a href="./references#CD015477-bbs2-0126" title="Oxford Vaccine Group. Vaccine Knowledge Project: independent information about vaccines and infectious diseases. vk.ovg.ox.ac.uk/vk (accessed prior to 1 November 2022).">Oxford Vaccine Group 2020</a>). This platform has been used against hepatitis B and human papillomavirus (HPV), and constitutes another protein‐based vaccine composed of proteins from the viral capsid (<a href="./references#CD015477-bbs2-0091" title="FuenmayorJ , GòdiaF , CerveraL . Production of virus-like particles for vaccines. New Biotechnology2017;39(Pt B):174-80.">Fuenmayor 2017</a>). VLP vaccines consist of self‐assembled viral structural proteins that mimic the conformation of native SARS‐CoV virions (<a href="./references#CD015477-bbs2-0119" title="MortolaE , RoyP . Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system. FEBS Letters2004;576(1-2):174-8.">Mortola 2004</a>), making them immunogenic and inducing highly neutralizing‐antibody titres. In light of their non‐replicating and non‐infectious constructs, VLPs may have an enhanced safety profile.  </p> <p>Unlike previous vaccines, viral vectors and nucleic acid‐based RNA and DNA vaccines do not contain antigens, but rather nucleic acid sequences (RNA or DNA) that code for the proteins of interest inside the organism (<a href="./references#CD015477-bbs2-0134" title="PollardAJ , BijkerEM . A guide to vaccinology: from basic principles to new developments. Nature Reviews Immunology2021;21(2):83-100.">Pollard 2021</a>). </p> <section id="CD015477-sec-0015"> <h5 class="title">Viral vector vaccines </h5> <p>They differ from most conventional vaccines because they do not contain antigens (<a href="./references#CD015477-bbs2-0092" title="Gavi. What are viral vector-based vaccines and how could they be used against COVID-19?www.gavi.org/vaccineswork/what-are-viral-vector-based-vaccines-and-how-could-they-be-used-against-covid-19 (accessed prior to 1 November 2022).">Gavi 2020</a>). They are generally constructed from a carrier virus, such as an adeno‐ or pox‐virus, and are engineered to carry the key target for COVID‐19 vaccines (<a href="./references#CD015477-bbs2-0077" title="DongY , DaiT , WeiY , ZhangL , ZhengM , ZhouF . A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy2020;5(1):237.">Dong 2020</a>). Whilst vector vaccines confer the key advantage of including the innate immune responses required for eliciting adaptive immune responses, a potential disadvantage is that the host may already possess immunity against the vector due to prior exposure, thus reducing its effect (<a href="./references#CD015477-bbs2-0134" title="PollardAJ , BijkerEM . A guide to vaccinology: from basic principles to new developments. Nature Reviews Immunology2021;21(2):83-100.">Pollard 2021</a>). However, this disadvantage does not exist for all vectors. If the anti‐vector response is likely to interfere with the efficacy induced by adenovirus vectors widely used for SARS‐CoV‐2 vaccines, this is not the case with Pox virus vectors (<a href="./references#CD015477-bbs2-0077" title="DongY , DaiT , WeiY , ZhangL , ZhengM , ZhouF . A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy2020;5(1):237.">Dong 2020</a>). </p> </section> <section id="CD015477-sec-0016"> <h5 class="title">Nucleic acid‐based vaccine – mRNA vaccine </h5> <p>Whilst mRNA vaccines are considered a new type of vaccine (<a href="./references#CD015477-bbs2-0066" title="Centers for Disease Control and Prevention. Understanding mRNA COVID-19 vaccines. www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html (accessed prior to 1 November 2022).">CDC 2021</a>), this platform has garnered interest among researchers for decades. The mechanism of action of mRNA vaccines is to instruct cells how to make a protein that may trigger an immune response (<a href="./references#CD015477-bbs2-0066" title="Centers for Disease Control and Prevention. Understanding mRNA COVID-19 vaccines. www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html (accessed prior to 1 November 2022).">CDC 2021</a>). mRNA translation occurs in the host cell's cytosol, circumventing the risk of integration into the host genome (<a href="./references#CD015477-bbs2-0066" title="Centers for Disease Control and Prevention. Understanding mRNA COVID-19 vaccines. www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html (accessed prior to 1 November 2022).">CDC 2021</a>). Like viral vectors, mRNA vaccines induce dendritic cell sensing – mRNA can stimulate TLR7, thus avoiding the use of adjuvants. Like viral vectors, attenuated vaccines and DNA vaccines, these vaccines can induce a CD8 T cell response. Finally, RNAs rapidly destroy mRNAs in the extracellular medium; these vaccines must be encapsulated. </p> </section> <section id="CD015477-sec-0017"> <h5 class="title">Nucleic acid‐based vaccine – DNA vaccine </h5> <p>DNA vaccine candidates function by injecting a plasmid containing the DNA sequence encoding a SARS‐CoV‐2 antigen which will stimulate the immune response. Due to the biocompatibility of plasmid DNA, their cost‐efficient production and long shelf life, DNA vaccine‐based immunotherapeutic strategies have been developed for treatment of infections (<a href="./references#CD015477-bbs2-0102" title="HobernikD , BrosM . DNA vaccines – how far from clinical use?International Journal of Molecular Sciences2018;19(11):3605.">Hobernik 2018</a>). However, their disadvantage is that the DNA molecules must cross the nuclear membrane to be transcribed, and they generally have low immunogenicity (<a href="./references#CD015477-bbs2-0077" title="DongY , DaiT , WeiY , ZhangL , ZhengM , ZhouF . A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy2020;5(1):237.">Dong 2020</a>). </p> <p>These vaccines are used systemically (usually intramuscular injection), but mucosal SARS‐CoV‐2 vaccines are under development. This type of vaccine is predicted to have a better efficacy against infection. Apart from COVID‐19, only one vaccine used via the nasal route has been approved to date: an attenuated vaccine against the influenza virus. </p> </section> </section> </section> <section id="CD015477-sec-0018"> <h3 class="title" id="CD015477-sec-0018">Why it is important to do this review</h3> <p>Given the importance to global health and the increasing number of vaccine candidates now being tested in phase 2 and phase 3 trials, there is a need to produce and maintain a living synthesis of the efficacy and safety of COVID‐19 vaccines. </p> <p>This review is part of a larger project: the COVID‐NMA initiative (<a href="./references#CD015477-bbs2-0060" title="BoutronI , ChaimaniA , MeerpohlJJ , HróbjartssonA , DevaneD , RadaG , et al. The COVID-NMA Project: building an evidence ecosystem for the COVID-19 pandemic. Annals of Internal Medicine2020;173(12):1015-7.">Boutron 2020a</a>). The COVID‐NMA initiative provides decision‐makers with a complete, high‐quality, and up‐to‐date mapping and synthesis of evidence on interventions for preventing and treating COVID‐19. We developed a master protocol on the effect of all interventions for preventing and treating COVID‐19 (<a href="./references#CD015477-bbs2-0061" title="BoutronI , ChaimaniA , MeerpohlJJ , HróbjartssonA , DevaneD , RadaG , et al. Interventions for preventing and treating COVID-19: protocol for a living mapping of research and a living systematic review. Cochrane Database of Systematic Reviews2020, Issue 11. Art. No: CD013769. [DOI: 10.1002/14651858.CD013769]">Boutron 2020b</a>), followed by specific protocols for more specific questions. Our results are made available and updated bi‐weekly on the COVID‐NMA platform at <a href="https://covid-nma.com/" target="_blank">covid-nma.com</a>.  </p> <p>We followed the PRISMA guidelines (<a href="./references#CD015477-bbs2-0127" title="PageMJ , McKenzieJE , BossuytPM , BoutronI , HoffmannTC , MulrowCD , et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021;372:n71.">Page 2021</a>). The protocol is available at <a href="https://zenodo.org/record/6458272" target="_blank">doi.org/10.5281/zenodo.6458272</a> and registered on PROSPERO (<a href="https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021271897" target="_blank">www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021271897</a>). It was peer‐reviewed and processed by Cochrane's Central Editorial Service.  </p> <p>This review will be updated as soon as new evidence changes the conclusions or certainty of the evidence of the review, or at least twice a year if no substantial changes occur. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD015477-sec-0019" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD015477-sec-0019"></div> <p>To assess the efficacy and safety of COVID‐19 vaccines (as a full primary vaccination series or as a booster dose) against SARS‐CoV‐2. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD015477-sec-0020" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD015477-sec-0020"></div> <section id="CD015477-sec-0021"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD015477-sec-0022"> <h4 class="title">Types of studies</h4> <p>We included parallel individually or cluster‐randomized controlled trials (RCTs) evaluating COVID‐19 vaccines in humans with no restrictions on language. Single‐arm studies, non‐randomized studies, and modelling studies of interventions for COVID‐19 were not eligible to be included in the review.  </p> </section> <section id="CD015477-sec-0023"> <h4 class="title">Types of participants</h4> <p>We included individuals with no restriction on age and comorbidities, irrespective of their serological status at baseline. </p> </section> <section id="CD015477-sec-0024"> <h4 class="title">Types of interventions</h4> <p>Eligible interventions included any COVID‐19 vaccines, particularly:</p> <p> <ul id="CD015477-list-0006"> <li> <p>live attenuated virus vaccine;</p> </li> <li> <p>inactivated virus vaccine;</p> </li> <li> <p>protein subunit vaccine;</p> </li> <li> <p>virus‐like particle (VLP) vaccine;</p> </li> <li> <p>non‐replicating viral vector (e.g. recombinant adenovirus) vaccine;</p> </li> <li> <p>replicating viral vector vaccine;</p> </li> <li> <p>RNA‐based vaccine.</p> </li> <li> <p>DNA‐based vaccine; </p> </li> <li> <p>Other vaccine types for COVID‐19, if any.</p> </li> </ul> </p> <p>In the analysis, we included only results for vaccine candidates with a selected dose evaluated in phases 2‐3 or phase 3 trials and their corresponding early phases.  </p> <p>Comparators included placebo (placebo could consist of saline placebo, injecting only the vaccine adjuvant or injecting a vaccine protecting against other diseases, such as meningococcal conjugate vaccine), no vaccine, or another COVID‐19 vaccine. </p> </section> <section id="CD015477-sec-0025"> <h4 class="title">Types of outcome measures</h4> <p>Our outcomes were identified with content experts, considering the outcomes most frequently evaluated in the registered RCTs, and after consulting the main outcomes recommended by the US Food and Drug Administration (FDA) guidance for developing a vaccine (<a href="./references#CD015477-bbs2-0083" title="Food and Drug Administration. Development and licensure of vaccines to prevent COVID-19. Guidance for industry; June 2020. www.fda.gov/media/139638/download (accessed prior to 1 November 2022).">FDA 2020a</a>). </p> <section id="CD015477-sec-0026"> <h5 class="title">Efficacy outcomes</h5> <p> <ul id="CD015477-list-0007"> <li> <p>Incidence of confirmed SARS‐CoV‐2 infection after complete vaccination (all doses of the primary vaccination schedule)*  </p> </li> <li> <p>Incidence of confirmed symptomatic COVID‐19 after complete vaccination</p> </li> <li> <p>Severe or critical COVID‐19 after complete vaccination, as reported by authors (a table summarising the definitions used in each study can be found in <a href="./appendices#CD015477-sec-0301">Appendix 1</a>) </p> </li> <li> <p>All‐cause mortality </p> </li> </ul> </p> <p><i>*confirmed by reverse transcription polymerase chain reaction (RT‐PCR), nucleic acid amplification testing (NAAT), or any other validated test.</i> </p> </section> <section id="CD015477-sec-0027"> <h5 class="title">Safety outcomes</h5> <p> <ul id="CD015477-list-0008"> <li> <p>Incidence of systemic reactogenicity events (i.e. the immediate short‐term reactions of a system to vaccines mainly due to immunological responses, such as fever) reported at day 14 after first dose. </p> </li> </ul> </p> <p>When the number of participants with at least one systemic reactogenicity event is not reported, we used proxy measures as follows. </p> <p> <ul id="CD015477-list-0009"> <li> <p>For adults: the number of participants with malaise as first choice, headache as second choice, and fever 37.5 °C or greater as third choice;  </p> </li> <li> <p>For children: irritability as first choice, decreased activity/weakness as second choice, and fever 37.5 °C or greater as third choice.  </p> </li> <li> <p>Incidence of any adverse event (including non‐serious adverse events). We considered any adverse event reported by authors, prioritizing 'solicited' adverse events. However, when these were not available, we collected 'unsolicited' adverse events. </p> </li> <li> <p>Incidence of any serious adverse events (SAEs) as reported by authors (a table reporting the definitions used in each study can be found in <a href="./appendices#CD015477-sec-0301">Appendix 1</a>). </p> </li> </ul> </p> </section> <section id="CD015477-sec-0028"> <h5 class="title">Immunogenicity outcomes</h5> <p> <ul id="CD015477-list-0010"> <li> <p>Geometric mean titre (GMT) of a specific antibody against SARS‐CoV‐2 (two weeks after the first dose or nearest follow‐up, as mentioned in the manuscript) </p> </li> <li> <p>GMT of a neutralizing antibody against SARS‐CoV‐2 (two weeks after second dose or nearest follow‐up, as mentioned in the manuscript) </p> </li> <li> <p>Cellular immune responses (i.e. interferon gamma (IFN‐γ) enzyme‐linked immunospot (ELISpot)) (any time point reported by authors) </p> </li> </ul> </p> </section> <section id="CD015477-sec-0029"> <h5 class="title">Specific safety outcomes</h5> <p> <ul id="CD015477-list-0011"> <li> <p>Incidence of local reactogenicity events (i.e. the immediate local short‐term reactions of a system to vaccines mainly due to immunological responses, such as pain and swelling) reported at day seven after first dose. </p> </li> </ul> </p> <p>When the number of participants with at least one local adverse event is not reported, we used as a proxy measure pain as the first choice, local swelling/induration as the second choice, and erythema (redness) as the third choice. </p> <p> <ul id="CD015477-list-0012"> <li> <p>Incidence of specific safety outcomes </p> </li> <li> <p>Cardioembolic events (i.e. pulmonary embolism, stroke, venous thrombosis, cavernous sinus thrombosis, pericarditis, myocardial infarction)  </p> </li> <li> <p>Haematological events (i.e. thrombocytopenia, haemorrhage, neutropenia, anaemia, lymphadenopathy)</p> </li> <li> <p>Neurological events (i.e. nervous system diseases)</p> </li> <li> <p>Vaccine‐enhanced disease</p> </li> </ul> </p> <p>Note: as the start of follow‐up (T0) varies (e.g. follow‐up starts "14 days after the last dose" or "21 days after the first dose"), we systematically recorded the T0 considered in the study report. For safety outcomes, we considered T0 = time the first dose is injected when the comparison is vaccine versus placebo/no vaccine; T0 = time after the second dose when the comparison focuses on heterologous vaccination; and T0 = time after the booster or placebo when the comparison assessed the booster dose. We systematically recorded the follow‐up duration for the outcomes considered. When the same outcome was recorded at several time points, we recorded the latest.  </p> <p>For specific antibodies against SARS‐CoV‐2, we considered T0 = 2 weeks after the first dose where available, or the nearest time point. </p> <p>For neutralizing antibodies against SARS‐CoV‐2, we considered T0 = 2 weeks after the second dose where available, or the nearest time point. </p> </section> </section> </section> <section id="CD015477-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <p>We used the search strategies defined in the protocol of the larger COVID‐NMA initiative (<a href="https://covid-nma.com" target="_blank">covid-nma.com</a>) (<a href="./references#CD015477-bbs2-0061" title="BoutronI , ChaimaniA , MeerpohlJJ , HróbjartssonA , DevaneD , RadaG , et al. Interventions for preventing and treating COVID-19: protocol for a living mapping of research and a living systematic review. Cochrane Database of Systematic Reviews2020, Issue 11. Art. No: CD013769. [DOI: 10.1002/14651858.CD013769]">Boutron 2020b</a>), and outlined in <a href="./appendices#CD015477-sec-0302">Appendix 2</a> to identify randomized trials evaluating vaccines for COVID‐19. The search methods and strategies to identify records for this review are being revised approximately yearly, to ensure that they reflect any terminology changes in the topic area, or in the databases.  </p> <section id="CD015477-sec-0031"> <h4 class="title">Electronic searches</h4> <p>The Epistemonikos L·OVE COVID‐19 platform was searched regularly from 4 September 2020 until 5 November 2021 (<a href="./references#CD015477-bbs2-0082" title="Epistemonikos. Epistemonikos L·OVE COVID-19 platform. Available at app.iloveevidence.com/loves/5e6fdb9669c00e4ac072701d?utm=ile.">Epistemonikos</a>) (<a href="https://app.iloveevidence.com/covid19" target="_blank">app.iloveevidence.com/covid19</a>). This platform is a digital repository built by systematic searches in multiple databases, trial registries and preprint servers. Complete data sources and search methods are available at: <a href="https://app.iloveevidence.com/covid19/methods" target="_blank">app.iloveevidence.com/covid19/methods</a>. </p> <p>The Cochrane<b> </b>COVID‐19 Study Register has been searched on a regular basis (<a href="https://covid-19.cochrane.org/" target="_blank">covid-19.cochrane.org/</a>; last searched 5 November 2021). The Cochrane COVID‐19 Study Register is a specialized register built within the Cochrane Register of Studies (CRS) and is maintained by Cochrane Information Specialists. The register contains study reports from several sources, including:  </p> <p> <ul id="CD015477-list-0013"> <li> <p>daily searches of PubMed;</p> </li> <li> <p>daily searches of ClinicalTrials.gov;</p> </li> <li> <p>weekly searches of Embase.com;</p> </li> <li> <p>weekly searches of the WHO International Clinical Trials Registry Platform (ICTRP);</p> </li> <li> <p>weekly searches of medRxiv;</p> </li> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL).</p> </li> </ul> </p> <p>Complete data sources and search methods for the register are available at: <a href="http://community.cochrane.org/about-covid-19-study-register" target="_blank">community.cochrane.org/about-covid-19-study-register</a>. </p> <p>We also searched the Retraction Watch Database for retracted studies (<a href="https://retractionwatch.com/retracted-coronavirus-covid-19-papers/" target="_blank">retractionwatch.com/retracted-coronavirus-covid-19-papers/</a>; last searched 5 November 2021). </p> <p>We also systematically searched for updates or publications of preprints using a preprint tracker, developed in collaboration with a research team from the French National Centre for Scientific Research (CNRS) (<a href="./references#CD015477-bbs2-0064" title="CabanacG , OikonomidiT , BoutronI . Day-to-day discovery of preprint-publication links. Scientometrics2021;126(6):5285-304.">Cabanac 2021</a>).  </p> </section> <section id="CD015477-sec-0032"> <h4 class="title">Searching other resources</h4> <p>We searched the following trial registries for unpublished and ongoing studies.</p> <p> <ul id="CD015477-list-0014"> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="https://trialsearch.who.int/" target="_blank">trialsearch.who.int/</a>), to identify ongoing and completed clinical trials on COVID‐19 (last searched 3 November 2021). We used the <i>List by Health Topic</i>: 2019‐nCoV / COVID‐19 filter to retrieve all studies identified.  </p> </li> <li> <p>European Medicines Agency (EMA) clinical data website (<a href="https://clinicaldata.ema.europa.eu/web/cdp/home" target="_blank">clinicaldata.ema.europa.eu/web/cdp/home</a>) to identify trials submitted to the EMA and also for the clinical study report (CSR) of eligible studies (last searched 5 November 2021).  </p> </li> <li> <p>FDA website (<a href="https://www.fda.gov/" target="_blank">www.fda.gov</a>) to identify FDA approval trials (last searched 5 November 2021). </p> </li> </ul> </p> </section> </section> <section id="CD015477-sec-0033"> <h3 class="title" id="CD015477-sec-0033">Data collection and analysis</h3> <p>We search, screen and extract data weekly. The analysis is updated online every 2 weeks (<a href="https://covid-nma.com" target="_blank">covid-nma.com</a>). The next update will be conducted soon after the publication of this review. </p> <section id="CD015477-sec-0034"> <h4 class="title">Selection of studies</h4> <p> We searched and screened the citations retrieved and used a spreadsheet to document search dates and citations identified. We identified duplicates in Rayyan (<a href="./references#CD015477-bbs2-0125" title="OuzzaniM , HammadyH , FedorowiczZ , ElmagarmidA . Rayyanv – a web and mobile app for systematic reviews. Systematic Reviews2016;5(1):210.">Ouzzani 2016</a>), and then in a spreadsheet to enhance sensitivity. Two review authors (CR, HB) independently screened records and abstracts; a third review author (RA) resolved any disagreements. </p> <p>We did not check the references of included reports as the living search process identifies COVID‐19 trial records prospectively from the point of trial registration.  </p> <p>Whenever both preprints and subsequent peer‐reviewed publications were available, we favoured the latter as they are the latest documents of trial findings (<a href="./references#CD015477-bbs2-0061" title="BoutronI , ChaimaniA , MeerpohlJJ , HróbjartssonA , DevaneD , RadaG , et al. Interventions for preventing and treating COVID-19: protocol for a living mapping of research and a living systematic review. Cochrane Database of Systematic Reviews2020, Issue 11. Art. No: CD013769. [DOI: 10.1002/14651858.CD013769]">Boutron 2020b</a>). </p> <p>We retrieved CSRs for four vaccines (BNT162b2 – BioNtech/Fosun Pharma/Pfizer; mRNA‐123 – ModernaTX; ChAdOx1 – Astra Zeneca+University of Oxford; and AD26.COV2.S – Janssen Pharmaceutical Companies) from the EMA website (<a href="https://www.ema.europa.eu/en" target="_blank">www.ema.europa.eu/en</a>). For three vaccines (BNT162b2, mRNA‐123 – ModernaTX and Ad26.COV2.S), we found minor discrepancies when compared to the data reported in the peer‐reviewed publication. Discrepancies were due to different cut‐off dates and follow‐up lengths. We were unable to compare data between the CSR and the peer‐reviewed publication for one vaccine (ChAdOx1) since the publication reports pooled results for four trials (COV001, COV002, COV003, and COV005) and the CSR contains data for only two of them (COV002 and COV003).  </p> </section> <section id="CD015477-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>All data were extracted in duplicate. Two review authors (HB, BB) independently read each preprint, publication, protocol, or other study reports, evaluated the completeness of the data, and assessed the risk of bias. Based on a pilot data extraction form, we designed, evaluated and modified a specific structured data extraction form whenever needed to ensure consistency in the extraction of information. The form was implemented on the COVID‐NMA platform on the extraction module explicitly developed for this purpose (<a href="https://covid-nma.com/" target="_blank">covid-nma.com</a>). All discrepancies automatically identified by the platform data extraction module were discussed by the two review authors to reach a consensus. </p> <p>Information extracted included study characteristics (such as first author, publication year and journal), number of participants randomized, patient characteristics (age, sex, pre‐existing neutralizing or specific antibodies or participants seropositive, comorbidities), intervention details (type of vaccines, dosing, schedule and route of administration), outcome measures, and risk of bias assessment.  </p> <p>For dichotomous outcomes, we extracted the number of events and number of total participants in each study arm.  </p> <p>For <i>efficacy outcomes</i>, we extracted vaccine efficacy as reported by the authors and 95% confidence interval (CI) for each outcome, when available. Vaccine efficacy measures the percentage reduction in incidence of cases among vaccinated persons compared to unvaccinated persons. It is usually calculated as the incidence rate among unvaccinated – incidence rate among vaccinated / the incidence rate among unvaccinated.  </p> <p>For <i>immunogenicity outcomes</i>, we recorded GMTs and 95% CIs for specific and neutralizing antibodies in the control and intervention. We extracted results related to cellular response as reported by authors. </p> <p>For <i>safety outcomes,</i> we extracted the data as analyzed by the authors. </p> <p>We extracted the data as analyzed by the trial authors. </p> <p>To explore vaccine efficacy on variants of concern, such as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529), we also took into account that: </p> <p> <ul id="CD015477-list-0015"> <li> <p>vaccine efficacy on variants of concern is determined by sequencing all available cases where available; </p> </li> <li> <p>study authors extrapolated vaccine efficacy on variants of concern </p> <ul id="CD015477-list-0016"> <li> <p>considering the prevalent variant during the study period</p> </li> <li> <p>from other sources: the information was extrapolated from data on the prevalence of the variant in the population during the study period. This information was obtained from <a href="https://outbreak.info/" target="_blank">outbreak.info</a> or other sources. </p> </li> </ul> </li> </ul> </p> <p>This was done only for critical outcomes of efficacy. </p> </section> <section id="CD015477-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed each study with the Cochrane RoB 2 tool for randomized controlled trials (<a href="./references#CD015477-bbs2-0155" title="SterneJA , SavovićJ , PageMJ , ElbersRG , BlencoweNS , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomized trials. BMJ2019;366:l4898.">Sterne 2019</a>). We assessed risk of bias for the critical outcomes of the review. We recorded judgements for each domain using the online data extraction tool we developed. Risk of bias was assessed independently, in duplicate with consensus by researchers with epidemiological training (currently 4 people) or Cochrane Response members (the number of people involved varies). All have been previously trained in clinical epidemiology and systematic reviews. All have participated in a training programme where they had to read the training material and perform data extraction and RoB assessments with a team of experienced researchers. The data quality was assessed by the Cochrane Bias Methods Group, who checked a random sample of 10% of the extracted reports. </p> <p>The Cochrane RoB 2 tool is structured into five domains: 1) risk of bias arising from the randomisation process; 2) risk of bias due to deviations from intended interventions; 3) risk of bias due to missing outcome data; 4) risk of bias in the measurement of the outcome; and 5) risk of bias in the selection of the reported result. Within each domain, a series of 'signalling questions' elicit information relevant to the risk of bias assessment. The response options to the signalling questions are: "yes"; "probably yes"; "probably no"; "no"; and "no information." A risk of bias judgement for each domain is generated by an algorithm, based on answers to the signalling questions. Judgement can be 'low', ‘some concerns’ or 'high' risk of bias. Overall, risk of bias will be considered as "low risk of bias" if all domains are at 'low risk;' "some concerns" if at least one domain is of ‘some concern’ and no domains are 'high risk of bias;' and "high risk of bias" if there is at least one domain assessed as 'high risk,' or several domains with 'some concerns.' In the context of this review, we are interested in quantifying the effect of assignment to the interventions at baseline, regardless of whether the interventions are received as intended (i.e. the intention‐to‐treat effect). </p> <p>For cluster‐randomized trials, if any, we planned to rely on the extension of the RoB tool 2 for cluster‐randomized trials. Particularly, we planned to add the domain 1b: risk of bias arising from the timing of identification or recruitment of participants in a cluster‐randomized trial. There were no cluster‐RCTs reported by the date of the last search. </p> <p>While we relied on the signalling questions to assess each domain and justify our assessment, we did not record the answers of systematic reviewers or how consensus was obtained for the signalling questions; this was done only at the domain level. </p> <p>The risk of bias assessment was considered part of an evaluation of the certainty of the evidence and sensitivity analysis. </p> </section> <section id="CD015477-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we used vaccine efficacy and risk ratio accompanied by the 95% CI as a measure of effect. For outcomes measured with GMTs, we calculated the geometric mean ratios (GMRs) by taking the anti‐log of the mean difference of the log transformed data between arms. </p> <p>To date, all trials reported vaccine efficacy. In the future if we identify trials reporting only rate ratio, we will calculate vaccine efficacy using the formula rate ratio = 1 − VE/100. </p> </section> <section id="CD015477-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>We analyzed separately different comparisons from multiple‐arm trials for all pairwise meta‐analyses.  </p> </section> <section id="CD015477-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>For missing outcome data, we extracted the number of participants who dropped out before the completion of the study, and how the study authors handled missing data. We assessed the appropriateness of any imputation methods used to account for early dropouts in our risk of bias assessments. We conducted sensitivity analysis to assess the potential impact of missing outcome data on the results. </p> </section> <section id="CD015477-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>We first generated descriptive statistics for study and population characteristics, and we examined the distribution of important clinical and methodological variables (such as age, immunocompromized status, location etc.). We have considered the variability in point estimates and the overlap in CIs in addition to the I<sup>2</sup> statistic to assess the level of statistical heterogeneity (<a href="./references#CD015477-bbs2-0139" title="RileyRD , HigginsJP , DeeksJJ . Interpretation of random effects meta-analyses. BMJ2011;342:d549.">Riley 2011</a>).  </p> </section> <section id="CD015477-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed the selective non‐reporting or under‐reporting of results in the trials identified according to the framework proposed in Chapter 13 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015477-bbs2-0101" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Higgins 2021</a>). </p> </section> <section id="CD015477-sec-0042"> <h4 class="title">Assessment of risk of bias due to missing results in the included studies</h4> <p>We checked whether the results of all our critical and important outcomes were reported as prespecified in the first version of the trial registry. When more than one version was available and the outcomes were modified, we checked the date of the modification using “history of changes.” Of note, some platforms do not provide information about previous versions of the registers. In these cases, we could not know whether we were assessing the original. When registration was not prospective, we also checked the protocol or statistical analysis plan if available. </p> <p>We used a matrix indicating the availability of study results as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015477-bbs2-0101" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Higgins 2021</a>; <a href="./references#CD015477-bbs2-0104" title="KirkhamJJ , AltmanDG , ChanAW , GambleC , DwanKM , WilliamsonPR . Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews. BMJ2018;362:k3802.">Kirkham 2018</a>). </p> <p>We evaluated whether results were unavailable because of the results' P value, magnitude, or direction. We considered the risk of bias due to missing results if an outcome specified in the registry was missing from the main report. </p> <p>Due to the small number of trials, we could not assess the potential for reporting bias across studies graphically or statistically. </p> </section> <section id="CD015477-sec-0043"> <h4 class="title">Data synthesis</h4> <p>We analyzed each type of vaccine separately. We combined trials with comparators as placebo or adjuvant or other control together under the same comparison at the specific vaccine level. We included all eligible RCTs in the primary analysis, whatever the risk of bias assessment. We included early‐phase trials in the analysis only when the selected dose was clearly defined and efficacy outcomes (usually assessed in Phase 3 trials) were available. </p> <p>We performed a pairwise meta‐analysis and presented summary effect estimates with 95% CIs for each direct comparison, with at least two studies providing data. We used the random‐effects model to incorporate the anticipated clinical and methodological heterogeneity across studies. We presented trials reporting zero events in both arms in the forest plot but did not incorporate these in the analysis. </p> <p>In the presence of excessive heterogeneity across studies (i.e. diverse forest plots or Tau<sup>2</sup> &gt; 75% quartile of empirical distributions, or both) (<a href="./references#CD015477-bbs2-0157" title="TurnerRM , DaveyJ , ClarkeMJ , ThompsonSG , HigginsJP . Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. International Journal of Epidemiology2012;41(3):818-27.">Turner 2012</a>), we did not synthesize the trial data quantitatively but qualitatively unless we could set up homogeneous subsets of the available trials. </p> <p>All analyses were undertaken with the statistical software environment R (version 4.0.3) using the packages metafor and meta (<a href="./references#CD015477-bbs2-0058" title="BalduzziS , RückerG , SchwarzerG . How to perform a meta-analysis with R: a practical tutorial. Evidence-Based Mental Health2019;22:153-60.">Balduzzi 2019</a>; <a href="./references#CD015477-bbs2-0159" title="ViechtbauerW . Conducting meta-analyses in R with the metafor package. Journal of Statistical Software2010;36(3):1-48.">Viechtbauer 2010</a>). </p> <p>We initially planned to conduct a network meta‐analysis (NMA); however, the network of vaccines appeared very sparse, included mainly comparisons of vaccines against placebo, and only one or two studies informed most of the available comparisons (<a href="#CD015477-fig-0001">Figure 1</a>). A network of such structure does not allow proper evaluation of the synthesis assumptions. Additionally, the NMA estimates from this network would not be substantially more precise (and could even be less precise for some comparisons) than the direct ones. We will reassess the feasibility of conducting an NMA regularly as part of the living systematic review process (details of the NMA methods considered for future update versions are available in <a href="./appendices#CD015477-sec-0305">Appendix 3</a>). </p> <div class="figure" id="CD015477-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Network graph. The size of the nodes is proportional to the number of participants randomized and the thickness of the lines to the number of studies in each comparison." data-id="CD015477-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Network graph. The size of the nodes is proportional to the number of participants randomized and the thickness of the lines to the number of studies in each comparison. </p> </div> </div> </div> </section> <section id="CD015477-sec-0044"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We had planned to perform subgroup analyses for critical outcomes only (<a href="./references#CD015477-bbs2-0061" title="BoutronI , ChaimaniA , MeerpohlJJ , HróbjartssonA , DevaneD , RadaG , et al. Interventions for preventing and treating COVID-19: protocol for a living mapping of research and a living systematic review. Cochrane Database of Systematic Reviews2020, Issue 11. Art. No: CD013769. [DOI: 10.1002/14651858.CD013769]">Boutron 2020b</a>). For future updates, we will pursue our prespecified subgroup analyses to explore whether the following population characteristics explain sources of heterogeneity. </p> <p> <ul id="CD015477-list-0017"> <li> <p>Age:</p> <ul id="CD015477-list-0018"> <li> <p>children or adolescents (aged less than 18 years);</p> </li> <li> <p>adults (aged 18 to 59 years);</p> </li> <li> <p>older adults (aged greater than 60 years).</p> </li> </ul> </li> <li> <p>Specific populations:</p> <ul id="CD015477-list-0019"> <li> <p>immunocompromized people;</p> </li> <li> <p>pregnant women.</p> </li> </ul> </li> </ul> </p> <p>It should be noted that, as the evidence base on COVID‐19/SARS‐CoV‐2 and its variants continues to evolve, we will reassess the feasibility of performing these subgroup analyses in future updates of the review when we could also evaluate the impact of the different SARS‐CoV‐2 variants in a meta‐regression model. </p> <p>For the current review, we assessed the level of heterogeneity by visual inspection of forest plots, the I<sup>2</sup> statistic, the between‐study variance (Tau<sup>2</sup>), and prediction intervals.  </p> </section> <section id="CD015477-sec-0045"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses for critical outcomes only. We performed sensitivity analyses by excluding RCTs reported in preprint only and early‐phase trials (1 and 2). We also ran the analyses using the number of participants randomized instead of those analyzed for safety outcomes to assess the potential impact of missing outcome data on the results. For efficacy outcomes, it was not possible to calculate the effect estimate (vaccine efficacy) using the number of participants randomized. We did not perform the planned sensitivity analysis that excluded RCTs with an overall high risk of bias since no RCTs were considered at high risk of bias.  </p> </section> <section id="CD015477-sec-0046"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>To evaluate the certainty of the evidence in the results of the pairwise comparisons for all outcomes except immunogenetic outcomes, overall certainty of the evidence for each outcome was assessed by one review author (KP) and cross‐checked by another review author (AJ) using the GRADE approach (<a href="./references#CD015477-bbs2-0149" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Schünemann 2021</a>). We used the five GRADE considerations (risk of bias, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence. The assessment of imprecision was based on a non‐contextualized approach i.e. rating the certainty that there is any effect (<a href="./references#CD015477-bbs2-0103" title="HultcrantzM , RindD , AklEA , TreweekS , MustafaRA , IorioA , et al. The GRADE Working Group clarifies the construct of certainty of evidence. Journal of Clinical Epidemiology2017;87:4-13.">Hultcrantz 2017</a>; <a href="./references#CD015477-bbs2-0176" title="ZengL , Brignardello-PetersenR , HultcrantzM , SiemieniukRA , SantessoN , TraversyG , et al. GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings. Journal of Clinical Epidemiology2021;137:163-75.">Zeng 2021a</a>), with the null effect as the threshold for the critical outcomes of mortality and SAEs (<a href="./references#CD015477-bbs2-0096" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence – imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93.">Guyatt 2011</a>). In the description of the results for each outcome, we use different thresholds for the size of the effects. </p> <p>For outcomes reported as vaccine efficacy, we used a threshold of 30%, based on the WHO guidance document which indicated that the primary efficacy endpoint estimate for a placebo‐controlled trial should be at least 50%, with a statistical success criterion that the lower bound of the confidence interval be more than 30% (<a href="./references#CD015477-bbs2-0165" title="World Health Organization. Considerations for evaluation of COVID19 vaccines. Points to consider for manufacturers of COVID-19 vaccines. Version 24 September 2020. www.who.int/docs/default-source/in-vitro-diagnostics/covid19/who-evaluation-covid-vaccine-w-lines.pdf?sfvrsn=701d3a65_2 (accessed prior to 1 November 2022).">WHO 2020b</a>; <a href="./references#CD015477-bbs2-0166" title="World Health Organization. WHO target product profiles for COVID-19 vaccines. Version 3 – 29 April 2020. www.who.int/docs/default-source/blue-print/who-target-product-profiles-for-covid-19-vaccines.pdf (accessed prior to 1 November 2022).">WHO 2020c</a>). For additional adverse event outcomes (i.e. any adverse event, systemic reactogenicity events, and local reactogenicity events), we considered the thresholds for an effect to be RRs of 0.75 and 1.25 for downgrading imprecision.  </p> <p>For all‐cause mortality and SAEs, we considered the effect was "large" when the absolute difference was greater than 5%; there was a "slight" effect when the absolute difference was from 1% to 5%, and there was "little or no effect" when the absolute difference was less than 1%.  </p> <p>For vaccine efficacy outcomes, when the effect estimate was 70% or greater we considered the vaccine to have a "large effect" (<a href="./references#CD015477-bbs2-0165" title="World Health Organization. Considerations for evaluation of COVID19 vaccines. Points to consider for manufacturers of COVID-19 vaccines. Version 24 September 2020. www.who.int/docs/default-source/in-vitro-diagnostics/covid19/who-evaluation-covid-vaccine-w-lines.pdf?sfvrsn=701d3a65_2 (accessed prior to 1 November 2022).">WHO 2020b</a>; <a href="./references#CD015477-bbs2-0166" title="World Health Organization. WHO target product profiles for COVID-19 vaccines. Version 3 – 29 April 2020. www.who.int/docs/default-source/blue-print/who-target-product-profiles-for-covid-19-vaccines.pdf (accessed prior to 1 November 2022).">WHO 2020c</a>). </p> <p>For any adverse event, systemic reactogenicity events, and local reactogenicity events, we considered the effect as a "large effect" when the absolute difference was greater than 25%; a "slight effect" when the absolute difference was from 10% to 25%, and "little or no effect" when the absolute difference was less than 10%.  </p> <p>We prepared summary of findings tables to present estimated relative and absolute risks for critical and important outcomes, except for immunogenicity outcomes. We calculated absolute effects with <a href="./references#CD015477-bbs2-0095" title="GRADEpro GDT. Version accessed 6 December 2021. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a> using the pooled baseline risks from the control groups of the included studies. Absolute effects are presented per 1000 for the outcomes 'any adverse event,' 'systemic adverse events,' and 'local adverse events,' and in remaining outcomes with low baseline risk (control group event rates less than 1%) per 100,000. We did not report absolute effect for results with low or very low certainty. For outcomes where vaccine efficacy is presented as the effect measure in the summary of findings tables, we used the corresponding RR to calculate the absolute effect. The rationale for using a footnote for the length of follow‐up was to add the specific time per individual study for each outcome.  </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD015477-sec-0047" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD015477-sec-0047"></div> <section id="CD015477-sec-0048"> <h3 class="title">Description of studies</h3> <p>The full description of included studies is available at <a href="https://zenodo.org/record/6963352#.YuvhdhzP3RY" target="_blank">zenodo.org/record/6963352#.YuvhdhzP3RY</a>. Characteristics of excluded studies and unpublished registered studies are summarized in the <a href="./references#CD015477-sec-0491" title="">Characteristics of excluded studies</a> section and in <a href="./appendices#CD015477-sec-0313">Appendix 4</a>, respectively. </p> <section id="CD015477-sec-0049"> <h4 class="title">Results of the search</h4> <p>The results of the searches are detailed in <a href="#CD015477-fig-0002">Figure 2</a>. On 5 November 2021, after excluding duplicates, we screened 48,047 records: 701 were eligible for full‐text screening; we included 111 reports of 76 studies evaluating vaccine candidates against SARS‐CoV‐2. Thirty early‐phase randomized trials (36 reports) are pending due to uncertainty regarding concentration of the vaccine candidate to be selected for the phase 3 trial or lack of results on efficacy for the selected dose reported in a phase 3 trial (<a href="./appendices#CD015477-sec-0314">Appendix 5</a>). In seven reports of trials already included in the analysis and in five other reports of trials not included in the analysis, we did not find any outcomes of interest or we were unable to extract the data (i.e. results reported only as figures or in graphs) (<a href="./appendices#CD015477-sec-0315">Appendix 6</a>). Overall, we included 41 studies in the analyses. These studies assessed four different types of vaccine platforms: RNA‐based vaccines (six studies), non‐replicating viral vector vaccines (10 studies), inactivated virus vaccines (13 studies), and protein subunit vaccines (six studies). They also assessed heterologous vaccine schedules and the effect of booster doses (six studies). Of note, we did not identify any trials reporting the efficacy outcome of interest for the vaccine Ad5‐vectored (non‐replicant viral vector) (<a href="./references#CD015477-bbs2-0180" title="ZhuF , JinP , ZhuT , WangW , YeH , PanH , et al. Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomized, double-blind, placebo-controlled, phase 2b trial. Clinical Infectious Diseases2022;75(1):e783-91. [DOI: 10.1093/cid/ciab845]">Zhu 2021a</a>); however, its efficacy as part of a heterologous scheme is assessed in a trial included in the analysis (<a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>).  </p> <div class="figure" id="CD015477-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="PRISMA flow diagram of included randomized controlled trials (RCTs) (last search date 5 November 2021). COVID‐NMA is a living systematic review of all trials assessing treatment and preventive interventions for COVID‐19 (Boutron 2020a). This review is a subreview of the COVID‐NMA.FDA: Food and Drug Administration; ICTRP: World Health Organization (WHO) International Clinical Trials Registry Platform." data-id="CD015477-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram of included randomized controlled trials (RCTs) (last search date 5 November 2021). COVID‐NMA is a living systematic review of all trials assessing treatment and preventive interventions for COVID‐19 (<a href="./references#CD015477-bbs2-0060" title="BoutronI , ChaimaniA , MeerpohlJJ , HróbjartssonA , DevaneD , RadaG , et al. The COVID-NMA Project: building an evidence ecosystem for the COVID-19 pandemic. Annals of Internal Medicine2020;173(12):1015-7.">Boutron 2020a</a>). This review is a subreview of the COVID‐NMA. </p> <p>FDA: Food and Drug Administration; ICTRP: World Health Organization (WHO) International Clinical Trials Registry Platform. </p> </div> </div> </div> </section> <section id="CD015477-sec-0050"> <h4 class="title">Included studies</h4> <section id="CD015477-sec-0051"> <h5 class="title">Source of the data</h5> <p>We identified 41 trials overall. There were 37 primary analyses (<a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a>; <a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>; <a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a>; <a href="./references#CD015477-bbs2-0004" title="BonelliM , MrakD , TobudicS , SieghartD , KoblischkeM , MandlP , et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.05.21263125]">Bonelli 2021</a>; <a href="./references#CD015477-bbs2-0005" title="BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.03.31.21254494]BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile. Clinical Infectious Diseases 2021 Sep 19 [Epub ahead of print]. [DOI: 10.1093/cid/ciab823]">Bueno 2021</a>;  <a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>; <a href="./references#CD015477-bbs2-0008" title="EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. A Phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.12.11.20210419]EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomized, phase 1 trial. Lancet Infectious Diseases2021;21(5):637-46. ">Ella 2021a</a>; <a href="./references#CD015477-bbs2-0009" title="EllaR , ReddyS , BlackwelderW , PotdarV , YadavP , SarangiV , et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.06.30.21259439]">Ella 2021b</a>; <a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a>;  <a href="./references#CD015477-bbs2-0012" title="FadlyanaE , RusmilK , TariganR , RahmadiAR , ProdjosoewojoS , SofiatinY , et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: an interim analysis in Indonesia. Vaccine2021;39(44):6520-8. ">Fadlyana 2021</a>; <a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a>; <a href="./references#CD015477-bbs2-0014" title="FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. PLOS Medicine2021;18(10):e1003769. FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.26.21252482]">Formica 2021</a>; <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a>; <a href="./references#CD015477-bbs2-0016" title="GuoW , DuanK , ZhangY , YuanZ , ZhangYB , WangZ , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 1/2 trial. eClinicalMedicine2021;38:101010. ">Guo 2021</a>; <a href="./references#CD015477-bbs2-0017" title="HallVG , FerreiraVH , KuT , IerulloM , Majchrzak-KitaB , ChaparroC , et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. New England Journal of Medicine2021;385(13):1244-6. ">Hall 2021</a>; <a href="./references#CD015477-bbs2-0018" title="HanB , SongY , LiC , YangW , MaQ , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(12):1645-53. ">Han 2021</a>; <a href="./references#CD015477-bbs2-0019" title="HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine2021;385(13):1172-83. HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant. medRxiv 2021 [Preprint]. ">Heath 2021</a>; <a href="./references#CD015477-bbs2-0020" title="KeechC , AlbertG , ChoI , RobertsonA , ReedP , NealS , et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. New England Journal of Medicine 2020;383:2320-32. ">Keech 2020</a>; <a href="./references#CD015477-bbs2-0021" title="KremsnerPG , Ahuad GuerreroRA , Arana-ArriE , Aroca MartinezGJ , BontenM , ChandlerR , et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3, randomized, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3911826]">Kremsner 2021</a>; <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>; <a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>; <a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>; <a href="./references#CD015477-bbs2-0025" title="LogunovDY , DolzhikovaIV , ShcheblyakovDV , TukhvatulinAI , ZubkovaOV , DzharullaevaAS , et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia. Lancet2021;397(10275):671-81. ">Logunov 2021</a>;  <a href="./references#CD015477-bbs2-0028" title="MokC , ChengS , ChenC , YiuK , ChanTO , LaiKC , et al. A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.11.02.21265843]">Mok 2021</a>; <a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>; <a href="./references#CD015477-bbs2-0030" title="SablerollesRS , RietdijkWJ , GoorhuisA , PostmaDF , VisserLG , GeersD , et al. Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.18.21264979]">Sablerolles 2021</a>; <a href="./references#CD015477-bbs2-0031" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; February 26, 2021; FDA briefing document: Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. www.fda.gov/media/146217/download (accessed prior to 1 November 2022). SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Interim results of a Phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. New England Journal of Medicine2021;384(19):1824-35. SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.09.23.20199604]">Sadoff 2021a</a>; <a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a>; <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a>; <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>; <a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a>; <a href="./references#CD015477-bbs2-0036" title="Toledo-RomaniME , Garcia-CarmenateM , Silva-ValenzuelaC , Baldoquin-RodriguezW , Martínez-PérezM , Rodríguez-GonzálezM , et al. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomized, placebo-controlled phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.31.21265703]">Toledo‐Romani 2021</a>; <a href="./references#CD015477-bbs2-0038" title="WalshEE , FrenckR , FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.08.17.20176651]WalshEE , Frenck RW Jr, FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine2020;383(25):2439-50. ">Walsh 2020</a>; <a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>; <a href="./references#CD015477-bbs2-0040" title="XiaS , DuanK , ZhangY , ZhaoD , ZhangH , XieZ , et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA2020;324(10):951-60. XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infectious Diseases2020;21(1):39-51. ">Xia 2020</a>; <a href="./references#CD015477-bbs2-0041" title="XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1/2 trial. Lancet Infectious Diseases2021;22(2):196-208. ">Xia 2021</a>; <a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a>), and <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>, which was a combined analysis of four trials ((COV001 (NCT04324606), COV002 (NCT04400838), COV003 (ISRCTN89951424), COV005 (NCT04444674)). </p> <p>We also identified four articles reporting secondary analyses of the four trials included in <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>. <a href="./references#CD015477-bbs2-0011" title="EmaryKR , GolubchikT , AleyPK , ArianiCV , AngusB , BibiS , et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomized controlled trial. Lancet2021;397(10282):1351-62. ">Emary 2021</a> reported results by variants for COV002 (NCT04400838); <a href="./references#CD015477-bbs2-0006" title="ClemensSA , FolegattiPM , EmaryKR , WeckxLY , RatcliffJ , BibiS , et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. Nature Communications2021;12(1):5861. ">Clemens 2021</a> reported results by variants for COV003 (ISRCTN89951424); <a href="./references#CD015477-bbs2-0027" title="MadhiSA , BaillieV , CutlandCL , VoyseyM , KoenAL , FairlieL , et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1885-98. ">Madhi 2021b</a> reported results by variants for COV005 (NCT04444674); and <a href="./references#CD015477-bbs2-0026" title="MadhiSA , KoenAL , IzuA , FairlieL , CutlandCL , BaillieV , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomized, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV2021;8(9):e568-80. ">Madhi 2021a</a> reported results for participants with HIV included in COV005 (NCT04444674). </p> <p>The 41 included trials were reported in 63 reports (34 peer‐reviewed publications, 22 reports of preprints, four clinical study reports, and three FDA briefings). Of the 34 peer‐reviewed publications, 17 were published with earlier versions (<a href="./appendices#CD015477-sec-0316">Appendix 7</a>). Data were initially extracted from these reports and then updated with subsequent publications. Only the latest versions of the reports are referenced. Most of the trials included were performed and results were retrieved before the detection of variants of concern. Overall, 10 trials reported results for a specific SARS‐CoV‐2 variant of concern; four trials presented results on the Alpha variant (B.1.1.7) (<a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>; <a href="./references#CD015477-bbs2-0011" title="EmaryKR , GolubchikT , AleyPK , ArianiCV , AngusB , BibiS , et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomized controlled trial. Lancet2021;397(10282):1351-62. ">Emary 2021</a>; <a href="./references#CD015477-bbs2-0019" title="HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine2021;385(13):1172-83. HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant. medRxiv 2021 [Preprint]. ">Heath 2021</a>; <a href="./references#CD015477-bbs2-0021" title="KremsnerPG , Ahuad GuerreroRA , Arana-ArriE , Aroca MartinezGJ , BontenM , ChandlerR , et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3, randomized, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3911826]">Kremsner 2021</a>), four on Beta variant (B.1.351) (<a href="./references#CD015477-bbs2-0027" title="MadhiSA , BaillieV , CutlandCL , VoyseyM , KoenAL , FairlieL , et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1885-98. ">Madhi 2021b</a>; <a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a>; <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a>; <a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a>), two on Gamma variant (P.1) (<a href="./references#CD015477-bbs2-0006" title="ClemensSA , FolegattiPM , EmaryKR , WeckxLY , RatcliffJ , BibiS , et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. Nature Communications2021;12(1):5861. ">Clemens 2021</a>; <a href="./references#CD015477-bbs2-0021" title="KremsnerPG , Ahuad GuerreroRA , Arana-ArriE , Aroca MartinezGJ , BontenM , ChandlerR , et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3, randomized, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3911826]">Kremsner 2021</a>), and one on Delta (B.1.617.2) (<a href="./references#CD015477-bbs2-0009" title="EllaR , ReddyS , BlackwelderW , PotdarV , YadavP , SarangiV , et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.06.30.21259439]">Ella 2021b</a>). </p> </section> <section id="CD015477-sec-0052"> <h5 class="title">Study design</h5> <p>All trials used a parallel‐group individually randomized design. Twenty‐six of the RCTs included in the analysis had two arms (63.4%) and 15 (36.6%) were multiple‐arm trials. There were 13 early‐phase trials: three phase 1 (<a href="./references#CD015477-bbs2-0008" title="EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. A Phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.12.11.20210419]EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomized, phase 1 trial. Lancet Infectious Diseases2021;21(5):637-46. ">Ella 2021a</a>; <a href="./references#CD015477-bbs2-0020" title="KeechC , AlbertG , ChoI , RobertsonA , ReedP , NealS , et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. New England Journal of Medicine 2020;383:2320-32. ">Keech 2020</a>; <a href="./references#CD015477-bbs2-0038" title="WalshEE , FrenckR , FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.08.17.20176651]WalshEE , Frenck RW Jr, FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine2020;383(25):2439-50. ">Walsh 2020</a>), seven phase 1‐2 (<a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a>; <a href="./references#CD015477-bbs2-0016" title="GuoW , DuanK , ZhangY , YuanZ , ZhangYB , WangZ , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 1/2 trial. eClinicalMedicine2021;38:101010. ">Guo 2021</a>; <a href="./references#CD015477-bbs2-0018" title="HanB , SongY , LiC , YangW , MaQ , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(12):1645-53. ">Han 2021</a>; <a href="./references#CD015477-bbs2-0031" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; February 26, 2021; FDA briefing document: Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. www.fda.gov/media/146217/download (accessed prior to 1 November 2022). SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Interim results of a Phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. New England Journal of Medicine2021;384(19):1824-35. SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.09.23.20199604]">Sadoff 2021a</a>; <a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>; <a href="./references#CD015477-bbs2-0041" title="XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1/2 trial. Lancet Infectious Diseases2021;22(2):196-208. ">Xia 2021</a>; <a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a>), and three phase 2 (<a href="./references#CD015477-bbs2-0014" title="FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. PLOS Medicine2021;18(10):e1003769. FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.26.21252482]">Formica 2021</a>; <a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>; <a href="./references#CD015477-bbs2-0040" title="XiaS , DuanK , ZhangY , ZhaoD , ZhangH , XieZ , et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA2020;324(10):951-60. XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infectious Diseases2020;21(1):39-51. ">Xia 2020</a>). In 40 trials (97.5%) the outcome assessor was blinded. All trials evaluating BNT162b2 (three), mRNA‐1273 (two), CVnCoV RNA (one), Ad26.COV2.S (two), and NVX‐CoV2373 (five) used placebo (normal saline) in the control arm. All trials assessing Gam‐COVID‐Vac (one), CoronaVac (six), WIBP‐CorV (two), BBIBP‐CorV (three), BBV152 (two), and FINLAY‐FR‐2 (one) used adjuvant in the control arm. In the case of ChAdOx1/SII‐ChAdOx1, three trials used placebo (normal saline) in the control arm (<a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a>; <a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a>; <a href="./references#CD015477-bbs2-0027" title="MadhiSA , BaillieV , CutlandCL , VoyseyM , KoenAL , FairlieL , et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1885-98. ">Madhi 2021b</a>), three used a non‐COVID‐19 vaccine (MenACWY) (COV001, COV002 and COV003 included in <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>), and one used adjuvant (<a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>). Two trials assessing heterologous vaccine schedules used regular homologous vaccine schedules as control (<a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>; <a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>), and four trials compared the effect of different vaccine booster schedules (<a href="./references#CD015477-bbs2-0004" title="BonelliM , MrakD , TobudicS , SieghartD , KoblischkeM , MandlP , et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.05.21263125]">Bonelli 2021</a>; <a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>; <a href="./references#CD015477-bbs2-0028" title="MokC , ChengS , ChenC , YiuK , ChanTO , LaiKC , et al. A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.11.02.21265843]">Mok 2021</a>; <a href="./references#CD015477-bbs2-0030" title="SablerollesRS , RietdijkWJ , GoorhuisA , PostmaDF , VisserLG , GeersD , et al. Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.18.21264979]">Sablerolles 2021</a>). </p> <p>Recruitment was completed for 33 trials (80.4%), ongoing for seven trials that reported results of prespecified interim analyses (<a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a>; <a href="./references#CD015477-bbs2-0031" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; February 26, 2021; FDA briefing document: Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. www.fda.gov/media/146217/download (accessed prior to 1 November 2022). SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Interim results of a Phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. New England Journal of Medicine2021;384(19):1824-35. SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.09.23.20199604]">Sadoff 2021a</a>; <a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a>; <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>), and one trial was terminated due to an emergency use authorization for the vaccine candidate (<a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>). The mean sample size was 10,581 participants with median of 504 (interquartile range (IQR) 180 to 21,977; range: minimum 42 to maximum 44,325). </p> </section> <section id="CD015477-sec-0053"> <h5 class="title">Study registration</h5> <p>All trial registration records were available; three trials were registered retrospectively (<a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a>; <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a>; <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>). </p> </section> <section id="CD015477-sec-0054"> <h5 class="title">Settings</h5> <p>Overall, 32 RCTs were multicentre and nine were single‐centre trials (<a href="./references#CD015477-bbs2-0004" title="BonelliM , MrakD , TobudicS , SieghartD , KoblischkeM , MandlP , et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.05.21263125]">Bonelli 2021</a>; <a href="./references#CD015477-bbs2-0012" title="FadlyanaE , RusmilK , TariganR , RahmadiAR , ProdjosoewojoS , SofiatinY , et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: an interim analysis in Indonesia. Vaccine2021;39(44):6520-8. ">Fadlyana 2021</a>; <a href="./references#CD015477-bbs2-0017" title="HallVG , FerreiraVH , KuT , IerulloM , Majchrzak-KitaB , ChaparroC , et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. New England Journal of Medicine2021;385(13):1244-6. ">Hall 2021</a>; <a href="./references#CD015477-bbs2-0018" title="HanB , SongY , LiC , YangW , MaQ , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(12):1645-53. ">Han 2021</a>; <a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>; <a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>; <a href="./references#CD015477-bbs2-0040" title="XiaS , DuanK , ZhangY , ZhaoD , ZhangH , XieZ , et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA2020;324(10):951-60. XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infectious Diseases2020;21(1):39-51. ">Xia 2020</a>; <a href="./references#CD015477-bbs2-0041" title="XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1/2 trial. Lancet Infectious Diseases2021;22(2):196-208. ">Xia 2021</a>; <a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a>). The trials took place in Asia (14 trials, 34.1%), Europe (eight trials, 19.5%), North America (seven trials, 17.0%), worldwide (five trials, 12.1%), South America (four trials, 9.7%), Africa (two trials, 4.8%), and Oceania (one trial, 2.4%). </p> </section> <section id="CD015477-sec-0055"> <h5 class="title">Characteristics of participants</h5> <p>There were 433,838 participants randomized; 250,200 (57.7%) were assigned to the intervention and 183,638 (42.3%) to the control arm. The number of participants analyzed varied by outcome, from 408 to 418,803 participants. The age range was between three and 100 years; 26 trials included participants 18 years of age or older, seven trials included adults between 18 and 65 years of age, two trials included participants 50 years or older (<a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>; <a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>), two trials included participants 12 years old or older (<a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a>; <a href="./references#CD015477-bbs2-0038" title="WalshEE , FrenckR , FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.08.17.20176651]WalshEE , Frenck RW Jr, FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine2020;383(25):2439-50. ">Walsh 2020</a>), two trials included only adolescents 12 to 17 years old (<a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a>; <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a>). Two trials included children and adolescents three to 17 years of age (<a href="./references#CD015477-bbs2-0018" title="HanB , SongY , LiC , YangW , MaQ , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(12):1645-53. ">Han 2021</a>; <a href="./references#CD015477-bbs2-0041" title="XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1/2 trial. Lancet Infectious Diseases2021;22(2):196-208. ">Xia 2021</a>). Overall, 54.0% of participants were male and the mean age ranged between 14 years (minimum) to 61 years (maximum). </p> <p>Most trials (n = 35, 85.3%) enrolled healthy or clinically stable participants with no history of SARS‐CoV‐2 infection or COVID‐19 diagnosis, four trials enrolled healthcare workers or individuals considered at substantial risk of exposure to and infection with SARS‐CoV‐2 (<a href="./references#CD015477-bbs2-0005" title="BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.03.31.21254494]BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile. Clinical Infectious Diseases 2021 Sep 19 [Epub ahead of print]. [DOI: 10.1093/cid/ciab823]">Bueno 2021</a>; <a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>; <a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>; <a href="./references#CD015477-bbs2-0030" title="SablerollesRS , RietdijkWJ , GoorhuisA , PostmaDF , VisserLG , GeersD , et al. Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.18.21264979]">Sablerolles 2021</a>), and two trials included immunocompromized participants in trials assessing booster dose; transplant recipients (<a href="./references#CD015477-bbs2-0017" title="HallVG , FerreiraVH , KuT , IerulloM , Majchrzak-KitaB , ChaparroC , et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. New England Journal of Medicine2021;385(13):1244-6. ">Hall 2021</a>) and adults under current rituximab therapy (<a href="./references#CD015477-bbs2-0004" title="BonelliM , MrakD , TobudicS , SieghartD , KoblischkeM , MandlP , et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.05.21263125]">Bonelli 2021</a>). Thirty‐seven of 41 trials reported that pregnancy was an exclusion criterion. No trials reported data on vaccine efficacy and safety in pregnant women. </p> </section> <section id="CD015477-sec-0056"> <h5 class="title">Details of the intervention</h5> <p>The included trials reported on four types of vaccine platforms and 12 vaccine candidates: three RNA‐based vaccines (BNT162b2, mRNA‐1273 and CVnCoV), three non‐replicating viral vector vaccines (Ad26.COV2.S, ChAdOx1/SII‐ChAdOx1 and Gam‐COVID‐Vac), four inactivated virus vaccines (CoronaVac, WIBP‐CorV, BBIBP‐CorV and BBV152), and two protein subunit vaccines (NVX‐CoV2373 and FINLAY‐FR‐2). As SII‐ChAdOx1, manufactured in India at Serum Institute of India, is the equivalent of ChAdOx1, we pooled the results for both vaccines in the analysis. </p> <p>All COVID‐19 vaccine candidates are to be administered through an intramuscular injection. Most of the vaccine candidates full vaccination schedules relied on two doses with a between‐dose time interval varying from 14 to 28 days; however, four trials reported a time interval between doses of less than six weeks to 12 weeks or greater for ChAdOx1 (<a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>), and one trial one to three months for heterologous compared to a homologous scheme (CoronaVac/Ad5 versus CoronaVac/CoronaVac) (<a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>). One vaccine candidate had a two‐dose schedule in adults and three‐dose schedule in children and adolescents (BBIBP‐CorV); one vaccine candidate necessitates a single dose (Ad26.COV2.S), and six studies evaluated the effect of a homologous compared to a heterologous booster dose; the time intervals between complete vaccination and boosters are 28 days (<a href="./references#CD015477-bbs2-0036" title="Toledo-RomaniME , Garcia-CarmenateM , Silva-ValenzuelaC , Baldoquin-RodriguezW , Martínez-PérezM , Rodríguez-GonzálezM , et al. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomized, placebo-controlled phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.31.21265703]">Toledo‐Romani 2021</a>), one month (<a href="./references#CD015477-bbs2-0004" title="BonelliM , MrakD , TobudicS , SieghartD , KoblischkeM , MandlP , et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.05.21263125]">Bonelli 2021</a>), two months (<a href="./references#CD015477-bbs2-0017" title="HallVG , FerreiraVH , KuT , IerulloM , Majchrzak-KitaB , ChaparroC , et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. New England Journal of Medicine2021;385(13):1244-6. ">Hall 2021</a>), three months (<a href="./references#CD015477-bbs2-0030" title="SablerollesRS , RietdijkWJ , GoorhuisA , PostmaDF , VisserLG , GeersD , et al. Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.18.21264979]">Sablerolles 2021</a>), four months (mean) (<a href="./references#CD015477-bbs2-0028" title="MokC , ChengS , ChenC , YiuK , ChanTO , LaiKC , et al. A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.11.02.21265843]">Mok 2021</a>), and three to six months (<a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>). There were no studies on variant‐adapted booster doses. </p> </section> <section id="CD015477-sec-0057"> <h5 class="title">Outcome measurement</h5> <p>There was some heterogeneity in the way outcomes were assessed. </p> <p>The definition of 'severe or critical disease' was most often based on the WHO clinical progression scale (<a href="./references#CD015477-bbs2-0116" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">Marshall 2020</a>). 'Serious adverse events' were assessed using different grading scales such as ICH and EU Guidelines on Pharmacovigilance for Medicinal Products for Human Use (<a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a>), Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (<a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>), and toxicity grading scales adapted from Food and Drug Administration (FDA) grading guidance (<a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a>). The list of definitions used for both outcomes is in <a href="./appendices#CD015477-sec-0301">Appendix 1</a>.  </p> </section> <section id="CD015477-sec-0058"> <h5 class="title">Funding and conflict of interest</h5> <p>Trials received mixed (private and public) funding (20 trials, 48.78%), public/non‐profit funding (14 trials, 34.14%), and private funding (seven trials, 17.07%). Overall, 37 trials declared competing interests and four trials declared no competing interests (<a href="./references#CD015477-bbs2-0012" title="FadlyanaE , RusmilK , TariganR , RahmadiAR , ProdjosoewojoS , SofiatinY , et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: an interim analysis in Indonesia. Vaccine2021;39(44):6520-8. ">Fadlyana 2021</a>; <a href="./references#CD015477-bbs2-0028" title="MokC , ChengS , ChenC , YiuK , ChanTO , LaiKC , et al. A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.11.02.21265843]">Mok 2021</a>; <a href="./references#CD015477-bbs2-0030" title="SablerollesRS , RietdijkWJ , GoorhuisA , PostmaDF , VisserLG , GeersD , et al. Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.18.21264979]">Sablerolles 2021</a>; <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>). </p> </section> </section> <section id="CD015477-sec-0059"> <h4 class="title">Excluded studies</h4> <p>We excluded 590 reports; 579 were RCTs evaluating other interventions and were consequently included in the COVID‐NMA platform (<a href="https://covid-nma.com" target="_blank">covid-nma.com</a>); 11 reports evaluated vaccines but were not eligible for the review (<a href="./references#CD015477-bbs2-0043" title="BadenLR , El SahlyHM , EssinkB , FollmannD , NeuzilKM , AugustA , et al. Covid-19 in the phase 3 trial of mRNA-1273 during the Delta-variant surge. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.17.21263624]">Baden 2021</a>; <a href="./references#CD015477-bbs2-0044" title="BarrettJR , Belij-RammerstorferS , DoldC , EwerKJ , FolegattiPM , GilbrideC , et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine2021;27(2):279-88. ">Barrett 2021</a>; <a href="./references#CD015477-bbs2-0045" title="EwerKJ , BarrettJR , Belij-RammerstorferS , SharpeH , MakinsonR , MorterR , et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine2021;27(2):270-8. ">Ewer 2021</a>; <a href="./references#CD015477-bbs2-0046" title="FlaxmanA , MarchevskyNG , JenkinD , AboagyeJ , AleyPK , AngusB , et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomized controlled trials (COV001 and COV002). Lancet2021;398(10304):981-90. ">Flaxman 2021</a>; <a href="./references#CD015477-bbs2-0047" title="HsiehSM , LiuWD , HuangYS , LinYJ , HsiehEF , LianWC , et al. Safety and immunogenicity of a recombinant stabilized prefusion SARS-CoV-2 spike protein vaccine (MVC-COV1901) adjuvanted with CpG 1018 and aluminum hydroxide in healthy adults: a phase 1, dose-escalation study. eClinicalMedicine2021;38:100989. ">Hsieh 2021</a>; <a href="./references#CD015477-bbs2-0048" title="IrfanN , ChaglaZ . In South Africa, a 2-dose Oxford/AZ vaccine did not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant). Annals of Internal Medicine2021;174(5):JC50. ">Irfan 2021</a>; <a href="./references#CD015477-bbs2-0049" title="LazarusR , BaosS , Cappel-PorterH , Carson-StevensA , CloutM , CullifordL , et al. The safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults: a phase IV, multicentre randomized controlled trial with blinding (ComFluCOV). SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3931758]">Lazarus 2021</a>; <a href="./references#CD015477-bbs2-0050" title="PatamatamkulS , ThammawatS , BuranratB . Induction of robust neutralizing antibodies against the COVID-19 Delta variant with ChAdOx1 nCoV-19 or BNT162b2 as a booster following a primary vaccination series with CoronaVac. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.25.21264099]">Patamatamkul 2021</a>; <a href="./references#CD015477-bbs2-0051" title="WardBJ , SéguinA , CouillardJ , TrépanierS , LandryN . Phase III: randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18-49 years of age. Vaccine2021;39(10):1528-33. ">Ward 2021a</a>; <a href="./references#CD015477-bbs2-0052" title="WuK , ChoiA , KochM , MaLZ , HillA , NunnaN , et al. Preliminary analysis of safety and immunogenicity of a SARS-CoV-2 variant vaccine booster. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.05.05.21256716]">Wu 2021b</a>; <a href="./references#CD015477-bbs2-0053" title="ZdanowskiW , WaśniewskiT . Evaluation of SARS-CoV-2 spike protein antibody titers in cord blood after COVID-19 vaccination during pregnancy in Polish healthcare workers: preliminary results. Vaccines2021;9(6):675. ">Zdanowski 2021</a>). Reasons for exclusion included: not randomized (five reports), secondary analysis (two reports), intervention not relevant to the review (two reports), exploratory analysis (one report), and comment (one report). See <a href="./references#CD015477-sec-0491" title="">Characteristics of excluded studies</a> table. </p> <section id="CD015477-sec-0060"> <h5 class="title">Ongoing studies</h5> <p>We identified 343 trials from registries; 10 were completed, two were terminated, 172 were not recruiting, 155 were ongoing and four were cancelled (<a href="./appendices#CD015477-sec-0313">Appendix 4</a>).  </p> <section id="CD015477-sec-0061"> <h6 class="title">RNA‐based vaccine</h6> <p>We identified 73 unpublished trials; 34 were not recruiting (67,412 participants planned) and 39 were ongoing (192 participants planned). </p> </section> <section id="CD015477-sec-0062"> <h6 class="title">Non‐replicating viral vector</h6> <p>We identified 73 unpublished trials; there was one completed trial without results available (27 participants planned), 39 not recruiting (60,018 participants planned), 32 ongoing (157,387 participants planned), and one cancelled (1210 participants planned). </p> </section> <section id="CD015477-sec-0063"> <h6 class="title">Replicating viral vector</h6> <p>We identified 10 unpublished trials; one completed trial without results available (90 participants planned), four not recruiting (40,950 participants planned), three ongoing (6434 participants planned), and two terminated (495 participants planned). </p> </section> <section id="CD015477-sec-0064"> <h6 class="title">Inactivated virus</h6> <p>We identified 61 unpublished trials; four completed trials without results available (19,512 participants planned), 25 not recruiting (146,312 participants planned), and 32 ongoing (122,182 participants planned). </p> </section> <section id="CD015477-sec-0065"> <h6 class="title">Protein subunit</h6> <p>We identified 91 unpublished trials; two completed trials without results available (173 participants planned), 56 not recruiting (605,200 participants planned), 31 ongoing (260,273 participants planned), and two terminated (no participants). </p> </section> <section id="CD015477-sec-0066"> <h6 class="title">Live attenuated virus</h6> <p>We identified two studies not recruiting (163 participants planned).</p> </section> <section id="CD015477-sec-0067"> <h6 class="title">DNA‐based vaccine</h6> <p>We identified 18 unpublished trials; two completed trials without results available (30 participants planned), nine not recruiting (16,238 participants planned), and seven ongoing (997 participants planned). </p> </section> <section id="CD015477-sec-0068"> <h6 class="title">Virus‐like particles</h6> <p>We identified 12 unpublished trials; two not recruiting (1818 participants planned), nine ongoing (2546 participants planned), and one terminated (997 participants planned). </p> </section> <section id="CD015477-sec-0069"> <h6 class="title">Any SARS‐CoV‐2 vaccine</h6> <p>We identified three trials; two recruiting (2300 participants planned) and one not recruiting (1314 participants planned).  </p> </section> </section> </section> </section> <section id="CD015477-sec-0070"> <h3 class="title">Risk of bias in included studies</h3> <p>For the overall risk of bias across trials, we judged 34 trials to have 'some concerns' for at least one outcome; eight trials were at low risk of bias for all outcomes (<a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a>; <a href="./references#CD015477-bbs2-0017" title="HallVG , FerreiraVH , KuT , IerulloM , Majchrzak-KitaB , ChaparroC , et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. New England Journal of Medicine2021;385(13):1244-6. ">Hall 2021</a>; <a href="./references#CD015477-bbs2-0018" title="HanB , SongY , LiC , YangW , MaQ , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(12):1645-53. ">Han 2021</a>; <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>; <a href="./references#CD015477-bbs2-0031" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; February 26, 2021; FDA briefing document: Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. www.fda.gov/media/146217/download (accessed prior to 1 November 2022). SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Interim results of a Phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. New England Journal of Medicine2021;384(19):1824-35. SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.09.23.20199604]">Sadoff 2021a</a>; <a href="./references#CD015477-bbs2-0038" title="WalshEE , FrenckR , FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.08.17.20176651]WalshEE , Frenck RW Jr, FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine2020;383(25):2439-50. ">Walsh 2020</a>; <a href="./references#CD015477-bbs2-0040" title="XiaS , DuanK , ZhangY , ZhaoD , ZhangH , XieZ , et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA2020;324(10):951-60. XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infectious Diseases2020;21(1):39-51. ">Xia 2020</a>; <a href="./references#CD015477-bbs2-0041" title="XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1/2 trial. Lancet Infectious Diseases2021;22(2):196-208. ">Xia 2021</a>). Further details of these assessments are available in the risk of bias assessment tables (<a href="./appendices#CD015477-sec-0317">Appendix 8</a>). </p> <section id="CD015477-sec-0071"> <h4 class="title">Risk of bias arising from the randomisation process</h4> <p>We judged the risk of bias due to randomization to be appropriate and adequately done in 32 trials. In other trials, the allocation concealment was either unclear (<a href="./references#CD015477-bbs2-0005" title="BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.03.31.21254494]BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile. Clinical Infectious Diseases 2021 Sep 19 [Epub ahead of print]. [DOI: 10.1093/cid/ciab823]">Bueno 2021</a>; <a href="./references#CD015477-bbs2-0016" title="GuoW , DuanK , ZhangY , YuanZ , ZhangYB , WangZ , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 1/2 trial. eClinicalMedicine2021;38:101010. ">Guo 2021</a>; <a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a>), or not reported (<a href="./references#CD015477-bbs2-0004" title="BonelliM , MrakD , TobudicS , SieghartD , KoblischkeM , MandlP , et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.05.21263125]">Bonelli 2021</a>; <a href="./references#CD015477-bbs2-0014" title="FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. PLOS Medicine2021;18(10):e1003769. FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.26.21252482]">Formica 2021</a>; <a href="./references#CD015477-bbs2-0020" title="KeechC , AlbertG , ChoI , RobertsonA , ReedP , NealS , et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. New England Journal of Medicine 2020;383:2320-32. ">Keech 2020</a>; <a href="./references#CD015477-bbs2-0028" title="MokC , ChengS , ChenC , YiuK , ChanTO , LaiKC , et al. A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.11.02.21265843]">Mok 2021</a>; <a href="./references#CD015477-bbs2-0030" title="SablerollesRS , RietdijkWJ , GoorhuisA , PostmaDF , VisserLG , GeersD , et al. Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.18.21264979]">Sablerolles 2021</a>); we downgraded <a href="./references#CD015477-bbs2-0036" title="Toledo-RomaniME , Garcia-CarmenateM , Silva-ValenzuelaC , Baldoquin-RodriguezW , Martínez-PérezM , Rodríguez-GonzálezM , et al. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomized, placebo-controlled phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.31.21265703]">Toledo‐Romani 2021</a> due to imbalances in baseline characteristics. </p> </section> <section id="CD015477-sec-0072"> <h4 class="title">Risk of bias due to deviations from intended interventions</h4> <p>Thirty‐four trials were blinded for participants, outcome assessors or healthcare providers, or both. Participants were blinded in six trials (<a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>; <a href="./references#CD015477-bbs2-0030" title="SablerollesRS , RietdijkWJ , GoorhuisA , PostmaDF , VisserLG , GeersD , et al. Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.18.21264979]">Sablerolles 2021</a>; <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> (which reported pooled results for four trials)), and blinding was unclear in one (<a href="./references#CD015477-bbs2-0028" title="MokC , ChengS , ChenC , YiuK , ChanTO , LaiKC , et al. A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.11.02.21265843]">Mok 2021</a>). Nevertheless, no deviations from the intended intervention occurred due to awareness of the intervention received, and we did not downgrade the trials for this reason. </p> <p>For efficacy outcomes, we judged the risk of bias due to deviation from intended interventions to be low in 13 trials and have 'some concerns' in 28 trials, mainly because analyses used to estimate the effect of assignment to intervention was inappropriate as most analyses were per protocol for efficacy outcomes. Participants were excluded for positive or unknown baseline SARS‐CoV‐2 status, not receiving a scheduled injection, not receiving the correct injection or major protocol deviation. We considered there would be no substantial impact of failure to analyse participants according to their randomized assignment due to the relatively small number of exclusions or a balanced number of exclusions between arms. In contrast, safety outcomes mainly were analyzed using intention‐to‐treat analysis. We considered this method appropriate to estimate the effect of assignment to intervention. </p> </section> <section id="CD015477-sec-0073"> <h4 class="title">Risk of bias due to missing outcome data</h4> <p>We judged the risk of bias due to missing outcome data as low for all outcomes for 33 trials. There were no missing data or any missing outcome data were reasonably well‐balanced across intervention groups, with similar reasons for missing data across the groups. Additionally, when missingness was related to deviations from the protocol, it was accounted for in the assessment of bias due to deviations from intended interventions and we did not downgrade the trial due to missing outcome data. For eight trials (<a href="./references#CD015477-bbs2-0004" title="BonelliM , MrakD , TobudicS , SieghartD , KoblischkeM , MandlP , et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.05.21263125]">Bonelli 2021</a>; <a href="./references#CD015477-bbs2-0005" title="BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.03.31.21254494]BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile. Clinical Infectious Diseases 2021 Sep 19 [Epub ahead of print]. [DOI: 10.1093/cid/ciab823]">Bueno 2021</a>; <a href="./references#CD015477-bbs2-0009" title="EllaR , ReddyS , BlackwelderW , PotdarV , YadavP , SarangiV , et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.06.30.21259439]">Ella 2021b</a>; <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a>; <a href="./references#CD015477-bbs2-0017" title="HallVG , FerreiraVH , KuT , IerulloM , Majchrzak-KitaB , ChaparroC , et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. New England Journal of Medicine2021;385(13):1244-6. ">Hall 2021</a>; <a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>; <a href="./references#CD015477-bbs2-0030" title="SablerollesRS , RietdijkWJ , GoorhuisA , PostmaDF , VisserLG , GeersD , et al. Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.18.21264979]">Sablerolles 2021</a>; <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a>), we judged the risk of bias as having 'some concerns' since trialists failed to report data for all or nearly all participants for at least one outcome, and missingness could depend on the true value of the outcome, for instance, unbalanced loss to follow‐up due to adverse events or deceased participants not included in the analysis.  </p> </section> <section id="CD015477-sec-0074"> <h4 class="title">Risk of bias in the measurement of the outcome</h4> <p>We judged the risk of bias as low for all outcomes in 38 trials. We judged three trials as having 'some concerns' due to unclear or not blinded assessment of the safety outcomes whose evaluation can be influenced by knowledge of the intervention assignment (<a href="./references#CD015477-bbs2-0004" title="BonelliM , MrakD , TobudicS , SieghartD , KoblischkeM , MandlP , et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.05.21263125]">Bonelli 2021</a>; <a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>; <a href="./references#CD015477-bbs2-0028" title="MokC , ChengS , ChenC , YiuK , ChanTO , LaiKC , et al. A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.11.02.21265843]">Mok 2021</a>). </p> </section> <section id="CD015477-sec-0075"> <h4 class="title">Risk of bias in the selection of the reported results</h4> <p>Thirty‐three trials had prospective registrations or protocols (or both) available with no discrepancies between prespecified and reported outcomes; we judged these trials to be at low risk of bias. Six trials had risk of bias concerns due to reported outcomes that were not prespecified or had discrepancies in time points (<a href="./references#CD015477-bbs2-0004" title="BonelliM , MrakD , TobudicS , SieghartD , KoblischkeM , MandlP , et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.05.21263125]">Bonelli 2021</a>; <a href="./references#CD015477-bbs2-0008" title="EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. A Phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.12.11.20210419]EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomized, phase 1 trial. Lancet Infectious Diseases2021;21(5):637-46. ">Ella 2021a</a>; <a href="./references#CD015477-bbs2-0012" title="FadlyanaE , RusmilK , TariganR , RahmadiAR , ProdjosoewojoS , SofiatinY , et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: an interim analysis in Indonesia. Vaccine2021;39(44):6520-8. ">Fadlyana 2021</a>; <a href="./references#CD015477-bbs2-0014" title="FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. PLOS Medicine2021;18(10):e1003769. FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.26.21252482]">Formica 2021</a>; <a href="./references#CD015477-bbs2-0028" title="MokC , ChengS , ChenC , YiuK , ChanTO , LaiKC , et al. A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.11.02.21265843]">Mok 2021</a>; <a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>).  </p> </section> <section id="CD015477-sec-0076"> <h4 class="title">Bias due to missing results in the synthesis</h4> <p>We present matrices indicating the availability of trial results for critical and important review outcomes in <a href="./appendices#CD015477-sec-0416">Appendix 9</a>. There was evidence of bias due to missing results in four trials: <a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a>, <a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>, <a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a>, and <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a> planned to assess 'GMTs of neutralizing and specific antibodies' but did not report on them. <a href="./references#CD015477-bbs2-0036" title="Toledo-RomaniME , Garcia-CarmenateM , Silva-ValenzuelaC , Baldoquin-RodriguezW , Martínez-PérezM , Rodríguez-GonzálezM , et al. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomized, placebo-controlled phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.31.21265703]">Toledo‐Romani 2021</a> reported 'total adverse events', but only reported on 'local and systemic reactogenicity events', in addition to outcomes 'confirmed SARS‐CoV‐2 infection after complete vaccination' and 'GMTs of neutralizing and specific antibodies', which were not reported as well. <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a> did not report on the preplanned analysis for 'GMTs of neutralizing and specific antibodies' as well as 'systemic and local reactogenicity events' when compared to placebo. <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a> planned to assess 'GMTs of neutralizing and specific antibodies' and 'confirmed SARS‐CoV‐2 infection after complete vaccination' but did not report on them. <a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a> in phase 2 did not report on the results of 'serious adverse events'. <a href="./references#CD015477-bbs2-0006" title="ClemensSA , FolegattiPM , EmaryKR , WeckxLY , RatcliffJ , BibiS , et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. Nature Communications2021;12(1):5861. ">Clemens 2021</a> did not report on the prespecified outcomes 'systemic and serious adverse events'. <a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a> did not report on the prespecified 'local and systemic reactogenicity events'. <a href="./references#CD015477-bbs2-0017" title="HallVG , FerreiraVH , KuT , IerulloM , Majchrzak-KitaB , ChaparroC , et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. New England Journal of Medicine2021;385(13):1244-6. ">Hall 2021</a> and <a href="./references#CD015477-bbs2-0021" title="KremsnerPG , Ahuad GuerreroRA , Arana-ArriE , Aroca MartinezGJ , BontenM , ChandlerR , et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3, randomized, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3911826]">Kremsner 2021</a> did not report on the prespecified outcome 'confirmed SARS‐CoV‐2 infection after complete vaccination'. Finally, <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> reporting on results of four trials did not report on results of 'local adverse events'. Ten registered trials are completed but not yet published (19,832 participants planned); the dates of completion range between 15 January 2021 and 13 October 2021. Publication delay since study completion ranged between 23 days and 295 days. </p> </section> <section id="CD015477-sec-0077"> <h4 class="title">Overview of the risk of bias assessments by outcome</h4> <p>The outcome 'SARS‐CoV‐2 infection after complete vaccination' was reported in seven trials; in all trials we assessed the overall risk of bias to have 'some concerns'.  </p> <p>The outcome 'confirmed symptomatic COVID‐19 after complete vaccination' was reported in 18 trials; in all trials we assessed the overall risk of bias to have 'some concerns'. </p> <p>The outcome 'severe or critical COVID‐19 after complete vaccination' was reported in 11 trials. In one of them, we assessed the overall risk of bias for this outcome to be 'low' (<a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a>). In 10 trials, we assessed the overall risk of bias for this outcome to have 'some concerns'. </p> <p>The outcome 'all‐cause mortality' was reported in 22 trials. In 17 trials, we assessed the overall risk of bias for this outcome to be 'low'. In five trials, we assessed the overall risk of bias for this outcome to have 'some concerns'. </p> <p>The outcome 'serious adverse events' was reported in 32 trials. In 21 of them, we assessed the overall risk of bias for this outcome to be low. In 11 trials, we assessed the overall risk of bias for this outcome to have 'some concerns'.  </p> <p>The outcome 'any adverse event' was reported in 35 trials. In 24 of them, we assessed the overall risk of bias for this outcome to be 'low'. In 11 trials, we assessed the overall risk of bias for this outcome to have 'some concerns'. </p> <p>The outcome 'systemic adverse events' was reported in 31 trials. In 15 of them, we assessed the overall risk of bias for this outcome to be 'low'. In 16 trials, we assessed the overall risk of bias for this outcome to have 'some concerns'.  </p> </section> </section> <section id="CD015477-sec-0078"> <h3 class="title" id="CD015477-sec-0078">Effects of interventions</h3> <p>See: <a href="./full#CD015477-tbl-0001"><b>Summary of findings 1</b> BNT162b2 – Pfizer/BioNTech + Fosun Pharma compared to placebo for vaccination against COVID‐19<sup>a</sup> </a>; <a href="./full#CD015477-tbl-0002"><b>Summary of findings 2</b> mRNA‐1273 – ModernaTX compared to placebo for vaccination against COVID‐19<sup>a</sup> </a>; <a href="./full#CD015477-tbl-0003"><b>Summary of findings 3</b> CVnCoV – CureVac AG compared to placebo for vaccination against COVID‐19<sup>a</sup> </a>; <a href="./full#CD015477-tbl-0004"><b>Summary of findings 4</b> ChAdOx1 – AstraZeneca + University of Oxford  compared to placebo for vaccination against COVID‐19<sup>a</sup> </a>; <a href="./full#CD015477-tbl-0005"><b>Summary of findings 5</b> SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of Oxford compared to ChAdOx1 – University of Oxford for vaccination against COVID‐19<sup>a</sup> </a>; <a href="./full#CD015477-tbl-0006"><b>Summary of findings 6</b> AD26.COV2.S – Janssen Pharmaceutical Companies compared to placebo for vaccination against COVID‐19<sup>a</sup> </a>; <a href="./full#CD015477-tbl-0007"><b>Summary of findings 7</b> Gam‐COVID‐VAC – Sputnik V compared to placebo for vaccination against COVID‐19<sup>a</sup> </a>; <a href="./full#CD015477-tbl-0008"><b>Summary of findings 8</b> CoronaVac – Sinovac compared to placebo for vaccination against COVID‐19<sup>a</sup> </a>; <a href="./full#CD015477-tbl-0009"><b>Summary of findings 9</b> WIBP‐CorV – Sinopharm‐Wuhan compared to placebo for vaccination against COVID‐19<sup>a</sup> </a>; <a href="./full#CD015477-tbl-0010"><b>Summary of findings 10</b> BBIBP‐CorV – Sinopharm‐Beijing  compared to placebo for vaccination against COVID‐19<sup>a</sup> </a>; <a href="./full#CD015477-tbl-0011"><b>Summary of findings 11</b> BBV152 – Bharat Biotech compared to placebo for vaccination against COVID‐19<sup>a</sup> </a>; <a href="./full#CD015477-tbl-0012"><b>Summary of findings 12</b> NVX‐CoV2373 – Novavax compared to placebo for vaccination against COVID‐19<sup>a</sup> </a>; <a href="./full#CD015477-tbl-0013"><b>Summary of findings 13</b> FINLAY‐FR‐2 – Instituto Finlay de Vacunas compared to placebo for vaccination against COVID‐19<sup>a</sup> </a>; <a href="./full#CD015477-tbl-0014"><b>Summary of findings 14</b> Heterologous vaccination scheme compared to homologous vaccination scheme for vaccination against COVID‐19<sup>a</sup> </a>; <a href="./full#CD015477-tbl-0015"><b>Summary of findings 15</b> Booster compared to placebo/no booster for vaccination against COVID‐19<sup>a</sup> </a> </p> <p>We report the network structure, irrespective of the outcomes in <a href="#CD015477-fig-0001">Figure 1</a> and the certainty of evidence for all critical outcomes in the summary of findings tables.  </p> <section id="CD015477-sec-0079"> <h4 class="title">RNA‐based vaccines</h4> <section id="CD015477-sec-0080"> <h5 class="title">BNT162b2 – BioNtech/Fosun Pharma/Pfizer versus placebo (normal saline)</h5> <p>See <a href="./full#CD015477-tbl-0001">summary of findings Table 1</a> and table of results in <a href="./appendices#CD015477-sec-0448">Appendix 10</a>. </p> <p>We identified and included three trials in the analysis assessing BNT162b2. The outcomes 'confirmed SARS‐CoV‐2 infection after complete vaccination', 'systemic reactogenicity events', 'GMT of specific antibodies against SARS‐CoV‐2' and 'cellular immune response' were not reported for this comparison. </p> <section id="CD015477-sec-0081"> <h6 class="title">Critical outcomes</h6> <section id="CD015477-sec-0082"> <p><b>Confirmed symptomatic COVID‐19 after complete vaccination</b></p> <p>Two trials reported this outcome (<a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a>; <a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a>). BNT162b2 results in a large reduction in the incidence of symptomatic COVID‐19 after complete vaccination compared to placebo measured at 1.8 months' and six months' follow‐up (vaccine efficacy (VE) 97.84%, 95% confidence interval (CI) 44.25% to 99.92%; I² = 66%; 2 RCTs, 44,077 participants; high‐certainty evidence; <a href="#CD015477-fig-0003">Figure 3</a>).<b> </b> </p> <div class="figure" id="CD015477-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Analysis 1.1.2: RNA‐based vaccine. Outcome: confirmed symptomatic COVID‐19 after complete vaccination.Ali 2021 included only participants 3 to 17 years of age. Frenck 2021 included only participants 12 to 15 years of age." data-id="CD015477-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-03.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 1.1.2: RNA‐based vaccine. Outcome: confirmed symptomatic COVID‐19 after complete vaccination. </p> <p><a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> included only participants 3 to 17 years of age. <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a> included only participants 12 to 15 years of age. </p> </div> </div> </div> </section> <section id="CD015477-sec-0083"> <p><b>Severe or critical COVID‐19 after complete vaccination</b></p> <p>One trial reported severe or critical COVID‐19 (<a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a>). BNT162b2 results in a large reduction in the incidence of severe or critical disease due to COVID‐19 compared to placebo measured at six months' follow‐up (VE 95.70%, 95% CI 73.90% to 99.90%; 1 RCT, 46,077 participants; high‐certainty evidence; <a href="#CD015477-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD015477-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Analysis 1.1.3: RNA‐based vaccine. Outcome: severe or critical COVID‐19 after complete vaccination.*Thomas 2021 reports pooled results including adults' participants from Thomas 2021 and adolescent participants from Frenck 2021." data-id="CD015477-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-04.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 1.1.3: RNA‐based vaccine. Outcome: severe or critical COVID‐19 after complete vaccination. </p> <p>*<a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a> reports pooled results including adults' participants from <a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a> and adolescent participants from <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a>. </p> </div> </div> </div> </section> <section id="CD015477-sec-0084"> <p><b>All‐cause mortality</b></p> <p>Two trials reported the outcome in 2302 participants at 1.7 months and 4.7 months' follow‐up (<a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a>; <a href="./references#CD015477-bbs2-0038" title="WalshEE , FrenckR , FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.08.17.20176651]WalshEE , Frenck RW Jr, FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine2020;383(25):2439-50. ">Walsh 2020</a>); there were no events and the trials did not contribute to the effect estimate. Only one study contributed to the analysis (<a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a>), with a follow‐up of six months. The evidence is uncertain for an effect of BNT162b2 on all‐cause mortality compared to placebo due to very serious imprecision (risk ratio (RR) 1.07, 95% CI 0.52 to 2.22; 1 RCT, 43,847 participants; low‐certainty evidence; <a href="#CD015477-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD015477-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Analysis 1.1.4: RNA‐based vaccine. Outcome: all‐cause mortality.Ali 2021 included only participants 3 to 17 years of age. Frenck 2021 included only participants 12 to 15 years of age." data-id="CD015477-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-05.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 1.1.4: RNA‐based vaccine. Outcome: all‐cause mortality.</p> <p><a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> included only participants 3 to 17 years of age. <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a> included only participants 12 to 15 years of age. </p> </div> </div> </div> </section> <section id="CD015477-sec-0085"> <p><b>Serious adverse events</b></p> <p>One trial reported the outcome in 42 participants at 1.7 months' follow‐up (<a href="./references#CD015477-bbs2-0038" title="WalshEE , FrenckR , FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.08.17.20176651]WalshEE , Frenck RW Jr, FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine2020;383(25):2439-50. ">Walsh 2020</a>); there were no events and the trial did not contribute to the effect estimate. Two trials contributed to the analysis at 1.7 months' follow‐up (<a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a>; <a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a>). The evidence is uncertain for an effect of BNT162b2 on SAEs compared to placebo due to serious inconsistency and serious imprecision (RR 1.30, 95% CI 0.55 to 3.07; I² = 76%; 2 RCTs, 46,107 participants; low‐certainty evidence; <a href="#CD015477-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD015477-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Analysis 1.1.5: RNA‐based vaccine. Outcome: serious adverse events (SAEs).Ali 2021 included only participants 3 to 17 years of age. Frenck 2021 included only participants 12 to 15 years of age." data-id="CD015477-fig-0006" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-06.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 1.1.5: RNA‐based vaccine. Outcome: serious adverse events (SAEs).</p> <p><a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> included only participants 3 to 17 years of age. <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a> included only participants 12 to 15 years of age. </p> </div> </div> </div> </section> <section id="CD015477-sec-0086"> <p><b>Any adverse event</b></p> <p>Three RCTs reported the outcome at 1.7 months' follow‐up (<a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a>; <a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a>; <a href="./references#CD015477-bbs2-0038" title="WalshEE , FrenckR , FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.08.17.20176651]WalshEE , Frenck RW Jr, FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine2020;383(25):2439-50. ">Walsh 2020</a>). We decided not to pool the results due to considerable heterogeneity (I² = 90%) probably caused by studies assessing participants in different age groups; <a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a> included adults while <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a> included adolescents. </p> <p>One trial reported results for 43,847 participants 16 years and older (<a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a>), the RR for any adverse event was 2.17 (95% CI 2.09 to 2.26). Another trial reported results for 2260 participants between 12 and 15 years of age (<a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a>); the RR for any adverse event was 1.01 (95% CI 0.73 to 1.41). A third trial reported results for 42 participants 18 years or older (<a href="./references#CD015477-bbs2-0038" title="WalshEE , FrenckR , FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.08.17.20176651]WalshEE , Frenck RW Jr, FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine2020;383(25):2439-50. ">Walsh 2020</a>); the RR for any adverse event in the study was 1.50 (95% CI 0.53 to 4.21) (<a href="#CD015477-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD015477-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Analysis 1.1.7: RNA‐based vaccine. Outcome: any adverse event (AE).Ali 2021 included only participants 3 to 17 years of age. Frenck 2021 included only participants 12 to 15 years of age." data-id="CD015477-fig-0007" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-07.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 1.1.7: RNA‐based vaccine. Outcome: any adverse event (AE).</p> <p><a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> included only participants 3 to 17 years of age. <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a> included only participants 12 to 15 years of age. </p> </div> </div> </div> </section> </section> <section id="CD015477-sec-0087"> <h6 class="title">Important outcomes</h6> <section id="CD015477-sec-0088"> <p><b>GMTs of a neutralizing antibody against SARS‐COV‐2</b></p> <p>Two trials reported GMTs of neutralizing antibodies against SARS‐COV‐2 (<a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a>; <a href="./references#CD015477-bbs2-0038" title="WalshEE , FrenckR , FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.08.17.20176651]WalshEE , Frenck RW Jr, FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine2020;383(25):2439-50. ">Walsh 2020</a>). Results are detailed in <a href="./appendices#CD015477-sec-0449">Appendix 11</a>.  </p> </section> <section id="CD015477-sec-0089"> <p><b>Incidence of specific safety outcomes</b></p> <p>Specific safety outcomes were not consistently reported throughout the included trials. <a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a> reported the number of participants with stroke and myocardial infarction, <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a> reported the number of participants with cavernous sinus thrombosis, venous thrombosis and lymphadenopathy, and <a href="./references#CD015477-bbs2-0038" title="WalshEE , FrenckR , FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.08.17.20176651]WalshEE , Frenck RW Jr, FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine2020;383(25):2439-50. ">Walsh 2020</a> did not report any specific safety outcome of interest. These outcomes are summarized in detail in <a href="./appendices#CD015477-sec-0456">Appendix 12</a>. </p> </section> <section id="CD015477-sec-0090"> <p><b>Vaccine‐enhanced disease</b></p> <p>This outcome was reported in a single trial which reported no vaccine‐enhanced disease effect (<a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a>). </p> </section> </section> </section> <section id="CD015477-sec-0091"> <h5 class="title">mRNA‐1273 – ModernaTX versus placebo (normal saline) </h5> <p>See <a href="./full#CD015477-tbl-0002">summary of findings Table 2</a> and table of results in <a href="./appendices#CD015477-sec-0460">Appendix 13</a>. </p> <p>We identified and included two trials in the analysis assessing mRNA‐1273. The outcomes 'GMT of specific antibodies against SARS‐CoV‐2', 'GMT of neutralizing antibodies against SARS‐CoV‐2' and 'cellular immune response' were not reported for this comparison. </p> <section id="CD015477-sec-0092"> <h6 class="title">Critical outcomes</h6> <section id="CD015477-sec-0093"> <p><b>Confirmed SARS‐CoV‐2 infection after complete vaccination</b></p> <p>Two trials reported this outcome (<a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a>; <a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a>). mRNA‐1273 probably results in a large reduction in the incidence of SARS‐CoV‐2 infection compared to placebo at 2.3 months (median) and 5.3 months' follow‐up (VE 73.27%, 95% CI 35.82% to 88.87%; I² = 66%; 2 RCTs, 31,632 participants; moderate‐certainty evidence; <a href="#CD015477-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD015477-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Analysis 1.1.1: RNA‐based vaccine. Outcome: confirmed SARS‐CoV‐2 infection after complete vaccination.Ali 2021 included only participants 3 to 17 years of age. " data-id="CD015477-fig-0008" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-08.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 1.1.1: RNA‐based vaccine. Outcome: confirmed SARS‐CoV‐2 infection after complete vaccination. </p> <p><a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> included only participants 3 to 17 years of age.  </p> </div> </div> </div> </section> <section id="CD015477-sec-0094"> <p><b>Confirmed symptomatic COVID‐19 after complete vaccination</b></p> <p>Two trials reported on this outcome (<a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a>; <a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a>). mRNA‐1273 results in a large reduction in the incidence of confirmed symptomatic COVID‐19 after complete vaccination compared to placebo at 2.3 months (median) and 5.3 months' follow‐up (VE 93.20%, 95% CI 91.06% to 94.83%; I² = 0%; 2 RCTs, 31,632 participants; high‐certainty evidence; <a href="#CD015477-fig-0003">Figure 3</a>). </p> </section> <section id="CD015477-sec-0095"> <p><b>Severe or critical COVID‐19 after complete vaccination</b></p> <p>The outcome was reported in one trial (<a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a>). mRNA‐1273 results in a large reduction of the incidence of severe or critical disease due to COVID‐19 compared to placebo at 5.3 months' follow‐up (VE 98.20%, 95% CI 92.80% to 99.60%; 1 RCT, 28,451 participants; high‐certainty evidence; <a href="#CD015477-fig-0004">Figure 4</a>). </p> </section> <section id="CD015477-sec-0096"> <p><b>All‐cause mortality</b></p> <p>One study reported the outcome in 3726 participants at 2.3 months (median) follow‐up (<a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a>); there were no events and the trial did not contribute to the effect estimate. One trial contributed to the analysis with follow‐up of 5.3 months (<a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a>). The evidence is uncertain for an effect of mRNA‐1273 on all‐cause mortality compared to placebo due to very serious imprecision (RR 1.06, 95% CI 0.54 to 2.10; 1 RCT, 30,346 participants; low‐certainty evidence; <a href="#CD015477-fig-0005">Figure 5</a>). </p> </section> <section id="CD015477-sec-0097"> <p><b>Serious adverse events</b></p> <p>Two trials reported SAEs (<a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a>; <a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a>). mRNA‐1273 probably results in no or little difference in the incidence of SAEs compared to placebo at 2.8 months (median) and 5.3 months' follow‐up (RR 0.92, 95% CI 0.78 to 1.08; I² = 0%; 2 RCTs, 34,072 participants; absolute effect: 143 fewer per 100,000 (from 394 fewer to 143 more); moderate‐certainty evidence; <a href="#CD015477-fig-0006">Figure 6</a>). </p> </section> <section id="CD015477-sec-0098"> <p><b>Systemic reactogenicity events</b></p> <p>Two trials reported the outcome (<a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a>; <a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a>). mRNA‐1273 results in a slight increase in the occurrence of any systemic reactogenicity event compared to placebo (RR 1.28, 95% CI 1.22 to 1.34; I² = 61%; 2 RCTs, 34,037 participants; absolute effect: 121 more with systemic reactogenicity events per 1000 (from 95 fewer to 147 more); high‐certainty evidence; <a href="#CD015477-fig-0009">Figure 9</a>). </p> <div class="figure" id="CD015477-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Analysis 1.1.6: RNA‐based vaccine. Outcome: systemic reactogenicity events.Ali 2021 included only participants 3 to 17 years of age. " data-id="CD015477-fig-0009" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 1.1.6: RNA‐based vaccine. Outcome: systemic reactogenicity events.</p> <p><a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> included only participants 3 to 17 years of age.  </p> </div> </div> </div> </section> <section id="CD015477-sec-0099"> <p><b>Any adverse event</b></p> <p>Two RCTs reported the outcome at 2.8 months (median) and 5.3 months' follow‐up (<a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a>; <a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a>). We decided not to pool the results due to considerable heterogeneity (I² = 100%) probably caused by studies assessing participants in different age groups; <a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> included participants aged three years to 17 years while <a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a> included adults. One trial reported results for 3726 participants between 12 and 17 years of age (<a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a>); the risk for any adverse event in the study was 1.47 (95% CI 1.41 to 1.54), the other study reported results for 29,269 participants 18 years and older (<a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a>), the risk for any adverse event in this study was 2.15 (95% CI 2.11 to 2.19) (<a href="#CD015477-fig-0007">Figure 7</a>). </p> </section> </section> <section id="CD015477-sec-0100"> <h6 class="title">Important outcomes</h6> <section id="CD015477-sec-0101"> <p><b>Local reactogenicity events</b></p> <p>Two trials reported this outcome (<a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a>; <a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a>). mRNA‐1273 results in a large increase of local reactogenicity events compared to placebo (RR 3.30, 95% CI 2.02 to 5.40; I² = 99%; 2 RCTs, 34,037 participants; absolute effect: 486 more with local reactogenicity events per 1000 (from 216 more to 930 more); high‐certainty evidence; <a href="#CD015477-fig-0010">Figure 10</a>). </p> <div class="figure" id="CD015477-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Analysis 1.1.8: RNA‐based vaccine. Outcome: local reactogenicity events. Ali 2021 included only participants 3 to 17 years of age. " data-id="CD015477-fig-0010" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 1.1.8: RNA‐based vaccine. Outcome: local reactogenicity events. </p> <p><a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> included only participants 3 to 17 years of age.  </p> </div> </div> </div> </section> <section id="CD015477-sec-0102"> <p><b>Incidence of specific safety outcomes</b></p> <p>Specific safety outcomes were not consistently reported throughout the included trials. One trial reported number of participants with pulmonary embolism, pericarditis, venous thrombosis, myocardial infarction, thrombocytopaenia, anaemia and nervous system diseases (<a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a>); the other trial reported number of participants with pericarditis myocardial infarction and lymphadenopathy (<a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a>). Outcomes were summarized in detail in <a href="./appendices#CD015477-sec-0456">Appendix 12</a>.  </p> </section> <section id="CD015477-sec-0103"> <p><b>Vaccine‐enhanced disease</b></p> <p>One trial reported no vaccine‐enhanced disease effect (<a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a>). </p> </section> </section> </section> <section id="CD015477-sec-0104"> <h5 class="title">CVnCoV – CureVac AG versus placebo (normal saline)</h5> <p>See <a href="./full#CD015477-tbl-0003">summary of findings Table 3</a> and table of results in <a href="./appendices#CD015477-sec-0461">Appendix 14</a>. </p> <p>We identified and included in the analysis one trial assessing CVnCoV. The outcomes 'SARS‐CoV‐2 infection after complete vaccination', 'GMT of specific antibodies against SARS‐CoV‐2', 'GMT of neutralizing antibodies against SARS‐CoV‐2', 'cellular immune response', 'incidence of specific safety outcomes' and 'vaccine‐enhanced disease' were not reported for this comparison. </p> <section id="CD015477-sec-0105"> <h6 class="title">Critical outcomes</h6> <section id="CD015477-sec-0106"> <p><b>Confirmed symptomatic COVID‐19 after complete vaccination</b></p> <p>One trial reported this outcome at 6.2 months' follow‐up (<a href="./references#CD015477-bbs2-0021" title="KremsnerPG , Ahuad GuerreroRA , Arana-ArriE , Aroca MartinezGJ , BontenM , ChandlerR , et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3, randomized, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3911826]">Kremsner 2021</a>). CVnCoV probably results in a small reduction of confirmed symptomatic COVID‐19 after complete vaccination compared to placebo (VE 48.20%, 95% CI 31.70% to 60.90%; 1 RCT, 25,062 participants; moderate‐certainty evidence; <a href="#CD015477-fig-0003">Figure 3</a>). </p> </section> <section id="CD015477-sec-0107"> <p><b>Severe or critical COVID‐19 after complete vaccination </b></p> <p>One trial reported the outcome at six months' follow‐up (<a href="./references#CD015477-bbs2-0021" title="KremsnerPG , Ahuad GuerreroRA , Arana-ArriE , Aroca MartinezGJ , BontenM , ChandlerR , et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3, randomized, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3911826]">Kremsner 2021</a>). The evidence is very uncertain for an effect of CVnCoV in reducing severe or critical COVID‐19 compared to placebo due to serious indirectness and very serious imprecision (VE 63.80%, 95% CI 0.00% to 91.70%; 1 RCT, 25,062 participants; very low‐certainty evidence; <a href="#CD015477-fig-0004">Figure 4</a>). </p> </section> <section id="CD015477-sec-0108"> <p><b>All‐cause mortality</b></p> <p>One trial reported this outcome at six months' follow‐up (<a href="./references#CD015477-bbs2-0021" title="KremsnerPG , Ahuad GuerreroRA , Arana-ArriE , Aroca MartinezGJ , BontenM , ChandlerR , et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3, randomized, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3911826]">Kremsner 2021</a>). The evidence is very uncertain for an effect of CVnCoV on all‐cause mortality compared to placebo due to serious indirectness and very serious imprecision (RR 1.33, 95% CI 0.46 to 3.83; 1 RCT, 39,529 participants; very low‐certainty evidence; <a href="#CD015477-fig-0005">Figure 5</a>). </p> </section> <section id="CD015477-sec-0109"> <p><b>Serious adverse events</b></p> <p>One trial reported this outcome (<a href="./references#CD015477-bbs2-0021" title="KremsnerPG , Ahuad GuerreroRA , Arana-ArriE , Aroca MartinezGJ , BontenM , ChandlerR , et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3, randomized, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3911826]">Kremsner 2021</a>). The evidence is very uncertain for an effect of CVnCoV on SAEs compared to placebo at 1.7 months' follow‐up (RR 1.24, 95% CI 0.90 to 1.71; 1 RCT, 39,529 participants; low‐certainty evidence; <a href="#CD015477-fig-0006">Figure 6</a>). </p> </section> <section id="CD015477-sec-0110"> <p><b>Systemic reactogenicity events</b></p> <p>One trial reported this outcome (<a href="./references#CD015477-bbs2-0021" title="KremsnerPG , Ahuad GuerreroRA , Arana-ArriE , Aroca MartinezGJ , BontenM , ChandlerR , et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3, randomized, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3911826]">Kremsner 2021</a>). CVnCoV results in a large increase in the incidence of systemic reactogenicity events compared to placebo at 6.2 months' follow‐up (RR 1.48, 95% CI 1.43 to 1.53; 1 RCT, 3982 participants; absolute effect: 305 more with systemic reactogenicity events per 1000 (from 273 more to 336 more); high‐certainty evidence; <a href="#CD015477-fig-0009">Figure 9</a>). </p> </section> <section id="CD015477-sec-0111"> <p><b>Any adverse event</b></p> <p>One trial reported this outcome (<a href="./references#CD015477-bbs2-0021" title="KremsnerPG , Ahuad GuerreroRA , Arana-ArriE , Aroca MartinezGJ , BontenM , ChandlerR , et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3, randomized, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3911826]">Kremsner 2021</a>). CVnCoV probably results in a large increase in the incidence of any adverse event compared to placebo at one‐month follow‐up (RR 1.42, 95% CI 1.38 to 1.47; 1 RCT, 3982 participants; absolute effect: 285 more with any adverse event per 1000 (from 258 more to 319 more); moderate‐certainty evidence; <a href="#CD015477-fig-0007">Figure 7</a>).  </p> </section> </section> <section id="CD015477-sec-0112"> <h6 class="title">Important outcomes</h6> <section id="CD015477-sec-0113"> <p><b>Local reactogenicity events</b></p> <p>One trial reported this outcome (<a href="./references#CD015477-bbs2-0021" title="KremsnerPG , Ahuad GuerreroRA , Arana-ArriE , Aroca MartinezGJ , BontenM , ChandlerR , et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3, randomized, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3911826]">Kremsner 2021</a>). CVnCoV results in a large increase in the incidence of local reactogenicity events compared to placebo (RR 3.51, 95% CI 3.24 to 3.81; 1 RCT, 3982 participants; absolute effect: 606 more with local reactogenicity events per 1000 (from 541 more to 678 more); high‐certainty evidence; <a href="#CD015477-fig-0010">Figure 10</a>). </p> </section> </section> </section> </section> <section id="CD015477-sec-0114"> <h4 class="title">Non‐replicant viral vector vaccines</h4> <section id="CD015477-sec-0115"> <h5 class="title">ChAdOx1/SII‐ChAdOx1 – AstraZeneca+University of Oxford/Serum Institute of India versus placebo (normal saline/adjuvant/MenACWY) </h5> <p>See <a href="./full#CD015477-tbl-0004">summary of findings Table 4</a> and table of results in <a href="./appendices#CD015477-sec-0462">Appendix 15</a>. </p> <p>We identified and included in the analysis seven trials assessing ChAdOx1 – AstraZeneca/University of Oxford and one trial assessing SII‐ChAdOx1, the equivalent of ChAdOx1 manufactured in India at Serum Institute of India (<a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>). The latter did not report efficacy outcomes. </p> <p>The outcomes 'severe or critical COVID‐19 after complete vaccination', 'GMT of neutralizing antibodies against SARS‐CoV‐2' and 'cellular immune response' were not reported for this comparison. </p> <section id="CD015477-sec-0116"> <h6 class="title">Critical outcomes</h6> <section id="CD015477-sec-0117"> <p><b>Confirmed SARS‐CoV‐2 infection after complete vaccination</b></p> <p>This outcome was reported in five RCTs (<a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a>; <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> (which reported pooled results for four trials)). ChAdOx1 probably reduces SARS‐CoV‐2 infection compared to placebo and MenACWY vaccine at 1.3 months (median) and two months (median) follow‐up (VE 59.35%, 95% CI 48.00% to 68.22%; I² = 68%; 5 RCTs, 43,390 participants; moderate‐certainty evidence; <a href="#CD015477-fig-0011">Figure 11</a>). </p> <div class="figure" id="CD015477-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Analysis 2.1.1: Non‐replicating viral vector vaccine. Outcome: confirmed SARS‐CoV‐2 infection after complete vaccination.Voysey 2021a: data pooled from four trials." data-id="CD015477-fig-0011" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-11.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.1.1: Non‐replicating viral vector vaccine. Outcome: confirmed SARS‐CoV‐2 infection after complete vaccination. </p> <p><a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>: data pooled from four trials. </p> </div> </div> </div> </section> <section id="CD015477-sec-0118"> <p><b>Confirmed symptomatic COVID‐19 after complete vaccination</b></p> <p>Five RCTs reported this outcome (<a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a>; <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>) (<a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> (which reported pooled results for four trials)). ChAdOx1 results in a large reduction of the incidence of confirmed symptomatic COVID‐19 after complete vaccination compared to placebo and MenACWY vaccine at 1.3 months (median) and two months (median) follow‐up (VE 70.23%, 95% CI 62.10% to 76.62%; I² = 38%; 5 RCTs, 43,390 participants; high‐certainty evidence; <a href="#CD015477-fig-0012">Figure 12</a>). </p> <div class="figure" id="CD015477-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Analysis 2.1.2: non‐replicating viral vector vaccine. Outcome: confirmed symptomatic COVID‐19 after complete vaccination.Voysey 2021a: data pooled from four trials." data-id="CD015477-fig-0012" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-12.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.1.2: non‐replicating viral vector vaccine. Outcome: confirmed symptomatic COVID‐19 after complete vaccination. </p> <p><a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>: data pooled from four trials. </p> </div> </div> </div> </section> <section id="CD015477-sec-0119"> <p><b>All‐cause mortality</b></p> <p>Two trials reported this outcome in 1456 participants at 2‐month follow‐up (<a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a>; <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>); there were no events and the trials did not contribute to the effect estimate. Five trials contributed to the analysis with follow‐up from 2.0 months to 4.2 months (<a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a>; <a href="./references#CD015477-bbs2-0026" title="MadhiSA , KoenAL , IzuA , FairlieL , CutlandCL , BaillieV , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomized, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV2021;8(9):e568-80. ">Madhi 2021a</a> (which reported on HIV‐positive participants who were not included in this pooled analysis); <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> (which reported pooled results for four trials)). The evidence is uncertain for an effect of ChAdOx1 on all‐cause mortality compared to placebo and MenACWY vaccine due to very serious imprecision (RR 0.48, 95% CI 0.20 to 1.14; I² = 0%; 5 RCTs, 56,727 participants; low‐certainty evidence; <a href="#CD015477-fig-0013">Figure 13</a>). </p> <div class="figure" id="CD015477-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="Analysis 2.1.4: non‐replicating viral vector vaccine. Outcome: all‐cause mortality.In Kulkarni 2021, the control arm received adjuvant. Voysey 2021a: data pooled from four trials." data-id="CD015477-fig-0013" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-13.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.1.4: non‐replicating viral vector vaccine. Outcome: all‐cause mortality.</p> <p>In <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>, the control arm received adjuvant. <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>: data pooled from four trials. </p> </div> </div> </div> </section> <section id="CD015477-sec-0120"> <p><b>Serious adverse events</b></p> <p>Seven trials reported this outcome (<a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a>; <a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a>; <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>; <a href="./references#CD015477-bbs2-0026" title="MadhiSA , KoenAL , IzuA , FairlieL , CutlandCL , BaillieV , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomized, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV2021;8(9):e568-80. ">Madhi 2021a</a> (which reported on HIV‐positive participants who were not included in this pooled analysis); <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> (which reported pooled results for four trials)). ChAdOx1 probably results in no or little increase in the incidence of SAEs compared to placebo and at one month' to 6 months' follow‐up (RR 0.88, 95% CI 0.72 to 1.07; I² = 6%; 7 RCTs, 58,182 participants; absolute effect: 1 fewer with SAEs per 1000 (from 2 fewer to 1 more); moderate‐certainty evidence; <a href="#CD015477-fig-0014">Figure 14</a>). </p> <div class="figure" id="CD015477-fig-0014"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 14</div> </div> <hr class="top"/><img alt="Analysis 2.1.5: non‐replicating viral vector vaccine. Outcome: serious adverse events (SAEs).In Kulkarni 2021, the control arm received adjuvant. Voysey 2021a: data pooled from four trials." data-id="CD015477-fig-0014" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-14.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.1.5: non‐replicating viral vector vaccine. Outcome: serious adverse events (SAEs). </p> <p>In <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>, the control arm received adjuvant. <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>: data pooled from four trials. </p> </div> </div> </div> </section> <section id="CD015477-sec-0121"> <p><b>Systemic reactogenicity events</b></p> <p>This outcome was reported in one trial (<a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a>). ChAdOx1 probably results in a large increase of systemic reactogenicity events compared to placebo (RR 3.93, 95% CI 2.11 to 7.29; 1 RCT, 256 participants; absolute effect: 412 more with systemic reactogenicity events per 1000 (from 156 more to 885 more); moderate‐certainty evidence; <a href="#CD015477-fig-0015">Figure 15</a>). </p> <div class="figure" id="CD015477-fig-0015"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 15</div> </div> <hr class="top"/><img alt="Analysis 2.1.6: non‐replicating viral vector vaccine. Outcome: systemic reactogenicity events." data-id="CD015477-fig-0015" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-15.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.1.6: non‐replicating viral vector vaccine. Outcome: systemic reactogenicity events. </p> </div> </div> </div> </section> <section id="CD015477-sec-0122"> <p><b>Any adverse event</b></p> <p>Seven trials reported this outcome (<a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a>; <a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a>; <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>; <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> (which reported pooled results for four trials). Due to considerable heterogeneity, we decided not to pool the results (I² = 90%). <a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a> reported results for 256 participants at 1.2 months' follow‐up; the risk of any adverse event in the study was 2.54 (95% CI 1.73 to 3.74). <a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a> reported results for 32,379 participants at one‐month follow‐up; the risk for any adverse event was 1.37 (95% CI 1.33 to 1.42). <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a> reported results for 1200 participants at 1.9 months' follow‐up; the risk for any adverse event was 1.39 (95% CI 1.12 to 1.74). Lastly, a report pooling four trials presented results for 23,745 participants, the risk for any adverse event was 0.74 (95% CI 0.56 to 0.96) at 3.4 months' follow‐up  (<a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>). Of note, participants in the control arm received different interventions across studies; three trials used normal saline as placebo (<a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a>; COV005 included in <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>; <a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a>) and three used MenACWY vaccine (COV001, COV002, COV003 included in <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>) and one trial used adjuvant (<a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>) (<a href="#CD015477-fig-0016">Figure 16</a>). </p> <div class="figure" id="CD015477-fig-0016"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 16</div> </div> <hr class="top"/><img alt="Analysis 2.1.7: non‐replicating viral vector vaccine. Outcome: any adverse event (AE).In Kulkarni 2021, the control arm received adjuvant. Voysey 2021a merged results from four different trials where three used quadrivalent meningococcal conjugate vaccine as placebo and one trial used normal saline." data-id="CD015477-fig-0016" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-16.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.1.7: non‐replicating viral vector vaccine. Outcome: any adverse event (AE).</p> <p>In <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>, the control arm received adjuvant. <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> merged results from four different trials where three used quadrivalent meningococcal conjugate vaccine as placebo and one trial used normal saline. </p> </div> </div> </div> </section> </section> <section id="CD015477-sec-0123"> <h6 class="title">Important outcomes</h6> <section id="CD015477-sec-0124"> <p><b>GMTs of a specific antibody against SARS‐COV‐2</b></p> <p><a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> reported GMTs of specific antibodies against SARS‐COV‐2. Results are detailed in <a href="./appendices#CD015477-sec-0463">Appendix 16</a>. </p> </section> <section id="CD015477-sec-0125"> <p><b>Local reactogenicity events</b></p> <p>The outcome was reported in one trial (<a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a>). ChAdOx1 probably results in a large increase in the number of local reactogenicity events compared to placebo (RR 6.44, 95% CI 2.98 to 13.92; 1 RCT, 256 participants; absolute effect: 510 more with local reactogenicity events per 1000 (from 186 more to 1000 more); moderate‐certainty evidence; <a href="#CD015477-fig-0017">Figure 17</a>). </p> <div class="figure" id="CD015477-fig-0017"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 17</div> </div> <hr class="top"/><img alt="Analysis 2.1.8: non‐replicating viral vector vaccine. Outcome: local reactogenicity events." data-id="CD015477-fig-0017" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-17.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.1.8: non‐replicating viral vector vaccine. Outcome: local reactogenicity events. </p> </div> </div> </div> </section> <section id="CD015477-sec-0126"> <p><b>Incidence of specific safety outcomes</b></p> <p>Specific safety outcomes were not consistently reported throughout the included trials. <a href="./references#CD015477-bbs2-0026" title="MadhiSA , KoenAL , IzuA , FairlieL , CutlandCL , BaillieV , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomized, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV2021;8(9):e568-80. ">Madhi 2021a</a> reported number of participants with subsequent nervous system diseases, <a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a> reported number of participants with stroke, cavernous sinus thrombosis, venous thrombosis and nervous system disorders, <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> presented results for the number of participants with pulmonary embolism, pericarditis, venous thrombosis, myocardial infarction, anaemia and nervous system diseases, and <a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a> and <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a> did not report any specific safety outcome of interest. Outcomes are summarized in detail in <a href="./appendices#CD015477-sec-0456">Appendix 12</a>. </p> </section> <section id="CD015477-sec-0127"> <p><b>Vaccine‐enhanced disease</b></p> <p><a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a> reported no vaccine‐enhanced disease effect. </p> </section> </section> </section> <section id="CD015477-sec-0128"> <h5 class="title">ChAdOx1 – AstraZeneca+University of Oxford versus SII‐ChAdOx1 – Serum Institute of India  </h5> <p>See <a href="./full#CD015477-tbl-0005">summary of findings Table 5</a> and table of results in <a href="./appendices#CD015477-sec-0469">Appendix 17</a>. </p> <p><a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a> reported results on ChAdOx1 compared to SII‐ChAdOx1 (the equivalent of ChAdOx1 manufactured in India at Serum Institute of India). </p> <section id="CD015477-sec-0129"> <h6 class="title">Critical outcomes</h6> <section id="CD015477-sec-0130"> <p><b>All‐cause mortality</b></p> <p><a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a> reported this outcome at six months' follow‐up. The trial including 400 participants reported zero events for both groups for this outcome (<a href="#CD015477-fig-0018">Figure 18</a>). </p> <div class="figure" id="CD015477-fig-0018"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 18</div> </div> <hr class="top"/><img alt="Analysis 2.2.1: serum Institute of India/Astra Zeneca+University of Oxford – SII‐ChAdOx1 versus University of Oxford – ChAdOx1. Outcome: all‐cause mortality." data-id="CD015477-fig-0018" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-18.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.2.1: serum Institute of India/Astra Zeneca+University of Oxford – SII‐ChAdOx1 versus University of Oxford – ChAdOx1. Outcome: all‐cause mortality. </p> </div> </div> </div> </section> <section id="CD015477-sec-0131"> <p><b>Serious adverse events</b></p> <p><a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a> reported this outcome at six months' follow‐up. The evidence is uncertain for an effect of SII‐ChAdOx1 on the incidence of SAEs compared to ChAdOx1 due to very serious imprecision (RR 0.50, 95% CI 0.08 to 2.95; 1 RCT, 400 participants; low‐certainty evidence; <a href="#CD015477-fig-0019">Figure 19</a>). </p> <div class="figure" id="CD015477-fig-0019"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 19</div> </div> <hr class="top"/><img alt="Analysis 2.2.2: SII‐ChAdOx1 versus ChAdOx1. Outcome: serious adverse events (SAEs)." data-id="CD015477-fig-0019" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-19.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.2.2: SII‐ChAdOx1 versus ChAdOx1. Outcome: serious adverse events (SAEs).</p> </div> </div> </div> </section> <section id="CD015477-sec-0132"> <p><b>Systemic reactogenicity events</b></p> <p><a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a> reported this outcome. SII‐ChAdOx1 probably results in a slight decrease in the number of systemic reactogenicity events compared to ChAdOx1 (RR 0.73, 95% CI 0.54 to 0.98; 1 RCT, 400 participants; absolute effect: 105 fewer with systemic reactogenicity events per 1000 (from 179 fewer to 8 fewer); moderate‐certainty evidence; <a href="#CD015477-fig-0020">Figure 20</a>). </p> <div class="figure" id="CD015477-fig-0020"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 20</div> </div> <hr class="top"/><img alt="Analysis 2.2.3: SII‐ChAdOx1 versus ChAdOx1. Outcome: systemic reactogenicity events." data-id="CD015477-fig-0020" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-20.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.2.3: SII‐ChAdOx1 versus ChAdOx1. Outcome: systemic reactogenicity events.</p> </div> </div> </div> </section> <section id="CD015477-sec-0133"> <p><b>Any adverse event</b></p> <p><a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a> reported this outcome at 1.9 months' follow‐up. The evidence is uncertain for an effect of SII‐ChAdOx1 on the incidence of any adverse event compared to ChAdOx1 due to very serious imprecision (RR 0.83, 95% CI 0.52 to 1.33; 1 RCT, 400 participants; low‐certainty evidence; <a href="#CD015477-fig-0021">Figure 21</a>). </p> <div class="figure" id="CD015477-fig-0021"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 21</div> </div> <hr class="top"/><img alt="Analysis 2.2.4: SII‐ChAdOx1 versus ChAdOx1. Outcome: any adverse event (AE)." data-id="CD015477-fig-0021" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-21.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.2.4: SII‐ChAdOx1 versus ChAdOx1. Outcome: any adverse event (AE).</p> </div> </div> </div> </section> </section> <section id="CD015477-sec-0134"> <h6 class="title">Important outcomes</h6> <section id="CD015477-sec-0135"> <p><b>Immunogenicity outcomes</b></p> <p><a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a> reported that SII‐ChAdOx1 elicited slightly higher levels of specific antibodies against SARS‐COV‐2 (GMR 1.52, 95% CI 1.03 to 2.26) compared to ChAdOx1 (<a href="./appendices#CD015477-sec-0463">Appendix 16</a>). Results for neutralizing antibodies against SARS‐COV‐2 were not conclusive because of imprecision (GMR 1.23, 95% CI 0.92 to 1.63). </p> </section> <section id="CD015477-sec-0136"> <p><b>Local reactogenicity events</b></p> <p><a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a> reported this outcome. The evidence is uncertain for an effect of SII‐ChAdOx1 on the incidence of local reactogenicity events compared to ChAdOx1 (RR 0.76, 95% CI 0.55 to 1.05; 1 RCT, 400 participants; low‐certainty evidence; <a href="#CD015477-fig-0022">Figure 22</a>). </p> <div class="figure" id="CD015477-fig-0022"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 22</div> </div> <hr class="top"/><img alt="Analysis 2.2.5: SII‐ChAdOx1 versus ChAdOx1. Outcome: local reactogenicity events. " data-id="CD015477-fig-0022" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-22.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.2.5: SII‐ChAdOx1 versus ChAdOx1. Outcome: local reactogenicity events. </p> </div> </div> </div> </section> </section> </section> <section id="CD015477-sec-0137"> <h5 class="title">Ad26.COV2.S – Janssen Pharmaceutical Companies versus placebo (normal saline)</h5> <p>See <a href="./full#CD015477-tbl-0006">summary of findings Table 6</a> and table of results in <a href="./appendices#CD015477-sec-0470">Appendix 18</a>. </p> <p>We identified and included in the analysis two trials assessing Ad26.COV2.S. The outcomes 'SARS‐CoV‐2 infection after complete vaccination', 'GMT of specific antibodies against SARS‐CoV‐2', and 'cellular immune response' were not reported for this comparison. </p> <section id="CD015477-sec-0138"> <h6 class="title">Critical outcomes</h6> <section id="CD015477-sec-0139"> <p><b>Confirmed symptomatic COVID‐19 after complete vaccination</b></p> <p>This outcome was reported in <a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a>. Ad26.COV2.S reduces the incidence of confirmed symptomatic COVID‐19 after complete vaccination compared to placebo at 1.9 months (median) follow‐up (VE 66.90%, 95% CI 59.10% to 73.40%; 1 RCT, 39,058 participants; high‐certainty evidence; <a href="#CD015477-fig-0012">Figure 12</a>). </p> </section> <section id="CD015477-sec-0140"> <p><b>Severe or critical COVID‐19 after complete vaccination</b></p> <p>This outcome was reported in <a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a>. Ad26.COV2.S results in a large reduction of severe or critical COVID‐19 compared to placebo at 1.9 months (median) follow‐up (VE 76.30%, 95% CI 57.90% to 87.50%; 1 RCT, 39,058 participants; high‐certainty evidence; <a href="#CD015477-fig-0023">Figure 23</a>). </p> <div class="figure" id="CD015477-fig-0023"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 23</div> </div> <hr class="top"/><img alt="Analysis 2.1.3: non‐replicating viral vector vaccine. Outcome: severe or critical COVID‐19 after complete vaccination." data-id="CD015477-fig-0023" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-23.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.1.3: non‐replicating viral vector vaccine. Outcome: severe or critical COVID‐19 after complete vaccination. </p> </div> </div> </div> </section> <section id="CD015477-sec-0141"> <p><b>All‐cause mortality</b></p> <p>This outcome was reported in <a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a>. Ad26.COV2.S probably results in a reduction in all‐cause mortality compared to placebo at 1.9 months (median) follow‐up (RR 0.25, 95% CI 0.09 to 0.67; 1 RCT, 43,783 participants; absolute effect: 69 fewer per 100,000 (from 83 fewer to 30 fewer); high‐certainty evidence; <a href="#CD015477-fig-0013">Figure 13</a>). </p> </section> <section id="CD015477-sec-0142"> <p><b>Serious adverse events</b></p> <p>This outcome was reported in <a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a>. Ad26.COV2.S probably results in little or no difference in the incidence of SAEs at 1.9 months (median) follow‐up (RR 0.92, 95% CI 0.69 to 1.22; 1 RCT, 43,783 participants; absolute effect: 36 fewer per 100,000 (from 139 fewer to 99 more); moderate‐certainty evidence; <a href="#CD015477-fig-0014">Figure 14</a>). </p> </section> <section id="CD015477-sec-0143"> <p><b>Systemic reactogenicity events</b></p> <p>Two trials reported this outcome (<a href="./references#CD015477-bbs2-0031" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; February 26, 2021; FDA briefing document: Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. www.fda.gov/media/146217/download (accessed prior to 1 November 2022). SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Interim results of a Phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. New England Journal of Medicine2021;384(19):1824-35. SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.09.23.20199604]">Sadoff 2021a</a>; <a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a>). Ad26.COV2.S results in a large increase in systemic reactogenicity events compared to placebo (RR 1.83, 95% CI 1.29 to 2.60; I² = 83%; 2 RCTs, 7222 participants; absolute effect: 28,697 more per 100,000 (from 10,027 more to 55,320 more); high‐certainty evidence; <a href="#CD015477-fig-0015">Figure 15</a>). </p> </section> <section id="CD015477-sec-0144"> <p><b>Any adverse event</b></p> <p>The outcome was reported in two trials (<a href="./references#CD015477-bbs2-0031" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; February 26, 2021; FDA briefing document: Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. www.fda.gov/media/146217/download (accessed prior to 1 November 2022). SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Interim results of a Phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. New England Journal of Medicine2021;384(19):1824-35. SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.09.23.20199604]">Sadoff 2021a</a>; <a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a>). We decided not to pool the results due to considerable heterogeneity (I² = 96%). <a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a> reported results for 6736 participants at one‐month follow‐up; the risk for any adverse event was 1.09 (95% CI 0.96 to 1.24). <a href="./references#CD015477-bbs2-0031" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; February 26, 2021; FDA briefing document: Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. www.fda.gov/media/146217/download (accessed prior to 1 November 2022). SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Interim results of a Phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. New England Journal of Medicine2021;384(19):1824-35. SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.09.23.20199604]">Sadoff 2021a</a> reported results for 486 participants; the risk for adverse events was 2.31 (95% CI 1.80 to 2.97; <a href="#CD015477-fig-0016">Figure 16</a>). </p> </section> </section> <section id="CD015477-sec-0145"> <h6 class="title">Important outcomes</h6> <section id="CD015477-sec-0146"> <p><b>Immunogenicity outcomes</b></p> <p><a href="./references#CD015477-bbs2-0031" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; February 26, 2021; FDA briefing document: Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. www.fda.gov/media/146217/download (accessed prior to 1 November 2022). SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Interim results of a Phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. New England Journal of Medicine2021;384(19):1824-35. SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.09.23.20199604]">Sadoff 2021a</a> reported GMTs of neutralizing antibodies against SARS‐COV‐2. Results are detailed in <a href="./appendices#CD015477-sec-0449">Appendix 11</a>. </p> </section> <section id="CD015477-sec-0147"> <p><b>Local reactogenicity events</b></p> <p>Two trials reported this outcome (<a href="./references#CD015477-bbs2-0031" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; February 26, 2021; FDA briefing document: Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. www.fda.gov/media/146217/download (accessed prior to 1 November 2022). SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Interim results of a Phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. New England Journal of Medicine2021;384(19):1824-35. SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.09.23.20199604]">Sadoff 2021a</a>; <a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a>). Ad26.COV2.S results in a large increase in local reactogenicity events compared to placebo (RR 3.27, 95% CI 1.91 to 5.62; I² = 84%; 2 RCTs, 7222 participants; absolute effect: 433 more with local reactogenicity events per 1000 (from 174 more to 881 more); high‐certainty evidence; <a href="#CD015477-fig-0017">Figure 17</a>). </p> </section> <section id="CD015477-sec-0148"> <p><b>Incidence of specific safety outcomes</b></p> <p>Specific safety outcomes were not consistently reported throughout the included trials: <a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a> reported the number of participants with pulmonary embolism, cavernous sinus thrombosis, pericarditis and venous thrombosis; <a href="./references#CD015477-bbs2-0031" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; February 26, 2021; FDA briefing document: Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. www.fda.gov/media/146217/download (accessed prior to 1 November 2022). SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Interim results of a Phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. New England Journal of Medicine2021;384(19):1824-35. SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.09.23.20199604]">Sadoff 2021a</a> did not report any specific safety outcomes of interest. Outcomes are summarized in detail in <a href="./appendices#CD015477-sec-0456">Appendix 12</a>. </p> </section> <section id="CD015477-sec-0149"> <p><b>Vaccine‐enhanced disease</b></p> <p><a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a> reported no vaccine‐enhanced disease effect. </p> </section> </section> </section> <section id="CD015477-sec-0150"> <h5 class="title">Gam‐COVID‐Vac – Gamaleya Research Institute (Sputnik V) versus placebo (adjuvant)</h5> <p>See <a href="./full#CD015477-tbl-0007">summary of findings Table 7</a> and table of results in <a href="./appendices#CD015477-sec-0471">Appendix 19</a>. </p> <p>We identified and included one trial in the analysis assessing Gam‐COVID‐Vac (<a href="./references#CD015477-bbs2-0025" title="LogunovDY , DolzhikovaIV , ShcheblyakovDV , TukhvatulinAI , ZubkovaOV , DzharullaevaAS , et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia. Lancet2021;397(10275):671-81. ">Logunov 2021</a>). </p> <p>The outcomes 'SARS‐CoV‐2 infection after complete vaccination', 'incidence of any adverse event', 'systemic reactogenicity events' and 'vaccine‐enhanced disease' were not reported for this comparison. </p> <p>Some important concerns were raised concerning <a href="./references#CD015477-bbs2-0025" title="LogunovDY , DolzhikovaIV , ShcheblyakovDV , TukhvatulinAI , ZubkovaOV , DzharullaevaAS , et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia. Lancet2021;397(10275):671-81. ">Logunov 2021</a>: lack of clarity in the definition of the primary outcome; addition of interim analyses; change in outcomes; inadequate reporting with inconsistencies in numbers; and excess of homogeneity of vaccine efficacy across age groups (<a href="./references#CD015477-bbs2-0062" title="BucciEM , BerkhofJ , GillibertA , GopalakrishnaG , CalogeroRA , BouterLM , et al. Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial. Lancet2021;397(10288):1881-3.">Bucci 2021</a>). The authors responded to some of these concerns and the manuscript was corrected (<a href="./references#CD015477-bbs2-0025" title="LogunovDY , DolzhikovaIV , ShcheblyakovDV , TukhvatulinAI , ZubkovaOV , DzharullaevaAS , et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia. Lancet2021;397(10275):671-81. ">Logunov 2021</a>). Nevertheless, uncertainty persists related to the prespecification of the interim analysis and excess of homogeneity of vaccine efficacy across age groups. Consequently, we decided to downgrade the certainty of evidence for these reasons. </p> <section id="CD015477-sec-0151"> <h6 class="title">Critical outcomes</h6> <section id="CD015477-sec-0152"> <p><b>Confirmed symptomatic COVID‐19 after complete vaccination</b></p> <p>This outcome was reported in <a href="./references#CD015477-bbs2-0025" title="LogunovDY , DolzhikovaIV , ShcheblyakovDV , TukhvatulinAI , ZubkovaOV , DzharullaevaAS , et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia. Lancet2021;397(10275):671-81. ">Logunov 2021</a>. Gam‐COVID‐Vac probably results in a large reduction in the incidence of confirmed symptomatic COVID‐19 after complete vaccination compared to placebo (follow‐up time not reported) (VE 91.10%, 95% CI 83.80% to 95.10%; 1 RCT, 18,695 participants; moderate‐certainty evidence). Of note, vaccine efficacy for this outcome was calculated using RR (<a href="#CD015477-fig-0012">Figure 12</a>). </p> </section> <section id="CD015477-sec-0153"> <p><b>Severe or critical COVID‐19 after complete vaccination</b></p> <p>This outcome was reported in <a href="./references#CD015477-bbs2-0025" title="LogunovDY , DolzhikovaIV , ShcheblyakovDV , TukhvatulinAI , ZubkovaOV , DzharullaevaAS , et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia. Lancet2021;397(10275):671-81. ">Logunov 2021</a>. Gam‐COVID‐Vac probably results in a large reduction in the incidence of severe or critical COVID‐19 compared to placebo (follow‐up time not reported) (VE 100.00%, 95% CI 94.40% to 100.00%; 1 RCT, 19,866 participants; moderate‐certainty evidence; <a href="#CD015477-fig-0023">Figure 23</a>). </p> </section> <section id="CD015477-sec-0154"> <p><b>All‐cause mortality</b></p> <p><a href="./references#CD015477-bbs2-0025" title="LogunovDY , DolzhikovaIV , ShcheblyakovDV , TukhvatulinAI , ZubkovaOV , DzharullaevaAS , et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia. Lancet2021;397(10275):671-81. ">Logunov 2021</a> reported this outcome at 1.6 months' follow‐up. The evidence is very uncertain for an effect of Gam‐COVID‐Vac in all‐cause mortality compared to placebo due to serious imprecision (RR 0.99, 95% CI 0.10 to 9.54; 1 RCT, 21,862 participants; very low‐certainty evidence; <a href="#CD015477-fig-0013">Figure 13</a>). </p> </section> <section id="CD015477-sec-0155"> <p><b>Serious adverse events</b></p> <p><a href="./references#CD015477-bbs2-0025" title="LogunovDY , DolzhikovaIV , ShcheblyakovDV , TukhvatulinAI , ZubkovaOV , DzharullaevaAS , et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia. Lancet2021;397(10275):671-81. ">Logunov 2021</a> reported this outcome. The evidence is uncertain for an effect of Gam‐COVID‐Vac in the incidence of SAEs compared to placebo at 1.6 months' follow‐up (RR 0.65, 95% CI 0.39 to 1.07; 1 RCT, 21,862 participants; low‐certainty evidence; <a href="#CD015477-fig-0014">Figure 14</a>). </p> </section> </section> <section id="CD015477-sec-0156"> <h6 class="title">Important outcomes</h6> <section id="CD015477-sec-0157"> <p><b>Immunogenicity outcomes</b></p> <p><a href="./references#CD015477-bbs2-0025" title="LogunovDY , DolzhikovaIV , ShcheblyakovDV , TukhvatulinAI , ZubkovaOV , DzharullaevaAS , et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia. Lancet2021;397(10275):671-81. ">Logunov 2021</a> reported GMTs of neutralizing and specific antibodies against SARS‐CoV‐2, and cellular immune response. Results are detailed in <a href="./appendices#CD015477-sec-0449">Appendix 11</a>, <a href="./appendices#CD015477-sec-0463">Appendix 16</a>, and <a href="./appendices#CD015477-sec-0472">Appendix 20</a>, respectively. </p> </section> <section id="CD015477-sec-0158"> <p><b>Incidence of specific safety outcomes</b></p> <p><a href="./references#CD015477-bbs2-0025" title="LogunovDY , DolzhikovaIV , ShcheblyakovDV , TukhvatulinAI , ZubkovaOV , DzharullaevaAS , et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia. Lancet2021;397(10275):671-81. ">Logunov 2021</a> reported number of participants with cavernous sinus thrombosis, venous thrombosis, myocardial infarction, lymphadenopathy and nervous system diseases. Details are in <a href="./appendices#CD015477-sec-0456">Appendix 12</a>. </p> </section> </section> </section> </section> <section id="CD015477-sec-0159"> <h4 class="title">Inactivated virus vaccines</h4> <section id="CD015477-sec-0160"> <h5 class="title">CoronaVac – Sinovac versus placebo (adjuvant) </h5> <p>See <a href="./full#CD015477-tbl-0008">summary of findings Table 8</a> and table of results in <a href="./appendices#CD015477-sec-0473">Appendix 21</a>. </p> <p>We identified and included in the analysis seven trials assessing CoronaVac – Sinovac. The outcome 'SARS‐CoV‐2 infection after complete vaccination' was not reported for this comparison. </p> <section id="CD015477-sec-0161"> <h6 class="title">Critical outcomes</h6> <section id="CD015477-sec-0162"> <p><b>Confirmed symptomatic COVID‐19 after complete vaccination</b></p> <p>This outcome was reported in two trials at 1.4 months (median) to 2 months (median) follow‐up (<a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>; <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>). The evidence is uncertain for an effect of CoronaVac on the incidence of confirmed symptomatic COVID‐19 after complete vaccination compared to adjuvant due to serious inconsistency and imprecision (VE 69.81%, 95% CI 12.27% to 89.61%; I² = 92%; 2 RCTs, 19,852 participants; low‐certainty evidence). There was considerable heterogeneity between included studies which could be due to participant’s different level of exposure to the virus across studies (all participants included in <a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a> were healthcare workers compared to a third in <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>) (<a href="#CD015477-fig-0024">Figure 24</a>). </p> <div class="figure" id="CD015477-fig-0024"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 24</div> </div> <hr class="top"/><img alt="Analysis 3.1.2: inactivated virus vaccine. Outcome: confirmed symptomatic COVID‐19 after complete vaccination.Al Kaabi 2021.1 and Al Kaabi N 2021.2 refers to two different comparisons from the same report (Al Kaabi 2021)." data-id="CD015477-fig-0024" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-24.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 3.1.2: inactivated virus vaccine. Outcome: confirmed symptomatic COVID‐19 after complete vaccination. </p> <p>Al Kaabi 2021.1 and Al Kaabi N 2021.2 refers to two different comparisons from the same report (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). </p> </div> </div> </div> </section> <section id="CD015477-sec-0163"> <p><b>Severe or critical COVID‐19 after complete vaccination</b></p> <p>Two trials reported this outcome (<a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>; <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>). We did not conduct a meta‐analysis for this outcome since the typical normality assumption of the meta‐analysis model would be invalid due to the skewness of the data. This can be seen in the forest plots where the CI is not symmetric around the point estimate. <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>, with 0/6559 events in the CoronaVac group versus 1/3470 events in the control group reported a vaccine efficacy of 100.00%, 95% CI 20.40% to 100.00% at 1.4 months (median) follow‐up; and <a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>, with 0/4953 events in the CoronaVac group and 6/4870 events in the control group reported a vaccine efficacy of 100.00%, 95% CI 16.90% to 100.00% at two months (median) follow‐up (<a href="#CD015477-fig-0025">Figure 25</a>). </p> <div class="figure" id="CD015477-fig-0025"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 25</div> </div> <hr class="top"/><img alt="Analysis 3.1.3: inactivated virus vaccine. Outcome: severe or critical COVID‐19 after complete vaccination." data-id="CD015477-fig-0025" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-25.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 3.1.3: inactivated virus vaccine. Outcome: severe or critical COVID‐19 after complete vaccination. </p> </div> </div> </div> </section> <section id="CD015477-sec-0164"> <p><b>All‐cause mortality</b></p> <p>This outcome was reported in two trials at 1.4 months (median) to two months (median) follow‐up (<a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>; <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>). The evidence is uncertain for an effect of CoronaVac on all‐cause mortality compared to adjuvant due to very serious imprecision (RR 0.50, 95% CI 0.05 to 5.52; 2 RCTs, 22,610 participants; I² = 32%; low‐certainty evidence; <a href="#CD015477-fig-0026">Figure 26</a>). </p> <div class="figure" id="CD015477-fig-0026"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 26</div> </div> <hr class="top"/><img alt="Analysis 3.1.4: inactivated virus vaccine. Outcome: all‐cause mortality.Al Kaabi 2021.1 and Al Kaabi N 2021.2 refers to two different comparisons from the same report (Al Kaabi 2021)." data-id="CD015477-fig-0026" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-26.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 3.1.4: inactivated virus vaccine. Outcome: all‐cause mortality.</p> <p>Al Kaabi 2021.1 and Al Kaabi N 2021.2 refers to two different comparisons from the same report (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). </p> </div> </div> </div> </section> <section id="CD015477-sec-0165"> <p><b>Serious adverse events</b></p> <p>Two trials reported this outcome in 482 participants at 1.4 months' follow‐up (<a href="./references#CD015477-bbs2-0005" title="BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.03.31.21254494]BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile. Clinical Infectious Diseases 2021 Sep 19 [Epub ahead of print]. [DOI: 10.1093/cid/ciab823]">Bueno 2021</a>; <a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a>); there were no events and the trials did not contribute to the effect estimate. Four RCTs contributed to the analysis with follow‐up of two months (median) to four months (<a href="./references#CD015477-bbs2-0018" title="HanB , SongY , LiC , YangW , MaQ , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(12):1645-53. ">Han 2021</a>; <a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>; <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>; <a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>). The evidence is uncertain for an effect of CoronaVac on SAEs compared to adjuvant due to very serious imprecision (RR 0.97, 95% CI 0.62 to 1.51; 4 RCTs, 23,139 participants; I² = 0%; low‐certainty evidence; <a href="#CD015477-fig-0027">Figure 27</a>). </p> <div class="figure" id="CD015477-fig-0027"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 27</div> </div> <hr class="top"/><img alt="Analysis 3.1.5: inactivated virus vaccine. Outcome: serious adverse events (SAEs).Han 2021 included only participants 3 to 17 years of age. Wu 2021a included only participants 60 years of age and older.Wu 2021a reports data for phase 1 and 2. Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (Al Kaabi 2021)." data-id="CD015477-fig-0027" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-27.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 3.1.5: inactivated virus vaccine. Outcome: serious adverse events (SAEs).</p> <p><a href="./references#CD015477-bbs2-0018" title="HanB , SongY , LiC , YangW , MaQ , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(12):1645-53. ">Han 2021</a> included only participants 3 to 17 years of age. <a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a> included only participants 60 years of age and older. </p> <p><a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a> reports data for phase 1 and 2. Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). </p> </div> </div> </div> </section> <section id="CD015477-sec-0166"> <p><b>Systemic reactogenicity events</b></p> <p>Six trials reported this outcome (<a href="./references#CD015477-bbs2-0005" title="BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.03.31.21254494]BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile. Clinical Infectious Diseases 2021 Sep 19 [Epub ahead of print]. [DOI: 10.1093/cid/ciab823]">Bueno 2021</a>; <a href="./references#CD015477-bbs2-0012" title="FadlyanaE , RusmilK , TariganR , RahmadiAR , ProdjosoewojoS , SofiatinY , et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: an interim analysis in Indonesia. Vaccine2021;39(44):6520-8. ">Fadlyana 2021</a>; <a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>; <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>; <a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>; <a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a>). The evidence is uncertain for an effect of CoronaVac on systemic reactogenicity events compared to adjuvant due to serious inconsistency and imprecision (RR 1.19, 95% CI 1.00 to 1.42; 6 RCTs, 23,966 participants; I² = 55%; low‐certainty evidence; <a href="#CD015477-fig-0028">Figure 28</a>). </p> <div class="figure" id="CD015477-fig-0028"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 28</div> </div> <hr class="top"/><img alt="Analysis 3.1.6: inactivated virus vaccine. Outcome: systemic reactogenicity events.Xia S 2021 included only participants 3 to 17 years of age (Xia 2021). Wu Z 2021 included only participants 60 years of age and older (Wu 2021a).Wu Z 2021 reports data for phase 2 (Wu 2021a). Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (Al Kaabi 2021). Zhang 2020.1 and Zhang 2020.2 refers to two different comparisons from the same report (Zhang 2021)." data-id="CD015477-fig-0028" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-28.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 3.1.6: inactivated virus vaccine. Outcome: systemic reactogenicity events.</p> <p>Xia S 2021 included only participants 3 to 17 years of age (<a href="./references#CD015477-bbs2-0041" title="XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1/2 trial. Lancet Infectious Diseases2021;22(2):196-208. ">Xia 2021</a>). Wu Z 2021 included only participants 60 years of age and older (<a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>). </p> <p>Wu Z 2021 reports data for phase 2 (<a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>). Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). Zhang 2020.1 and Zhang 2020.2 refers to two different comparisons from the same report (<a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a>). </p> </div> </div> </div> </section> <section id="CD015477-sec-0167"> <p><b>Any adverse event</b></p> <p>This outcome was reported in five trials at one month' to three months' (median) follow‐up (<a href="./references#CD015477-bbs2-0018" title="HanB , SongY , LiC , YangW , MaQ , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(12):1645-53. ">Han 2021</a>; <a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>; <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>; <a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>; <a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a>). CoronaVac results in a slight difference in the incidence of any adverse event compared to adjuvant (RR 1.09, 95% CI 1.07 to 1.11; 6 RCTs, 23,367 participants; absolute effect: 48 more with any adverse event per 1000 (from 37 more to 58 more); high‐certainty evidence; <a href="#CD015477-fig-0029">Figure 29</a>). </p> <div class="figure" id="CD015477-fig-0029"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 29</div> </div> <hr class="top"/><img alt="Analysis 3.1.7: inactivated virus vaccine. Outcome: any adverse event (AE).Han B 2021 and Xia 2021 included only participants 3 to 17 years of age (Han 2021; Xia 2021). Wu Z 2021 included only participants 60 years of age and older (Wu 2021a).Wu Z 2021 reports data for phase 1 and 2 (Wu 2021a), Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (Al Kaabi 2021). Zhang 2020.1 and Zhang 2020.2 refers to two different comparisons from the same report (Zhang 2021)." data-id="CD015477-fig-0029" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-29.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 3.1.7: inactivated virus vaccine. Outcome: any adverse event (AE).</p> <p>Han B 2021 and Xia 2021 included only participants 3 to 17 years of age (<a href="./references#CD015477-bbs2-0018" title="HanB , SongY , LiC , YangW , MaQ , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(12):1645-53. ">Han 2021</a>; <a href="./references#CD015477-bbs2-0041" title="XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1/2 trial. Lancet Infectious Diseases2021;22(2):196-208. ">Xia 2021</a>). Wu Z 2021 included only participants 60 years of age and older (<a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>). </p> <p>Wu Z 2021 reports data for phase 1 and 2 (<a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>), Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). Zhang 2020.1 and Zhang 2020.2 refers to two different comparisons from the same report (<a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a>). </p> </div> </div> </div> </section> </section> <section id="CD015477-sec-0168"> <h6 class="title">Important outcomes</h6> <section id="CD015477-sec-0169"> <p><b>Immunogenicity outcomes</b></p> <p>Five trials reported GMTs of neutralizing and specific antibodies against SARS‐COV‐2 (<a href="./references#CD015477-bbs2-0005" title="BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.03.31.21254494]BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile. Clinical Infectious Diseases 2021 Sep 19 [Epub ahead of print]. [DOI: 10.1093/cid/ciab823]">Bueno 2021</a>; <a href="./references#CD015477-bbs2-0012" title="FadlyanaE , RusmilK , TariganR , RahmadiAR , ProdjosoewojoS , SofiatinY , et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: an interim analysis in Indonesia. Vaccine2021;39(44):6520-8. ">Fadlyana 2021</a>; <a href="./references#CD015477-bbs2-0018" title="HanB , SongY , LiC , YangW , MaQ , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(12):1645-53. ">Han 2021</a>; <a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>; <a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a>), and one trial reported results for cellular immune response (<a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a>). Results are detailed in <a href="./appendices#CD015477-sec-0449">Appendix 11</a>, <a href="./appendices#CD015477-sec-0463">Appendix 16</a>, and <a href="./appendices#CD015477-sec-0472">Appendix 20</a>. </p> </section> <section id="CD015477-sec-0170"> <p><b>Local reactogenicity events</b></p> <p>Six trials reported this outcome (<a href="./references#CD015477-bbs2-0005" title="BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.03.31.21254494]BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile. Clinical Infectious Diseases 2021 Sep 19 [Epub ahead of print]. [DOI: 10.1093/cid/ciab823]">Bueno 2021</a>; <a href="./references#CD015477-bbs2-0012" title="FadlyanaE , RusmilK , TariganR , RahmadiAR , ProdjosoewojoS , SofiatinY , et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: an interim analysis in Indonesia. Vaccine2021;39(44):6520-8. ">Fadlyana 2021</a>; <a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>; <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>; <a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>; <a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a>)  CoronaVac results in a slight increase in the occurrence of local reactogenicity events compared to adjuvant (RR 1.76, 95% CI 1.69 to 1.82; 6 RCTs, 23,962 participants; I² = 0%; absolute effect: 173 more per 1000 (from 157 more to 187 more); high‐certainty evidence; <a href="#CD015477-fig-0030">Figure 30</a>). </p> <div class="figure" id="CD015477-fig-0030"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 30</div> </div> <hr class="top"/><img alt="Analysis 3.1.8: inactivated virus vaccine. Outcome: local reactogenicity events.Xia S 2021 included only participants 3 to 17 years of age (Xia 2021). Wu Z 2021 included only participants 60 years of age and older (Wu 2021a).Wu Z 2021 reports data for phase 2 (Wu 2021a). Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (Al Kaabi 2021). Zhang 2020.1 and Zhang 2020.2 refers to two different comparisons from the same report (Zhang 2021)." data-id="CD015477-fig-0030" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-30.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 3.1.8: inactivated virus vaccine. Outcome: local reactogenicity events.</p> <p>Xia S 2021 included only participants 3 to 17 years of age (<a href="./references#CD015477-bbs2-0041" title="XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1/2 trial. Lancet Infectious Diseases2021;22(2):196-208. ">Xia 2021</a>). Wu Z 2021 included only participants 60 years of age and older (<a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>). </p> <p>Wu Z 2021 reports data for phase 2 (<a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>). Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). Zhang 2020.1 and Zhang 2020.2 refers to two different comparisons from the same report (<a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a>). </p> </div> </div> </div> </section> <section id="CD015477-sec-0171"> <p><b>Incidence of specific safety outcomes</b></p> <p>Specific safety outcomes were not consistently reported throughout the included trials: <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a> reported number of participants with myocardial infarction and nervous system diseases; <a href="./references#CD015477-bbs2-0012" title="FadlyanaE , RusmilK , TariganR , RahmadiAR , ProdjosoewojoS , SofiatinY , et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: an interim analysis in Indonesia. Vaccine2021;39(44):6520-8. ">Fadlyana 2021</a> reported the number of participants with venous thrombosis and nervous system diseases; and five trials reported no specific safety outcome of interest (<a href="./references#CD015477-bbs2-0005" title="BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.03.31.21254494]BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile. Clinical Infectious Diseases 2021 Sep 19 [Epub ahead of print]. [DOI: 10.1093/cid/ciab823]">Bueno 2021</a>; <a href="./references#CD015477-bbs2-0018" title="HanB , SongY , LiC , YangW , MaQ , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(12):1645-53. ">Han 2021</a>; <a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>; <a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>; <a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a>). Outcomes of interest are summarized in <a href="./appendices#CD015477-sec-0456">Appendix 12</a>. </p> </section> <section id="CD015477-sec-0172"> <p><b>Vaccine‐enhanced disease</b></p> <p><a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a> reported no vaccine‐enhanced disease effect. </p> </section> </section> </section> <section id="CD015477-sec-0173"> <h5 class="title">WIBP‐CorV – Sinopharm‐Wuhan versus placebo (adjuvant)</h5> <p>See <a href="./full#CD015477-tbl-0009">summary of findings Table 9</a> and table of results in <a href="./appendices#CD015477-sec-0474">Appendix 22</a>. </p> <p>We identified and included two trials in the analysis assessing WIBP‐CorV. The outcomes 'severe or critical COVID‐19 after complete vaccination', 'cellular immune response' and 'incidence of specific safety outcomes' were not reported for this comparison. </p> <section id="CD015477-sec-0174"> <h6 class="title">Critical outcomes</h6> <section id="CD015477-sec-0175"> <p><b>Confirmed SARS‐CoV‐2 infection after complete vaccination</b></p> <p>This outcome was reported in <a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>. WIBP‐CorV results in a reduction in the incidence of confirmed SARS‐CoV‐2 infection compared to adjuvant at 2.6 months (median) follow‐up (VE 64.00%, 95% CI 48.80% to 74.70%; 1 RCT, 25,449 participants; high‐certainty evidence; <a href="#CD015477-fig-0031">Figure 31</a>). </p> <div class="figure" id="CD015477-fig-0031"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 31</div> </div> <hr class="top"/><img alt="Analysis 3.1.1: inactivated virus vaccine. Outcome: confirmed SARS‐CoV‐2 infection after complete vaccination.Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (Al Kaabi 2021)." data-id="CD015477-fig-0031" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-31.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 3.1.1: inactivated virus vaccine. Outcome: confirmed SARS‐CoV‐2 infection after complete vaccination. </p> <p>Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). </p> </div> </div> </div> </section> <section id="CD015477-sec-0176"> <p><b>Confirmed symptomatic COVID‐19 after complete vaccination</b></p> <p>This outcome was reported in <a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>. WIBP‐CorV results in a large reduction in the incidence of confirmed symptomatic COVID‐19 after complete vaccination compared to adjuvant at 2.6 months (median) follow‐up (VE 72.80%, 95% CI 58.10% to 82.40%; 1 RCT, 25,480 participants; high‐certainty evidence; <a href="#CD015477-fig-0024">Figure 24</a>). </p> </section> <section id="CD015477-sec-0177"> <p><b>All‐cause mortality</b></p> <p>This outcome was assessed in one trial (26,917 participants) at 2.6 months (median) follow‐up (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). There were zero events in both groups, therefore no effect estimate could be calculated for this outcome (<a href="#CD015477-fig-0026">Figure 26</a>).  </p> </section> <section id="CD015477-sec-0178"> <p><b>Serious adverse events</b></p> <p>Two trials assessed this outcome (<a href="./references#CD015477-bbs2-0016" title="GuoW , DuanK , ZhangY , YuanZ , ZhangYB , WangZ , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 1/2 trial. eClinicalMedicine2021;38:101010. ">Guo 2021</a>; <a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). The evidence is uncertain for an effect of WIBP‐CorV on SAEs compared to adjuvant at 1.6 months (median) and 2.6 months (median) follow‐up due to serious imprecision (RR 0.83, 95% CI 0.60 to 1.15; I² = 0%; 2 RCTs, 27,029 participants; low‐certainty evidence; <a href="#CD015477-fig-0027">Figure 27</a>). </p> </section> <section id="CD015477-sec-0179"> <p><b>Systemic reactogenicity events</b></p> <p>Two trials reported this outcome (<a href="./references#CD015477-bbs2-0016" title="GuoW , DuanK , ZhangY , YuanZ , ZhangYB , WangZ , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 1/2 trial. eClinicalMedicine2021;38:101010. ">Guo 2021</a>; <a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). WIBP‐CorV results in no or little difference in the occurrence of systemic reactogenicity events compared to adjuvant (RR 0.99, 95% CI 0.95 to 1.03; I² = 0%; 2 RCTs, 27,029 participants; absolute effect: 3 fewer with systemic reactogenicity events per 1000 (from 14 fewer to 8 more); high‐certainty evidence; <a href="#CD015477-fig-0028">Figure 28</a>). </p> </section> <section id="CD015477-sec-0180"> <p><b>Any adverse event</b></p> <p>Two trials assessed the outcome (<a href="./references#CD015477-bbs2-0016" title="GuoW , DuanK , ZhangY , YuanZ , ZhangYB , WangZ , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 1/2 trial. eClinicalMedicine2021;38:101010. ">Guo 2021</a>; <a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). WIBP‐CorV results in little difference in the incidence of any adverse event compared to adjuvant at one‐month follow‐up (RR 0.96, 95% CI 0.93 to 0.98; I² = 0%; 2 RCTs, 27,029 participants; absolute effect: 20 fewer with any adverse event per 1000 (from 35 fewer to 10 fewer); high‐certainty evidence; <a href="#CD015477-fig-0029">Figure 29</a>). </p> </section> </section> <section id="CD015477-sec-0181"> <h6 class="title">Important outcomes</h6> <section id="CD015477-sec-0182"> <p><b>Immunogenicity outcomes</b></p> <p>Two trials reported GMTs of  neutralizing and specific antibodies against SARS‐COV‐2 (<a href="./references#CD015477-bbs2-0016" title="GuoW , DuanK , ZhangY , YuanZ , ZhangYB , WangZ , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 1/2 trial. eClinicalMedicine2021;38:101010. ">Guo 2021</a>; <a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). Results are reported in <a href="./appendices#CD015477-sec-0449">Appendix 11</a> and <a href="./appendices#CD015477-sec-0463">Appendix 16</a>. </p> </section> <section id="CD015477-sec-0183"> <p><b>Local reactogenicity events</b></p> <p>Two trials reported this outcome (<a href="./references#CD015477-bbs2-0016" title="GuoW , DuanK , ZhangY , YuanZ , ZhangYB , WangZ , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 1/2 trial. eClinicalMedicine2021;38:101010. ">Guo 2021</a>; <a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). WIBP‐CorV results in little difference in the occurrence of local reactogenicity events compared to adjuvant (RR 0.88, 95% CI 0.85 to 0.92; I² = 0%; 2 RCTs, 27,029 participants; absolute effect: 35 fewer with local reactogenicity events per 1000 (from 44 fewer to 23 fewer); high‐certainty evidence; <a href="#CD015477-fig-0030">Figure 30</a>). </p> </section> <section id="CD015477-sec-0184"> <p><b>Vaccine‐enhanced disease</b></p> <p>One trial reported no vaccine‐enhanced disease effect (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). </p> </section> </section> </section> <section id="CD015477-sec-0185"> <h5 class="title">BBIBP‐CorV – Sinopharm‐Beijing versus placebo (adjuvant)</h5> <p>See <a href="./full#CD015477-tbl-0010">summary of findings Table 10</a> and table of results in <a href="./appendices#CD015477-sec-0475">Appendix 23</a>. </p> <p>We identified and included in the analysis three trials assessing BBIBP‐CorV. The outcomes 'severe or critical COVID‐19 after complete vaccination', 'cellular immune response' and 'incidence of specific safety outcomes' were not reported for this comparison. </p> <section id="CD015477-sec-0186"> <h6 class="title">Critical outcomes</h6> <section id="CD015477-sec-0187"> <p><b>Confirmed SARS‐CoV‐2 infection after complete vaccination</b></p> <p>This outcome was reported in one trial (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). BBIBP‐CorV results in a large reduction in SARS‐CoV‐2 infection compared to adjuvant (VE 73.50%, 95% CI 60.60% to 82.20%; 1 RCT, 25,435 participants; high‐certainty evidence; <a href="#CD015477-fig-0031">Figure 31</a>). </p> </section> <section id="CD015477-sec-0188"> <p><b>Confirmed symptomatic COVID‐19 after complete vaccination</b></p> <p>This outcome was reported in one trial (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). BBIBP‐CorV results in a large reduction in the incidence of confirmed symptomatic COVID‐19 after complete vaccination compared to placebo (adjuvant) (VE 78.10%, 95% CI 64.80% to 86.30%; 1 RCT, 25,463 participants; high‐certainty evidence; <a href="#CD015477-fig-0024">Figure 24</a>). </p> </section> <section id="CD015477-sec-0189"> <p><b>All‐cause mortality</b></p> <p>This outcome was assessed in one trial (26,924 participants) (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). There were zero events in both groups, therefore no effect estimate could be calculated for this outcome (<a href="#CD015477-fig-0026">Figure 26</a>). </p> </section> <section id="CD015477-sec-0190"> <p><b>Serious adverse events</b></p> <p>One study assessed this outcome in 112 participants (<a href="./references#CD015477-bbs2-0040" title="XiaS , DuanK , ZhangY , ZhaoD , ZhangH , XieZ , et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA2020;324(10):951-60. XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infectious Diseases2020;21(1):39-51. ">Xia 2020</a>). There were zero events in both groups and the trial did not contribute to the analysis. One trial contributed to the analysis (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). The evidence is uncertain for an effect of BBIBP‐CorV on SAEs compared to adjuvant at 2.6 months (median) follow‐up (RR 0.76, 95% CI 0.54 to 1.06; 1 RCT, 26,924 participants; low‐certainty evidence; <a href="#CD015477-fig-0027">Figure 27</a>). </p> </section> <section id="CD015477-sec-0191"> <p><b>Systemic reactogenicity events</b></p> <p>This outcome was reported in three trials (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>; <a href="./references#CD015477-bbs2-0040" title="XiaS , DuanK , ZhangY , ZhaoD , ZhangH , XieZ , et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA2020;324(10):951-60. XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infectious Diseases2020;21(1):39-51. ">Xia 2020</a>; <a href="./references#CD015477-bbs2-0041" title="XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1/2 trial. Lancet Infectious Diseases2021;22(2):196-208. ">Xia 2021</a>). BBIBP‐CorV probably results in no or little difference in the occurrence of systemic reactogenicity events compared to adjuvant (RR 1.05, 95% CI 0.86 to 1.28; 3 RCTs, 27,540 participants; absolute effect: 14 more per 1000 (from 38 fewer to 77 more); moderate‐certainty evidence; <a href="#CD015477-fig-0028">Figure 28</a>). </p> </section> <section id="CD015477-sec-0192"> <p><b>Any adverse event</b></p> <p>This outcome was reported in three trials (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>; <a href="./references#CD015477-bbs2-0040" title="XiaS , DuanK , ZhangY , ZhaoD , ZhangH , XieZ , et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA2020;324(10):951-60. XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infectious Diseases2020;21(1):39-51. ">Xia 2020</a>; <a href="./references#CD015477-bbs2-0041" title="XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1/2 trial. Lancet Infectious Diseases2021;22(2):196-208. ">Xia 2021</a>). We decided not to pool the results due to considerable heterogeneity (I² = 90%) probably caused by studies assessing participants in different age groups; reported data for participants aged three years to 17 years old. <a href="./references#CD015477-bbs2-0041" title="XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1/2 trial. Lancet Infectious Diseases2021;22(2):196-208. ">Xia 2021</a> reported results for 504 participants at 2.9 months' follow‐up; the risk of any adverse event in the study was 2.05 (95% CI 1.47 to 2.87). <a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a> reported results for 26,941 participants at one‐month follow‐up; the risk for any adverse event was 0.91 (95% CI 0.89 to 0.94). <a href="./references#CD015477-bbs2-0040" title="XiaS , DuanK , ZhangY , ZhaoD , ZhangH , XieZ , et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA2020;324(10):951-60. XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infectious Diseases2020;21(1):39-51. ">Xia 2020</a> reported results for 112 participants at one‐month follow‐up; the risk for any adverse event was 0.83 (95% CI 0.36 to 1.94; <a href="#CD015477-fig-0029">Figure 29</a>). </p> </section> </section> <section id="CD015477-sec-0193"> <h6 class="title">Important outcomes</h6> <section id="CD015477-sec-0194"> <p><b>Immunogenicity outcomes</b></p> <p>Three trials reported GMTs of neutralizing and specific antibodies against SARS‐COV‐2 (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>; <a href="./references#CD015477-bbs2-0040" title="XiaS , DuanK , ZhangY , ZhaoD , ZhangH , XieZ , et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA2020;324(10):951-60. XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infectious Diseases2020;21(1):39-51. ">Xia 2020</a>; <a href="./references#CD015477-bbs2-0041" title="XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1/2 trial. Lancet Infectious Diseases2021;22(2):196-208. ">Xia 2021</a>). Results are reported in <a href="./appendices#CD015477-sec-0449">Appendix 11</a> and <a href="./appendices#CD015477-sec-0463">Appendix 16</a>.  </p> </section> <section id="CD015477-sec-0195"> <p><b>Local reactogenicity events</b></p> <p>This outcome was reported in three trials (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>; <a href="./references#CD015477-bbs2-0040" title="XiaS , DuanK , ZhangY , ZhaoD , ZhangH , XieZ , et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA2020;324(10):951-60. XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infectious Diseases2020;21(1):39-51. ">Xia 2020</a>; <a href="./references#CD015477-bbs2-0041" title="XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1/2 trial. Lancet Infectious Diseases2021;22(2):196-208. ">Xia 2021</a>). We decided not to pool the results due to considerable heterogeneity (I² = 90%) probably caused by studies assessing participants in different age groups. <a href="./references#CD015477-bbs2-0041" title="XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1/2 trial. Lancet Infectious Diseases2021;22(2):196-208. ">Xia 2021</a> reported results for 504 participants at seven days' follow‐up; the risk of local reactogenicity events in the study was 10.00 (95% CI 2.36 to 42.34). <a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a> reported results for 26,924 participants at seven days' follow‐up; the risk for local reactogenicity events was 0.71 (95% CI 0.68 to 0.74). <a href="./references#CD015477-bbs2-0040" title="XiaS , DuanK , ZhangY , ZhaoD , ZhangH , XieZ , et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA2020;324(10):951-60. XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infectious Diseases2020;21(1):39-51. ">Xia 2020</a> reported results for 112 participants at seven days' follow‐up; the risk for local reactogenicity events was 3.33 (95% CI 0.45 to 24.89; <a href="#CD015477-fig-0030">Figure 30</a>). </p> </section> <section id="CD015477-sec-0196"> <p><b>Vaccine‐enhanced disease</b></p> <p>One trial reported no vaccine‐enhanced disease effect (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). </p> </section> </section> </section> <section id="CD015477-sec-0197"> <h5 class="title">BBV152 – Bharat Biotech versus placebo (adjuvant)</h5> <p>See <a href="./full#CD015477-tbl-0011">summary of findings Table 11</a> and table of results in <a href="./appendices#CD015477-sec-0476">Appendix 24</a>. </p> <p>We identified and included two trials in the analysis assessing BBV152. The outcome 'vaccine‐enhanced disease' was not reported for this comparison. </p> <section id="CD015477-sec-0198"> <h6 class="title">Critical outcomes</h6> <section id="CD015477-sec-0199"> <p><b>Confirmed SARS‐CoV‐2 infection after complete vaccination</b></p> <p>One trial reported this outcome (<a href="./references#CD015477-bbs2-0009" title="EllaR , ReddyS , BlackwelderW , PotdarV , YadavP , SarangiV , et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.06.30.21259439]">Ella 2021b</a>). BBV152 results in a reduction in the incidence of SARS‐CoV‐2 infections compared to adjuvant at 3.3 months (median) follow‐up (VE 68.80%, 95% CI 46.70% to 82.50%; 1 RCT, 6289 participants; high‐certainty evidence; <a href="#CD015477-fig-0031">Figure 31</a>). </p> </section> <section id="CD015477-sec-0200"> <p><b>Confirmed symptomatic COVID‐19 after complete vaccination</b></p> <p>This outcome was reported in one trial (<a href="./references#CD015477-bbs2-0009" title="EllaR , ReddyS , BlackwelderW , PotdarV , YadavP , SarangiV , et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.06.30.21259439]">Ella 2021b</a>). BBV152 results in a large reduction in the incidence of confirmed symptomatic COVID‐19 after complete vaccination compared to adjuvant at 3.3 months (median) follow‐up (VE 77.80%, 95% CI 65.20% to 86.40%; 1 RCT, 16,973 participants; high‐certainty evidence; <a href="#CD015477-fig-0024">Figure 24</a>). </p> </section> <section id="CD015477-sec-0201"> <p><b>Severe or critical COVID‐19 after complete vaccination</b></p> <p>This outcome was reported in one trial at 3.3 months (median) follow‐up (<a href="./references#CD015477-bbs2-0009" title="EllaR , ReddyS , BlackwelderW , PotdarV , YadavP , SarangiV , et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.06.30.21259439]">Ella 2021b</a>). BBV152 results in a large reduction of severe or critical COVID‐19 after complete vaccination compared to adjuvant due to very serious imprecision (VE 93.40%, 95% CI 57.10% to 99.80%; 1 RCT, 16,976 participants; high‐certainty evidence; <a href="#CD015477-fig-0025">Figure 25</a>). </p> </section> <section id="CD015477-sec-0202"> <p><b>All‐cause mortality</b></p> <p>One trial reported this outcome at 3.3 months (median) follow‐up (<a href="./references#CD015477-bbs2-0009" title="EllaR , ReddyS , BlackwelderW , PotdarV , YadavP , SarangiV , et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.06.30.21259439]">Ella 2021b</a>). The evidence is uncertain for an effect of BBV152 on all‐cause mortality compared to adjuvant due to very serious imprecision (RR 0.50, 95% CI 0.17 to 1.46; 1 RCT, 25,753 participants; low‐certainty evidence; <a href="#CD015477-fig-0026">Figure 26</a>). </p> </section> <section id="CD015477-sec-0203"> <p><b>Serious adverse events</b></p> <p>This outcome was reported in two trials (<a href="./references#CD015477-bbs2-0008" title="EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. A Phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.12.11.20210419]EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomized, phase 1 trial. Lancet Infectious Diseases2021;21(5):637-46. ">Ella 2021a</a>; <a href="./references#CD015477-bbs2-0009" title="EllaR , ReddyS , BlackwelderW , PotdarV , YadavP , SarangiV , et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.06.30.21259439]">Ella 2021b</a>); <a href="./references#CD015477-bbs2-0009" title="EllaR , ReddyS , BlackwelderW , PotdarV , YadavP , SarangiV , et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.06.30.21259439]">Ella 2021b</a> contributed to the analysis. BBV152 results in little or no difference in the incidence of SAEs compared to adjuvant at 4.9 months (median) follow‐up (RR 0.65, 95% CI 0.43 to 0.97; 1 RCT, 25,928 participants; absolute effect: 162 fewer per 100,000 (from 264 fewer to 14 fewer); high‐certainty evidence; <a href="#CD015477-fig-0027">Figure 27</a>).  </p> </section> <section id="CD015477-sec-0204"> <p><b>Systemic reactogenicity events</b></p> <p>This outcome was reported in two trials (<a href="./references#CD015477-bbs2-0008" title="EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. A Phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.12.11.20210419]EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomized, phase 1 trial. Lancet Infectious Diseases2021;21(5):637-46. ">Ella 2021a</a>; <a href="./references#CD015477-bbs2-0009" title="EllaR , ReddyS , BlackwelderW , PotdarV , YadavP , SarangiV , et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.06.30.21259439]">Ella 2021b</a>). BBV152 results in little increase in the occurrence of systemic reactogenicity events compared to adjuvant (RR 1.34, 95% CI 1.15 to 1.58; I² = 0%; 2 RCTs, 25,925 participants; absolute effect: 7 more with systemic reactogenicity events per 1000 (from 3 more to 11 more); high‐certainty evidence; <a href="#CD015477-fig-0028">Figure 28</a>). </p> </section> <section id="CD015477-sec-0205"> <p><b>Any adverse event</b></p> <p>This outcome was reported in <a href="./references#CD015477-bbs2-0009" title="EllaR , ReddyS , BlackwelderW , PotdarV , YadavP , SarangiV , et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.06.30.21259439]">Ella 2021b</a>. BBV152 results in no or little difference in the occurrence of any adverse event compared to adjuvant at 4.9 months (median) follow‐up (RR 1.00, 95% CI 0.94 to 1.07; 1 RCT, 25,753 participants; absolute effect: 0 fewer with any adverse event per 1000 (from 7 fewer to 9 more); high‐certainty evidence; <a href="#CD015477-fig-0029">Figure 29</a>). </p> </section> </section> <section id="CD015477-sec-0206"> <h6 class="title">Important outcomes</h6> <section id="CD015477-sec-0207"> <p><b>Immunogenicity outcomes</b></p> <p>Two trials reported GMTs of neutralizing and specific antibodies against SARS‐COV‐2 (<a href="./references#CD015477-bbs2-0008" title="EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. A Phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.12.11.20210419]EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomized, phase 1 trial. Lancet Infectious Diseases2021;21(5):637-46. ">Ella 2021a</a>; <a href="./references#CD015477-bbs2-0009" title="EllaR , ReddyS , BlackwelderW , PotdarV , YadavP , SarangiV , et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.06.30.21259439]">Ella 2021b</a>), and <a href="./references#CD015477-bbs2-0008" title="EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. A Phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.12.11.20210419]EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomized, phase 1 trial. Lancet Infectious Diseases2021;21(5):637-46. ">Ella 2021a</a> reported results for cellular immune response. Results are detailed in <a href="./appendices#CD015477-sec-0449">Appendix 11</a>, <a href="./appendices#CD015477-sec-0463">Appendix 16</a> and <a href="./appendices#CD015477-sec-0472">Appendix 20</a>. </p> </section> <section id="CD015477-sec-0208"> <p><b>Local reactogenicity events</b></p> <p>This outcome was reported in two trials (<a href="./references#CD015477-bbs2-0009" title="EllaR , ReddyS , BlackwelderW , PotdarV , YadavP , SarangiV , et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.06.30.21259439]">Ella 2021b</a>; <a href="./references#CD015477-bbs2-0008" title="EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. A Phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.12.11.20210419]EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomized, phase 1 trial. Lancet Infectious Diseases2021;21(5):637-46. ">Ella 2021a</a>). BBV152 results in no or little difference in the occurrence of local reactogenicity events compared to adjuvant (RR 1.08, 95% CI 0.95 to 1.24; I² = 0%; 2 RCTs, 25,750 participants; absolute effect: 2 more with local reactogenicity events per 1000 (from 2 fewer to 7 more); high‐certainty evidence; <a href="#CD015477-fig-0030">Figure 30</a>). </p> </section> <section id="CD015477-sec-0209"> <p><b>Incidence of specific safety outcomes</b></p> <p>Specific safety outcomes were not consistently reported throughout the included trials and are summarized in detail in <a href="./appendices#CD015477-sec-0456">Appendix 12</a>, rather than pooled in a meta‐analysis. </p> </section> </section> </section> </section> <section id="CD015477-sec-0210"> <h4 class="title">Protein subunit vaccines</h4> <section id="CD015477-sec-0211"> <h5 class="title">NVX‐CoV2373 – Novavax versus placebo (normal saline)</h5> <p>See <a href="./full#CD015477-tbl-0012">summary of findings Table 12</a> and table of results in <a href="./appendices#CD015477-sec-0477">Appendix 25</a>. </p> <p>We identified and included five trials in the analysis assessing NVX‐CoV2373. The outcomes 'SARS‐CoV‐2 infection after complete vaccination', 'severe or critical COVID‐19 after complete vaccination' and 'cellular immune response' were not reported for this comparison. </p> <p>Low‐certainty evidence for the efficacy outcomes might be explained by the inclusion of results from a trial conducted in South Africa during a period of high prevalence of the Beta variant (<a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a>). Vaccine efficacy against this variant was considerably lower than the efficacy reported in the primary analysis or against the Alpha variant. </p> <section id="CD015477-sec-0212"> <h6 class="title">Critical outcomes</h6> <section id="CD015477-sec-0213"> <p><b>Confirmed symptomatic COVID‐19 after complete vaccination</b></p> <p>This outcome was reported in three trials at two months (median) and three months (median) follow‐up (<a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>; <a href="./references#CD015477-bbs2-0019" title="HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine2021;385(13):1172-83. HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant. medRxiv 2021 [Preprint]. ">Heath 2021</a>; <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a>). NVX‐CoV2373 probably results in a large reduction of the incidence of confirmed symptomatic COVID‐19 after complete vaccination compared to placebo (VE 82.91%, 95% CI 50.49% to 94.10%; I² = 65%; 3 RCTs, 42,175 participants; moderate‐certainty evidence; <a href="#CD015477-fig-0032">Figure 32</a>). </p> <div class="figure" id="CD015477-fig-0032"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 32</div> </div> <hr class="top"/><img alt="Analysis 4.1.1: protein subunit vaccine. Outcome: confirmed symptomatic COVID‐19 after complete vaccination." data-id="CD015477-fig-0032" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-32.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 4.1.1: protein subunit vaccine. Outcome: confirmed symptomatic COVID‐19 after complete vaccination. </p> </div> </div> </div> </section> <section id="CD015477-sec-0214"> <p><b>Severe or critical COVID‐19 after complete vaccination</b></p> <p>This outcome was reported in one trial at two months (median) follow‐up (<a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>). NVX‐CoV2373 results in a large reduction of severe or critical COVID‐19 after complete vaccination compared to adjuvant due to very serious imprecision (VE 100.00%, 95% CI 86.99% to 100.00%; 1 RCT, 25,452 participants; moderate‐certainty evidence; <a href="#CD015477-fig-0033">Figure 33</a>). </p> <div class="figure" id="CD015477-fig-0033"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 33</div> </div> <hr class="top"/><img alt="Analysis 4.1.2: protein subunit vaccine. Outcome: severe or critical COVID‐19 after complete vaccination." data-id="CD015477-fig-0033" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-33.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 4.1.2: protein subunit vaccine. Outcome: severe or critical COVID‐19 after complete vaccination. </p> </div> </div> </div> </section> <section id="CD015477-sec-0215"> <p><b>All‐cause mortality</b></p> <p>One trial reported this outcome in 14,039 participants at three months (median) follow‐up (<a href="./references#CD015477-bbs2-0019" title="HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine2021;385(13):1172-83. HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant. medRxiv 2021 [Preprint]. ">Heath 2021</a>); there were no events and the trial did not contribute to the effect estimate. <a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a> contributed to the analysis with follow‐up of two months (median); the evidence is uncertain for an effect of NVX‐CoV2373 on all‐cause mortality compared to placebo due to very serious imprecision (RR 0.90, 95% CI 0.30 to 2.68; 1 RCT, 29,582 participants; low‐certainty evidence; <a href="#CD015477-fig-0034">Figure 34</a>). </p> <div class="figure" id="CD015477-fig-0034"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 34</div> </div> <hr class="top"/><img alt="Analysis 4.1.3: protein subunit vaccine. Outcome: all‐cause mortality." data-id="CD015477-fig-0034" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-34.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 4.1.3: protein subunit vaccine. Outcome: all‐cause mortality.</p> </div> </div> </div> </section> <section id="CD015477-sec-0216"> <p><b>Serious adverse events</b></p> <p>One trial reported the outcome in 52 participants at 1.15 months' follow‐up (<a href="./references#CD015477-bbs2-0020" title="KeechC , AlbertG , ChoI , RobertsonA , ReedP , NealS , et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. New England Journal of Medicine 2020;383:2320-32. ">Keech 2020</a>); there were no events and the trial did not contribute to the effect estimate. Four trials contributed to the analysis with follow‐up of 1.15 months, two months (median), and three months (<a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>; <a href="./references#CD015477-bbs2-0014" title="FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. PLOS Medicine2021;18(10):e1003769. FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.26.21252482]">Formica 2021</a>; <a href="./references#CD015477-bbs2-0019" title="HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine2021;385(13):1172-83. HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant. medRxiv 2021 [Preprint]. ">Heath 2021</a>; <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a>). The evidence is uncertain for an effect of NVX‐CoV2373 on SAEs compared to placebo due to very serious imprecision (RR 0.92, 95% CI 0.74 to 1.14, I² = 0%; 4 RCTs, 38,802 participants; low‐certainty evidence; <a href="#CD015477-fig-0035">Figure 35</a>). </p> <div class="figure" id="CD015477-fig-0035"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 35</div> </div> <hr class="top"/><img alt="Analysis 4.1.4: protein subunit vaccine. Outcome: serious adverse events (SAEs)." data-id="CD015477-fig-0035" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-35.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 4.1.4: protein subunit vaccine. Outcome: serious adverse events (SAEs).</p> </div> </div> </div> </section> <section id="CD015477-sec-0217"> <p><b>Systemic reactogenicity events</b></p> <p>This outcome was reported in three trials (<a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>; <a href="./references#CD015477-bbs2-0014" title="FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. PLOS Medicine2021;18(10):e1003769. FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.26.21252482]">Formica 2021</a>; <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a>). NVX‐CoV2373 increases slightly the occurrence of systemic reactogenicity events compared to placebo (RR 1.21, 95% CI 1.17 to 1.25, I² = 27%, 3 RCTs, 31,063 participants; absolute effect 76 more per 1000 (from 62 more to 91 more); high‐certainty evidence; <a href="#CD015477-fig-0036">Figure 36</a>). </p> <div class="figure" id="CD015477-fig-0036"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 36</div> </div> <hr class="top"/><img alt="Analysis 4.1.5: protein subunit vaccine. Outcome: systemic reactogenicity events." data-id="CD015477-fig-0036" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-36.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 4.1.5: protein subunit vaccine. Outcome: systemic reactogenicity events.</p> </div> </div> </div> </section> <section id="CD015477-sec-0218"> <p><b>Any adverse event</b></p> <p>This outcome was reported in five trials (<a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>; <a href="./references#CD015477-bbs2-0014" title="FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. PLOS Medicine2021;18(10):e1003769. FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.26.21252482]">Formica 2021</a>; <a href="./references#CD015477-bbs2-0019" title="HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine2021;385(13):1172-83. HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant. medRxiv 2021 [Preprint]. ">Heath 2021</a>; <a href="./references#CD015477-bbs2-0020" title="KeechC , AlbertG , ChoI , RobertsonA , ReedP , NealS , et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. New England Journal of Medicine 2020;383:2320-32. ">Keech 2020</a>; <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a>). NVX‐CoV2373 probably results in little increase in the incidence of any adverse event compared to placebo at 1.15 months (median) to three months (median) follow‐up (RR 1.15, 95% CI 1.05 to 1.26; I² = 57%; 5 RCTs, 46,231 participants; absolute effect: 26 more with any adverse event per 1000 (from 9 more to 45 more); moderate‐certainty evidence; <a href="#CD015477-fig-0037">Figure 37</a>). </p> <div class="figure" id="CD015477-fig-0037"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 37</div> </div> <hr class="top"/><img alt="Analysis 4.1.6: protein subunit vaccine. Outcome: any adverse event (AE)." data-id="CD015477-fig-0037" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-37.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 4.1.6: protein subunit vaccine. Outcome: any adverse event (AE).</p> </div> </div> </div> </section> </section> <section id="CD015477-sec-0219"> <h6 class="title">Important outcomes</h6> <section id="CD015477-sec-0220"> <p><b>Immunogenetic outcomes</b></p> <p>Two trials reported GMTs of specific antibodies against SARS‐COV‐2 (<a href="./references#CD015477-bbs2-0014" title="FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. PLOS Medicine2021;18(10):e1003769. FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.26.21252482]">Formica 2021</a>; <a href="./references#CD015477-bbs2-0020" title="KeechC , AlbertG , ChoI , RobertsonA , ReedP , NealS , et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. New England Journal of Medicine 2020;383:2320-32. ">Keech 2020</a>), and <a href="./references#CD015477-bbs2-0020" title="KeechC , AlbertG , ChoI , RobertsonA , ReedP , NealS , et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. New England Journal of Medicine 2020;383:2320-32. ">Keech 2020</a> reported GMTs of neutralizing antibodies against SARS‐COV‐2. Results are detailed in <a href="./appendices#CD015477-sec-0463">Appendix 16</a> and <a href="./appendices#CD015477-sec-0449">Appendix 11</a>. </p> </section> <section id="CD015477-sec-0221"> <p><b>Local reactogenicity events</b></p> <p>Three trials reported the outcome (<a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>; <a href="./references#CD015477-bbs2-0014" title="FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. PLOS Medicine2021;18(10):e1003769. FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.26.21252482]">Formica 2021</a>; <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a>). NVX‐CoV2373 results in a large increase in local reactogenicity events compared to placebo (RR 2.78, 95% CI 1.99 to 3.88; I² = 86%; 3 RCTs, 31,063 participants; absolute effect: 340 more with local reactogenicity events per 1000 (from 189 more to 551 more); high‐certainty evidence; <a href="#CD015477-fig-0038">Figure 38</a>). </p> <div class="figure" id="CD015477-fig-0038"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 38</div> </div> <hr class="top"/><img alt="Analysis 4.1.7 Protein subunit vaccine. Outcome: local reactogenicity events" data-id="CD015477-fig-0038" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-38.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 4.1.7 Protein subunit vaccine. Outcome: local reactogenicity events</p> </div> </div> </div> </section> <section id="CD015477-sec-0222"> <p><b>Incidence of specific safety outcomes</b></p> <p>Specific safety outcomes were not consistently reported throughout the included trials: <a href="./references#CD015477-bbs2-0014" title="FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. PLOS Medicine2021;18(10):e1003769. FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.26.21252482]">Formica 2021</a> reported number of participants with venous thrombosis, lymphadenopathy and nervous system diseases; <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a> reported number of participants with anaemia and nervous system diseases; <a href="./references#CD015477-bbs2-0019" title="HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine2021;385(13):1172-83. HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant. medRxiv 2021 [Preprint]. ">Heath 2021</a> reported number of participants with myocardial infarction, thrombocytopaenia and nervous system diseases; and <a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a> reported on the number of events for pulmonary embolism, stroke, venous thrombosis, thrombocytopenia, haemorrhage, neutropenia, anaemia, lymphadenopathy and nervous system diseases. Outcomes are summarized in detail in <a href="./appendices#CD015477-sec-0456">Appendix 12</a>. </p> </section> <section id="CD015477-sec-0223"> <p><b>Vaccine‐enhanced disease</b></p> <p>One report mentioned this outcome without presenting results (<a href="./references#CD015477-bbs2-0020" title="KeechC , AlbertG , ChoI , RobertsonA , ReedP , NealS , et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. New England Journal of Medicine 2020;383:2320-32. ">Keech 2020</a>), and two trials reported no vaccine‐enhanced disease effect (<a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>; <a href="./references#CD015477-bbs2-0019" title="HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine2021;385(13):1172-83. HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant. medRxiv 2021 [Preprint]. ">Heath 2021</a>). </p> </section> </section> </section> <section id="CD015477-sec-0224"> <h5 class="title">FINLAY‐FR‐2 – Instituto Finlay de Vacunas versus placebo (adjuvant)</h5> <p>See <a href="./full#CD015477-tbl-0013">summary of findings Table 13</a> and table of results in <a href="./appendices#CD015477-sec-0478">Appendix 26</a>. </p> <p>We identified and included in the analysis one trial assessing FINLAY‐FR‐2. The outcomes 'SARS‐CoV‐2 infection after complete vaccination', 'severe or critical COVID‐19 after complete vaccination', 'systemic reactogenicity events', 'incidence of any adverse event', 'incidence of serious adverse events', 'GMT of specific antibodies against SARS‐CoV‐2', 'GMT of neutralizing antibodies against SARS‐CoV‐2', 'cellular immune response', 'incidence of specific safety outcomes' and 'vaccine‐enhanced disease' were not reported for this comparison. </p> <section id="CD015477-sec-0225"> <h6 class="title">Critical outcomes</h6> <section id="CD015477-sec-0226"> <p><b>Confirmed symptomatic COVID‐19 after complete vaccination</b></p> <p>We found one trial reporting this outcome (<a href="./references#CD015477-bbs2-0036" title="Toledo-RomaniME , Garcia-CarmenateM , Silva-ValenzuelaC , Baldoquin-RodriguezW , Martínez-PérezM , Rodríguez-GonzálezM , et al. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomized, placebo-controlled phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.31.21265703]">Toledo‐Romani 2021</a>). FINLAY‐FR‐2 probably results in a large reduction in the incidence of confirmed symptomatic COVID‐19 after complete vaccination compared to adjuvant (VE 71.00%, 95% CI 58.90% to 79.10%; 1 RCT, 28,674 participants; moderate‐certainty evidence; <a href="#CD015477-fig-0032">Figure 32</a>). </p> </section> <section id="CD015477-sec-0227"> <p><b>All‐cause mortality</b></p> <p>This outcome was reported in one trial (<a href="./references#CD015477-bbs2-0036" title="Toledo-RomaniME , Garcia-CarmenateM , Silva-ValenzuelaC , Baldoquin-RodriguezW , Martínez-PérezM , Rodríguez-GonzálezM , et al. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomized, placebo-controlled phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.31.21265703]">Toledo‐Romani 2021</a>). FINLAY‐FR‐2 probably results in a reduction of all‐cause mortality compared to adjuvant due to serious risk of bias and imprecision (RR 0.37, 95% CI 0.17 to 0.80; 1 RCT, 28,674 participants; absolute effect: 106 fewer per 100,000 (from 139 fewer to 34 fewer) moderate‐certainty evidence; <a href="#CD015477-fig-0034">Figure 34</a>). </p> </section> </section> </section> </section> <section id="CD015477-sec-0228"> <h4 class="title">Primary series heterologous vaccination scheme versus homologous vaccination scheme</h4> <p>See <a href="./full#CD015477-tbl-0014">summary of findings Table 14</a> and table of results in <a href="./appendices#CD015477-sec-0479">Appendix 27</a>. </p> <p>Two publications reported results for three different comparisons involving an RNA‐based vaccine (BNT162b2 – BioNtech/Fosun Pharma/Pfizer), non‐replicating viral vector vaccine (ChAdOx1 – AstraZeneca/University of Oxford), and inactivated virus vaccine (CoronaVac – Sinovac). More specifically the following schemes were compared (vaccine first dose/vaccine second dose): BNT162b2/ChAdOx1 versus BNT162b2/BNT162b2 (<a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>), and ChAdOx1/BNT162b2 versus ChAdOx1/ChAdOx1 (<a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>), and CoronaVac/Ad5 versus CoronaVac/CoronaVac (<a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>). </p> <p>The outcomes 'SARS‐CoV‐2 infection after complete vaccination', 'symptomatic COVID‐19 after complete vaccination', 'severe or critical COVID‐19', 'all‐cause mortality', 'systemic reactogenicity events' and 'vaccine‐enhanced disease' were not reported for these comparisons. </p> <section id="CD015477-sec-0229"> <h5 class="title">Critical outcomes</h5> <section id="CD015477-sec-0230"> <h6 class="title">Serious adverse events</h6> <p>One trial reported this outcome in 101 participants at one‐month follow‐up for the comparison CoronaVac/Ad5 versus CoronaVac homologous (<a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>), and reported zero events in both groups. <a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a> reported the outcome in 234 participants for the comparison BNT162b2/ChAdOx1 versus BNT162b2 homologous and also reported zero events in both groups. The same trial reported the outcome for the comparison ChAdOx1/BNT162b2 versus ChAdOx1 homologous. The evidence is uncertain for an effect of ChAdOx1/BNT162b2 on SAEs compared to ChAdOx1/ChAdOx1 due to serious risk of bias, inconsistency and imprecision (RR 0.34, 95% CI 0.01 to 8.17; 1 RCT, 229 participants; very low‐certainty evidence; <a href="#CD015477-fig-0039">Figure 39</a>). </p> <div class="figure" id="CD015477-fig-0039"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 39</div> </div> <hr class="top"/><img alt="Analysis 5.1.1: heterologous vaccination scheme versus homologous vaccination scheme. Outcome: serious adverse events (SAEs).Liu X 2021.1 and Liu X 2021.2 are different comparisons for the same report (Liu 2021)." data-id="CD015477-fig-0039" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-39.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 5.1.1: heterologous vaccination scheme versus homologous vaccination scheme. Outcome: serious adverse events (SAEs). </p> <p>Liu X 2021.1 and Liu X 2021.2 are different comparisons for the same report (<a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>). </p> </div> </div> </div> </section> <section id="CD015477-sec-0231"> <h6 class="title">Systemic reactogenicity events</h6> <p>There was one comparison with results for this outcome (<a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>). The evidence is uncertain for an effect of CoronaVac/Ad5 on the incidence of systemic reactogenicity events compared to CoronaVac/CoronaVac due to very serious imprecision (RR 1.96, 95% CI 0.52 to 7.41; 1 RCT, 101 participants; low‐certainty evidence; <a href="#CD015477-fig-0040">Figure 40</a>). </p> <div class="figure" id="CD015477-fig-0040"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 40</div> </div> <hr class="top"/><img alt="Analysis 5.1.2: heterologous vaccination scheme versus homologous vaccination scheme. Outcome: systemic reactogenicity events." data-id="CD015477-fig-0040" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-40.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 5.1.2: heterologous vaccination scheme versus homologous vaccination scheme. Outcome: systemic reactogenicity events. </p> </div> </div> </div> </section> <section id="CD015477-sec-0232"> <h6 class="title">Any adverse event</h6> <p>Two trials reported any adverse event on three different comparisons (<a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>; <a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>). CoronaVac/Ad5 versus CoronaVac homologous at 1‐month follow‐up (RR 3.19, 95% CI 1.11 to 9.11), BNT162b2/ChAdOx1 versus BNT162b2 homologous at two months' follow‐up (RR 1.21, 95% CI 0.87 to 1.68) and ChAdOx1/BNT162b2 versus ChAdOx1 homologous at 2 months' follow‐up (RR 1.03, 95% CI 0.75 to 1.43). The evidence is very uncertain about the effect of heterologous schemes on the incidence of any adverse event compared to homologous schemes due to serious risk of bias, inconsistency and imprecision (<a href="#CD015477-fig-0041">Figure 41</a>). </p> <div class="figure" id="CD015477-fig-0041"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 41</div> </div> <hr class="top"/><img alt="Analysis 5.1.3: heterologous vaccination scheme versus homologous vaccination scheme. Outcome: any adverse event (AE).Liu 2021 included only participants 50 years of age or older.Liu X 2021.1 and Liu X 2021.2 are different comparisons for the same report (Liu 2021)." data-id="CD015477-fig-0041" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-41.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 5.1.3: heterologous vaccination scheme versus homologous vaccination scheme. Outcome: any adverse event (AE). </p> <p><a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a> included only participants 50 years of age or older. </p> <p>Liu X 2021.1 and Liu X 2021.2 are different comparisons for the same report (<a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>). </p> </div> </div> </div> </section> </section> <section id="CD015477-sec-0233"> <h5 class="title">Important outcomes</h5> <section id="CD015477-sec-0234"> <h6 class="title">Immunogenicity outcomes</h6> <p><a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a> reported that the heterologous schedule CoronaVac/Ad5 elicited higher levels of specific antibodies against SARS‐COV‐2 (GMR 6.11, 95% CI 3.90 to 9.57) and neutralizing antibodies against SARS‐COV‐2 (GMR 4.25, 95% CI 2.63 to 6.86) compared to the homologous schedule CoronaVac/CoronaVac (<a href="./appendices#CD015477-sec-0463">Appendix 16</a> and <a href="./appendices#CD015477-sec-0449">Appendix 11</a>). </p> <p><a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a> reported this outcome for two different comparisons. The outcome was measured using IFN‐γ ELISpot 28 days after the administration of the second dose.  </p> <p>The heterologous schedule ChAdOx1/BNT162b2 elicited a larger immune cellular response compared to the homologous schedule ChAdOx1/ChAdOx1 (GMR of number of spot‐forming cells (SFCs) per million peripheral blood mononuclear cell (PBMC)) 3.9 (95% CI 2.9 to 5.3)). </p> <p>The GMR of SFCs per million PBMCs was 1.2 (95% CI 0.87 to 1.7) for the comparison of the heterologous schedule BNT162b2/ChAdOx to the homologous schedule BNT162b2/BNT162b2 (<a href="./appendices#CD015477-sec-0472">Appendix 20</a>). </p> </section> <section id="CD015477-sec-0235"> <h6 class="title">Local reactogenicity events</h6> <p>One trial reported this outcome (<a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>). The heterologous schedule (CoronaVac/Ad5) probably results in a large increase in the number of local reactogenicity events compared to the homologous schedule (CoronaVac/CoronaVac) (RR 11.76, 95% CI 1.59 to 87.14; 1 RCT, 101 participants; absolute effect: 215 more with local reactogenicity events per 1000 (from 12 more to 1000 more); low‐certainty evidence; <a href="#CD015477-fig-0042">Figure 42</a>). </p> <div class="figure" id="CD015477-fig-0042"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 42</div> </div> <hr class="top"/><img alt="Analysis 5.1.4: heterologous vaccination scheme versus homologous vaccination scheme. Outcome: local reactogenicity events." data-id="CD015477-fig-0042" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-42.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 5.1.4: heterologous vaccination scheme versus homologous vaccination scheme. Outcome: local reactogenicity events. </p> </div> </div> </div> </section> <section id="CD015477-sec-0236"> <h6 class="title">Incidence of specific safety outcomes</h6> <p>Specific safety outcomes were not consistently reported throughout the included trials. Two trials reported on the number of participants with venous thrombosis (<a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>; <a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>). Outcomes are summarized in detail in <a href="./appendices#CD015477-sec-0456">Appendix 12</a>.  </p> </section> </section> </section> <section id="CD015477-sec-0237"> <h4 class="title">Boosters</h4> <section id="CD015477-sec-0238"> <h5 class="title">Homologous or heterologous booster versus placebo/no booster</h5> <p>See <a href="./full#CD015477-tbl-0015">summary of findings Table 15</a> and table of results in <a href="./appendices#CD015477-sec-0480">Appendix 28</a>. </p> <p>We identified and included two trials in the analysis (<a href="./references#CD015477-bbs2-0017" title="HallVG , FerreiraVH , KuT , IerulloM , Majchrzak-KitaB , ChaparroC , et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. New England Journal of Medicine2021;385(13):1244-6. ">Hall 2021</a>; <a href="./references#CD015477-bbs2-0036" title="Toledo-RomaniME , Garcia-CarmenateM , Silva-ValenzuelaC , Baldoquin-RodriguezW , Martínez-PérezM , Rodríguez-GonzálezM , et al. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomized, placebo-controlled phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.31.21265703]">Toledo‐Romani 2021</a>). <a href="./references#CD015477-bbs2-0017" title="HallVG , FerreiraVH , KuT , IerulloM , Majchrzak-KitaB , ChaparroC , et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. New England Journal of Medicine2021;385(13):1244-6. ">Hall 2021</a> included only kidney transplant recipient participants; in our judgement results from this trial are not generally applicable. </p> <section id="CD015477-sec-0239"> <h6 class="title">mRNA‐1273 booster versus placebo (normal saline)</h6> <p><a href="./references#CD015477-bbs2-0017" title="HallVG , FerreiraVH , KuT , IerulloM , Majchrzak-KitaB , ChaparroC , et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. New England Journal of Medicine2021;385(13):1244-6. ">Hall 2021</a> compared a booster dose of mRNA‐1273 to placebo after complete vaccination of mRNA‐1273 in kidney transplant recipients. They reported three outcomes of interest. </p> <section id="CD015477-sec-0240"> <p><b>Systemic reactogenicity events</b></p> <p>Follow‐up was seven days, starting after injection of the booster dose. There were 11 systemic reactogenicity events in the intervention arm (60 participants) compared to six in the control arm (59 participants). We assessed the overall risk of bias for the outcome to be low. </p> <p>The evidence is uncertain for an effect of mRNA‐1273 booster on the incidence of systemic reactogenicity events compared to placebo due to serious imprecision (RR 1.80, 95% CI 0.71 to 4.56; 1 RCT, 119 participants; low‐certainty evidence; <a href="#CD015477-fig-0043">Figure 43</a>). </p> <div class="figure" id="CD015477-fig-0043"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 43</div> </div> <hr class="top"/><img alt="Analysis 6.1.2: booster versus placebo/no booster. Outcome: systemic reactogenicity events." data-id="CD015477-fig-0043" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-43.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 6.1.2: booster versus placebo/no booster. Outcome: systemic reactogenicity events. </p> </div> </div> </div> </section> <section id="CD015477-sec-0241"> <p><b>Immunogenicity outcomes</b></p> <p>One trial reported results for cellular immune response (<a href="./references#CD015477-bbs2-0017" title="HallVG , FerreiraVH , KuT , IerulloM , Majchrzak-KitaB , ChaparroC , et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. New England Journal of Medicine2021;385(13):1244-6. ">Hall 2021</a>). The outcome was measured using intracellular cytokine staining 28 days after the administration of the booster or placebo. The median CD4+ T cells per million was higher in the booster arm than in the placebo arm (432 versus 67 cells per 100 CD4+ T cells; 95% CI for the between‐group difference, 46 to 986; <a href="./appendices#CD015477-sec-0472">Appendix 20</a>).  </p> </section> <section id="CD015477-sec-0242"> <p><b>Local reactogenicity events</b></p> <p>The follow‐up period was seven days starting after the injection of the booster dose. There were 46 local reactogenicity events in the intervention arm (N = 60) compared to seven in the control arm (N = 59). We assessed the overall risk of bias for the outcome to be low. A‐1273 booster probably results in a large increase in the number of local reactogenicity events compared to placebo (RR 6.46, 95% CI 3.18 to 13.13; 1 RCT, 119 participants; absolute effect: 648 more local adverse event per 1000 (from 259 more to 1000 more); moderate‐certainty evidence; <a href="#CD015477-fig-0044">Figure 44</a>). </p> <div class="figure" id="CD015477-fig-0044"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 44</div> </div> <hr class="top"/><img alt="Analysis 6.1.3: booster versus placebo/no booster. Outcome: local reactogenicity events." data-id="CD015477-fig-0044" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-44.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 6.1.3: booster versus placebo/no booster. Outcome: local reactogenicity events.</p> </div> </div> </div> </section> </section> <section id="CD015477-sec-0243"> <h6 class="title">FINLAY‐FR‐1 booster versus no booster dose</h6> <section id="CD015477-sec-0244"> <p><b>All‐cause mortality</b></p> <p><a href="./references#CD015477-bbs2-0036" title="Toledo-RomaniME , Garcia-CarmenateM , Silva-ValenzuelaC , Baldoquin-RodriguezW , Martínez-PérezM , Rodríguez-GonzálezM , et al. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomized, placebo-controlled phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.31.21265703]">Toledo‐Romani 2021</a> compared a booster dose of FINLAY‐FR‐1 to no booster dose after complete vaccination of FINLAY‐FR‐2 in adults; only all‐cause mortality with a median follow‐up of 1.7 months was reported. </p> <p>There were 11 deaths in the intervention arm (of 13,883 participants) compared to nine in the control arm (of 14,371 participants). We assessed the overall risk of bias for the outcome to have some concerns due to lack of information about allocation concealment and the use of per‐protocol analysis.  </p> <p>The evidence is very uncertain about the effect of the booster dose of FR‐1 compared to adjuvant due to serious risk of bias and very serious imprecision (RR 1.27, 95% CI 0.52 to 3.05; 1 RCT, 28,254 participants; very low‐certainty evidence; <a href="#CD015477-fig-0045">Figure 45</a>). </p> <div class="figure" id="CD015477-fig-0045"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 45</div> </div> <hr class="top"/><img alt="Analysis 6.1.1: booster versus placebo/no booster. Outcome: all‐cause mortality." data-id="CD015477-fig-0045" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-45.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 6.1.1: booster versus placebo/no booster. Outcome: all‐cause mortality.</p> </div> </div> </div> </section> </section> </section> <section id="CD015477-sec-0245"> <h5 class="title">Homologous booster versus heterologous booster </h5> <p>We identified four trials for this comparison (<a href="./references#CD015477-bbs2-0004" title="BonelliM , MrakD , TobudicS , SieghartD , KoblischkeM , MandlP , et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.05.21263125]">Bonelli 2021</a>; <a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>; <a href="./references#CD015477-bbs2-0028" title="MokC , ChengS , ChenC , YiuK , ChanTO , LaiKC , et al. A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.11.02.21265843]">Mok 2021</a>; <a href="./references#CD015477-bbs2-0030" title="SablerollesRS , RietdijkWJ , GoorhuisA , PostmaDF , VisserLG , GeersD , et al. Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.18.21264979]">Sablerolles 2021</a>). Of note, in all trials specific safety outcomes were not consistently reported; these are summarized in <a href="./appendices#CD015477-sec-0416">Appendix 9</a>. </p> <section id="CD015477-sec-0246"> <h6 class="title">BNT162b2 or mRNA‐1273 with homologous booster versus heterologous ChAdOx1 booster</h6> <p>One trial compared a homologous booster dose of BNT162b2 or mRNA‐1273 to a booster dose of ChAdOx1 in immunocompromized adults under current rituximab therapy (<a href="./references#CD015477-bbs2-0004" title="BonelliM , MrakD , TobudicS , SieghartD , KoblischkeM , MandlP , et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.05.21263125]">Bonelli 2021</a>). They only reported on two outcomes of interest. </p> <section id="CD015477-sec-0247"> <p><b>Immunogenicity outcomes</b></p> <p><a href="./references#CD015477-bbs2-0004" title="BonelliM , MrakD , TobudicS , SieghartD , KoblischkeM , MandlP , et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.05.21263125]">Bonelli 2021</a> reported results for cellular immune response. The outcome was measured using IFN‐γ ELISpot seven days after the administration of the booster dose. The median interquartile range (IQR) number of SFCs per million PBMCs was 459 (133 to 722) in the heterologous booster arm versus 305 (717 to 416) in the homologous booster arm (<a href="./appendices#CD015477-sec-0472">Appendix 20</a>). </p> </section> <section id="CD015477-sec-0248"> <p><b>Local reactogenicity events</b></p> <p>Follow‐up was two days starting after the injection of the booster dose. There were fewer local reactogenicity events in the ChAdOx1 heterologous booster arm (8/27) compared to the homologous booster arm (16/28) (RR 0.52, 95% CI 0.27 to 1.01). We assessed the overall risk of bias for the outcome to have some concerns due to lack of information about allocation concealment, missingness of outcome data, unclear blinding which could have influenced the measurement of the outcome, and no information on whether the outcome was analyzed as prespecified (<a href="#CD015477-fig-0046">Figure 46</a>). </p> <div class="figure" id="CD015477-fig-0046"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 46</div> </div> <hr class="top"/><img alt="Analysis 6.2.4: homologous booster versus heterologous booster. Outcome: local reactogenicity events.Bonelli 2021 included only participants under current Rituximab therapy." data-id="CD015477-fig-0046" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-46.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 6.2.4: homologous booster versus heterologous booster. Outcome: local reactogenicity events. </p> <p><a href="./references#CD015477-bbs2-0004" title="BonelliM , MrakD , TobudicS , SieghartD , KoblischkeM , MandlP , et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.05.21263125]">Bonelli 2021</a> included only participants under current Rituximab therapy. </p> </div> </div> </div> </section> <section id="CD015477-sec-0249"> <p><b>Incidence of specific safety outcomes</b></p> <p><a href="./references#CD015477-bbs2-0004" title="BonelliM , MrakD , TobudicS , SieghartD , KoblischkeM , MandlP , et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.05.21263125]">Bonelli 2021</a> reported on the number of participants with thrombocytopaenia and nervous system diseases; details are in <a href="./appendices#CD015477-sec-0456">Appendix 12</a>. </p> </section> </section> <section id="CD015477-sec-0250"> <h6 class="title">Ad26.COV2.S with homologous booster versus heterologous mRNA‐1273 booster</h6> <p>One trial compared a homologous booster dose of Ad26.COV2.S to a booster dose of mRNA‐1273 in healthcare workers (<a href="./references#CD015477-bbs2-0030" title="SablerollesRS , RietdijkWJ , GoorhuisA , PostmaDF , VisserLG , GeersD , et al. Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.18.21264979]">Sablerolles 2021</a>). They only reported on three outcomes of interest. </p> <section id="CD015477-sec-0251"> <p><b>Systemic reactogenicity events</b></p> <p>Follow‐up was seven days starting after the injection of the booster dose. There were fewer systemic reactogenicity events in the homologous booster arm (62/106) compared to the mRNA‐1273 booster arm (84/111) (RR 0.77, 95% CI 0.64 to 0.94). We assessed the overall risk of bias for the outcome to have some concerns due to lack of information on allocation concealment, use of per‐protocol analysis and missing outcome data (<a href="#CD015477-fig-0047">Figure 47</a>). </p> <div class="figure" id="CD015477-fig-0047"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 47</div> </div> <hr class="top"/><img alt="Analysis 6.2.2: homologous booster versus heterologous booster. Outcome: systemic reactogenicity events." data-id="CD015477-fig-0047" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-47.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 6.2.2: homologous booster versus heterologous booster. Outcome: systemic reactogenicity events. </p> </div> </div> </div> </section> <section id="CD015477-sec-0252"> <p><b>Immunogenicity outcomes</b></p> <p><a href="./references#CD015477-bbs2-0030" title="SablerollesRS , RietdijkWJ , GoorhuisA , PostmaDF , VisserLG , GeersD , et al. Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.18.21264979]">Sablerolles 2021</a> reported results for cellular immune response. The proportion of responders was measured using IFN‐y release assay (cut‐off is 0.15 IU/mL) 28 days after the administration of the booster dose. The proportion of responders was lower in the homologous booster arm (32/44; 72.7%) than in the heterologous booster arm (44/48; 91.7%) (RR 0.79, 95% CI 0.64 to 0.96; <a href="./appendices#CD015477-sec-0472">Appendix 20</a>). </p> </section> <section id="CD015477-sec-0253"> <p><b>Local reactogenicity events</b></p> <p>Follow‐up was seven days starting after the injection of the booster dose. There were fewer local reactogenicity events in the homologous booster arm (73/106) compared to the mRNA‐1273 booster arm (103/111) (RR 0.74, 95% CI 0.65 to 0.85). We assessed the overall risk of bias for the outcome to have some concerns due to lack of information on allocation concealment, use of per‐protocol analysis and missing outcome data (<a href="#CD015477-fig-0046">Figure 46</a>). </p> </section> </section> <section id="CD015477-sec-0254"> <h6 class="title">Ad26.COV2.S with homologous booster versus heterologous BNT162b2 booster</h6> <p><a href="./references#CD015477-bbs2-0030" title="SablerollesRS , RietdijkWJ , GoorhuisA , PostmaDF , VisserLG , GeersD , et al. Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.18.21264979]">Sablerolles 2021</a> assessed complete vaccination of Ad26.COV2.S with a homologous booster dose of Ad26.COV2.S versus a heterologous booster dose of BNT162b2 in healthcare workers. They reported on three outcomes of interest. </p> <section id="CD015477-sec-0255"> <p><b>Systemic reactogenicity events</b></p> <p>Follow‐up was seven days starting after the injection of the booster dose. There were 62/106 systemic reactogenicity events in the homologous booster arm compared to 70/111 in the BNT162b2 booster arm (RR 0.93, 95% CI 0.75 to 1.15). We assessed the overall risk of bias for the outcome to have some concerns due to lack of information on allocation concealment, use of per‐protocol analysis and missing outcome data (<a href="#CD015477-fig-0047">Figure 47</a>). </p> </section> <section id="CD015477-sec-0256"> <p><b>Immunogenicity outcomes</b></p> <p><a href="./references#CD015477-bbs2-0030" title="SablerollesRS , RietdijkWJ , GoorhuisA , PostmaDF , VisserLG , GeersD , et al. Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.18.21264979]">Sablerolles 2021</a> reported results for cellular immune response. The proportion of responders was measured using IFN‐y release assay (cut‐off is 0.15 IU/mL) 28 days after the administration of the booster dose. The response rate was lower in the homologous booster arm (32/44; 72.7%) than in the heterologous booster arm (43/47; 91.5%) (RR 0.79, 95% CI 0.65 to 0.97; <a href="./appendices#CD015477-sec-0472">Appendix 20</a>). </p> </section> <section id="CD015477-sec-0257"> <p><b>Local reactogenicity events</b></p> <p>Follow‐up was seven days starting after the injection of the booster dose. There were fewer local reactogenicity events in the homologous booster arm (73/106) compared to the BNT162b2 booster arm (97/111) (RR 0.79, 95% CI 0.66 to 0.91). We assessed the overall risk of bias for the outcome to have some concerns due to lack of information on allocation concealment, use of per‐protocol analysis and missing outcome data (<a href="#CD015477-fig-0046">Figure 46</a>). </p> </section> </section> <section id="CD015477-sec-0258"> <h6 class="title">CoronaVac with homologous booster versus heterologous Ad5 booster</h6> <p>One trial compared a complete vaccination of CoronaVac with a homologous booster dose of CoronaVac to a heterologous booster dose of Ad5 in healthy adults (<a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>). They reported five outcomes of interest. </p> <section id="CD015477-sec-0259"> <p><b>Serious adverse events</b></p> <p>Zero SAEs were reported in both groups (<a href="#CD015477-fig-0048">Figure 48</a>). </p> <div class="figure" id="CD015477-fig-0048"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 48</div> </div> <hr class="top"/><img alt="Analysis 6.2.1: homologous booster versus heterologous booster. Outcome: serious adverse events." data-id="CD015477-fig-0048" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-48.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 6.2.1: homologous booster versus heterologous booster. Outcome: serious adverse events. </p> </div> </div> </div> </section> <section id="CD015477-sec-0260"> <p><b>Systemic reactogenicity events</b></p> <p>Follow‐up was one month starting after the injection of the booster dose. There were fewer systemic reactogenicity events in the homologous booster arm (3/102) compared to the Ad5 booster arm (14/96) (RR 0.20, 95% CI 0.06 to 0.68). We assessed the overall risk of bias for the outcome to have some concerns due to the use of per‐protocol analysis (<a href="#CD015477-fig-0047">Figure 47</a>). </p> </section> <section id="CD015477-sec-0261"> <p><b>Any adverse event</b></p> <p>Follow‐up was one month starting after the injection of the booster dose. There were fewer adverse events in the homologous booster arm (5/102) compared to the Ad5 booster arm (34/96) (RR 0.14, 95% CI 0.06 to 0.34). We assessed the overall risk of bias for the outcome to have some concerns due to the use of per‐protocol analysis (<a href="#CD015477-fig-0049">Figure 49</a>). </p> <div class="figure" id="CD015477-fig-0049"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 49</div> </div> <hr class="top"/><img alt="Analysis 6.2.3: homologous booster versus heterologous booster. Outcome: any adverse event." data-id="CD015477-fig-0049" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-49.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 6.2.3: homologous booster versus heterologous booster. Outcome: any adverse event. </p> </div> </div> </div> </section> <section id="CD015477-sec-0262"> <p><b>Immunogenicity outcomes </b></p> <p><a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a> reported that the heterologous booster CoronaVac/Ad5 elicited higher levels of specific antibodies against SARS‐COV‐2 (GMR 8.37, 95% CI 6.52 to 10.75) and neutralizing antibodies against SARS‐COV‐2 (GMR 5.87, 95% CI 4.64 to 7.43) compared to the homologous booster CoronaVac/CoronaVac (<a href="./appendices#CD015477-sec-0463">Appendix 16</a>; <a href="./appendices#CD015477-sec-0449">Appendix 11</a>).  </p> </section> <section id="CD015477-sec-0263"> <p><b>Local reactogenicity events</b></p> <p>Follow‐up was one month starting after the injection of the booster dose. There were fewer local reactogenicity events in the homologous booster arm (3/102) compared to the Ad5 booster arm (28/96) (RR 0.10, 95% CI 0.03 to 0.32). We assessed the overall risk of bias for the outcome to have some concerns due to the use of per‐protocol analysis (<a href="#CD015477-fig-0046">Figure 46</a>). </p> </section> </section> <section id="CD015477-sec-0264"> <h6 class="title">CoronaVac with a homologous booster versus heterologous BNT162b2 booster</h6> <p>One trial compared complete vaccination of CoronaVac with a homologous booster dose of CoronaVac to a heterologous booster dose of BNT162b2 in adults with low‐immune response against SARS‐CoV‐2 after complete vaccination of CoronaVac (<a href="./references#CD015477-bbs2-0028" title="MokC , ChengS , ChenC , YiuK , ChanTO , LaiKC , et al. A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.11.02.21265843]">Mok 2021</a>). They reported two outcomes of interest. </p> <section id="CD015477-sec-0265"> <p><b>Systemic reactogenicity events</b></p> <p>Follow‐up was one month starting after the injection of the booster dose. There were fewer systemic reactogenicity events in the homologous booster arm (24/40) compared to the BNT162b2 booster arm (32/40) (RR 0.75, 95% CI 0.56 to 1.01). We assessed the overall risk of bias for the outcome to have some concerns due to lack of information on allocation concealment, unclear blinding which could have influenced the measurement of the outcome, and the outcome not being prespecified (<a href="#CD015477-fig-0047">Figure 47</a>). </p> </section> <section id="CD015477-sec-0266"> <p><b>Local reactogenicity events</b></p> <p>Follow‐up was one month starting after the injection of the booster dose. There were fewer local reactogenicity events in the homologous booster arm (12/40) compared to the BNT162b2 booster arm (34/40) (RR 0.35, 95% CI 0.22 to 0.58). We assessed the overall risk of bias for the outcome to have some concerns due to lack of information on allocation concealment, unclear blinding which could have influenced the measurement of the outcome, and the outcome not being prespecified (<a href="#CD015477-fig-0046">Figure 46</a>). </p> </section> </section> </section> <section id="CD015477-sec-0267"> <h5 class="title">Heterologous booster versus heterologous booster </h5> <section id="CD015477-sec-0268"> <h6 class="title">Ad26.COV2.S with mRNA‐1273 booster versus Ad26.COV2.S with BNT162b2 booster</h6> <p>One trial compared mRNA‐1273 booster to BNT162b2 booster in healthcare workers vaccinated with Ad26.COV2.S (<a href="./references#CD015477-bbs2-0030" title="SablerollesRS , RietdijkWJ , GoorhuisA , PostmaDF , VisserLG , GeersD , et al. Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.18.21264979]">Sablerolles 2021</a>). They reported on three outcomes of interest. </p> <section id="CD015477-sec-0269"> <p><b>Systemic reactogenicity events</b></p> <p>Follow‐up was seven days starting after the injection of the booster dose. There were more systemic reactogenicity events in the mRNA‐1273 booster arm (84/111) compared to the BNT162b2 booster arm (70/111) (RR 1.20, 95% CI 1.01 to 1.43). We assessed the overall risk of bias for the outcome to have some concerns due to lack of information on allocation concealment, use of per‐protocol analysis, and missing outcome data (<a href="#CD015477-fig-0047">Figure 47</a>). </p> </section> <section id="CD015477-sec-0270"> <p><b>Immunogenicity outcomes</b></p> <p><a href="./references#CD015477-bbs2-0030" title="SablerollesRS , RietdijkWJ , GoorhuisA , PostmaDF , VisserLG , GeersD , et al. Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.18.21264979]">Sablerolles 2021</a> reported results for cellular immune response. The proportion of responders was measured using IFN‐y release assay (cut‐off is 0.15 IU/mL) 28 days after the administration of the booster dose. The number of responders was similar in the mRNA‐1273 booster arm (44/48; 91.7%) compared to the BNT162b2 booster arm (43/47; 91.5%) (RR 1.00, 95% CI 0.88 to 1.13; <a href="./appendices#CD015477-sec-0472">Appendix 20</a>). </p> </section> <section id="CD015477-sec-0271"> <p><b>Local reactogenicity events</b></p> <p>Follow‐up was seven days starting after the injection of the booster dose. There were 103/111 participants with local reactogenicity events in the mRNA‐1273 booster arm compared to 97/111 in the BNT162b2 booster arm (RR 1.06, 95% CI 0.97 to 1.16). We assessed the overall risk of bias for the outcome to have some concerns due to lack of information on allocation concealment, use of per‐protocol analysis, and missing outcome data (<a href="#CD015477-fig-0046">Figure 46</a>). </p> </section> </section> </section> </section> <section id="CD015477-sec-0272"> <h4 class="title">Effects of the intervention on variants of concern </h4> <p>Given that the prevalence of more than one variant in the same population changes and shifts over time, it is to be expected that most of the trials, which collect data over several months, reflect the heterogeneity of COVID‐19 variants in their sample. However, among our included studies, 10 did report vaccine efficacy on confirmed symptomatic COVID‐19 after complete vaccination against four variants of concern: Alpha (<a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>; <a href="./references#CD015477-bbs2-0011" title="EmaryKR , GolubchikT , AleyPK , ArianiCV , AngusB , BibiS , et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomized controlled trial. Lancet2021;397(10282):1351-62. ">Emary 2021</a>; <a href="./references#CD015477-bbs2-0019" title="HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine2021;385(13):1172-83. HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant. medRxiv 2021 [Preprint]. ">Heath 2021</a>; <a href="./references#CD015477-bbs2-0021" title="KremsnerPG , Ahuad GuerreroRA , Arana-ArriE , Aroca MartinezGJ , BontenM , ChandlerR , et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3, randomized, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3911826]">Kremsner 2021</a>), Beta (<a href="./references#CD015477-bbs2-0027" title="MadhiSA , BaillieV , CutlandCL , VoyseyM , KoenAL , FairlieL , et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1885-98. ">Madhi 2021b</a>; <a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a>; <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a>; <a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a>), Gamma (<a href="./references#CD015477-bbs2-0006" title="ClemensSA , FolegattiPM , EmaryKR , WeckxLY , RatcliffJ , BibiS , et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. Nature Communications2021;12(1):5861. ">Clemens 2021</a>; <a href="./references#CD015477-bbs2-0021" title="KremsnerPG , Ahuad GuerreroRA , Arana-ArriE , Aroca MartinezGJ , BontenM , ChandlerR , et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3, randomized, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3911826]">Kremsner 2021</a>), and Delta (<a href="./references#CD015477-bbs2-0009" title="EllaR , ReddyS , BlackwelderW , PotdarV , YadavP , SarangiV , et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.06.30.21259439]">Ella 2021b</a>). No study had yet reported data regarding the Omicron variant at the time of the data cut‐off (5 November 2021).  </p> <p>We considered the direct evidence when study reports provided evidence on a sequenced sample. When sequencing was not performed, we extrapolated the exposure to variants from the prevalence in the study setting.  </p> <section id="CD015477-sec-0273"> <h5 class="title">Alpha variant (B.1.1.7)</h5> <p>Vaccine efficacy against the Alpha variant was reported in three trials, assessing three different vaccines. All cases of the Alpha variant were detected with genome sequencing. Of note, <a href="./references#CD015477-bbs2-0011" title="EmaryKR , GolubchikT , AleyPK , ArianiCV , AngusB , BibiS , et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomized controlled trial. Lancet2021;397(10282):1351-62. ">Emary 2021</a> includes only participants of the COV002 trial (<a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>).  </p> <p>Reported vaccine efficacy on confirmed symptomatic COVID‐19 after complete vaccination was 55.10%, 95% CI 23.50% to 73.60% for CVnCoV (<a href="./references#CD015477-bbs2-0021" title="KremsnerPG , Ahuad GuerreroRA , Arana-ArriE , Aroca MartinezGJ , BontenM , ChandlerR , et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3, randomized, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3911826]">Kremsner 2021</a>); 70.40%, 95% CI 43.60% to 84.50% for ChAdOx1 (<a href="./references#CD015477-bbs2-0011" title="EmaryKR , GolubchikT , AleyPK , ArianiCV , AngusB , BibiS , et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomized controlled trial. Lancet2021;397(10282):1351-62. ">Emary 2021</a>); and for NVX‐CoV2373 was 86.30%, 95% CI 71.30% to 93.50% (<a href="./references#CD015477-bbs2-0019" title="HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine2021;385(13):1172-83. HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant. medRxiv 2021 [Preprint]. ">Heath 2021</a>) and 93.60%, 95% CI 81.70% to 97.80% (<a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>) (<a href="#CD015477-fig-0050">Figure 50</a>). </p> <div class="figure" id="CD015477-fig-0050"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 50</div> </div> <hr class="top"/><img alt="Analysis 7.1.1: variant‐Alpha. Outcome: confirmed symptomatic COVID‐19 after complete vaccination." data-id="CD015477-fig-0050" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-50.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 7.1.1: variant‐Alpha. Outcome: confirmed symptomatic COVID‐19 after complete vaccination. </p> </div> </div> </div> </section> <section id="CD015477-sec-0274"> <h5 class="title">Beta variant (B.1.351) </h5> <p>Vaccine efficacy against the Beta variant was reported in four trials, assessing four different vaccines. Results from three trials are based only on genetically sequenced cases (direct evidence) (<a href="./references#CD015477-bbs2-0027" title="MadhiSA , BaillieV , CutlandCL , VoyseyM , KoenAL , FairlieL , et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1885-98. ">Madhi 2021b</a>; <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a>; <a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a>). In contrast, results in <a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a> include all cases identified and the prevalence of the Beta variant among participants (94.5%), obtained by sequencing a sample of RT‐PCR positive cases, was extrapolated to the results (indirect evidence). Of note, <a href="./references#CD015477-bbs2-0027" title="MadhiSA , BaillieV , CutlandCL , VoyseyM , KoenAL , FairlieL , et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1885-98. ">Madhi 2021b</a> includes only participants of the COV005 trial (<a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>). </p> <p>Reported vaccine efficacy on confirmed symptomatic COVID‐19 after complete vaccination was 100.00%, 95% CI 53.50% to 100.00% for BNT16b2 (<a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a>); 10.40%, 95% CI 0.00% to 54.80% for ChAdOx1 (<a href="./references#CD015477-bbs2-0027" title="MadhiSA , BaillieV , CutlandCL , VoyseyM , KoenAL , FairlieL , et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1885-98. ">Madhi 2021b</a>); 52.00%, 95% CI 30.30% to 67.40% for Ad26.COV2.S (<a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a>), and 43.00%, 95% CI 0.00% to 70.40% for NVX‐CoV2373 (<a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a>) (<a href="#CD015477-fig-0051">Figure 51</a>). </p> <div class="figure" id="CD015477-fig-0051"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 51</div> </div> <hr class="top"/><img alt="Analysis 7.2.1: variant‐Beta. Outcome: confirmed symptomatic COVID‐19 after complete vaccination." data-id="CD015477-fig-0051" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-51.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 7.2.1: variant‐Beta. Outcome: confirmed symptomatic COVID‐19 after complete vaccination. </p> </div> </div> </div> </section> <section id="CD015477-sec-0275"> <h5 class="title">Gamma variant (P.1)</h5> <p>Vaccine efficacy against the Gamma variant was reported in two trials, assessing two different vaccines. All cases of the Gamma variant were detected with genome sequencing. Reported vaccine efficacy on confirmed symptomatic COVID‐19 after complete vaccination was 67.10%, 95% CI 29.80% to 84.60% for CVnCoV (<a href="./references#CD015477-bbs2-0021" title="KremsnerPG , Ahuad GuerreroRA , Arana-ArriE , Aroca MartinezGJ , BontenM , ChandlerR , et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3, randomized, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3911826]">Kremsner 2021</a>), and 63.60%, 95% CI 0.00% to 87.00% for ChAdOx1 (<a href="./references#CD015477-bbs2-0006" title="ClemensSA , FolegattiPM , EmaryKR , WeckxLY , RatcliffJ , BibiS , et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. Nature Communications2021;12(1):5861. ">Clemens 2021</a>) (<a href="#CD015477-fig-0052">Figure 52</a>). </p> <div class="figure" id="CD015477-fig-0052"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 52</div> </div> <hr class="top"/><img alt="Analysis 7.3.1: variant‐Gamma. Outcome: confirmed symptomatic COVID‐19 after complete vaccination." data-id="CD015477-fig-0052" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-52.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 7.3.1: variant‐Gamma. Outcome: confirmed symptomatic COVID‐19 after complete vaccination. </p> </div> </div> </div> </section> <section id="CD015477-sec-0276"> <h5 class="title">Delta (B.1.617.2)</h5> <p>Vaccine efficacy against the Delta variant was reported in one trial. All cases of the Delta variant were detected with genome sequencing. </p> <p>Reported vaccine efficacy on confirmed symptomatic COVID‐19 after complete vaccination was 65.20%, 95% CI 33.10% to 83.00% for BBV152 (<a href="./references#CD015477-bbs2-0009" title="EllaR , ReddyS , BlackwelderW , PotdarV , YadavP , SarangiV , et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.06.30.21259439]">Ella 2021b</a>) (<a href="#CD015477-fig-0053">Figure 53</a>). </p> <div class="figure" id="CD015477-fig-0053"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 53</div> </div> <hr class="top"/><img alt="Analysis 7.4.1: variant‐Delta. Outcome: confirmed symptomatic COVID‐19 after complete vaccination." data-id="CD015477-fig-0053" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-53.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 7.4.1: variant‐Delta. Outcome: confirmed symptomatic COVID‐19 after complete vaccination. </p> </div> </div> </div> </section> </section> <section id="CD015477-sec-0277"> <h4 class="title">Assessment of vaccine efficacy over time</h4> <p>Out of the 41 included trials, only two studies reported on the change of vaccine efficacy over time for the outcome 'incidence of confirmed symptomatic COVID‐19 after complete vaccination' for comparisons BNT162b2 versus placebo (BioNtech/Fosun Pharma/Pfizer) and mRNA‐1273 versus placebo (ModernaTX) (<a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a>; <a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a>). </p> <p>For the comparison BNT162b2 versus placebo, vaccine efficacy seems to decrease slightly over time. However, the effect remains large: VE 96.20%, 95% CI 93.30% to 98.10% after a median follow‐up less than 2 months and VE 83.70%, 95% CI 74.70% to 89.90% after a median follow‐up of 4 months to 6 months (<a href="#CD015477-fig-0054">Figure 54</a>). </p> <div class="figure" id="CD015477-fig-0054"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 54</div> </div> <hr class="top"/><img alt="Analysis 8.1: follow‐up. RNA‐based vaccine. Outcome: confirmed symptomatic COVID‐19 after complete vaccination." data-id="CD015477-fig-0054" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-54.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 8.1: follow‐up. RNA‐based vaccine. Outcome: confirmed symptomatic COVID‐19 after complete vaccination. </p> </div> </div> </div> <p>When comparing mRNA‐1273 with placebo, vaccine efficacy was consistent over time (VE 91.80%, 95% CI 86.90% to 95.10%; median follow‐up less than two months and VE 92.40%, 84.30% to 96.80%; median follow‐up four months or greater) (<a href="#CD015477-fig-0054">Figure 54</a>). </p> </section> <section id="CD015477-sec-0278"> <h4 class="title">Exploration of heterogeneity</h4> <section id="CD015477-sec-0279"> <h5 class="title">Subgroup analysis</h5> <p>We had planned to perform subgroup analysis for different age groups and immunocompromized patients; however due to the low number of studies we could not undertake formal subgroup analyses for each comparison.  </p> </section> <section id="CD015477-sec-0280"> <h5 class="title">Sensitivity analysis </h5> <p>Overall, all results for all outcomes were consistent in every sensitivity analysis as compared with the primary analysis. Small differences were mostly observed due to the increase of uncertainty in the summary estimate when excluding some trials. </p> </section> <section id="CD015477-sec-0281"> <h5 class="title">RNA‐based vaccines</h5> <p>Overall, results were consistent in all the analyses (<a href="#CD015477-tbl-0016">Table 1</a>). </p> <div class="table" id="CD015477-tbl-0016"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analysis: RNA‐based vaccines</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Developer – comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Analyses<sup>a</sup> </b> </p> </th> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SARS‐CoV‐2 infection</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Symptomatic COVID‐19</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Severe COVID‐19</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>All‐cause mortality</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SAEs</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Systemic reactogenicity events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>AEs</b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>VE (95% CI)</b> </p> <p><b>No. of trials (No. of participants) </b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="top"> <p><b>RR (95% CI)</b> </p> <p><b>No. of trials (No. of participants) </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>BNT162b2 <b>–</b> Pfizer/BioNTech+Fosun Pharma versus placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.84% (44.25% to 99.92%)</p> <p>2 RCTs (44,077)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.70% (73.90% to 99.90%)</p> <p>1 RCT (46,077)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.07 (0.52 to 2.22)</p> <p>1 RCT (43,846)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.30 (0.55 to 3.07)</p> <p>2 RCTs (46,107)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.52 (0.88 to 2.63)</p> <p>3 RCTs (46,419)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.07 (0.52 to 2.22)</p> <p>1 RCT (44,165)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.30 (0.55 to 3.05)</p> <p>2 RCTs (46,429)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.52 (0.88 to 2.63)</p> <p>3 RCTs (46,471)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>—</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>—</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>—</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>mRNA‐1273 <b>–</b> ModernaTX  versus placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.27% (35.82% to 88.87%)</p> <p>2 RCTs (31,632)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.20% (91.06% to 94.83%)</p> <p>2 RCTs (31,632)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.20% (92.80% to 99.60%)</p> <p>1 RCT (28,451)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.06 (0.54 to 2.10)</p> <p>1 RCT (30,346)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.78 to 1.08)</p> <p>2 RCTs (34,072)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.28 (1.22 to 1.34)</p> <p>2 RCTs (34,037)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.19 (0.79 to 1.80)</p> <p>2 RCTs (34,072)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.06 (0.54 to 2.10)</p> <p>1 RCT (30,415)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.78 to 1.09)</p> <p>2 RCTs (34,147)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.28 (1.22 to 1.34)</p> <p>2 RCTs (34,147)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.20 (0.79 to 1.80)</p> <p>2 RCTs (34,147)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>—</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>—</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>CVnCoV <b>–</b> CureVac AG versus placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.20% (31.70% to 60.90%)</p> <p>1 RCT (25,062)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.80% (0.00% to 91.70%)</p> <p>1 RCT (25,062)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.33 (0.46 to 3.83)</p> <p>1 RCT (39,529)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.24 (0.90 to 1.71)</p> <p>1 RCT (39,529)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.48 (1.43 to 1.53)</p> <p>1 RCT (3982)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.42 (1.38 to 1.47)</p> <p>1 RCT (3982)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.49 (1.39 to 1.60)</p> <p>1 RCT (39,529)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.43 (1.34 to 1.53)</p> <p>1 RCT (39,529)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>—</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>—</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>—</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p>AE: adverse event; CI: confidence interval; COVID‐19: coronavirus disease 2019; RCT: randomized controlled trial; RR: risk ratio; SAE: serious adverse event; SARS‐CoV‐2: severe acute respiratory syndrome coronavirus 2; VE: vaccine efficacy. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup><b>Sensitivity 1:</b> participants randomized; <b>Sensitivity 2:</b> early‐phase studies excluded; <b>Sensitivity 3:</b> only published studies. </p> </div> </div> </section> <section id="CD015477-sec-0282"> <h5 class="title">Non‐replicating viral vector vaccines</h5> <p>Overall, results were consistent in all the analyses (<a href="#CD015477-tbl-0017">Table 2</a>). An important but not statistically significant reduction in the RR for adverse event was observed, though, when excluding the early‐phase trial. </p> <div class="table" id="CD015477-tbl-0017"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analysis: non‐replicating viral vector vaccine </span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Developer – comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p>Analyses<b><sup>a</sup> </b> </p> </th> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SARS‐CoV‐2 infection</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Symptomatic COVID‐19</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Severe COVID‐19</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>All‐cause mortality</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SAEs</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Systemic <b>reactogenicity events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>AEs</b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>VE (95% CI)</b> </p> <p><b>No. of trials (No. of participants)</b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="top"> <p><b>RR (95% CI)</b> </p> <p><b>No. of trials (No. of participants)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>ChAdOx1 – AstraZeneca + University of Oxford versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.35% (48.00% to 68.22%)</p> <p>5 RCTs (43,390)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.23% (62.10% to 76.62%)</p> <p>5 RCTs (43,390)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48 (0.20 to 1.14)</p> <p>5 RCTs (56,726)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.72 to 1.07)</p> <p>7 RCTs (58,182)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.93 (2.11 to 7.29)</p> <p> </p> <p>1 RCT (256)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50 (0.20 to 1.21)</p> <p>5 RCTs (56,873)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.86 (0.70 to 1.06)</p> <p>7 RCTs (58,329)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> —</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48 (0.20 to 1.14)</p> <p>5 RCTs (56,623)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.72 to 1.08)</p> <p>6 RCTs (57,823)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> —</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> —</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50 (0.20 to 1.21)</p> <p>5 RCTs (56,623)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.86 (0.70 to 1.05)</p> <p>6 RCTs (56,879)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> —</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Ad26.COV2.S – Janssen Pharmaceutical Companies  versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.90% (59.10% to 73.40%)</p> <p>1 RCT (39,058)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.30% (57.90% to 87.50%)</p> <p>1 RCT (39,058)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 (0.09 to 0.67)</p> <p>1 RCT (43,783)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.69 to 1.22)</p> <p>1 RCT (43,783)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.83 (1.29 to 2.60)</p> <p>2 RCTs (7222)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.57 (0.75 to 3.29)</p> <p>2 RCTs (7222)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 (0.09 to 0.67)</p> <p>1 RCT (44,325)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.69 to 1.22)</p> <p>1 RCT (44,325)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.83 (1.27 to 2.63)</p> <p>2 RCTs (44,813)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.57 (0.74 to 3.32)</p> <p>2 RCTs (44,813)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.09 (0.96 to 1.24)</p> <p>1 RCT (6736)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Gam‐COVID‐Vac – Gamaleya Research Institute (Sputnik V) Gam‐COVID‐Vac versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.10% (83.80% to 95.10%)</p> <p>1 RCT (18,695)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.00% (94.40% to 100.00%)</p> <p>1 RCT (19,866)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99 (0.10 to 9.54)</p> <p>1 RCT (21,862)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 (0.39 to 1.07)</p> <p>1 RCT (21,862)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.10 to 9.57)</p> <p>1 RCT (21,977)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 (0.39 to 1.07)</p> <p>1 RCT (21,977)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p>AE: adverse event; CI: confidence interval; COVID‐19: coronavirus disease 2019; RCT: randomized controlled trial; RR: risk ratio; SAE: serious adverse event; SARS‐CoV‐2: severe acute respiratory syndrome coronavirus 2; VE: vaccine efficacy. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b><sup>a</sup>Sensitivity 1:</b> participants randomized; <b>Sensitivity 2:</b> early‐phase studies excluded; <b>Sensitivity 3:</b> only published studies. </p> </div> </div> </section> <section id="CD015477-sec-0283"> <h5 class="title">Inactivated virus vaccines</h5> <p>Results were consistent, with the exception of an increase in vaccine efficacy against confirmed symptomatic COVID‐19 after complete vaccination for CoronaVac compared to placebo when excluding results reported as preprints (VE 83.5%, 95% CI 65.4% to 92.1%) (<a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>) (<a href="#CD015477-tbl-0018">Table 3</a>). Using the participants randomized instead of those analyzed seemed to increase the heterogeneity, whereas excluding early‐phase trials slightly decreased the heterogeneity and increased the precision of the summary estimate. </p> <div class="table" id="CD015477-tbl-0018"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sensitivity analysis: inactivated virus vaccine</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Developer – comparison </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p>Analyses<b><sup>a</sup> </b> </p> </th> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>SARS‐CoV‐2 infection</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Symptomatic COVID‐19</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Severe COVID‐19</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>All‐cause mortality</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>SAEs</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p>Systemic <b>reactogenicity events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>AEs</b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>VE (95% CI)</b> </p> <p><b>No. of trials (No. of participants) </b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="top"> <p><b>RR (95% CI)</b> </p> <p><b>No. of trials (No. of participants) </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>CoronaVac – Sinovac versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.81% (12.27% to 89.61%)</p> <p>2 RCTs (19,852)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50 (0.05 to 5.52)</p> <p>1 RCT (12,396)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (0.62 to 1.51)</p> <p>4 RCTs (23,139)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95 (0.55 to 1.62)</p> <p>7 RCTs (23,956)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.09 (1.07 to 1.11)</p> <p>6 RCTs (23,367)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50 (0.05 to 5.52)</p> <p>1 RCT (12,408)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99 (0.64 to 1.51)</p> <p>4 RCTs (23,157)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.56 (0.91 to 2.69)</p> <p>7 RCTs (25,106)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.09 (1.07 to 1.11)</p> <p>6 RCTs (23,385)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99 (0.63 to 1.55)</p> <p>2 RCTs (22,610)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.21 (0.98 to 1.49)</p> <p>4 RCTs (23,584)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.09 (1.07 to 1.11)</p> <p>2 RCTs (22,610)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.50% (65.40% to 92.10%)</p> <p>1 RCT (10,029)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.24 to 2.21)</p> <p>4 RCTs (10,894)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (0.49 to 1.81)</p> <p>6 RCTs (11,617)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.13 (1.04 to 1.23)</p> <p>4 RCTs (10,640)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>WIBP‐CorV – Sinopharm‐Wuhan versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.00% (48.80% to 74.70%)</p> <p>1 RCT (25,449)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.80% (58.10% to 82.40%)</p> <p>1 RCT (25,480)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.60 to 1.15)</p> <p>2 RCTs (27,029)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99 (0.95 to 1.03)</p> <p>2 RCTs (27,029)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.93 to 0.98)</p> <p>2 RCTs (27,029)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.60 to 1.15)</p> <p>2 RCTs (27,053)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99 (0.95 to 1.03)</p> <p>2 RCTs (27,053)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.93 to 0.98)</p> <p>2 RCTs (27,053)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82 (0.59 to 1.14)</p> <p>1 RCT (26,917)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99 (0.95 to 1.03)</p> <p>1 RCT (26,917)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.93 to 0.98)</p> <p>1 RCT (26,917)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> —</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>BBIBP‐CorV – Sinopharm‐Beijing <br/> versus placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.50% (60.60% to 82.20%)</p> <p>1 RCT (25,463)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.10% (64.80% to 86.30%)</p> <p>1 RCT (25,463)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.76 (0.54 to 1.06)</p> <p>1 RCT (26,924)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.05 (0.86 to 1.28)</p> <p>3 RCTs (27,540)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.05 (0.86 to 1.28)</p> <p>3 RCTs (27,557)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> —</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02 (0.98 to 1.06)</p> <p>1 RCT (26,924)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>BBV152 – Bharat Biotech<br/> versus placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.80% (46.70% to 82.50%)</p> <p>1 RCT (6289)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.80% (65.20% to 86.40%)</p> <p>1 RCT (16,973)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.70% (96.79% to 99.79%)</p> <p>1 RCT (16,976)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50 (0.17 to 1.46)</p> <p>1 RCT (25,753)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 (0.43 to 0.97)</p> <p>1 RCT (25,753)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.34 (1.15 to 1.58)</p> <p>2 RCTs (25,925)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.94 to 1.07)</p> <p>1 RCT (25,753)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50 (0.17 to 1.46)</p> <p>1 RCT (25,778)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 (0.43 to 0.97)</p> <p>2 RCTs (25,953)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.35 (1.15 to 1.58)</p> <p>2 RCTs (25,953)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.94 to 1.07)</p> <p>1 RCT (25,778)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 (0.43 to 0.97)</p> <p>1 RCT (25,753)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.34 (1.14 to 1.58)</p> <p>1 RCT (25,753)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.47 (0.63 to 3.47)</p> <p>1 RCT (172)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p>AE: adverse event; CI: confidence interval; COVID‐19: coronavirus disease 2019; RCT: randomized controlled trial; RR: risk ratio; SAE: serious adverse event; SARS‐CoV‐2: severe acute respiratory syndrome coronavirus 2; VE: vaccine efficacy. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b><sup>a</sup>Sensitivity 1:</b> participants randomized; <b>Sensitivity 2:</b> early‐phase studies excluded; <b>Sensitivity 3:</b> only published studies. </p> </div> </div> </section> <section id="CD015477-sec-0284"> <h5 class="title">Protein subunit vaccines</h5> <p>Overall, results were consistent in all the analyses (<a href="#CD015477-tbl-0019">Table 4</a>). </p> <div class="table" id="CD015477-tbl-0019"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analysis: protein subunit vaccine</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Developer‐comparison </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Analyses<sup>a</sup> </b> </p> </th> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SARS‐CoV‐2 infection</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Symptomatic COVID‐19</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Severe COVID‐19</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>All‐cause mortality</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SAEs</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Systemic</b> </p> <p><b>reactogenicity events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>AEs</b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>VE (95% CI)</b> </p> <p><b>No. of trials (No. of participants) </b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="top"> <p><b>RR (95% CI)</b> </p> <p><b>No. of trials (No. of participants) </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NVX‐CoV2373 – Novavax <br/>versus placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.91% (50.49% to 94.10%)</p> <p>3 RCTs (42,175)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.00% (86.99% to 100.00%)</p> <p>1 RCT (25,452)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.30 to 2.68)</p> <p>1 RCT (29,582)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.74 to 1.14)</p> <p> 4 RCTs (46,202)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.21 (1.17 to 1.25)</p> <p>3 RCTs (31,063)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.15 (1.05 to 1.26)</p> <p>5 RCTs (46,231)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.74 to 1.14)</p> <p>4 RCTs (50,111)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.21 (1.17 to 1.26)</p> <p>3 RCTs (34,870)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.16 (1.05 to 1.27)</p> <p>5 RCTs (50,111)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (0.75 to 1.15)</p> <p>3 RCTs (45,689)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.20 (1.17 to 1.24)</p> <p>2 RCTs (30,550)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.14 (1.02 to 1.27)</p> <p>3 RCTs (45,689)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.10% (0.00% to 95.19%)</p> <p>2 RCTs (16,723)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99 (0.65 to 1.51)</p> <p>3 RCTs (16,620)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.24 (1.03 to 1.49)</p> <p>2 RCTs (1481)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.18 (1.03 to 1.35)</p> <p>4 RCTs (16,672)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>FINLAY‐FR‐2 – Instituto Finlay de Vacunas<br/> versus placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.00% (58.90% to 79.10%)</p> <p>1 RCT (28,674)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.37 (0.17 to 0.80)</p> <p>1 RCT (28,674)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> —</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p>AE: adverse event; CI: confidence interval; COVID‐19: coronavirus disease 2019; RCT: randomized controlled trial; RR: risk ratio; SAE: serious adverse event; SARS‐CoV‐2: severe acute respiratory syndrome coronavirus 2; VE: vaccine efficacy. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b><sup>a</sup>Sensitivity 1:</b> participants randomized; <b>Sensitivity 2:</b> early‐phase studies excluded; <b>Sensitivity 3:</b> only published studies. </p> </div> </div> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD015477-sec-0285" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD015477-sec-0285"></div> <section id="CD015477-sec-0286"> <h3 class="title" id="CD015477-sec-0286">Summary of main results</h3> <p>We identified and included 41 RCTs  evaluating four different vaccine platforms and 12 vaccine candidates published in 65 reports in the analysis. Six RCTs reported results for three RNA‐based vaccines (BNT162b2 from BioNtech/Fosun Pharma/Pfizer; mRNA‐1273 from ModernaTX; CVnCoV by CureVac AG), and 10 RCTs evaluated three non‐replicating viral vector vaccines (ChAdOx1 by AstraZeneca/University of Oxford and SII‐ChAdOx1; Ad26.COV2.S by Janssen Pharmaceutical Companies; Gam‐COVID‐Vac by Gamaleya Research Institute), 13 RCTs evaluated four inactivated virus vaccines (CoronaVac by Sinovac; WIBP‐CorV by Sinopharm‐Wuhan; BBIBP‐CorV by Sinopharm‐Beijing; BBV152 by Bharat Biotech), and 6 RCTs evaluated two protein subunit vaccines (NVX‐CoV2373 by Novavax; FINLAY‐FR‐2 by Instituto Finlay de Vacunas).  </p> <p>Our review also retrieved two trials comparing heterologous vaccination schemes with homologous vaccination schemes, two trials comparing booster versus placebo/no booster, and four trials comparing homologous and heterologous booster doses. Only 10 studies reported results on vaccine efficacy of six different vaccine candidates against any specific variant, which limits our ability to make any variant‐specific claims.  </p> <section id="CD015477-sec-0287"> <h4 class="title">Efficacy outcomes for vaccines versus placebo</h4> <p>There is moderate‐ to high‐certainty evidence that several vaccine candidates are effective in preventing SARS‐CoV‐2 infection (i.e. mRNA‐1273, ChAdOx1, WIBP‐CorV, BBIBP‐CorV, BBV152); symptomatic COVID‐19 (i.e. BNT162b2, mRNA‐1273, CVnCoV, ChAdOx1, Ad26.COV2.S, Gam‐COVID‐Vac, WIBP‐CorV, BBIBP‐CorV, BBV152, NVX‐CoV2373, FINLAY‐FR‐2), and severe or critical disease compared to placebo (i.e. BNT162b2, mRNA‐1273, Ad26.COV2.S, Gam‐COVID‐Vac, BBV152, NVX‐CoV2373).  </p> <p>There is moderate‐certainty evidence that Ad26.COV2.S and FINLAY‐FR‐2 result in a decrease in all‐cause mortality compared to placebo. Evidence was uncertain and very uncertain for death for all other vaccines because of the low number of events.  </p> </section> <section id="CD015477-sec-0288"> <h4 class="title">Safety outcomes for vaccines versus placebo</h4> <p>Overall, we identified an increase in local reactogenicity events such as pain, redness, swelling, and systemic reactogenicities such as tiredness, headache, muscle pain, chills, fever, and nausea. There is moderate‐ to high‐certainty evidence that most vaccine candidates have an increased risk of systemic reactogenicity events (e.g. fever) compared to placebo (mRNA‐1273, CVnCoV, ChAdOx1, Ad26.COV2.S, WIBP‐CorV, BBIBP‐CorV, BBV152, NVX‐CoV2373). These events were expected. </p> <p>We did not find evidence of an increase in SAEs. There is moderate‐ to high‐certainty evidence that there is probably little or no difference between mRNA‐1273, ChAdOx1, Ad26.COV2.S and BBV152, and placebo in terms of SAEs. Evidence was uncertain and very uncertain for SAEs for other vaccines because of the low number of events. </p> <p>We also extracted some specific adverse events, that is, cardioembolic events (pulmonary embolism, stroke, cavernous sinus thrombosis, pericarditis, venous thrombosis, myocardial infarction); haematological events (thrombocytopaenia, haemorrhage, neutropenia, anaemia, lymphadenopathy); and neurological events. The reporting of these events was very inconsistent and the number of events reported was very low.  </p> <p>The outcome 'any adverse event' was reported inconsistently. Some considered only the non‐SAE including local and systemic reactogenicity events. Some also considered SAEs, and frequently it was unclear how these events were classified. Overall, we found moderate‐ to high‐certainty evidence that vaccine increases any adverse event for three vaccines (i.e. CVnCoV, NVX‐CoV2373, CoronaVac) and that vaccine results in no increase in any adverse event for two vaccines (i.e. WIBP‐CorV, BBV152). Evidence was uncertain for other vaccines. </p> <p>As trials' follow‐up was short and the incidence of SAEs was very low, vaccine safety surveillance systems have been put in place to detect rare adverse events and concerns have been raised related to the occurrence of vaccine‐induced immune thrombocytopaenia and thrombosis (<a href="./references#CD015477-bbs2-0114" title="MakrisM , PavordS , LesterW , ScullyM , HuntB . Vaccine-induced immune thrombocytopenia and thrombosis (VITT). Research and Practice in Thrombosis and Haemostasis2021;5(5):e12529.">Makris 2021</a>; <a href="./references#CD015477-bbs2-0124" title="OstrowskiSR , SøgaardOS , TolstrupM , StærkeNB , LundgrenJ , ØstergaardL , et al. Inflammation and platelet activation after COVID-19 vaccines – possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis. Frontiers in Immunology2021;12:779453.">Ostrowski 2021</a>; <a href="./references#CD015477-bbs2-0140" title="RizkJG , GuptaA , SardarP , HenryBM , LewinJC , LippiG , et al. Clinical characteristics and pharmacological management of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis: a review. JAMA Cardiology2021;6(12):1451-60.">Rizk 2021</a>; <a href="./references#CD015477-bbs2-0150" title="Sharifian-DorcheM , BahmanyarM , Sharifian-DorcheA , MohammadiP , NomoviM , MowlaA . Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. Journal of the Neurological Sciences2021;428:117607.">Sharifian‐Dorche 2021</a>).  </p> </section> <section id="CD015477-sec-0289"> <h4 class="title">Other evidence</h4> <p>We found little evidence regarding the differences between heterologous and homologous vaccination schemes, and the effect of booster vaccines (homologous or heterologous). Outcomes considered were mainly immunogenicity outcomes.  </p> <p>In the two studies (assessing mRNA‐1273 and BNT162b2) for which we have data at different time points, vaccine efficacy at short term was consistent with longer‐term results.  </p> </section> <section id="CD015477-sec-0290"> <h4 class="title">Effects of the interventions on specific subpopulations</h4> <p>Given the sparsity of data, we were unable to explore heterogeneity in the results by conducting subgroup analyses, and therefore decided to present results separately for specific subpopulations. We identified only four clinical trials including children and adolescents, and assessed BNT162b2, mRNA‐1273, CoronaVac and BBIBP‐CorV (<a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a>; <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a>; <a href="./references#CD015477-bbs2-0018" title="HanB , SongY , LiC , YangW , MaQ , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(12):1645-53. ">Han 2021</a>; <a href="./references#CD015477-bbs2-0040" title="XiaS , DuanK , ZhangY , ZhaoD , ZhangH , XieZ , et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA2020;324(10):951-60. XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infectious Diseases2020;21(1):39-51. ">Xia 2020</a>). We found more studies focused on, or reporting subgroup data for elderly participants, with single studies reporting different outcomes in elderly participants. However, data were still sparse and should be interpreted with caution. Finally, only three studies reported data for immunocompromized participants, each assessing a different vaccine candidate (ChAdOx1, NVX‐CoV2373, and mRNA‐1273 booster versus placebo). No studies were conducted on pregnant women, and pregnant women were very rarely included in trials although it has been reported that they are at greater risk of severe COVID‐19 disease (<a href="./references#CD015477-bbs2-0136" title="QiaoJ . What are the risks of COVID-19 infection in pregnant women?Lancet2020;395(10226):760-2.">Qiao 2020</a>). </p> </section> <section id="CD015477-sec-0291"> <h4 class="title">Impact of the results on future research</h4> <p>The high efficacy of several vaccine candidates, their marketing authorization and the rapid roll‐out population‐wide, raise the question of the feasibility and ethics of placebo RCTs assessing a new vaccine candidate.  </p> <p>For the ongoing placebo trials, the question is whether participants randomized to the placebo group should be unblinded and offered vaccine. Some argue the need to pursue follow‐up to obtain strong data on long‐term efficacy and safety (<a href="./references#CD015477-bbs2-0169" title="WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation. Placebo-controlled trials of covid-19 vaccines – why we still need them. New England Journal of Medicine2021;384:e2. [DOI: 10.1056/NEJMp2033538]">WHO Ad Hoc Expert Group 2021</a>); others argue that given the clear evidence of a benefit for important outcomes, it would be unethical not to provide a vaccine to all participants (<a href="./references#CD015477-bbs2-0073" title="Dal-RéR , BekkerLG , GluudC , HolmS , JhaV , PolandGA , et al. Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities. Lancet Infectious Diseases2021;21(11):e342-7.">Dal‐Ré 2021a</a>; <a href="./references#CD015477-bbs2-0074" title="Dal-RéR , OrensteinW , CaplanAL . Being fair to participants in placebo-controlled COVID-19 vaccine trials. Nature Medicine2021;27(6):938.">Dal‐Ré 2021b</a>).  </p> <p>Assessing vaccine efficacy and safety in randomized trials is also difficult considering the rapid evolution of the disease and the emergence of new variants that could impact vaccine efficacy. Large population‐based observational data provide useful complementary information, although they need to be interpreted carefully because of the risk of bias. </p> <p>Future research questions should focus on the efficacy and safety of vaccines on specific populations, such as pregnant women, immunosuppressed patients and other vulnerable populations, on variants of concerns, and on how we can overcome the waning of vaccine efficacy over time. </p> <p>An increasing number of trials consider only immunogenetic outcomes to allow a smaller sample size to generate a more rapid answer. However, there is considerable heterogeneity in assessing these outcomes and a consensus is needed on a core outcome set to enable effective comparison and synthesis of studies. Further, their results must be interpreted with caution. </p> </section> </section> <section id="CD015477-sec-0292"> <h3 class="title" id="CD015477-sec-0292">Overall completeness and applicability of evidence</h3> <p>The evidence identified is incomplete. We identified 344 registered RCTs from registries evaluating the efficacy of COVID‐19, of which 10 were completed but not published (non‐replicating viral vector, replicating viral vector, inactivated virus, protein subunit and DNA‐based platforms). The planned sample size of the completed trials for non‐replicating viral vector vaccines is 27 participants, 90 participants for replicating viral vector vaccines, 19,512 for inactivated virus vaccines, 173 for protein subunit vaccines, and 30 for DNA‐based vaccines, yielding a total planned sample size of 19,832.  </p> <p>The applicability of the results should be interpreted with caution. The trials spanned all geographical regions: seven trials were conducted in North America, 14 in Asia, four in South America, eight in Europe, two in Africa, and one in Oceania. Notwithstanding the worldwide geographical representation of trials, it is noteworthy that the representation is skewed. Inactivated vaccine and protein subunit vaccine trials were mostly limited to India, Cuba, and China. Furthermore, trials for mRNA‐1273 were only conducted in the USA.  </p> <p>Our review also highlights the lack of evidence from RCTs regarding the efficacy of vaccines against specific variants. This is not surprising, given the relatively short period between the dominance of one variant and the next. Future studies might report more consistently on the specific variant predominating in their sample or report results stratified by variant, which would allow for more specific meta‐analyses in the future. It is likely that data on efficacy by variant will mainly come from large population‐based observational studies. The COVID‐NMA initiative identified observational studies evaluating vaccine efficacy on the Delta variant, and provides some results on the platform (<a href="https://covid-nma.com" target="_blank">covid-nma.com</a>). Given that Omicron has replaced all other variants in most countries, data may not be applicable to the current situation. </p> <p>We found high‐ or moderate‐certainty evidence for many of the main efficacy results of our review. However, the impact of effect modifiers, such as age or immunocompromized status, could not be explored adequately through subgroup analyses nor by meta‐regression. Specific trials including these specific populations should be conducted. Vaccine efficacy on these subgroups could also be explored through large observational studies using routinely collected data. </p> </section> <section id="CD015477-sec-0293"> <h3 class="title" id="CD015477-sec-0293">Certainty of the evidence</h3> <p>Overall, evidence of the critical outcomes exhibited a certainty of evidence ranging from very low certainty to high certainty. The evidence for outcomes of efficacy against SARS‐CoV‐2 infection, symptomatic COVID‐19, and severe or critical COVID‐19 was most often of moderate or high certainty. In contrast, we frequently downgraded safety outcomes and all‐cause mortality. </p> <p>The reason for which we downgraded certainty of evidence most often, throughout the results for all vaccine types, was imprecision, referring to wide CIs in our results. This was often the result of a low number of events, and less often due to inconsistencies between the included studies or risk of bias. This explains why so few of the results related to mortality or severe adverse events, which are more rare events, achieved levels of moderate‐ or high‐certainty evidence. We expect higher levels of certainty to be reached as more studies are published, and the body of evidence grows. </p> <p>In one trial (<a href="./references#CD015477-bbs2-0025" title="LogunovDY , DolzhikovaIV , ShcheblyakovDV , TukhvatulinAI , ZubkovaOV , DzharullaevaAS , et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia. Lancet2021;397(10275):671-81. ">Logunov 2021</a>), we downgraded the certainty of evidence due to concerns about the trustfulness of the analyses (<a href="./references#CD015477-bbs2-0062" title="BucciEM , BerkhofJ , GillibertA , GopalakrishnaG , CalogeroRA , BouterLM , et al. Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial. Lancet2021;397(10288):1881-3.">Bucci 2021</a>). The authors responded to some of these concerns, and the manuscript was corrected (<a href="./references#CD015477-bbs2-0025" title="LogunovDY , DolzhikovaIV , ShcheblyakovDV , TukhvatulinAI , ZubkovaOV , DzharullaevaAS , et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia. Lancet2021;397(10275):671-81. ">Logunov 2021</a>). Nevertheless, uncertainty persists particularly related to the prespecification of the interim analysis and the excess of homogeneity of vaccine efficacy across age groups. </p> </section> <section id="CD015477-sec-0294"> <h3 class="title" id="CD015477-sec-0294">Potential biases in the review process</h3> <p>We followed the guidance of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> in order to minimize several potential biases in the review process (<a href="./references#CD015477-bbs2-0101" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Higgins 2021</a>). First, the search strategy was peer reviewed. We initially performed a thorough search in several electronic databases and then considered only high‐quality sources, particularly the L·OVE platform and the Cochrane COVID‐19 Study Register. Second, all data were extracted in duplicate with consensus. Third, to increase our review's informative value, we track all registered trials in a living mapping. Finally, the review is updated continually; each week, we search for new trials and collect data, and bi‐weekly we update the syntheses. All updates of this review are available on the COVID‐NMA platform (<a href="https://covid-nma.com" target="_blank">covid-nma.com</a>). </p> <p>Another consideration for this rapidly evolving field is the availability of preprint articles that have not yet undergone peer review. In this review, we also included preprints. However, we are aware of these publications' potentially differing quality and that results could change once the peer‐reviewed journal publications are available (<a href="./references#CD015477-bbs2-0123" title="OikonomidiT , BoutronI , PierreO , CabanacG , RavaudP , COVID-19 NMA Consortium. Changes in evidence for studies assessing interventions for COVID-19 reported in preprints: meta-research study. BMC Medicine2020;18(1):402.">Oikonomidi 2020</a>). To overcome this issue, we developed a preprint tracker to keep us informed of updates, so we can update data collection and data analysis when a preprint is modified or published (<a href="./references#CD015477-bbs2-0064" title="CabanacG , OikonomidiT , BoutronI . Day-to-day discovery of preprint-publication links. Scientometrics2021;126(6):5285-304.">Cabanac 2021</a>). We also conducted sensitivity analyses excluding preprints, and found consistent results. </p> </section> <section id="CD015477-sec-0295"> <h3 class="title" id="CD015477-sec-0295">Agreements and disagreements with other studies or reviews</h3> <p>We identified seven systematic reviews reporting on the efficacy of vaccines against COVID‐19 and whose search strategy was run in the second half of 2021 or later. One included only RCTs (<a href="./references#CD015477-bbs2-0143" title="RotshildV , Hirsh-RaccahB , MiskinI , MuszkatM , MatokI . Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Scientific Reports2021;11(1):22777.">Rotshild 2021</a>), three only observational studies (<a href="./references#CD015477-bbs2-0097" title="HarderT , KochJ , Vygen-BonnetS , Kulper-SchiekW , PilicA , RedaS , et al. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. Eurosurveillance2021;26(28):2100563.">Harder 2021</a>; <a href="./references#CD015477-bbs2-0106" title="KowCS , RamachandramDS , HasanSS . The effectiveness of mRNA-1273 vaccine against COVID-19 caused by Delta variant: a systematic review and meta-analysis. Journal of Medical Virology2022;94(5):2269-74.">Kow 2022</a>; <a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>), and three a hybrid of RCTs and observational studies (<a href="./references#CD015477-bbs2-0098" title="HayawiK , ShahriarS , SerhaniMA , AlashwalH , MasudMM . Vaccine versus variants (3Vs): are the COVID-19 vaccines effective against the variants? A systematic review. Vaccines2021;9(11):1305.">Hayawi 2021</a>; <a href="./references#CD015477-bbs2-0100" title="HigdonMM , WahlB , JonesCB , RosenJG , TrueloveSA , BaidyaA , et al. A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.17.21263549]">Higdon 2021</a>; <a href="./references#CD015477-bbs2-0177" title="ZengB , GaoL , ZhouQ , YuK , SunF . Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.23.21264048]">Zeng 2021b</a>). We identified one systematic review focused on children and adolescents (<a href="./references#CD015477-bbs2-0112" title="LvM , LuoX , ShenQ , LeiR , LiuX , LiuE , et al. Safety, immunogenicity, and efficacy of COVID-19 vaccines in children and adolescents: a systematic review. Vaccines2021;9(10):1102.">Lv 2021</a>). Overall, all the trials included in these reviews were identified in our search and our results are consistent. </p> <p>There are other living systematic reviews of vaccines for COVID‐19, such as <a href="./references#CD015477-bbs2-0065" title="Castagneto GisseyL , PanunziS , MalteseS , RussoMF , AngeliniG , De GaetanoA , et al. Living systematic meta-analysis of COVID-19 vaccines and dose allocation strategies. SSRN  2021 [Preprint]. [DOI: 10.2139/ssrn.3827806]">Castagneto Gissey 2021</a>, which includes only RCTs; <a href="./references#CD015477-bbs2-0097" title="HarderT , KochJ , Vygen-BonnetS , Kulper-SchiekW , PilicA , RedaS , et al. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. Eurosurveillance2021;26(28):2100563.">Harder 2021</a>, which includes, but is not limited to RCTs (the second interim results were published in October 2021). Finally, the Living Vaccine Project, a living systematic review with network meta‐analysis that includes only RCTs recently published their results (<a href="./references#CD015477-bbs2-0105" title="KorangSK , vonRohdenE , VeronikiAA , OngG , NgalamikaO , SiddiquiF , et al. Vaccines to prevent COVID-19: a living systematic review with trial sequential analysis and network meta-analysis of randomized clinical trials. PLOS One2022;17(1):e0260733.">Korang 2022</a>). All studies included in their review were included in our review (either the same publication or another with more up‐to‐date data). For the most part, their results are consistent with ours. Concurrently, there are over a dozen protocols of systematic reviews assessing the safety or efficacy of vaccines registered in PROSPERO and listed as ongoing. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD015477-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Network graph. The size of the nodes is proportional to the number of participants randomized and the thickness of the lines to the number of studies in each comparison." data-id="CD015477-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_t/tCD015477-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Network graph. The size of the nodes is proportional to the number of participants randomized and the thickness of the lines to the number of studies in each comparison. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-02" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram of included randomized controlled trials (RCTs) (last search date 5 November 2021). COVID‐NMA is a living systematic review of all trials assessing treatment and preventive interventions for COVID‐19 (Boutron 2020a). This review is a subreview of the COVID‐NMA.FDA: Food and Drug Administration; ICTRP: World Health Organization (WHO) International Clinical Trials Registry Platform." data-id="CD015477-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_t/tCD015477-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>PRISMA flow diagram of included randomized controlled trials (RCTs) (last search date 5 November 2021). COVID‐NMA is a living systematic review of all trials assessing treatment and preventive interventions for COVID‐19 (<a href="./references#CD015477-bbs2-0060" title="BoutronI , ChaimaniA , MeerpohlJJ , HróbjartssonA , DevaneD , RadaG , et al. The COVID-NMA Project: building an evidence ecosystem for the COVID-19 pandemic. Annals of Internal Medicine2020;173(12):1015-7.">Boutron 2020a</a>). This review is a subreview of the COVID‐NMA. </p> <p>FDA: Food and Drug Administration; ICTRP: World Health Organization (WHO) International Clinical Trials Registry Platform. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Analysis 1.1.2: RNA‐based vaccine. Outcome: confirmed symptomatic COVID‐19 after complete vaccination.Ali 2021 included only participants 3 to 17 years of age. Frenck 2021 included only participants 12 to 15 years of age." data-id="CD015477-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-03.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Analysis 1.1.2: RNA‐based vaccine. Outcome: confirmed symptomatic COVID‐19 after complete vaccination. </p> <p><a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> included only participants 3 to 17 years of age. <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a> included only participants 12 to 15 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-03.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Analysis 1.1.3: RNA‐based vaccine. Outcome: severe or critical COVID‐19 after complete vaccination.*Thomas 2021 reports pooled results including adults' participants from Thomas 2021 and adolescent participants from Frenck 2021." data-id="CD015477-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-04.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Analysis 1.1.3: RNA‐based vaccine. Outcome: severe or critical COVID‐19 after complete vaccination. </p> <p>*<a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a> reports pooled results including adults' participants from <a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a> and adolescent participants from <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-04.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Analysis 1.1.4: RNA‐based vaccine. Outcome: all‐cause mortality.Ali 2021 included only participants 3 to 17 years of age. Frenck 2021 included only participants 12 to 15 years of age." data-id="CD015477-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-05.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Analysis 1.1.4: RNA‐based vaccine. Outcome: all‐cause mortality.</p> <p><a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> included only participants 3 to 17 years of age. <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a> included only participants 12 to 15 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-05.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Analysis 1.1.5: RNA‐based vaccine. Outcome: serious adverse events (SAEs).Ali 2021 included only participants 3 to 17 years of age. Frenck 2021 included only participants 12 to 15 years of age." data-id="CD015477-fig-0006" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-06.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Analysis 1.1.5: RNA‐based vaccine. Outcome: serious adverse events (SAEs).</p> <p><a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> included only participants 3 to 17 years of age. <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a> included only participants 12 to 15 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-06.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Analysis 1.1.7: RNA‐based vaccine. Outcome: any adverse event (AE).Ali 2021 included only participants 3 to 17 years of age. Frenck 2021 included only participants 12 to 15 years of age." data-id="CD015477-fig-0007" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-07.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Analysis 1.1.7: RNA‐based vaccine. Outcome: any adverse event (AE).</p> <p><a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> included only participants 3 to 17 years of age. <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a> included only participants 12 to 15 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-07.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Analysis 1.1.1: RNA‐based vaccine. Outcome: confirmed SARS‐CoV‐2 infection after complete vaccination.Ali 2021 included only participants 3 to 17 years of age. " data-id="CD015477-fig-0008" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-08.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Analysis 1.1.1: RNA‐based vaccine. Outcome: confirmed SARS‐CoV‐2 infection after complete vaccination. </p> <p><a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> included only participants 3 to 17 years of age.  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-08.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Analysis 1.1.6: RNA‐based vaccine. Outcome: systemic reactogenicity events.Ali 2021 included only participants 3 to 17 years of age. " data-id="CD015477-fig-0009" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-09.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_t/tCD015477-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Analysis 1.1.6: RNA‐based vaccine. Outcome: systemic reactogenicity events.</p> <p><a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> included only participants 3 to 17 years of age.  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Analysis 1.1.8: RNA‐based vaccine. Outcome: local reactogenicity events. Ali 2021 included only participants 3 to 17 years of age. " data-id="CD015477-fig-0010" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-10.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_t/tCD015477-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Analysis 1.1.8: RNA‐based vaccine. Outcome: local reactogenicity events. </p> <p><a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> included only participants 3 to 17 years of age.  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-11" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.1.1: Non‐replicating viral vector vaccine. Outcome: confirmed SARS‐CoV‐2 infection after complete vaccination.Voysey 2021a: data pooled from four trials." data-id="CD015477-fig-0011" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-11.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Analysis 2.1.1: Non‐replicating viral vector vaccine. Outcome: confirmed SARS‐CoV‐2 infection after complete vaccination. </p> <p><a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>: data pooled from four trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-11.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-12" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.1.2: non‐replicating viral vector vaccine. Outcome: confirmed symptomatic COVID‐19 after complete vaccination.Voysey 2021a: data pooled from four trials." data-id="CD015477-fig-0012" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-12.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Analysis 2.1.2: non‐replicating viral vector vaccine. Outcome: confirmed symptomatic COVID‐19 after complete vaccination. </p> <p><a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>: data pooled from four trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-12.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-13" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.1.4: non‐replicating viral vector vaccine. Outcome: all‐cause mortality.In Kulkarni 2021, the control arm received adjuvant. Voysey 2021a: data pooled from four trials." data-id="CD015477-fig-0013" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-13.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Analysis 2.1.4: non‐replicating viral vector vaccine. Outcome: all‐cause mortality.</p> <p>In <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>, the control arm received adjuvant. <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>: data pooled from four trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-13.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-14" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.1.5: non‐replicating viral vector vaccine. Outcome: serious adverse events (SAEs).In Kulkarni 2021, the control arm received adjuvant. Voysey 2021a: data pooled from four trials." data-id="CD015477-fig-0014" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-14.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>Analysis 2.1.5: non‐replicating viral vector vaccine. Outcome: serious adverse events (SAEs). </p> <p>In <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>, the control arm received adjuvant. <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>: data pooled from four trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-14.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-15" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.1.6: non‐replicating viral vector vaccine. Outcome: systemic reactogenicity events." data-id="CD015477-fig-0015" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-15.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 15</div> <div class="figure-caption"> <p>Analysis 2.1.6: non‐replicating viral vector vaccine. Outcome: systemic reactogenicity events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-15.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-16" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.1.7: non‐replicating viral vector vaccine. Outcome: any adverse event (AE).In Kulkarni 2021, the control arm received adjuvant. Voysey 2021a merged results from four different trials where three used quadrivalent meningococcal conjugate vaccine as placebo and one trial used normal saline." data-id="CD015477-fig-0016" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-16.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 16</div> <div class="figure-caption"> <p>Analysis 2.1.7: non‐replicating viral vector vaccine. Outcome: any adverse event (AE).</p> <p>In <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>, the control arm received adjuvant. <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> merged results from four different trials where three used quadrivalent meningococcal conjugate vaccine as placebo and one trial used normal saline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-16.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-17" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.1.8: non‐replicating viral vector vaccine. Outcome: local reactogenicity events." data-id="CD015477-fig-0017" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-17.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 17</div> <div class="figure-caption"> <p>Analysis 2.1.8: non‐replicating viral vector vaccine. Outcome: local reactogenicity events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-17.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-18" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.2.1: serum Institute of India/Astra Zeneca+University of Oxford – SII‐ChAdOx1 versus University of Oxford – ChAdOx1. Outcome: all‐cause mortality." data-id="CD015477-fig-0018" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-18.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 18</div> <div class="figure-caption"> <p>Analysis 2.2.1: serum Institute of India/Astra Zeneca+University of Oxford – SII‐ChAdOx1 versus University of Oxford – ChAdOx1. Outcome: all‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-18.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-19" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.2.2: SII‐ChAdOx1 versus ChAdOx1. Outcome: serious adverse events (SAEs)." data-id="CD015477-fig-0019" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-19.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 19</div> <div class="figure-caption"> <p>Analysis 2.2.2: SII‐ChAdOx1 versus ChAdOx1. Outcome: serious adverse events (SAEs).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-19.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-20" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.2.3: SII‐ChAdOx1 versus ChAdOx1. Outcome: systemic reactogenicity events." data-id="CD015477-fig-0020" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-20.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 20</div> <div class="figure-caption"> <p>Analysis 2.2.3: SII‐ChAdOx1 versus ChAdOx1. Outcome: systemic reactogenicity events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-20.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-21" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.2.4: SII‐ChAdOx1 versus ChAdOx1. Outcome: any adverse event (AE)." data-id="CD015477-fig-0021" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-21.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 21</div> <div class="figure-caption"> <p>Analysis 2.2.4: SII‐ChAdOx1 versus ChAdOx1. Outcome: any adverse event (AE).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-21.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-22" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.2.5: SII‐ChAdOx1 versus ChAdOx1. Outcome: local reactogenicity events. " data-id="CD015477-fig-0022" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-22.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 22</div> <div class="figure-caption"> <p>Analysis 2.2.5: SII‐ChAdOx1 versus ChAdOx1. Outcome: local reactogenicity events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-22.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-23" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.1.3: non‐replicating viral vector vaccine. Outcome: severe or critical COVID‐19 after complete vaccination." data-id="CD015477-fig-0023" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-23.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 23</div> <div class="figure-caption"> <p>Analysis 2.1.3: non‐replicating viral vector vaccine. Outcome: severe or critical COVID‐19 after complete vaccination. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-23.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-24" target="_blank"><b></b></a></p> </div><img alt="Analysis 3.1.2: inactivated virus vaccine. Outcome: confirmed symptomatic COVID‐19 after complete vaccination.Al Kaabi 2021.1 and Al Kaabi N 2021.2 refers to two different comparisons from the same report (Al Kaabi 2021)." data-id="CD015477-fig-0024" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-24.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 24</div> <div class="figure-caption"> <p>Analysis 3.1.2: inactivated virus vaccine. Outcome: confirmed symptomatic COVID‐19 after complete vaccination. </p> <p>Al Kaabi 2021.1 and Al Kaabi N 2021.2 refers to two different comparisons from the same report (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-24.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-25" target="_blank"><b></b></a></p> </div><img alt="Analysis 3.1.3: inactivated virus vaccine. Outcome: severe or critical COVID‐19 after complete vaccination." data-id="CD015477-fig-0025" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-25.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 25</div> <div class="figure-caption"> <p>Analysis 3.1.3: inactivated virus vaccine. Outcome: severe or critical COVID‐19 after complete vaccination. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-25.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-26" target="_blank"><b></b></a></p> </div><img alt="Analysis 3.1.4: inactivated virus vaccine. Outcome: all‐cause mortality.Al Kaabi 2021.1 and Al Kaabi N 2021.2 refers to two different comparisons from the same report (Al Kaabi 2021)." data-id="CD015477-fig-0026" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-26.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 26</div> <div class="figure-caption"> <p>Analysis 3.1.4: inactivated virus vaccine. Outcome: all‐cause mortality.</p> <p>Al Kaabi 2021.1 and Al Kaabi N 2021.2 refers to two different comparisons from the same report (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-26.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-27" target="_blank"><b></b></a></p> </div><img alt="Analysis 3.1.5: inactivated virus vaccine. Outcome: serious adverse events (SAEs).Han 2021 included only participants 3 to 17 years of age. Wu 2021a included only participants 60 years of age and older.Wu 2021a reports data for phase 1 and 2. Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (Al Kaabi 2021)." data-id="CD015477-fig-0027" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-27.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 27</div> <div class="figure-caption"> <p>Analysis 3.1.5: inactivated virus vaccine. Outcome: serious adverse events (SAEs).</p> <p><a href="./references#CD015477-bbs2-0018" title="HanB , SongY , LiC , YangW , MaQ , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(12):1645-53. ">Han 2021</a> included only participants 3 to 17 years of age. <a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a> included only participants 60 years of age and older. </p> <p><a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a> reports data for phase 1 and 2. Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-27.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-28" target="_blank"><b></b></a></p> </div><img alt="Analysis 3.1.6: inactivated virus vaccine. Outcome: systemic reactogenicity events.Xia S 2021 included only participants 3 to 17 years of age (Xia 2021). Wu Z 2021 included only participants 60 years of age and older (Wu 2021a).Wu Z 2021 reports data for phase 2 (Wu 2021a). Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (Al Kaabi 2021). Zhang 2020.1 and Zhang 2020.2 refers to two different comparisons from the same report (Zhang 2021)." data-id="CD015477-fig-0028" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-28.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 28</div> <div class="figure-caption"> <p>Analysis 3.1.6: inactivated virus vaccine. Outcome: systemic reactogenicity events.</p> <p>Xia S 2021 included only participants 3 to 17 years of age (<a href="./references#CD015477-bbs2-0041" title="XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1/2 trial. Lancet Infectious Diseases2021;22(2):196-208. ">Xia 2021</a>). Wu Z 2021 included only participants 60 years of age and older (<a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>). </p> <p>Wu Z 2021 reports data for phase 2 (<a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>). Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). Zhang 2020.1 and Zhang 2020.2 refers to two different comparisons from the same report (<a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-28.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-29" target="_blank"><b></b></a></p> </div><img alt="Analysis 3.1.7: inactivated virus vaccine. Outcome: any adverse event (AE).Han B 2021 and Xia 2021 included only participants 3 to 17 years of age (Han 2021; Xia 2021). Wu Z 2021 included only participants 60 years of age and older (Wu 2021a).Wu Z 2021 reports data for phase 1 and 2 (Wu 2021a), Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (Al Kaabi 2021). Zhang 2020.1 and Zhang 2020.2 refers to two different comparisons from the same report (Zhang 2021)." data-id="CD015477-fig-0029" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-29.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 29</div> <div class="figure-caption"> <p>Analysis 3.1.7: inactivated virus vaccine. Outcome: any adverse event (AE).</p> <p>Han B 2021 and Xia 2021 included only participants 3 to 17 years of age (<a href="./references#CD015477-bbs2-0018" title="HanB , SongY , LiC , YangW , MaQ , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(12):1645-53. ">Han 2021</a>; <a href="./references#CD015477-bbs2-0041" title="XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1/2 trial. Lancet Infectious Diseases2021;22(2):196-208. ">Xia 2021</a>). Wu Z 2021 included only participants 60 years of age and older (<a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>). </p> <p>Wu Z 2021 reports data for phase 1 and 2 (<a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>), Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). Zhang 2020.1 and Zhang 2020.2 refers to two different comparisons from the same report (<a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-29.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-30" target="_blank"><b></b></a></p> </div><img alt="Analysis 3.1.8: inactivated virus vaccine. Outcome: local reactogenicity events.Xia S 2021 included only participants 3 to 17 years of age (Xia 2021). Wu Z 2021 included only participants 60 years of age and older (Wu 2021a).Wu Z 2021 reports data for phase 2 (Wu 2021a). Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (Al Kaabi 2021). Zhang 2020.1 and Zhang 2020.2 refers to two different comparisons from the same report (Zhang 2021)." data-id="CD015477-fig-0030" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-30.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 30</div> <div class="figure-caption"> <p>Analysis 3.1.8: inactivated virus vaccine. Outcome: local reactogenicity events.</p> <p>Xia S 2021 included only participants 3 to 17 years of age (<a href="./references#CD015477-bbs2-0041" title="XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1/2 trial. Lancet Infectious Diseases2021;22(2):196-208. ">Xia 2021</a>). Wu Z 2021 included only participants 60 years of age and older (<a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>). </p> <p>Wu Z 2021 reports data for phase 2 (<a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>). Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). Zhang 2020.1 and Zhang 2020.2 refers to two different comparisons from the same report (<a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-30.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-31" target="_blank"><b></b></a></p> </div><img alt="Analysis 3.1.1: inactivated virus vaccine. Outcome: confirmed SARS‐CoV‐2 infection after complete vaccination.Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (Al Kaabi 2021)." data-id="CD015477-fig-0031" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-31.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 31</div> <div class="figure-caption"> <p>Analysis 3.1.1: inactivated virus vaccine. Outcome: confirmed SARS‐CoV‐2 infection after complete vaccination. </p> <p>Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-31.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-32" target="_blank"><b></b></a></p> </div><img alt="Analysis 4.1.1: protein subunit vaccine. Outcome: confirmed symptomatic COVID‐19 after complete vaccination." data-id="CD015477-fig-0032" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-32.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 32</div> <div class="figure-caption"> <p>Analysis 4.1.1: protein subunit vaccine. Outcome: confirmed symptomatic COVID‐19 after complete vaccination. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-32.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-33" target="_blank"><b></b></a></p> </div><img alt="Analysis 4.1.2: protein subunit vaccine. Outcome: severe or critical COVID‐19 after complete vaccination." data-id="CD015477-fig-0033" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-33.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 33</div> <div class="figure-caption"> <p>Analysis 4.1.2: protein subunit vaccine. Outcome: severe or critical COVID‐19 after complete vaccination. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-33.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-34" target="_blank"><b></b></a></p> </div><img alt="Analysis 4.1.3: protein subunit vaccine. Outcome: all‐cause mortality." data-id="CD015477-fig-0034" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-34.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 34</div> <div class="figure-caption"> <p>Analysis 4.1.3: protein subunit vaccine. Outcome: all‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-34.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-35" target="_blank"><b></b></a></p> </div><img alt="Analysis 4.1.4: protein subunit vaccine. Outcome: serious adverse events (SAEs)." data-id="CD015477-fig-0035" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-35.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 35</div> <div class="figure-caption"> <p>Analysis 4.1.4: protein subunit vaccine. Outcome: serious adverse events (SAEs).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-35.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-36" target="_blank"><b></b></a></p> </div><img alt="Analysis 4.1.5: protein subunit vaccine. Outcome: systemic reactogenicity events." data-id="CD015477-fig-0036" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-36.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 36</div> <div class="figure-caption"> <p>Analysis 4.1.5: protein subunit vaccine. Outcome: systemic reactogenicity events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-36.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-37" target="_blank"><b></b></a></p> </div><img alt="Analysis 4.1.6: protein subunit vaccine. Outcome: any adverse event (AE)." data-id="CD015477-fig-0037" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-37.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 37</div> <div class="figure-caption"> <p>Analysis 4.1.6: protein subunit vaccine. Outcome: any adverse event (AE).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-37.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-38" target="_blank"><b></b></a></p> </div><img alt="Analysis 4.1.7 Protein subunit vaccine. Outcome: local reactogenicity events" data-id="CD015477-fig-0038" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-38.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 38</div> <div class="figure-caption"> <p>Analysis 4.1.7 Protein subunit vaccine. Outcome: local reactogenicity events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-38.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-39" target="_blank"><b></b></a></p> </div><img alt="Analysis 5.1.1: heterologous vaccination scheme versus homologous vaccination scheme. Outcome: serious adverse events (SAEs).Liu X 2021.1 and Liu X 2021.2 are different comparisons for the same report (Liu 2021)." data-id="CD015477-fig-0039" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-39.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_t/tCD015477-FIG-39.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 39</div> <div class="figure-caption"> <p>Analysis 5.1.1: heterologous vaccination scheme versus homologous vaccination scheme. Outcome: serious adverse events (SAEs). </p> <p>Liu X 2021.1 and Liu X 2021.2 are different comparisons for the same report (<a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-40" target="_blank"><b></b></a></p> </div><img alt="Analysis 5.1.2: heterologous vaccination scheme versus homologous vaccination scheme. Outcome: systemic reactogenicity events." data-id="CD015477-fig-0040" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-40.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 40</div> <div class="figure-caption"> <p>Analysis 5.1.2: heterologous vaccination scheme versus homologous vaccination scheme. Outcome: systemic reactogenicity events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-40.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-41" target="_blank"><b></b></a></p> </div><img alt="Analysis 5.1.3: heterologous vaccination scheme versus homologous vaccination scheme. Outcome: any adverse event (AE).Liu 2021 included only participants 50 years of age or older.Liu X 2021.1 and Liu X 2021.2 are different comparisons for the same report (Liu 2021)." data-id="CD015477-fig-0041" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-41.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 41</div> <div class="figure-caption"> <p>Analysis 5.1.3: heterologous vaccination scheme versus homologous vaccination scheme. Outcome: any adverse event (AE). </p> <p><a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a> included only participants 50 years of age or older. </p> <p>Liu X 2021.1 and Liu X 2021.2 are different comparisons for the same report (<a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-41.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-42" target="_blank"><b></b></a></p> </div><img alt="Analysis 5.1.4: heterologous vaccination scheme versus homologous vaccination scheme. Outcome: local reactogenicity events." data-id="CD015477-fig-0042" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-42.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 42</div> <div class="figure-caption"> <p>Analysis 5.1.4: heterologous vaccination scheme versus homologous vaccination scheme. Outcome: local reactogenicity events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-42.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-43" target="_blank"><b></b></a></p> </div><img alt="Analysis 6.1.2: booster versus placebo/no booster. Outcome: systemic reactogenicity events." data-id="CD015477-fig-0043" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-43.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 43</div> <div class="figure-caption"> <p>Analysis 6.1.2: booster versus placebo/no booster. Outcome: systemic reactogenicity events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-43.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-44" target="_blank"><b></b></a></p> </div><img alt="Analysis 6.1.3: booster versus placebo/no booster. Outcome: local reactogenicity events." data-id="CD015477-fig-0044" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-44.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 44</div> <div class="figure-caption"> <p>Analysis 6.1.3: booster versus placebo/no booster. Outcome: local reactogenicity events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-44.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-45" target="_blank"><b></b></a></p> </div><img alt="Analysis 6.1.1: booster versus placebo/no booster. Outcome: all‐cause mortality." data-id="CD015477-fig-0045" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-45.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 45</div> <div class="figure-caption"> <p>Analysis 6.1.1: booster versus placebo/no booster. Outcome: all‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-45.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-46" target="_blank"><b></b></a></p> </div><img alt="Analysis 6.2.4: homologous booster versus heterologous booster. Outcome: local reactogenicity events.Bonelli 2021 included only participants under current Rituximab therapy." data-id="CD015477-fig-0046" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-46.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 46</div> <div class="figure-caption"> <p>Analysis 6.2.4: homologous booster versus heterologous booster. Outcome: local reactogenicity events. </p> <p><a href="./references#CD015477-bbs2-0004" title="BonelliM , MrakD , TobudicS , SieghartD , KoblischkeM , MandlP , et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.05.21263125]">Bonelli 2021</a> included only participants under current Rituximab therapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-46.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-47" target="_blank"><b></b></a></p> </div><img alt="Analysis 6.2.2: homologous booster versus heterologous booster. Outcome: systemic reactogenicity events." data-id="CD015477-fig-0047" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-47.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 47</div> <div class="figure-caption"> <p>Analysis 6.2.2: homologous booster versus heterologous booster. Outcome: systemic reactogenicity events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-47.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-48" target="_blank"><b></b></a></p> </div><img alt="Analysis 6.2.1: homologous booster versus heterologous booster. Outcome: serious adverse events." data-id="CD015477-fig-0048" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-48.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 48</div> <div class="figure-caption"> <p>Analysis 6.2.1: homologous booster versus heterologous booster. Outcome: serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-48.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-49" target="_blank"><b></b></a></p> </div><img alt="Analysis 6.2.3: homologous booster versus heterologous booster. Outcome: any adverse event." data-id="CD015477-fig-0049" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-49.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 49</div> <div class="figure-caption"> <p>Analysis 6.2.3: homologous booster versus heterologous booster. Outcome: any adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-49.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-50" target="_blank"><b></b></a></p> </div><img alt="Analysis 7.1.1: variant‐Alpha. Outcome: confirmed symptomatic COVID‐19 after complete vaccination." data-id="CD015477-fig-0050" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-50.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 50</div> <div class="figure-caption"> <p>Analysis 7.1.1: variant‐Alpha. Outcome: confirmed symptomatic COVID‐19 after complete vaccination. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-50.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-51" target="_blank"><b></b></a></p> </div><img alt="Analysis 7.2.1: variant‐Beta. Outcome: confirmed symptomatic COVID‐19 after complete vaccination." data-id="CD015477-fig-0051" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-51.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 51</div> <div class="figure-caption"> <p>Analysis 7.2.1: variant‐Beta. Outcome: confirmed symptomatic COVID‐19 after complete vaccination. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-51.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-52" target="_blank"><b></b></a></p> </div><img alt="Analysis 7.3.1: variant‐Gamma. Outcome: confirmed symptomatic COVID‐19 after complete vaccination." data-id="CD015477-fig-0052" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-52.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 52</div> <div class="figure-caption"> <p>Analysis 7.3.1: variant‐Gamma. Outcome: confirmed symptomatic COVID‐19 after complete vaccination. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-52.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-53" target="_blank"><b></b></a></p> </div><img alt="Analysis 7.4.1: variant‐Delta. Outcome: confirmed symptomatic COVID‐19 after complete vaccination." data-id="CD015477-fig-0053" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-53.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_t/tCD015477-FIG-53.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 53</div> <div class="figure-caption"> <p>Analysis 7.4.1: variant‐Delta. Outcome: confirmed symptomatic COVID‐19 after complete vaccination. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-53.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015477-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/urn:x-wiley:14651858:media:CD015477:CD015477-FIG-54" target="_blank"><b></b></a></p> </div><img alt="Analysis 8.1: follow‐up. RNA‐based vaccine. Outcome: confirmed symptomatic COVID‐19 after complete vaccination." data-id="CD015477-fig-0054" src="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-54.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 54</div> <div class="figure-caption"> <p>Analysis 8.1: follow‐up. RNA‐based vaccine. Outcome: confirmed symptomatic COVID‐19 after complete vaccination. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015477/media/CDSR/CD015477/image_n/nCD015477-FIG-54.jpg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD015477-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">BNT162b2 – Pfizer/BioNTech + Fosun Pharma compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with BNT162b2 </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3923 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>85 per 100,000</b><br/>(3 to 2187) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 97.84</b> </p> <p>(44.25 to 99.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44,077<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b><sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>100 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>4 per 100,000</b><br/>(0 to 26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 95.70</b><br/>(73.90 to 99.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46,077<br/>(1 RCT)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b><sup>g</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>64 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>68 per 100,000</b><br/>(33 to 142) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.07</b><br/>(0.52 to 2.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43,847<br/>(1 RCT)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 additional studies (<a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a> (adolescents aged 12–15 years); <a href="./references#CD015477-bbs2-0038" title="WalshEE , FrenckR , FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.08.17.20176651]WalshEE , Frenck RW Jr, FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine2020;383(25):2439-50. ">Walsh 2020</a> (adults aged 18–85 years)) reported this outcome in 2302 participants (1131 versus 1129 participants and 24 versus 18 participants in the BNT162b2 versus placebo groups, respectively). There were no events in either group and the trials did not contribute to the effect estimate.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Outcome not pooled due to considerable heterogeneity (I² = 90%) between included studies: <a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a> (≥ 16 years): RR 2.17, 95% CI 2.09 to 2.26; n = 43,847; <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a> (12–15 years): RR 1.01, 95% CI 0.73 to 1.41; n = 2260; <a href="./references#CD015477-bbs2-0038" title="WalshEE , FrenckR , FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.08.17.20176651]WalshEE , Frenck RW Jr, FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine2020;383(25):2439-50. ">Walsh 2020</a> (≥ 18 years): RR 1.50, 95% CI 0.53 to 4.21; n = 42 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46,149<br/>(3 RCTs)<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>508 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>660 per 100,000</b><br/>(279 to 1558) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.30</b><br/>(0.55 to 3.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46,107<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>l,m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 additional trial (<a href="./references#CD015477-bbs2-0038" title="WalshEE , FrenckR , FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.08.17.20176651]WalshEE , Frenck RW Jr, FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine2020;383(25):2439-50. ">Walsh 2020</a> (adults aged 18–85 years)) reported this outcome in 42 participants (24 BNT162b2 versus 18 placebo). There were no events in either group and the trial did not contribute to the effect estimate.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019; <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 3 May 2022<br/><sup>b</sup>Follow‐up: from 7 days following the second dose to 1.81 months and six months.<br/><sup>c</sup>BioNTech/Fosun Pharma/Pfizer: <a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a> (adolescents and adults aged from 16 years); <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a> (adolescents aged 12–15 years)<br/><sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.<br/><sup>e</sup>Follow‐up: from seven days following the second dose to six months.<br/><sup>f</sup>BioNTech/Fosun Pharma/Pfizer: <a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a> (adolescents and adults aged from 16 years)<br/><sup>g</sup>Follow‐up: six months<br/><sup>h</sup>Imprecision: downgraded two levels due to small number of events observed and a wide CIs that encompasses a potential benefit and a potential harm with the intervention.<br/><sup>i</sup>Follow‐up: 1.7 months<br/><sup>j</sup>BioNTech/Fosun Pharma/Pfizer: <a href="./references#CD015477-bbs2-0035" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. www.fda.gov/media/144245/download (accessed prior to 1 November 2022). PolackFP , ThomasSJ , KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine2020;383(27):2603-15. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine2021;385(19):1761-773. ThomasSJ , Moreira ED Jr, KitchinN , AbsalonJ , GurtmanA , LockhartS , et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.07.28.21261159]">Thomas 2021</a> (adolescents and adults aged from 16 years); <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a> (adolescents aged 12–15 years); <a href="./references#CD015477-bbs2-0038" title="WalshEE , FrenckR , FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.08.17.20176651]WalshEE , Frenck RW Jr, FalseyAR , KitchinN , AbsalonJ , GurtmanA , et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine2020;383(25):2439-50. ">Walsh 2020</a> (adults aged 18–85 years)<br/><sup>k</sup>Inconsistency: downgraded two levels (I² = 90%)<br/><sup>l</sup>Inconsistency: downgraded one level (I² = 76%)<br/><sup>m</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of benefit and the possibility of harm. This outcome was not downgraded an additional level for imprecision because it was downgraded one level for inconsistency, which is related to and would have contributed to the severity of the imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">BNT162b2 – Pfizer/BioNTech + Fosun Pharma compared to placebo for vaccination against COVID‐19a </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015477-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">mRNA‐1273 – ModernaTX compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with mRNA‐1273 </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confirmed SARS‐CoV‐2 infection<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>8957 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>2394 per 100,000</b><br/>(997 to 5749) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 73.27</b><br/>(35.82 to 88.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31,632<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁◯<br/>Moderate<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Substantial heterogeneity (I² = 66%) between included studies: <a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> (adolescents aged 12–17 years, median 2.3 months' follow‐up): VE 55.7% (95% CI 16.8 to 76.4), n = 3181; <a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a> (adults aged 18–95 years, 5.3 months' follow‐up): VE 82% (95% CI 79.5 to 84.2), n = 28,451 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confirmed symptomatic COVID‐19 <sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4939 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>336 per 100,000</b><br/>(255 to 442) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 93.20</b> </p> <p>(91.06 to 94.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31,632<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁⨁<br/>High<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe or critical COVID‐19<sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>748 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>13 per 100,000</b><br/>(3 to 54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 98.20</b> </p> <p>(92.80 to 99.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28,451<br/>(1 RCT)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁⨁<br/>High<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality<sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>106 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> </p> <p><b>112 per 100,000</b><br/>(57 to 222) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.06</b><br/>(0.54 to 2.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30,346<br/>(1 RCT)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁◯◯<br/>Low<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 additional trial: (<a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> (adolescents aged 12–17 years)) reported on this outcome in 3726 participants (2486 mRNA‐1273 and 1240 placebo). There were no events in either group and the trial did not contribute to the pooled effect estimate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systemic reactogenicity events<sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>432 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>553 per 1000</b><br/>(527 to 579) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.28</b><br/>(1.22 to 1.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34,037<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁⨁<br/>High<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any adverse event<sup>k</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not pooled due to considerable heterogeneity (I² = 100%) between included studies: <a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> (all solicited adverse events, adolescents aged 12–17 years, median 2.8 months' follow‐up): RR 1.47 (95% CI 1.41 to 1.54), n = 3726; <a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a> (all solicited adverse events, adults aged 18–95 years, 5.3 months' follow‐up): RR 2.15 (95% CI 2.11 to 2.19), n = 29,269 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32,995<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁◯◯<br/>Low<sup>l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events<sup>l</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1792 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1649 per 100,000</b><br/>(1398 to 1936) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.92</b><br/>(0.78 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34,072<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁◯<br/>Moderate<sup>m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Local reactogenicity events<sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>211 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>697 per 1000</b><br/>(427 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.30</b><br/>(2.02 to 5.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34,037<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⨁⨁<br/>High<sup>n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>COVID‐19:</b> coronavirus disease 2019; <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Last updated: 01 March 2023</p> <p>b. Follow‐up: from 14 days after dose 2 to 2.3 months (median) and 5.3 months </p> <p>c. Moderna TX: <a href="./references#CD015477-bbs2-0001" title="AliK , BermanG , ZhouH , DengW , FaughnanV , Coronado-VogesM , et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine2021;385(24):2241-51. ">Ali 2021</a> (adolescents aged 12–17 years); <a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a> (adults aged 18–95 years) </p> <p>d. Despite some concerns with deviations from intervention, not downgraded for risk of bias </p> <p>e. Inconsistency: downgraded one level: I² = 66.37% </p> <p>f. Follow‐up: 5.3 months</p> <p>g. Moderna TX: <a href="./references#CD015477-bbs2-0010" title="BadenLR , El SahlyHM , EssinkB , KotloffK , FreyS , NovakR , et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine2021;384(5):403-16. El SahlyHM , BadenLR , EssinkB , Doblecki-LewisS , MartinJM , AndersonEJ , et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New England Journal of Medicine2021;385(19):1774-85. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download (accessed prior to 1 November 2022). ">El Sahly 2021</a> (adults aged 18–95 years) </p> <p>h. Imprecision downgraded two levels due to small number of events observed and wide CIs that encompass a potential benefit and a potential harm with the intervention </p> <p>i. Follow‐up: seven days</p> <p>j. Despite inconsistency (I² = 61%) not downgraded for inconsistency, as the same direction of effect in both effect estimates  </p> <p>k. Follow‐up: 2.8 months (median) and 5.3 months</p> <p>l. Inconsistency: downgraded two levels (I² = 100%) </p> <p>m. Imprecision: downgraded one level due to wide CIs that encompass a potential benefit and a potential harm with the intervention. </p> <p>n. Despite inconsistency (I² = 99%), not downgraded for inconsistency, as the same direction of effect in both effect estimates  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">mRNA‐1273 – ModernaTX compared to placebo for vaccination against COVID‐19a </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015477-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">CVnCoV – CureVac AG compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with CVnCOV</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1187 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>615 per 100,000</b><br/>(464 to 811) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 48.20</b> </p> <p>(31.70 to 60.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,062<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b><sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>82 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>30 per 100,000</b><br/>(7 to 82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 63.80</b> </p> <p>(0.00 to 91.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,062<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊖⊖⊖<br/><b>Very low</b><sup>d,e,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b><sup>h</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>30 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>40 per 100,000</b><br/>(14 to 116) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.33</b><br/>(0.46 to 3.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39,529<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊖⊖⊖<br/><b>Very low</b><sup>e,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>635 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>940 per 1000</b><br/>(908 to 971) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.48</b><br/>(1.43 to 1.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3982<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>j</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>679 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>965 per 1000</b><br/>(937 to 999) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.42</b><br/>(1.38 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3982<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>k</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>334 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>414 per 100,000</b><br/>(301 to 572) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.24</b><br/>(0.90 to 1.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39,529<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>e,l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b><sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>241 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>847 per 1000</b><br/>(782 to 920) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.51</b><br/>(3.24 to 3.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3982<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 10 May 2022<br/><sup>b</sup>Follow‐up: from 14 days following the second dose to 6.23 months<br/><sup>c</sup>CureVac AG: <a href="./references#CD015477-bbs2-0021" title="KremsnerPG , Ahuad GuerreroRA , Arana-ArriE , Aroca MartinezGJ , BontenM , ChandlerR , et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3, randomized, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3911826]">Kremsner 2021</a> (adults aged 18–98 years)<br/><sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.<br/><sup>e</sup>Indirectness: downgraded one level as data are from interim analyses of the trial and from the available information it is unclear whether these were preplanned.<br/><sup>f</sup>Follow‐up: from seven days following the second dose to six months<br/><sup>g</sup>Imprecision: downgraded two levels due to small number of events observed and wide CIs that encompass a potential benefit and a potential harm with the intervention.<br/><sup>h</sup>Follow‐up: 6.23 months<br/><sup>i</sup>Follow‐up: seven days<br/><sup>j</sup>Follow‐up: one month<br/><sup>k</sup>Follow‐up: 1.7 months<br/><sup>l</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of benefit and the possibility of harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">CVnCoV – CureVac AG compared to placebo for vaccination against COVID‐19a </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015477-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">ChAdOx1 – AstraZeneca + University of Oxford  compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with ChAdOx1</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3199 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1300 per 100,000</b><br/>(1017 to 1663) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 59.35</b> </p> <p>(48.00 to 68.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43,390<br/>(5 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Substantial heterogeneity (I² = 68%) between included studies: <a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a> (VE 64.35%, 95% CI 56.10% to 71.00%; n = 26,212); <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> (VE 54.10%, 95% CI 44.70% to 61.90%; n = 17,178) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2207 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>657 per 100,000</b><br/>(516 to 836) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 70.23</b> </p> <p>(62.10 to 76.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43,390<br/>(5 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b><sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>52 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>25 per 100,000</b><br/>(10 to 59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.48</b><br/>(0.20 to 1.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56,727<br/>(5 RCTs)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 additional trials (<a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a>; <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>) reported this outcome in 1392 participants (192 ChAdOx1 versus 64 placebo and 900 SII‐ChAdOx1 versus 300 placebo, respectively). There were no events in either group in either trial and they did not contribute to the pooled effect estimate.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>141 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>553 per 1000</b><br/>(297 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.93</b><br/>(2.11 to 7.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>256<br/>(1 RCT)<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>l</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Outcome not pooled due to considerable heterogeneity (I² = 90%) between included studies: <a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a> (RR 2.54, 95% CI 1.73 to 3.74; n = 256); <a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a> (RR 1.37, 95% CI 1.33 to 1.42; n = 32,379); <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a> (RR 1.39, 95% CI 1.12 to 1.74; n = 1200); <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> (RR 0.74, 95% CI 0.56 to 0.96; n = 23,745) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57,580<br/>(7 RCTs)<sup>m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>o</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>794 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>699 per 100,000</b><br/>(572 to 850) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.88</b><br/>(0.72 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58,182<br/>(7 RCTs)<sup>p</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>q</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b><sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>94 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>604 per 1000</b><br/>(279 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 6.44</b><br/>(2.98 to 13.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>256<br/>(1 RCT)<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>k,r</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 4 May 2022<br/><sup>b</sup>Follow‐up: from 14 days after second dose up to 1.34 months (median) and 2 months (median)<br/><sup>c</sup><a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a>; <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> (data from four pooled RCTs)<br/><sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.<br/><sup>e</sup>Inconsistency: downgraded one level (I² = 68%).<br/><sup>f</sup>Follow‐up: 2 months, 4.2 months and 2 months (median)<br/><sup>g</sup><a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a>; <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> (data from four pooled RCTs); <a href="./references#CD015477-bbs2-0026" title="MadhiSA , KoenAL , IzuA , FairlieL , CutlandCL , BaillieV , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomized, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV2021;8(9):e568-80. ">Madhi 2021a</a> (participants with HIV, trial already counted in <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>)<br/><sup>h</sup>Imprecision: downgraded two levels due to small number of events observed and wide CIs that encompass a potential benefit and a potential harm with the intervention.<br/><sup>i</sup>Follow‐up: seven days<br/><sup>j</sup><a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a><br/><sup>k</sup>Imprecision: downgraded one level due to low number of participants/few events observed.<br/><sup>l</sup>Follow‐up: 1 month, 1.16 months, 1.9 months, and 3.4 months<br/><sup>m</sup><a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a>; <a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a>; <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>; <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> (data from four pooled RCTs)<br/><sup>n</sup>Inconsistency: downgraded two levels (I² = 90%).<br/><sup>o</sup>Follow‐up: 1 month, 1.9 months, 6 months, and 3.64 months (median)<br/><sup>p</sup><a href="./references#CD015477-bbs2-0003" title="AsanoM , OkadaH , ItohY , HirataH , IshikawaK , YoshidaE , et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases2022;114:165-74. ">Asano 2022</a>; <a href="./references#CD015477-bbs2-0013" title="FalseyAR , SobieszczykME , HirschI , SprouleS , RobbML , CoreyL , et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. New England Journal of Medicine2021;385(25):2348-60. ">Falsey 2021</a>; <a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>; <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a> (data from four pooled RCTs). <a href="./references#CD015477-bbs2-0026" title="MadhiSA , KoenAL , IzuA , FairlieL , CutlandCL , BaillieV , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomized, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV2021;8(9):e568-80. ">Madhi 2021a</a> (participants with HIV, trial already counted in <a href="./references#CD015477-bbs2-0037" title="FolegattiPM , EwerKJ , AleyPK , AngusB , BeckerS , Belij-RammerstorferS , et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet2020;396(10249):467-78. [PMID: 32702298]VoyseyM , ClemensSA , MadhiSA , WeckxLY , FolegattiPM , AleyPK , et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet2021;397(10269):99-111. [PMID: 33306989]">Voysey 2021a</a>)<br/><sup>q</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of benefit and the possibility of no effect.<br/><sup>r</sup>Despite some concerns with selection of reported results, not downgraded for risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">ChAdOx1 – AstraZeneca + University of Oxford  compared to placebo for vaccination against COVID‐19a </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015477-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of Oxford compared to ChAdOx1 – University of Oxford for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with ChAdOx1</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with SII‐ChAdOx1</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 study reported this outcome in 400 participants (<a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a>). There were no events in either group and no effect estimate could be calculated.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>390 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>285 per 1000</b><br/>(211 to 382) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.73</b><br/>(0.54 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>200 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>166 per 1000</b><br/>(104 to 266) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.83</b><br/>(0.52 to 1.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>g</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2000 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1000 per 100,000</b><br/>(160 to 5900) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.50</b><br/>(0.08 to 2.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>360 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>274 per 1000</b><br/>(198 to 378) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.76</b><br/>(0.55 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 10 May 2022<br/><sup>b</sup>Follow‐up: seven days<br/><sup>c</sup><a href="./references#CD015477-bbs2-0022" title="KulkarniPS , PadmapriyadarsiniC , VekemansJ , BavdekarA , GuptaM , KulkarniP , et al. A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India. eClinicalMedicine2021;42:101218. ">Kulkarni 2021</a><br/><sup>d</sup>Imprecision: downgraded one level due to low number of events/participants.<br/><sup>e</sup>Follow‐up: 1.9 months<br/><sup>f</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit and the possibility of harm and low number of events/participants.<br/><sup>g</sup>Follow‐up: six months<br/><sup>h</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of no effect and the possibility of benefit and low number of events/participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of Oxford compared to ChAdOx1 – University of Oxford for vaccination against COVID‐19a </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015477-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">AD26.COV2.S – Janssen Pharmaceutical Companies compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with AD26.COV2.S</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1796 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>594 per 100,000</b><br/>(478 to 735) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 66.90</b> </p> <p>(59.10 to 73.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39,058<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>409 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>97 per 100,000</b><br/>(51 to 172) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 76.30</b> </p> <p>(57.90 to 87.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39,058<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>91 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>23 per 100,000</b><br/>(8 to 61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.25</b><br/>(0.09 to 0.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43,783<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>448 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>412 per 100,000</b><br/>(309 to 546) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.92</b><br/>(0.69 to 1.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43,783<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>34,575 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>63,273 per 100,000</b><br/>(44,602 to 89,896) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.83</b><br/>(1.29 to 2.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7222<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>h</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Outcome not pooled due to considerable heterogeneity (I² = 96%) between included studies: <a href="./references#CD015477-bbs2-0031" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; February 26, 2021; FDA briefing document: Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. www.fda.gov/media/146217/download (accessed prior to 1 November 2022). SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Interim results of a Phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. New England Journal of Medicine2021;384(19):1824-35. SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.09.23.20199604]">Sadoff 2021a</a> (RR 1.09, 95% CI 0.96 to 1.24; n = 6736); <a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a> (RR 2.31, 95% CI 1.80 to 2.97; n = 486) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7222<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>d,i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE</b>: vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 4 May 2022<br/><sup>b</sup>Follow‐up: 1.9 months (median)<br/><sup>c</sup><a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a><br/><sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.<br/><sup>e</sup>Follow‐up: seven days and 14 days<br/><sup>f</sup><a href="./references#CD015477-bbs2-0031" title="Food and Drug Administration. Vaccines and related biological products Advisory Committee Meeting; February 26, 2021; FDA briefing document: Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. www.fda.gov/media/146217/download (accessed prior to 1 November 2022). SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Interim results of a Phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. New England Journal of Medicine2021;384(19):1824-35. SadoffJ , Le GarsM , ShukarevG , HeerweghD , TruyersC , deGrootAM , et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.09.23.20199604]">Sadoff 2021a</a>; <a href="./references#CD015477-bbs2-0032" title="SadoffJ , GrayG , VandeboschA , CárdenasV , ShukarevG , GrinsztejnB , et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine2021;384(23):2187-201. ">Sadoff 2021b</a><br/><sup>g</sup>Despite I² = 83%, not downgraded for inconsistency, as the same direction of effect in both effect estimates.<br/><sup>h</sup>Follow‐up: 0.23 months and 0.92 months<br/><sup>i</sup>Inconsistency: downgraded two levels (I² = 96%).<br/><sup>j</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of no effect and the possibility of benefit.<br/><sup>k</sup>Follow‐up: seven days<br/><sup>l</sup>Despite I² = 84%, not downgraded for inconsistency, as the same direction of effect in both effect estimates. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">AD26.COV2.S – Janssen Pharmaceutical Companies compared to placebo for vaccination against COVID‐19a </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015477-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Gam‐COVID‐VAC – Sputnik V compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with Gam‐COVID‐VAC</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1022 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>92 per 100,000</b><br/>(51 to 167) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 91.10</b> </p> <p>(83.80 to 95.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18,695<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>408 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 100,000</b><br/>(0 to 23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 100.00</b> </p> <p>(94.40 to 100.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,866<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b><sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>18 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>18 per 100,000</b><br/>(2 to 176) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.99</b><br/>(0.10 to 9.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21,862<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊖⊖⊖<br/><b>Very low</b><sup>d,e,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>423 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>275 per 100,000</b><br/>(165 to 453) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65</b><br/>(0.39 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21,862<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>d,e,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019; <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 27 May 2022<br/><sup>b</sup>Follow‐up: from seven days after second dose<br/><sup>c</sup><a href="./references#CD015477-bbs2-0025" title="LogunovDY , DolzhikovaIV , ShcheblyakovDV , TukhvatulinAI , ZubkovaOV , DzharullaevaAS , et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia. Lancet2021;397(10275):671-81. ">Logunov 2021</a><br/><sup>d</sup>Indirectness: downgraded one level as data are from interim analyses of the trial and from the available information it is unclear whether these were preplanned.<br/><sup>e</sup>Concern regarding the internal validity of the trial.<br/><sup>f</sup>Follow‐up: 1.6 months (median)<br/><sup>g</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit and the possibility of harm and few events.<br/><sup>h</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of no effect and the possibility of benefit. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Gam‐COVID‐VAC – Sputnik V compared to placebo for vaccination against COVID‐19a </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015477-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">CoronaVac – Sinovac compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with CoronaVac</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2398 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>724 per 100,000</b><br/>(249 to 2104) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 69.81</b> </p> <p>(12.27 to 89.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,852<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>d,e,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Considerable heterogeneity (I² = 92%) between included studies: <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a> (VE 83.50%, 95% CI 65.40% to 92.10%; n = 10,029); <a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a> (VE 50.70%, 95% CI 35.90 to 62.00%; n = 9823) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>2 studies report on severe or critical disease due to COVID‐19: <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>, with 0/6559 events in the CoronaVac group versus 1/3470 events in the placebo group and a VE of 100%, 95% CI (20.40% to 100.00%); and <a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>, with 0/4953 events in the CoronaVac group and 6/4870 events in the placebo group and a VE of 100%, 95% CI (16.90% to 100.00%). (Note: estimates could not be pooled due to asymmetry in the CIs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,852<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>d,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b><sup>h</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>20 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>10 per 100,000</b><br/>(1 to 113) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.50</b><br/>(0.05 to 5.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22,610<br/>(2 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>j</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>409 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>487 per 1000</b><br/>(409 to 581) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.19</b><br/>(1.00 to 1.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23,966<br/>(6 RCTs)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>l,m,n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>o</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>531 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>579 per 1000</b><br/>(568 to 590) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.09</b><br/>(1.07 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23,367<br/>(6 RCTs)<sup>p</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>q</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>r</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>372 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>361 per 100,000</b><br/>(231 to 562) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.97</b><br/>(0.62 to 1.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23,139<br/>(4 RCTs)<sup>s</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>i,q</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 additional trials (<a href="./references#CD015477-bbs2-0005" title="BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.03.31.21254494]BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile. Clinical Infectious Diseases 2021 Sep 19 [Epub ahead of print]. [DOI: 10.1093/cid/ciab823]">Bueno 2021</a>; <a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a>) reported this outcome in 482 participants (270 versus 164 and 24 versus 24 respectively, receiving CoronaVac versus placebo). There were no events in either group and the trials did not contribute to the pooled effect estimate.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b><sup>j</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>227 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>400 per 1000</b><br/>(384 to 414) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.76</b><br/>(1.69 to 1.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23,962<br/>(6 RCTs)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 4 May 2022<br/><sup>b</sup>Follow‐up: from 14 days after the second dose up to two months (median)<br/><sup>c</sup><a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>; <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a><br/><sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.<br/><sup>e</sup>Inconsistency: downgraded one level (I² = 92%).<br/><sup>f</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of benefit and the possibility of harm.<br/><sup>g</sup>Imprecision: downgraded two levels due to low number of events and wide CIs.<br/><sup>h</sup>Follow‐up: 1.4 and 2 months (median)<br/><sup>i</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit and the possibility of harm and few events.<br/><sup>j</sup>Follow‐up: 7–28 days<br/><sup>k</sup><a href="./references#CD015477-bbs2-0005" title="BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.03.31.21254494]BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile. Clinical Infectious Diseases 2021 Sep 19 [Epub ahead of print]. [DOI: 10.1093/cid/ciab823]">Bueno 2021</a>; <a href="./references#CD015477-bbs2-0012" title="FadlyanaE , RusmilK , TariganR , RahmadiAR , ProdjosoewojoS , SofiatinY , et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: an interim analysis in Indonesia. Vaccine2021;39(44):6520-8. ">Fadlyana 2021</a>; <a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>; <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>; <a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>; <a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a><br/><sup>l</sup>Despite some concerns with adequate randomisation, deviation from intended intervention, missing data, and selection of reported results not downgraded for risk of bias.<br/><sup>m</sup>Inconsistency: downgraded one level (I² = 55%).<br/><sup>n</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of no effect and the possibility of harm.<br/><sup>o</sup>Follow‐up: one to three months (median)<br/><sup>p</sup><a href="./references#CD015477-bbs2-0005" title="BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.03.31.21254494]BuenoSM , AbarcaK , GonzálezPA , GálvezNM , SotoJA , DuarteLF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile. Clinical Infectious Diseases 2021 Sep 19 [Epub ahead of print]. [DOI: 10.1093/cid/ciab823]">Bueno 2021</a>; <a href="./references#CD015477-bbs2-0018" title="HanB , SongY , LiC , YangW , MaQ , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(12):1645-53. ">Han 2021</a>; <a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>; <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>; <a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a>; <a href="./references#CD015477-bbs2-0042" title="ZhangY , ZengG , PanH , LiC , HuY , ChuK , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(2):181-92. ">Zhang 2021</a><br/><sup>q</sup>Despite some concerns with adequate randomisation, not downgraded for risk of bias.<br/><sup>r</sup>Follow‐up: 4.1 months, 2 months (median), 3 months (median)<br/><sup>s</sup><a href="./references#CD015477-bbs2-0018" title="HanB , SongY , LiC , YangW , MaQ , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(12):1645-53. ">Han 2021</a>; <a href="./references#CD015477-bbs2-0029" title="PalaciosR , PatiñoEG , deOliveira PiorelliR , CondeMT , BatistaAP , ZengG , et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):853. ">Palacios 2020</a>; <a href="./references#CD015477-bbs2-0034" title="TanrioverMD , DoğanayHL , AkovaM , GünerHR , AzapA , AkhanS , et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet2021;398(10296):213-22. ">Tanriover 2021</a>; <a href="./references#CD015477-bbs2-0039" title="WuZ , HuY , XuM , ChenZ , YangW , JiangZ , et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases2021;21(6):803-12. ">Wu 2021a</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">CoronaVac – Sinovac compared to placebo for vaccination against COVID‐19a </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015477-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">WIBP‐CorV – Sinopharm‐Wuhan compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with WIBP‐CorV</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>912 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>328 per 100,000</b><br/>(231 to 467) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 64.00</b> </p> <p>(48.80 to 74.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,449<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>746 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>203 per 100,000</b><br/>(131 to 313) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 72.80</b> </p> <p>(58.10 to 82.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,480<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 trial reported on this outcome in 26,917 participants (13,464 WIBP‐CorV versus 13,453 placebo) (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). There were no events in either group and no effect estimate could be calculated for this outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>278 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>275 per 1000</b><br/>(264 to 286) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.99</b><br/>(0.95 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27,029<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>h</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>504 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>484 per 1000</b><br/>(469 to 494) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.96</b><br/>(0.93 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27,029<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>579 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>480 per 100,000</b><br/>(347 to 665) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.83</b><br/>(0.60 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27,029<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>g,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b><sup>k</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>290 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>255 per 1000</b><br/>(247 to 267) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.88</b><br/>(0.85 to 0.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27,029<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 4 May 2022<br/><sup>b</sup>Follow‐up: from 2 weeks after the second dose up to 2.6 months (median)<br/><sup>c</sup><a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a><br/><sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.<br/><sup>e</sup>Follow‐up: seven days and 28 days<br/><sup>f</sup><a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>; <a href="./references#CD015477-bbs2-0016" title="GuoW , DuanK , ZhangY , YuanZ , ZhangYB , WangZ , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 1/2 trial. eClinicalMedicine2021;38:101010. ">Guo 2021</a><br/><sup>g</sup>Despite some concerns with adequate randomisation, not downgraded for risk of bias.<br/><sup>h</sup>Follow‐up: one month<br/><sup>i</sup>Follow‐up: 1.6 and 2.6 months (median)<br/><sup>j</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of no effect and the possibility of benefit and few events.<br/><sup>k</sup>Follow‐up: seven days </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">WIBP‐CorV – Sinopharm‐Wuhan compared to placebo for vaccination against COVID‐19a </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015477-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">BBIBP‐CorV – Sinopharm‐Beijing  compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with BBIBP‐CorV</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>912 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>242 per 100,000</b><br/>(162 to 359) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 73.50</b> </p> <p>(60.60 to 82.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,435<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>746 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>163 per 100,000</b><br/>(102 to 263) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 78.10</b> </p> <p>(64.80 to 86.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,463<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 study reported this outcome in 26,924 participants (13,471 BBIBP‐CorV versus 13,453 placebo) (<a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>). There were no events in either group and no effect estimate could be calculated for this outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>274 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>288 per 1000</b><br/>(236 to 351) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.05</b><br/>(0.86 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27,540<br/>(3 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>h</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>3 studies (n = 27,540) reported any adverse event with 1 month or 2.9 months' follow‐up. 2 of the studies reported an effect estimate in favour of BBIBP‐CorV: 1 with RR 0.91, 95% CI 0.89 to 0.94; n = 26,924; and 1 with CIs crossing the line of no effect (RR 0.83, 95% CI 0.36 to 1.95; n = 112). 1 study reported an effect estimate in favour of placebo with CIs not crossing the line of null effect (RR 2.05, 95% CI 1.47 to 2.87; n = 504)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26,924<br/>(3 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>i,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>k</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>580 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>441 per 100,000</b><br/>(313 to 615) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.76</b><br/>(0.54 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26,924<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 additional study reported this outcome in 112 participants (84 BBIBP‐CorV versus 28 placebo) (<a href="./references#CD015477-bbs2-0040" title="XiaS , DuanK , ZhangY , ZhaoD , ZhangH , XieZ , et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA2020;324(10):951-60. XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infectious Diseases2020;21(1):39-51. ">Xia 2020</a>). There were no events in either group and the trial did not contribute to the effect estimate.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b><sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>3 studies (n = 27,540) reported local adverse events with 7 days' follow‐up. 1 study reported an effect estimate in favour of BBIBP‐CorV: RR 0.71, 95% CI 0.68 to 0.74; n = 26,924. 2 studies reported an effect estimate in favour of placebo with CIs not crossing the line of null effect (RR 10.00, 95% CI 2.36 to 42.34; n = 504 and RR 3.33, 95% CI 0.45 to 24.89; n = 112). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26,924<br/>(3 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>i,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 4 May 2022<br/><sup>b</sup>Follow‐up: from 2 weeks after second dose up to 2.6 months (median)<br/><sup>c</sup><a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a><br/><sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.<br/><sup>e</sup>Follow‐up: seven days<br/><sup>f</sup><a href="./references#CD015477-bbs2-0002" title="Al KaabiN , ZhangY , XiaS , YangY , Al QahtaniMM , AbdulrazzaqN , et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA2021;326(1):35-45. ">Al Kaabi 2021</a>; <a href="./references#CD015477-bbs2-0041" title="XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1/2 trial. Lancet Infectious Diseases2021;22(2):196-208. ">Xia 2021</a> (children); <a href="./references#CD015477-bbs2-0040" title="XiaS , DuanK , ZhangY , ZhaoD , ZhangH , XieZ , et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA2020;324(10):951-60. XiaS , ZhangY , WangY , WangH , YangY , GaoGF , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infectious Diseases2020;21(1):39-51. ">Xia 2020</a><br/><sup>g</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of no effect and the possibility of harm.<br/><sup>h</sup>Follow‐up: one month and 2.9 months<br/><sup>i</sup>Inconsistency: downgraded one level as studies are not pooled, effect estimates and direction of effect inconsistent between included studies.<br/><sup>j</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of benefit and the possibility of harm.<br/><sup>k</sup>Follow‐up: 2.6 months (median)<br/><sup>l</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of no effect and the possibility of benefit and few events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">BBIBP‐CorV – Sinopharm‐Beijing  compared to placebo for vaccination against COVID‐19a </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015477-tbl-0011"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">BBV152 – Bharat Biotech compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with BBV152 </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1841 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>575 per 100,000</b><br/>(322 to 982) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 68.80</b> </p> <p>(46.70 to 82.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6289<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1247 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>277 per 100,000</b><br/>(170 to 434) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 77.80</b> </p> <p>(65.20 to 86.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16,973<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>176 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>12 per 100,000</b><br/>(0 to 76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 93.40</b> </p> <p>(57.10 to 99.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16,976<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b><sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>78 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>39 per 100,000</b><br/>(13 to 113) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.50</b><br/>(0.17 to 1.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,753<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>g</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>26 per 1000</b><br/>(23 to 31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.34</b><br/>(1.15 to 1.58) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,925<br/>(2 RCTs)<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>124 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>124 per 1000</b><br/>(117 to 133) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.00</b><br/>(0.94 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,753<br/>(1 RCT)<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>463 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>301 per 100,000</b><br/>(199 to 449) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.65</b><br/>(0.43 to 0.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,928<br/>(1 RCT)<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 additional trial reported this outcome in 175 participants (100 BBV152 versus 75 placebo) (<a href="./references#CD015477-bbs2-0008" title="EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. A Phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.12.11.20210419]EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomized, phase 1 trial. Lancet Infectious Diseases2021;21(5):637-46. ">Ella 2021a</a>). There were no events in either group and the trial did not contribute to the pooled effect estimate.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b><sup>g</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>31 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>34 per 1000</b><br/>(30 to 39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.08</b><br/>(0.95 to 1.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,750<br/>(2 RCTs)<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 4 May 2022<br/><sup>b</sup>Follow‐up: from two weeks after second dose to 3.3 months (median)<br/><sup>c</sup><a href="./references#CD015477-bbs2-0008" title="EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. A Phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.12.11.20210419]EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomized, phase 1 trial. Lancet Infectious Diseases2021;21(5):637-46. ">Ella 2021a</a><br/><sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.<br/><sup>e</sup>Follow‐up: 3.3 months (median)<br/><sup>f</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit and the possibility of harm and low number of events.<br/><sup>g</sup>Follow‐up: seven days<br/><sup>h</sup><a href="./references#CD015477-bbs2-0008" title="EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. A Phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.12.11.20210419]EllaR , VadrevuKM , JogdandH , PrasadS , ReddyS , SarangiV , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomized, phase 1 trial. Lancet Infectious Diseases2021;21(5):637-46. ">Ella 2021a</a>; <a href="./references#CD015477-bbs2-0009" title="EllaR , ReddyS , BlackwelderW , PotdarV , YadavP , SarangiV , et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.06.30.21259439]">Ella 2021b</a><br/><sup>i</sup>Follow‐up: 4.9 months (median)<br/><sup>j</sup><a href="./references#CD015477-bbs2-0009" title="EllaR , ReddyS , BlackwelderW , PotdarV , YadavP , SarangiV , et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.06.30.21259439]">Ella 2021b</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">BBV152 – Bharat Biotech compared to placebo for vaccination against COVID‐19a </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015477-tbl-0012"> <div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">NVX‐CoV2373 – Novavax compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with NVX‐CoV2373</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1140 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>195 per 100,000</b><br/>(67 to 564) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 82.91</b> </p> <p>(50.49 to 94.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42,175<br/>(3 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Substantial heterogeneity (I² = 65%) between included studies: <a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a> (VE 90.40%, 95% CI 82.88 to 94.62%; n = 25,452); <a href="./references#CD015477-bbs2-0019" title="HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine2021;385(13):1172-83. HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant. medRxiv 2021 [Preprint]. ">Heath 2021</a> (VE 89.70%, 95% CI 80.20% to 94.60%; n = 14,039); <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a> (VE 49.40%, 95% CI 6.10% to 72.80%; n = 2684) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>172 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 100,000</b><br/>(0 to 22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 100.00</b><br/>(86.99 to 100.00) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25,452<br/>(1 RCT)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>d,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b><sup>h</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>51 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>46 per 100,000</b><br/>(15 to 136) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.90</b> (0.30 to 2.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29,582<br/>(1 RCT)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>d,i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 additional study reported on this outcome in 14,039 participants (7020 NVX‐CoV2373 versus 7019 placebo) (<a href="./references#CD015477-bbs2-0019" title="HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine2021;385(13):1172-83. HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant. medRxiv 2021 [Preprint]. ">Heath 2021</a>). There were no events in either group and the trial did not contribute to the pooled effect estimate.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>j</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>363 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>439 per 1000</b><br/>(425 to 454) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.21</b><br/>(1.17 to 1.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31,063<br/>(3 RCTs)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>m</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>173 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>199 per 1000</b><br/>(182 to 218) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.15</b><br/>(1.05 to 1.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46,231<br/>(5 RCTs)<sup>n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>l,o</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Substantial heterogeneity (I² = 57%) between the 5 included studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>m</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>777 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>715 per 100,000</b><br/>(575 to 886) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.92</b><br/>(0.74 to 1.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38,802<br/>(4 RCTs)<sup>p</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>i,q</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 additional trial reported on this outcome in 52 participants (29 NVX‐CoV2373 versus 23 placebo)  (<a href="./references#CD015477-bbs2-0020" title="KeechC , AlbertG , ChoI , RobertsonA , ReedP , NealS , et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. New England Journal of Medicine 2020;383:2320-32. ">Keech 2020</a>). There were no events in either group and the trial did not contribute to the pooled effect estimate.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b><sup>j</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>191 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>532 per 1000</b><br/>(381 to 742) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.78</b><br/>(1.99 to 3.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31,063<br/>(3 RCTs)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>High</b><sup>l,r</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 2 June 2022<br/><sup>b</sup>Follow‐up: from seven days after second dose up to three months (median)<br/><sup>c</sup><a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>; <a href="./references#CD015477-bbs2-0019" title="HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine2021;385(13):1172-83. HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant. medRxiv 2021 [Preprint]. ">Heath 2021</a>; <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a><br/><sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.<br/><sup>e</sup>Inconsistency: downgraded one level (I² = 65%).<br/><sup>f</sup><a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a><br/><sup>g</sup>Indirectness: downgraded one level as outcome in this trial included participants with moderate severity.<br/><sup>h</sup>Follow‐up: two months (median)<br/><sup>i</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit and the possibility of harm and few events.<br/><sup>j</sup>Follow‐up: seven days<br/><sup>k</sup><a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>; <a href="./references#CD015477-bbs2-0015" title="Frenck RW Jr, KleinNP , KitchinN , GurtmanA , AbsalonJ , LockhartS , et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine2021;385(3):239-50. ">Frenck 2021</a>; <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a><br/><sup>l</sup>Despite some concerns with adequate randomisation and missing data, not downgraded for risk of bias.<br/><sup>m</sup>Unsolicited adverse events, follow‐up to three months (median)<br/><sup>n</sup><a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>; <a href="./references#CD015477-bbs2-0014" title="FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. PLOS Medicine2021;18(10):e1003769. FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.26.21252482]">Formica 2021</a>; <a href="./references#CD015477-bbs2-0019" title="HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine2021;385(13):1172-83. HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant. medRxiv 2021 [Preprint]. ">Heath 2021</a>; <a href="./references#CD015477-bbs2-0020" title="KeechC , AlbertG , ChoI , RobertsonA , ReedP , NealS , et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. New England Journal of Medicine 2020;383:2320-32. ">Keech 2020</a>; <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a><br/><sup>o</sup>Inconsistency: downgraded one level (I² = 57%).<br/><sup>p</sup><a href="./references#CD015477-bbs2-0007" title="DunkleLM , KotloffKL , GayCL , ÁñezG , AdelglassJM , Barrat HernándezAQ , et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.05.21264567]">Dunkle 2021</a>; <a href="./references#CD015477-bbs2-0014" title="FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. PLOS Medicine2021;18(10):e1003769. FormicaN , MalloryR , AlbertG , RobinsonM , PlestedJS , ChoI , et al. Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.26.21252482]">Formica 2021</a>; <a href="./references#CD015477-bbs2-0019" title="HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine2021;385(13):1172-83. HeathPT , GalizaEP , BaxterDN , BoffitoM , BrowneD , BurnsF , et al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant. medRxiv 2021 [Preprint]. ">Heath 2021</a>; <a href="./references#CD015477-bbs2-0033" title="ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384(20):1899-909. ShindeV , BhikhaS , HoosainZ , ArcharyM , BhoratQ , FairlieL , et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.25.21252477]">Shinde 2021</a><br/><sup>q</sup>Despite some concerns with adequate randomisation, deviation from intended intervention and missing data, not downgraded for risk of bias.<br/><sup>r</sup>Despite I² = 86%, not downgraded for inconsistency, as the same direction of effect in both effect estimates. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">NVX‐CoV2373 – Novavax compared to placebo for vaccination against COVID‐19a </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015477-tbl-0013"> <div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">FINLAY‐FR‐2 – Instituto Finlay de Vacunas compared to placebo for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with FINLAY‐FR‐2</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1084 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>314 per 100,000</b><br/>(226 to 445) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VE 71.00</b> </p> <p>(58.90 to 79.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28,674<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b><sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>168 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>62 per 100,000</b><br/>(29 to 134) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.37</b><br/>(0.17 to 0.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28,674<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2; <b>VE:</b> vaccine efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 6 May 2022<br/><sup>b</sup>Follow‐up: from seven days after second dose up to three months (median)<br/><sup>c</sup><a href="./references#CD015477-bbs2-0036" title="Toledo-RomaniME , Garcia-CarmenateM , Silva-ValenzuelaC , Baldoquin-RodriguezW , Martínez-PérezM , Rodríguez-GonzálezM , et al. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomized, placebo-controlled phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.31.21265703]">Toledo‐Romani 2021</a><br/><sup>d</sup>Risk of bias downgraded one level: some concerns regarding adequate randomisation and deviation from intended intervention.<br/><sup>e</sup>Follow‐up: 1.7 months (median) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">FINLAY‐FR‐2 – Instituto Finlay de Vacunas compared to placebo for vaccination against COVID‐19a </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015477-tbl-0014"> <div class="table-heading"><span class="table-label">Summary of findings 14.</span> <span class="table-title">Heterologous vaccination scheme compared to homologous vaccination scheme for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with homologous vaccination scheme</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with heterologous vaccination scheme</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>60 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>118 per 1000</b><br/>(31 to 445) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.96</b><br/>(0.52 to 7.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b><sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>3 studies (n = 564) that compared heterologous versus homologous vaccination schemes reported any adverse event with 1 or 2 months' follow‐up. 2 of the studies reported an effect estimate in favour of homologous scheme but with CIs crossing the line of no effect (RR 1.21, 95% CI 0.87 to 1.68; n = 234; and RR 1.03, 95% CI 0.75 to 1.43; n = 229). 1 study reported an effect estimate in favour of homologous scheme with CIs not crossing the line of null effect (RR 3.19, 95% CI 1.11 to 9.11; n = 101) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(3 RCTs)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊖⊖⊖<br/><b>Very low</b><sup>h,i,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b><sup>k</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>1 study (<a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>: ChAdOx1/BNT162b2 versus ChAdOx1/ChAdOx1) that compared heterologous versus homologous vaccination schemes reported no serious adverse events in the heterologous scheme (0/114) versus 1 serious adverse event (1/115) in the homologous scheme (RR 0.34, 95% CI 0.01 to 8.17). 2 more studies reported the outcome, with 0 events in both groups: <a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>: CoronaVac/Ad5 versus CoronaVac/CoronaVac in n = 51 versus n = 50 and <a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>: BNT162b2/ChAdOx1 versus BNT162b2/BNT162b2 in n = 115 versus n = 119 respectively, in heterologous versus homologous scheme </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>229<br/>(1 RCT)<sup>l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊖⊖⊖<br/><b>Very low</b><sup>h,m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>235 per 1000</b><br/>(32 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 11.76</b><br/>(1.59 to 87.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>d,n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 4 May 2022<br/><sup>b</sup>Follow‐up: 28 days<br/><sup>c</sup><a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>: CoronaVac/Ad5 versus CoronaVac/CoronaVac<br/><sup>d</sup>Despite some concerns with deviation from intended intervention, not downgraded for risk of bias.<br/><sup>e</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit for heterologous and benefit for homologous vaccination scheme and the low number of events/participants.<br/><sup>f</sup>Follow‐up: one and two months<br/><sup>g</sup><a href="./references#CD015477-bbs2-0023" title="LiJ , HouL , GuoX , JinP , WuS , ZhuJ , et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.09.03.21263062]">Li 2021a</a>: CoronaVac/Ad5 versus CoronaVac/CoronaVac; <a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>: BNT162b2/ChAdOx1 versus BNT162b2/BNT162b2; <a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>: ChAdOx1/BNT162b2 versus ChAdOx1/ChAdOx1<br/><sup>h</sup>Risk of bias downgraded one level: some concerns regarding outcome measurement.<br/><sup>i</sup>Inconsistency: downgraded one level as studies are not pooled, effect estimates and direction of effect inconsistent between included studies.<br/><sup>j</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of no effect and benefit for homologous vaccination scheme and the low number of events/participants.<br/><sup>k</sup>Follow‐up: one month<br/><sup>l</sup><a href="./references#CD015477-bbs2-0024" title="LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial. Lancet2021;398(10303):856-69. LiuX , ShawRH , StuartAS , GreenlandM , AleyPK , AndrewsNJ , et al. Safety and immunogenicity report from the Com-COV Study – a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]">Liu 2021</a>: ChAdOx1/BNT162b2 versus ChAdOx1/ChAdOx1<br/><sup>m</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit for the heterologous and benefit for homologous vaccination scheme and the low number of events/participants.<br/><sup>n</sup>Imprecision: downgraded two levels due to very few events or participants (or both). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 14.</span> <span class="table-title">Heterologous vaccination scheme compared to homologous vaccination scheme for vaccination against COVID‐19a </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015477-tbl-0015"> <div class="table-heading"><span class="table-label">Summary of findings 15.</span> <span class="table-title">Booster compared to placebo/no booster for vaccination against COVID‐19a </span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo/no booster</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with booster</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed SARS‐CoV‐2 infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Confirmed symptomatic COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe or critical COVID‐19</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b><sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>63 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>80 per 100,000</b><br/>(33 to 191) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.27</b><br/>(0.52 to 3.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28,254<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊖⊖⊖<br/><b>Very low</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systemic reactogenicity events</b><sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>102 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>183 per 1000</b><br/>(72 to 464) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.80</b><br/>(0.71 to 4.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119<br/>(1 RCT)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖<br/><b>Low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not yet measured or reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Local reactogenicity events</b><sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>119 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>766 per 1000</b><br/>(377 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 6.46</b><br/>(3.18 to 13.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119<br/>(1 RCT)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖<br/><b>Moderate</b><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>COVID‐19:</b> coronavirus disease 2019 <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 4 May 2022<br/><sup>b</sup>Follow‐up: 1.7 months (median)<br/><sup>c</sup><a href="./references#CD015477-bbs2-0036" title="Toledo-RomaniME , Garcia-CarmenateM , Silva-ValenzuelaC , Baldoquin-RodriguezW , Martínez-PérezM , Rodríguez-GonzálezM , et al. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomized, placebo-controlled phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.31.21265703]">Toledo‐Romani 2021</a>: FINLAY‐FR‐2/booster FR‐1 versus FINLAY‐FR‐2<br/><sup>d</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit and the possibility of harm and few events.<br/><sup>e</sup>Risk of bias downgraded one level: some concerns regarding adequate randomization and deviation from intended intervention.<br/><sup>f</sup>Follow‐up: seven days<br/><sup>g</sup><a href="./references#CD015477-bbs2-0017" title="HallVG , FerreiraVH , KuT , IerulloM , Majchrzak-KitaB , ChaparroC , et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. New England Journal of Medicine2021;385(13):1244-6. ">Hall 2021</a>: mRNA‐1273 booster versus placebo (solid organ transplant recipients).<br/><sup>h</sup>Imprecision: downgraded one level due to low number of participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 15.</span> <span class="table-title">Booster compared to placebo/no booster for vaccination against COVID‐19a </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015477-tbl-0016"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analysis: RNA‐based vaccines</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Developer – comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Analyses<sup>a</sup> </b> </p> </th> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SARS‐CoV‐2 infection</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Symptomatic COVID‐19</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Severe COVID‐19</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>All‐cause mortality</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SAEs</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Systemic reactogenicity events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>AEs</b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>VE (95% CI)</b> </p> <p><b>No. of trials (No. of participants) </b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="top"> <p><b>RR (95% CI)</b> </p> <p><b>No. of trials (No. of participants) </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>BNT162b2 <b>–</b> Pfizer/BioNTech+Fosun Pharma versus placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.84% (44.25% to 99.92%)</p> <p>2 RCTs (44,077)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.70% (73.90% to 99.90%)</p> <p>1 RCT (46,077)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.07 (0.52 to 2.22)</p> <p>1 RCT (43,846)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.30 (0.55 to 3.07)</p> <p>2 RCTs (46,107)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.52 (0.88 to 2.63)</p> <p>3 RCTs (46,419)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.07 (0.52 to 2.22)</p> <p>1 RCT (44,165)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.30 (0.55 to 3.05)</p> <p>2 RCTs (46,429)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.52 (0.88 to 2.63)</p> <p>3 RCTs (46,471)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>—</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>—</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>—</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>mRNA‐1273 <b>–</b> ModernaTX  versus placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.27% (35.82% to 88.87%)</p> <p>2 RCTs (31,632)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.20% (91.06% to 94.83%)</p> <p>2 RCTs (31,632)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.20% (92.80% to 99.60%)</p> <p>1 RCT (28,451)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.06 (0.54 to 2.10)</p> <p>1 RCT (30,346)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.78 to 1.08)</p> <p>2 RCTs (34,072)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.28 (1.22 to 1.34)</p> <p>2 RCTs (34,037)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.19 (0.79 to 1.80)</p> <p>2 RCTs (34,072)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.06 (0.54 to 2.10)</p> <p>1 RCT (30,415)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.78 to 1.09)</p> <p>2 RCTs (34,147)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.28 (1.22 to 1.34)</p> <p>2 RCTs (34,147)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.20 (0.79 to 1.80)</p> <p>2 RCTs (34,147)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>—</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>—</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>CVnCoV <b>–</b> CureVac AG versus placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.20% (31.70% to 60.90%)</p> <p>1 RCT (25,062)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.80% (0.00% to 91.70%)</p> <p>1 RCT (25,062)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.33 (0.46 to 3.83)</p> <p>1 RCT (39,529)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.24 (0.90 to 1.71)</p> <p>1 RCT (39,529)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.48 (1.43 to 1.53)</p> <p>1 RCT (3982)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.42 (1.38 to 1.47)</p> <p>1 RCT (3982)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.49 (1.39 to 1.60)</p> <p>1 RCT (39,529)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.43 (1.34 to 1.53)</p> <p>1 RCT (39,529)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>—</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>—</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>—</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p>AE: adverse event; CI: confidence interval; COVID‐19: coronavirus disease 2019; RCT: randomized controlled trial; RR: risk ratio; SAE: serious adverse event; SARS‐CoV‐2: severe acute respiratory syndrome coronavirus 2; VE: vaccine efficacy. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>a</sup><b>Sensitivity 1:</b> participants randomized; <b>Sensitivity 2:</b> early‐phase studies excluded; <b>Sensitivity 3:</b> only published studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analysis: RNA‐based vaccines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015477-tbl-0017"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analysis: non‐replicating viral vector vaccine </span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Developer – comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p>Analyses<b><sup>a</sup> </b> </p> </th> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SARS‐CoV‐2 infection</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Symptomatic COVID‐19</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Severe COVID‐19</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>All‐cause mortality</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SAEs</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Systemic <b>reactogenicity events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>AEs</b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>VE (95% CI)</b> </p> <p><b>No. of trials (No. of participants)</b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="top"> <p><b>RR (95% CI)</b> </p> <p><b>No. of trials (No. of participants)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>ChAdOx1 – AstraZeneca + University of Oxford versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.35% (48.00% to 68.22%)</p> <p>5 RCTs (43,390)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.23% (62.10% to 76.62%)</p> <p>5 RCTs (43,390)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48 (0.20 to 1.14)</p> <p>5 RCTs (56,726)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.72 to 1.07)</p> <p>7 RCTs (58,182)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.93 (2.11 to 7.29)</p> <p> </p> <p>1 RCT (256)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50 (0.20 to 1.21)</p> <p>5 RCTs (56,873)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.86 (0.70 to 1.06)</p> <p>7 RCTs (58,329)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> —</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48 (0.20 to 1.14)</p> <p>5 RCTs (56,623)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.72 to 1.08)</p> <p>6 RCTs (57,823)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> —</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> —</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50 (0.20 to 1.21)</p> <p>5 RCTs (56,623)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.86 (0.70 to 1.05)</p> <p>6 RCTs (56,879)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> —</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Ad26.COV2.S – Janssen Pharmaceutical Companies  versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.90% (59.10% to 73.40%)</p> <p>1 RCT (39,058)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.30% (57.90% to 87.50%)</p> <p>1 RCT (39,058)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 (0.09 to 0.67)</p> <p>1 RCT (43,783)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.69 to 1.22)</p> <p>1 RCT (43,783)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.83 (1.29 to 2.60)</p> <p>2 RCTs (7222)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.57 (0.75 to 3.29)</p> <p>2 RCTs (7222)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 (0.09 to 0.67)</p> <p>1 RCT (44,325)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.69 to 1.22)</p> <p>1 RCT (44,325)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.83 (1.27 to 2.63)</p> <p>2 RCTs (44,813)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.57 (0.74 to 3.32)</p> <p>2 RCTs (44,813)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.09 (0.96 to 1.24)</p> <p>1 RCT (6736)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Gam‐COVID‐Vac – Gamaleya Research Institute (Sputnik V) Gam‐COVID‐Vac versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.10% (83.80% to 95.10%)</p> <p>1 RCT (18,695)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.00% (94.40% to 100.00%)</p> <p>1 RCT (19,866)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99 (0.10 to 9.54)</p> <p>1 RCT (21,862)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 (0.39 to 1.07)</p> <p>1 RCT (21,862)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.10 to 9.57)</p> <p>1 RCT (21,977)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 (0.39 to 1.07)</p> <p>1 RCT (21,977)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p>AE: adverse event; CI: confidence interval; COVID‐19: coronavirus disease 2019; RCT: randomized controlled trial; RR: risk ratio; SAE: serious adverse event; SARS‐CoV‐2: severe acute respiratory syndrome coronavirus 2; VE: vaccine efficacy. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><b><sup>a</sup>Sensitivity 1:</b> participants randomized; <b>Sensitivity 2:</b> early‐phase studies excluded; <b>Sensitivity 3:</b> only published studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analysis: non‐replicating viral vector vaccine </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015477-tbl-0018"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sensitivity analysis: inactivated virus vaccine</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Developer – comparison </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p>Analyses<b><sup>a</sup> </b> </p> </th> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>SARS‐CoV‐2 infection</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Symptomatic COVID‐19</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Severe COVID‐19</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>All‐cause mortality</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>SAEs</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p>Systemic <b>reactogenicity events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>AEs</b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>VE (95% CI)</b> </p> <p><b>No. of trials (No. of participants) </b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="top"> <p><b>RR (95% CI)</b> </p> <p><b>No. of trials (No. of participants) </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>CoronaVac – Sinovac versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.81% (12.27% to 89.61%)</p> <p>2 RCTs (19,852)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50 (0.05 to 5.52)</p> <p>1 RCT (12,396)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (0.62 to 1.51)</p> <p>4 RCTs (23,139)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95 (0.55 to 1.62)</p> <p>7 RCTs (23,956)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.09 (1.07 to 1.11)</p> <p>6 RCTs (23,367)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50 (0.05 to 5.52)</p> <p>1 RCT (12,408)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99 (0.64 to 1.51)</p> <p>4 RCTs (23,157)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.56 (0.91 to 2.69)</p> <p>7 RCTs (25,106)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.09 (1.07 to 1.11)</p> <p>6 RCTs (23,385)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99 (0.63 to 1.55)</p> <p>2 RCTs (22,610)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.21 (0.98 to 1.49)</p> <p>4 RCTs (23,584)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.09 (1.07 to 1.11)</p> <p>2 RCTs (22,610)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.50% (65.40% to 92.10%)</p> <p>1 RCT (10,029)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.24 to 2.21)</p> <p>4 RCTs (10,894)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (0.49 to 1.81)</p> <p>6 RCTs (11,617)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.13 (1.04 to 1.23)</p> <p>4 RCTs (10,640)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>WIBP‐CorV – Sinopharm‐Wuhan versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.00% (48.80% to 74.70%)</p> <p>1 RCT (25,449)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.80% (58.10% to 82.40%)</p> <p>1 RCT (25,480)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.60 to 1.15)</p> <p>2 RCTs (27,029)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99 (0.95 to 1.03)</p> <p>2 RCTs (27,029)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.93 to 0.98)</p> <p>2 RCTs (27,029)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.60 to 1.15)</p> <p>2 RCTs (27,053)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99 (0.95 to 1.03)</p> <p>2 RCTs (27,053)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.93 to 0.98)</p> <p>2 RCTs (27,053)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82 (0.59 to 1.14)</p> <p>1 RCT (26,917)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99 (0.95 to 1.03)</p> <p>1 RCT (26,917)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.93 to 0.98)</p> <p>1 RCT (26,917)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> —</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>BBIBP‐CorV – Sinopharm‐Beijing <br/> versus placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.50% (60.60% to 82.20%)</p> <p>1 RCT (25,463)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.10% (64.80% to 86.30%)</p> <p>1 RCT (25,463)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.76 (0.54 to 1.06)</p> <p>1 RCT (26,924)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.05 (0.86 to 1.28)</p> <p>3 RCTs (27,540)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.05 (0.86 to 1.28)</p> <p>3 RCTs (27,557)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> —</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02 (0.98 to 1.06)</p> <p>1 RCT (26,924)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>BBV152 – Bharat Biotech<br/> versus placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.80% (46.70% to 82.50%)</p> <p>1 RCT (6289)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.80% (65.20% to 86.40%)</p> <p>1 RCT (16,973)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.70% (96.79% to 99.79%)</p> <p>1 RCT (16,976)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50 (0.17 to 1.46)</p> <p>1 RCT (25,753)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 (0.43 to 0.97)</p> <p>1 RCT (25,753)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.34 (1.15 to 1.58)</p> <p>2 RCTs (25,925)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.94 to 1.07)</p> <p>1 RCT (25,753)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50 (0.17 to 1.46)</p> <p>1 RCT (25,778)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 (0.43 to 0.97)</p> <p>2 RCTs (25,953)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.35 (1.15 to 1.58)</p> <p>2 RCTs (25,953)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.94 to 1.07)</p> <p>1 RCT (25,778)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 (0.43 to 0.97)</p> <p>1 RCT (25,753)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.34 (1.14 to 1.58)</p> <p>1 RCT (25,753)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.47 (0.63 to 3.47)</p> <p>1 RCT (172)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p>AE: adverse event; CI: confidence interval; COVID‐19: coronavirus disease 2019; RCT: randomized controlled trial; RR: risk ratio; SAE: serious adverse event; SARS‐CoV‐2: severe acute respiratory syndrome coronavirus 2; VE: vaccine efficacy. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><b><sup>a</sup>Sensitivity 1:</b> participants randomized; <b>Sensitivity 2:</b> early‐phase studies excluded; <b>Sensitivity 3:</b> only published studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sensitivity analysis: inactivated virus vaccine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015477-tbl-0019"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analysis: protein subunit vaccine</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Developer‐comparison </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Analyses<sup>a</sup> </b> </p> </th> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SARS‐CoV‐2 infection</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Symptomatic COVID‐19</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Severe COVID‐19</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>All‐cause mortality</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SAEs</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Systemic</b> </p> <p><b>reactogenicity events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>AEs</b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>VE (95% CI)</b> </p> <p><b>No. of trials (No. of participants) </b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="top"> <p><b>RR (95% CI)</b> </p> <p><b>No. of trials (No. of participants) </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NVX‐CoV2373 – Novavax <br/>versus placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.91% (50.49% to 94.10%)</p> <p>3 RCTs (42,175)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.00% (86.99% to 100.00%)</p> <p>1 RCT (25,452)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.30 to 2.68)</p> <p>1 RCT (29,582)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.74 to 1.14)</p> <p> 4 RCTs (46,202)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.21 (1.17 to 1.25)</p> <p>3 RCTs (31,063)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.15 (1.05 to 1.26)</p> <p>5 RCTs (46,231)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.74 to 1.14)</p> <p>4 RCTs (50,111)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.21 (1.17 to 1.26)</p> <p>3 RCTs (34,870)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.16 (1.05 to 1.27)</p> <p>5 RCTs (50,111)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (0.75 to 1.15)</p> <p>3 RCTs (45,689)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.20 (1.17 to 1.24)</p> <p>2 RCTs (30,550)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.14 (1.02 to 1.27)</p> <p>3 RCTs (45,689)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.10% (0.00% to 95.19%)</p> <p>2 RCTs (16,723)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99 (0.65 to 1.51)</p> <p>3 RCTs (16,620)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.24 (1.03 to 1.49)</p> <p>2 RCTs (1481)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.18 (1.03 to 1.35)</p> <p>4 RCTs (16,672)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>FINLAY‐FR‐2 – Instituto Finlay de Vacunas<br/> versus placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.00% (58.90% to 79.10%)</p> <p>1 RCT (28,674)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.37 (0.17 to 0.80)</p> <p>1 RCT (28,674)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> —</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity 3 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p>AE: adverse event; CI: confidence interval; COVID‐19: coronavirus disease 2019; RCT: randomized controlled trial; RR: risk ratio; SAE: serious adverse event; SARS‐CoV‐2: severe acute respiratory syndrome coronavirus 2; VE: vaccine efficacy. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><b><sup>a</sup>Sensitivity 1:</b> participants randomized; <b>Sensitivity 2:</b> early‐phase studies excluded; <b>Sensitivity 3:</b> only published studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analysis: protein subunit vaccine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015477/full#CD015477-tbl-0019">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD015477&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD015477-note-0020">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD015477-note-0026">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD015477-note-0031">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD015477-note-0024">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD015477-note-0023">Hrvatski</a> </li> <li class="section-language"> <a class="" href="hu#CD015477-note-0025">Magyar</a> </li> <li class="section-language"> <a class="" href="ja#CD015477-note-0030">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD015477-note-0022">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD015477-note-0032">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD015477-note-0021">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD015477-note-0029">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD015477-note-0027">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD015477-note-0028">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015477\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015477\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015477\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015477"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015477\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015477\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015477\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015477\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015477\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015477"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015477\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015477\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015477\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015477"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015477\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015477\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015477\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015477"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=STpJR8yz&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015477&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015477';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD015477/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD015477/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015477%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714621079"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015477/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714621083"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015477/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d73205821937f',t:'MTc0MDcxNDYyMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 